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                                                                          SUMMARY 





Increased awareness of the fact that most infectious agents use mucosal 
membranes as portals of entry has led to efforts to develop vaccines and antigen delivery 
systems that can efficiently induce mucosal immunity.  Mucosal immunization offers 
many benefits, including reduced vaccine-associated side effects and the potential to 
overcome the known barriers of parenteral vaccination which includes preexisting 
systemic immunity from previous vaccination, or, in young animals, preexisting systemic 
immunity from maternal antibodies (Liljeqvist & Stahl, 1999).  Live vaccine vehicles 
offer a powerful approach for inducing protective immunity against pathogenic 
microorganisms, where genetically engineered agents provide a method for delivering 
heterologous antigens derived from other pathogens.  In this study, the potential of 
utilizing Lactobacillus spp. and yeast as oral vaccine delivery vehicle against 
coronaviruses was investigated 
In the first part of the study, the adhesion and colonization capacities of L.casei 
Shirota (LcS), S.boulardii, S.cerevisiae and P.pastoris on mucosal surfaces were 
determined.  In vitro interactions between the yeasts and human intestinal cells, Caco-2 
and HT29 were observed under scanning electron microscope, where P.pastoris 
demonstrated a stronger affinity to the intestinal cells than S.boulardii and S.cerevisiae.  
The in vivo adhesion abilities of LcS and the three yeasts were then determined in various 
segments of the gastrointestinal tract of mice fed with fluorescently labeled LcS or yeast.  
Adhesion of LcS and all three yeasts to murine intestinal tract, as determined by flow 
cytometry analysis of the intestinal samples, were observed.  The half times for wash-out 
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and the doubling times of the studied microorganisms were deduced from the data 
obtained.  Among the three yeasts, S.boulardii was found to have a higher adhesiveness 
as the half time for wash-out was the longest.  S.cerevisiae and P.pastoris detached from 
the upper segments of the intestine were capable of readhering to the lower segments of 
the intestinal tract.  A large part of LcS, S.boulardii, S.cerevisiae and P.pastoris fed were 
able to replicate in the intestinal environment, though at a slower rate in comparison to 
the growth rates achievable in laboratory conditions.  The results obtained in this part of 
the study were very encouraging especially when LcS was able to adhere and exist in the 
intestinal tract for a reasonable period of time, while P.pastoris was observed to possess 
higher capability to readhere and replicate in various segments of murine intestinal tract 
in comparison to the other two yeasts.   
Since LcS and P.pastoris have proven their potential to be developed as vehicles 
for oral delivery of coronavirus antigens in the adhesion studies, recombinant LcS and 
P.pastoris which constitutively express and secrete an N-terminal antigenic fragment of 
Transmissible Gastroenteritis coronavirus (TGEV) spike protein were constructed.  
Western blot analysis of the expressed protein, performed using convalescence swine 
serum against TGEV, demonstrated the immunogenicity of the expressed proteins.  
However, the expression of the TGEV spike protein fragment by LcS was less efficient 
than expression by recombinant P.pastoris.  Nevertheless, oral immunization of Balb/c 
mice with recombinant LcS or P.pastoris elicited specific local and systemic 
immunological responses, characterized by significant production of antigen specific 
intestinal IgA and serum IgG.  Isotyping of the IgG subclass revealed that most of the 
IgG responses induced by recombinant LcS and P.pastoris were of IgG2a isotype.  In 
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agreement to the higher levels of IgG2a in the sera of orally immunized mice, a T-helper 
1 (Th1) biased cellular response was observed in the Peyer’s patches of mice fed with 
recombinant LcS or P.pastoris.  However, in contrast to the potent neutralization 
activities of the antibodies generated by recombinant P.pastoris, antibodies induced by 
recombinant LcS demonstrated low neutralization abilities.  The poor neutralization 
capacity of the antibodies elicited by the recombinant LcS was attributed to the lack of 
post-translational modifications of the delivered TGEV spike protein fragment in the 
prokaryotic expression system.  Hence, results are in favor of P.pastoris as an oral 
vaccine carrier for the delivery of coronavirus antigen. 
 In the final part of the study, attempts were made to develop P.pastoris as an oral 
vaccine delivery vehicle against Severe Acute Respiratory Syndrome coronavirus (SARS 
CoV).  Recombinant P.pastoris capable of constitutive and extracellular expression of a 
fragment of SARS CoV spike glycoprotein, consisting of the receptor-binding domain 
(RBD) of the virus, was engineered.  Immunogenicity of the expressed SARS CoV spike 
protein fragment was confirmed with the aid of SARS-positive human sera in Western 
blotting.  The recombinant SARS CoV vaccine induced in Balb/c mice high titers of 
systemic and mucosal neutralizing antibodies (intestinal IgA and serum IgG) as well as 
potent cell-mediated immune responses, by intragastric administration.  In accordance to 
a higher level of IgG1 being produced, a T-helper 2 (Th2) dominated cellular response 
was observed in the Peyer’s patches and cervical lymph nodes of immunized animals.  
Results obtained in this part of the study indicate the use of P.pastoris as vehicle for the 
oral delivery coronavirus antigens to immunize animals is a promising approach. 
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1.0 LITERATURE REVIEW 
1.1 PROBIOTICS 
The term probiotic, as an antonym to the term antibiotic, was originally proposed 
by Lilley and Stillwell in 1965 to be used as substances that favor the growth of 
microorganisms (Lilley & Stillwell, 1965).  More than two decades later, Fuller (1989) 
broadly defined probiotics as “live microbial feed supplement that beneficially affects the 
host animal by improving its intestinal microbial balance”.  By the turn of the century, 
probiotics are commonly defined as viable microorganisms (bacteria or yeasts) that 
exhibit beneficial effects on the health of the host when ingested (Salminen et al., 1998a).  
Microorganisms that are probiotic in humans include yeast (Guslandi et al., 2000), bacilli 
(Pinchuk et al., 2001), Escherichia coli (Katz & Fiocchi, 2001), enterococci (Lund and 
Edlund, 2001) and the more commonly used bifidobacteria and lactic acid bacteria such 
as lactobacilli, lactococci and streptococci (Isolauri et al., 2002; Madsen, 2001).   
Probiotics have been used for many years in the animal feed industry, but they are 
now being increasingly made available in fermented dairy products, and can be 
purchased over the counter as freeze-dried preparations in health food stores.  The US 
Food and Drug Administration classifies some species of lactic acid bacteria that are 
found in both fermented food and in the gastrointestinal tract as GRAS (generally 
recognized as safe) organisms for human use (Teitelbaum & Walker, 2002).  Today, 
probiotics are not only widely used in foods especially in the preparation of fermented 
dairy products, but also in pharmaceutical preparations.   
                                                                           CHAPTER 1 
                                                                                                 LITERATURE REVIEW 
   2
 
1.1.1 Beneficial effects 
Several healths related effects associated with the intake of probiotics have been 
reported in human studies.  Probiotics have been used therapeutically to modulate 
immunity where consumption of Lactobacillus acidophilus and Bifidobacterium bifidum 
significantly enhances the non-specific immune phagocytic activity of circulating blood 
granulocytes (Schiffrin et al., 1995).  Several species of lactobacilli, killed by irradiation, 
were found to stimulate differentially dendritic cell activity with respect to interleukin-12 
and tumour necrosis factor-α production (Christensen et al., 2002).  Reports have also 
shown that infants suffering from rotavirus-induced diarrhea supplemented with a strain 
of Lactobacillus casei have enhanced concentration of circulating immunoglobulin A.  
This correlates with a shortened duration of diarrhea, giving an implication that 
probiotics might be effective in alleviating the effects of the infection (Kaila, 1992).  
Furthermore, it has been consistently reported that individual consuming probiotics 
fermented products had shortened episodes or reduced risk of the disease occurrence 
(Salminen et al., 1996).  Production of antimicrobials effective against intestinal 
pathogens and blocking the way from enteroinvasive microbes have also been suggested 
as possible causes of diarrhea prevention and cure (Salminen et al., 1998b).  Besides 
infection-associated diarrhea, probiotics have also been demonstrated in humans to 
reduce the effects of non-infection associated diarrhea as a result of lactose intolerance by 
improving lactose digestion as well as by slowing orocecal transit (Sanders, 1993 & 
Montes et al., 1995).  A recent metaanalysis of nine double blind placebo controlled 
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studies of the use of probiotic yeast and lactobacilli to prevent antibiotic associated 
diarrhea showed consistent benefit (D’Souza et al., 2002).    
Patients with chronic kidney failure usually have bacterial overgrowth in the 
small intestine, resulting in high levels dimethylamine and nitrosodimethylamine in the 
blood that can cause hepatotoxicity.   Probiotic treatment of patients seemed to be 
effective as these toxic compounds were significantly lower in patients treated with 
Lactobacillus acidophilus, resulting in better quality of life for these patients (Morishita 
et al., 1997). 
The anti-tumor effects of probiotics have also been documented.  The possible 
anti-carcinogenic effects in humans are very difficult to detect.  However, positive effects 
on superficial bladder cancer by Lactobacillus casei Shirota have been reported (Aso et 
al., 1995).  Reports have also indicated that consumption of probiotics could reduce 
levels of free amines and fecal microbial enzymes, such as β-glucoronidase, 
nitroreductase and urease, involved in the metabolic activation of miscellaneous 
mutagens and carcinogens, thereby reducing the risk of cancer development (Goldin & 
Gorbach, 1984).  In particular, the observations that Lactobacillus acidophilus 
consumption resulted in lower amounts of extractable fecal or urinary mutagens from 
human volunteers may also indicate a long-term anti-carcinogen effect (Lidbeck et al., 
1991). 
Although the causes of inflammatory bowel disease including ulcerative colitis 
and Crohn's disease remain incompletely understood, increasing evidence implicates 
intestinal microflora in the pathogenesis of this disorder.  Studies with a strain of 
Lactobacillus plantarum showed the administration of the probiotic to specific pathogen 
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free animals attenuated established inflammatory processed (Schultz et al., 2002).  
Patients who were in remission of Crohn’s disease who were treated with probiotic yeast 
Saccharomyces boulardii were found to have a significantly reduced chance of relapse 
(Guslandi et al., 2000).  There are increasing reports indicating that several probiotic 
strains are able to inhibit the attachment of pathogenic bacteria to intestinal epithelial 
cells through their ability to increase the production of intestinal mucins.  Lactobacillus 
plantarum 299v and Lactobacillus rhamnosus GG were reported to inhibit the adherence 
of enteropathogenic Escherichia coli to HT29 and Caco-2 cells by elevating the 
expression of mucins (MUC2 and MUC3) mRNA, and subsequent production of mucins 
(Mack et al., 1999; Mattar et al., 2002).   When purified MUC2 and MUC3 mucins were 
added to cells, adherence of pathogenic Escherichia coli was inhibited.  Therefore, 
modulation of microflora with probiotics may offer a plausible therapeutic approach 
(Schultz et al., 2003).   
 
1.1.2 Detrimental Effects of Probiotics 
 Probiotic agents are increasingly used for the treatment and prevention of a 
variety of infectious and inflammatory conditions. They are generally safe, but 
complications of probiotic use can occur.  Though infections associated with probiotic 
strains of lactobacilli are extremely rare, invasive disease can be associated with probiotic 
lactobacilli.  Cases of bacteremia and sepsis associated with ingestion of a Lactobacillus 
spp. have been reported in 2 patients and a child with short gut syndrome (De Groote et 
al., 2005).   
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Saccharomyces cerevisiae is a well-known yeast used in the food industry and has 
been documented to cause different forms of invasive infection (Cassone et al., 2003).  
However, the most important clinical syndrome caused by Saccharomyces cerevisiae is 
fungemia, because it is usually the most severe and well-proven clinical manifestation of 
the disease. Saccharomyces cerevisiae fungemia has been described not only in 
immunosuppressed patients and critically ill patients, but also in relatively healthy 
subjects (Herbrecht & Nivoix, 2005).   
 
1.1.3 Methods to Analyze Adhesion of Intestinal Microorganism 
Besides adhesion studies carried out in vitro, colonization studies in animals have 
also been carried out as in vitro studies of adhesive properties of probiotic strains might 
not be truly reflective of the interaction in vivo.  In vitro adhering Lactobacillus casei 
rhamnosus GG and Lactobacillus johnsonii La 1 were found to adhere to various 
segments of the intestine when orally fed to C3H/He/Oujco gnotobiotic mice (Hudault et 
al., 1997; Bernet-Camard et al., 1997).  Some Bifidobacterium strains were also capable 
of colonizing to the gastrointestinal tract in vivo (Crociani et al., 1995).  Oral 
administration of in vitro adhering Bifidobacterium infantis strain 1 and Bifidobacterium 
spp. CA1 and F9 strains established high levels of bacteria in the mucosa and intestinal 
contents of the gastrointestinal tract (Lievin et al., 2000). 
Fecal samples have also been used in colonization studies with probiotic bacteria.  
These, however, reflect only the bacteriologic situation in the fecal material and might 
not give an accurate picture of the various portions of the gut.  Colonic biopsies, 
combined with molecular biological techniques offers a more accurate means of 
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determining colonization (Johansson et al., 1993; Alander et al., 1997).  In particular, 
Alander and coworkers (1999) have shown that Lactobacillus rhamnosus GG can persist 
in colonic mucosa for several days before subsequently being discharged in the fecal 
samples. 
 
1.2 LACTOBACILLUS  
 The genus Lactobacillus comprises a remarkably diverse and heterogenous group 
of Gram-positive bacilli that are ubiquitous as normal indigenous flora of humans and 
other animals.  In addition to their role as members of the indigenous microbiota, 
lactobacilli can also be found naturally in fermented food and have been commonly used 
in the production of fermented products (Sharpe, 1981).  Lactobacillus strains have a 
number of properties that make them attractive candidates as delivery vehicles for the 
presentation of compounds of pharmaceutical interest (vaccines and immunomodulators) 
to the mucosal surfaces.  Besides being considered GRAS organisms, certain strains of 
Lactobacillus are able to colonize the gut and are believed to show health promoting 
activities (Havenaar & Huis in’t Veld, 1993; Pouwels et al., 1998).  However, it is 
important to note that different strains of the same species are often different in their 
abilities to colonize different habitats.  For instances, Lactobacillus acidophilus strains 
may be members of the human gastrointestinal microflora and colonize specific sites 
within the human intestine, whereas Lactobacillus acidophilus strains used in food 
production rarely interact with the intestinal mucosa (Clements et al., 1983; Marteau et 
al., 1993; Salminen et al., 1996).   
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 Interest in the expression of heterologous genes in Lactobacillus has increased in 
the recent years, as techniques for genetic manipulation of strains have been developed.  
Generally, heterologous proteins can be expressed in Lactobacillus strains either using 
expression vectors or via chromosomal integration of expression cassettes.  Currently, 
most of the efforts have been focused on the development of expression system that 
utilizes expression vectors.  Most vectors can be amplified in Escherichia coli and 
Lactobacillus spp. and comprise a broad host range replicon from Lactobacillus pentosus. 
An antibiotic resistance marker is also included to permit their replication in a wide 
variety of lactic acid in bacterial strains (Posno et al., 1991).  In addition, the 
heterologous protein can be chosen to be expressed intracellularly and be transported 
over the membrane and anchored to the cell wall, or to be secreted into the culture 
medium, under the control of regulatable or constitutive promoter from Lactobacillus.  
For instance, expression of cloned genes in the vectors can be driven by highly efficient, 
constitutive promoter of the Lactobacillus casei L-(+)-lactate dehydrogenase gene or 
regulatable promoter of the Lactobacillus amylovorous α-amylase gene (Boot et al., 
1996).  Most of the Lactobacillus strains can now be transformed by electroporation, 
including members of L.acidophilus A1 group which were previously refractory to 
transformation techniques (Walker et al., 1996). 
 In the recent years, there has been great interest in the development of 
Lactobacillus strains as vaccine vehicles.  This has lead to the construction of 
recombinant strains expressing vaccine antigens (Mercenier et al., 1996; Reveneau et al. 
2002).  The immunogencity of the expressed recombinant antigens have been examined.  
Gerritse et al. demonstrated that mice orally fed with trinitrophenylated-Lactobacillus 
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strains resulted in an induction of specific mucosal immunoglobulin A (Gerritse et al., 
1990).  In addition, this study indicated that Lactobacillus spp. could also provide T-cell 
help to the hapten expressed on the cell surface.  Besides mucosal immune responses, 
systemic immune responses were also elicited following intraperitoneal immunization of 
strains expressing Escherichia coli β-galactosidase (Claassen et al., 1995).    
 
1.3 SACCHAROMYCES CEREVISIAE 
The most well-known and commercially significant yeasts are the related species 
and strains of Saccharomyces cerevisiae. These organisms have long been utilized to 
ferment the sugars of rice, wheat, barley, and corn to produce alcoholic beverages and in 
the baking industry for the fermentation of bread dough.  Saccharomyces cerevisiae is a 
very attractive organism to work with since it is non-pathogenic.  Due to its long history 
of application in the production of consumable products such as ethanol and baker's yeast, 
it has been classified as a GRAS organism (Generally Regarded As Safe).  Also, the well-
established fermentation and process technology for large-scale production with 
Saccharomyces cerevisiae make this organism attractive for several biotechnological 
purposes.  Not only being useful in daily brewers and bakers practice, yeast, as a simple, 
unicellular eukaryote was developed as a unique powerful model system for biological 
research. Its prominent useful features are the cheap and easy cultivation, short 
generation times, the detailed genetic and biochemical knowledge accumulated in many 
years of research and the ease of the application of molecular techniques for its genetic 
manipulation. Therefore, this organism provides a highly suitable system to study basic 
biological processes that are relevant for many other higher eukaryotes including man. 
                                                                           CHAPTER 1 
                                                                                                 LITERATURE REVIEW 
   9
1.3.1 Protein Expression in Saccharomyces Cerevisiae 
Escherichia coli has been conventionally used for the expression of foreign 
proteins.  While the simplicity of Escherichia coli makes it a desirable host for 
production of a foreign protein, it also has its disadvantage as a host cell.  Being a 
prokaryote, proteins expressed in Escherichia coli are not post-translationally modified.  
As such, the expressed protein might not be functional due to the lack of post-
translational modifications.  Because of the handicap encountered when using 
Escherichia coli to produce eukaryotic proteins, other organisms like mammalian, insect 
and yeast cells have been studies as suitable replacements for Escherichia coli.  Of the 
three, yeast cells are the most desirable as they combine the ease of genetic manipulation 
and rapid growth characteristics of a prokaryotic organism with the subcellular 
machinery for performing post-translational modification of eukaryotic cells (Cregg et 
al., 1993).   
While many foreign proteins have been successfully expressed in 
Saccharomyces cerevisiae, it has several limitations.  Generally, the product yields are 
low, reaching a maximum of 1-5 percent of the total protein.  In addition, proteins 
expressed in Saccharomyces cerevisiae seemed to be hyperglycosylated, which may 
result in differences in immunogenicity, diminished activity, or decreased serum retention 
of the foreign protein (Cregg et al., 1987).  Problems may also be encountered during the 
purification of proteins expressed in Saccharomyces cerevisiae as many of the secreted 
proteins are not found secreted into the culture medium but trapped in the periplasmic 
space (Buckholz & Gleeson, 1991). 
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1.4 SACCHAROMYCES BOULARDII 
Saccharomyces boulardii which has been registered under the name 
Saccharomyces cerevisiae Hansen CBS 5926, as a non-pathogenic, non-colonizing yeast 
that is very closely related to the brewer's yeast, Saccharomyces cerevisiae.  Recognized 
to have probiotic effectiveness, Saccharomyces boulardii is sold in supplement form over 
the counter in Europe for prevention and treatment of diarrhea of different aetiologies 
(Czerucka & Rampal, 2002; Broussard & Surawicz, 2004; van der Aa Kuhle et al., 
2005).  Saccharomyces boulardii is generally administered in lyophilized powder and the 
application as a food additive has only been reported in a limited number of formulation 
such as in the fermentation of vegetable raw materials and incorporation into commercial 
yoghurts (Nguyen & Herve, 1997; Periti & Tonelli, 2001; Lourens-Hattingh & Viljoen, 
2001; Sindhu & Khetarpaul, 2002). 
Several possible mechanisms for the protective effect of Saccharomyces boulardii 
against infections of the gastrointestinal tract have been proposed.  Type I fimbrinated 
Escherichia coli which binds to mannose as receptor, were found to be more strongly 
bound to the surface of Saccharomyces boulardii than other probiotic strains of 
Saccharomyces cerevisiae when observed under scanning electron microscopy (Sharon & 
Ofck, 1986; Stefano et al., 1998).  It could be reasoned that the outer membrane of 
Saccharomyces boulardii, being richer in mannose than other yeast, enabled more type I 
Escherichia coli to be bound to Saccharomyces boulardii.  On the other hand, the 
therapeutic effect of Saccharomyces boulardii in the prevention and recurrence of 
Clostridium difficile associated diarrhea is likely attributable to the secretion of a 54 kDa 
protease that can digest toxins A and B of the pathogen (Castagliuolo et al., 1999).  This 
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proteolytic activity of Sacchromyces boulardii may explain the protective effect against 
Clostriduim difficile associated diarrhea.  
In addition to diarrhea associated problems, Sarrchromyces boulardii has also 
been reported to be effective in relieving constipation in the elderly without affecting the 
mucosal barrier and beneficial in treating inflammatory bowel disease (Ouwehand et al., 
2002; Guslandi et al., 2000).  In a recent study made by Lee et al. (2005), Saccharomyces 
boulardii was demonstrated to be able to stimulate the expression peroxisome 
proliferator-activated receptor-gamma (PPAR-gamma) expression, which plays a role in 
the regulation of inflammation in intestinal epithelial cells.  It was hypothesized that the 
anti-inflammatory effects of Saccharomyces boulardii are mediated through up 
regulation of PPAR-gamma expression, thus reducing the response of human colon cells 
to proinflammatory cytokines.   
 
1.5 PICHIA PASTORIS 
Pichia pastoris is established industrial methylotrophic yeast that uses methanol 
as its sole carbon source to produce energy and cellular materials at ultra-high levels.  
Though not commonly used in the food industry, U.S. Food and Drug administration has 
permitted Pichia pastoris as a food additive in feed formulation for animals (U.S. Food 
and Drug Administration).  In addition, Pichia pastoris has been developed to be a 
competent host for the production of foreign proteins (Romanos et al., 1992; Ilgen et al., 
2004).   
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 Being an excellent protein expression host, Pichia pastoris combines many of the 
benefits of E. coli expression with the advantages of expression in a eukaryotic system.  
When compared to other eukaryotic expression systems, Pichia pastoris offers many 
advantages, neither does it have endotoxin problem associated with bacteria nor viral 
contamination of proteins produced in animal cell culture.  Since the proteins produced in 
Pichia pastoris are typically folded correctly and secreted into the medium, the 
fermentation of genetically engineered Pichia pastoris provides an excellent alternative 
to Escherchia coli expression systems.  In addition, Pichia pastoris is capable of 
generating post-translational modifications that are more similar to human proteins 
modifications than Saccharomyces cerevisiae.  For example, the expression of Hepatitis 
B surface antigen (I-IBsAg) in Pichia pastoris leads to production of particles that are not 
only immunoreactive with anti-HBsAg antibodies but are also similar to Dane particles 
isolated from the sera of human carriers (Cregg et al., 1987).  A comparison of protein 
secreted by Saccharomyces cerevisiae and Pichia pastoris has shown distinct differences 
between N-linked oligosaccharide structures.  The length of the carbohydrates chains is 
much shorter in Pichia pastoris, ranging from 8 to 14 mannose residues, as compared to 
50 to 150 mannose residues typically found in Saccharomyces cerevisiae glycoproteins.  
In addition, glycans from Pichia pastoris do not have alpha 1,3-linked mannose residues, 
which are characteristic of Saccharomyces cerevisiae (Cregg et al., 1993).  These may in 
turn explain why Pichia pastoris does not appear to hypermannosylate it glycoproteins to 
the same extend as Saccharomyces.cerevisiae (Bretthauer & Castellino, 1999). 
Pichia pastoris has a strong inducible promoter that controls the expression of 
alcohol oxidase (AOX1), which is required for the metabolism of methanol (Ledeboer et 
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al., 1985).  The expression of this enzyme, coded for by AOX1 gene, is tightly regulated 
and induced by methanol to a level as high as thirty-five percent of the total cellular 
protein (Faber et al., 1995).  As such, gene of interest under the control of the AOX1 
promoter for inducible expression or the GAP promoter for constitutive expression will 
result in high yield of functional proteins.  A number of proteins have been produced 
using this system, including tetanus toxin fragment, Bordatella pertussis pertactin, human 
serum albumin and lysozyme (Tschopp et al., 1987; Digan et al., 1989; Clare et al., 1991; 
Cregg et al., 1993; Chen et al., 1996).  In addition, as Pichia pastoris grows on a simple 
mineral media and does not secrete high amounts of endogenous proteins, hence 
heterologous protein secreted into the culture is relatively pure and purification is easier 
to accomplish (Faber et al., 1995). 
 
1.6 ADHESION 
It is generally agreed that to have positive effects, a probiotic strain has to survive 
in the intestine in sufficient numbers to interact with the gut microflora and the host.  
Adhesion also provides an interaction with the mucosal surface facilitating the contact 
with gut associated lymphoid tissue mediating local and systemic immune effects.  
Hence, only adherent probiotics have been thought to effectively induce immune effects 
and further to stabilize the intestinal mucosal barrier (Salminen et al., 1996). 
In order to permanently establish a bacterial strain in the host’s intestine, the 
organism must be able to attach to intestinal mucosal cells (O’Sullivan et al., 1992).  The 
length of the lag phase of growth that an organism exhibits when encountering a new 
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environment is a decisive factor in determining whether the probiotic will successfully 
establish in the gastrointestinal tract.   
Appropriate polarized and fully differentiated human intestinal cell models in 
culture that mimic the human situation have been extensively used to study specific 
human intestinal cell functions (Zweibaum et al., 1991; Louvard et al., 1992).  Adhesion 
of organisms to the gut can be mimicked using cultured intestinal cell lines, which 
exhibits the specific characteristics of the several cell phenotypes that line the epithelium.  
The parental human epithelial cell line Caco-2 has been shown to undergo morphological 
and functional enterocytic differentiation in vitro, while HT29 displays the functions of 
mucus secreting cells.  In in vitro models, adhesion of probiotic strains to intestinal cells 
can be highly variable.  Variation in adhesion can occur within the same strain and 
differences between strains can be significant.   
Some strains of Lactobacillus, including Lactobacillus acidophilus strain 
BG2FO4 and HN017, Lactobacillus johnsonii strain La 1, Lactobacillus rhamonsus 
strain DR20 and Lactobacillus casei subsp. rhamnosus Lcr38 and GG strains, adhered to 
the enterocyte-like Caco-2 (Coconnier et al., 1992; Bernet et al., 1994; Hudault et al., 
1997; Tuomola & Salminen, 1998; Forestier et al., 2001; Gopal et al., 2001).  In 
particular, Lactobacillus acidophilus BG2FO4 and Lactobacillus johnsonii La 1 have 
also been reported to interact with the mucus secreted by HT29 cells.  Like lactobacilli, 
Bifidobacterium strains also display adhesiveness.  Bifidobacterium breve 4, B.infantis 1 
and Bifidobacterium lactis DR10 strains have been found adhering to both the brush 
border of Caco-2 cells and the mucus secreted by HT29 cells (Bernet et al., 1993; Gopal 
et al., 2001). 
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1.7 VACCINE 
When a new disease emerges or an existing one becomes a more significant 
health threat than it has been in the past, the need for a new way to prevent the disease 
will be recognized.  Vaccination has been one of the most important interventions 
designed to prevent disease to be employed on a worldwide basis.  The concept of 
vaccinology originated in the 18th century when the English physician Edward Jenner 
used cowpox virus inoculations in an attempt to combat smallpox infections (Tan, 2004).  
Since then, smallpox has been eradicated worldwide and other diseases such as 
poliomyelitis have virtually disappeared in countries of the Western Hemisphere. 
Over the last quarter century, scientific advances have created new tools and 
technologies to improve the safety and efficacy of vaccines.  These improvements are 
spurred by social and commercial needs to enhance existing vaccines or to create new 
ones against an expanding spectrum of diseases.  Live, attenuated, pathogenic bacteria 
are traditional vaccines that are originally developed to prevent infection by homologous 
pathogens.  More recently, strategies have been developed to use these bacterial vaccines 
as vectors to deliver a variety of protective, vaccine antigens via the mucosal route to 
protect not only against heterologous microbial infections, but also against non-
traditional threats such as biowarfare and cancer (Roland et al., 2005). 
 
1.7.1 Types of Vaccines    
 The effectiveness of vaccines and immunization in the prevention of major 
infectious diseases is recognized as one of the greatest successes in medicine.  Advances 
in recombinant DNA technology and other areas of bioengineering hold promise for 
improvements in available vaccines and to accelerate the development of several novel 
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and safe immunogenic vaccines.  Table 1.1 sets out to illustrate the characteristics of 
several forms of vaccines. 
 
1.7.1.1 Inactivated Vaccine 
Treating the pathogen with chemicals like formaldehyde or subjecting them to 
heat treatment for inactivation produces inactivated vaccines.  Such vaccines are stable 
and safe due to the inability of inactivated microorganism to revert to the virulent form.  
However, most inactivated vaccines stimulate a relatively weak immune response and 
several doses are required to generate sufficient immune responses to confer protection 
against invasion of pathogens.  Nevertheless, inactivated tick-borne encephalitis vaccine 
has been successfully used in Europe for almost 30 years, and continues to be improved 
by additional purification, new stabilizers, an adjuvant, and better immunization 
schedules (Eckels & Putnak, 2003).  
 
1.7.1.2 Live Attenuated Vaccine 
 Live attenuated vaccines are prepared by repeatedly culturing of viruses under 
special laboratory conditions that causes it to lose its virulence.  Measles vaccine, a live 
attenuated strain of measles virus, is one of the safest and most effective human vaccines 
available. Since the 1960s, it has been given to billions of children (Despres et al., 2005). 
Attenuated vaccines have an advantage over inactivated vaccines in that they produce 
both antibody-mediated and cell mediated immunity, and generally require only one 
booster dose to be effective.  However, live vaccines have to be carefully tested and 
  
   17
  Types of vaccines 
  Inactivated Attenuated Subunit Live recombinant  DNA Vaccine 
    vector  
Antibody response Y Y Y Y Y 
Antibody rise Fast Fast Fast Fast Slow 
Cytotoxic T lymphocyte induction N Y Variable Y Y 
T helper induction Y Y Y Y Y 
Complete antigen repertoire Y Y N N Possible 
Immune response(s) to vaccine 
carrier N N N Possibly N 
Duration of response Short Long Short Long Long 
No. of doses required Multiple One Multiple Multiple One or probably more 
Safety (for pregnant/ Y N Y N Probably 
immunocompromized individuals)       
Risk of reversion N Y N Y N 
Neonatalimmunization Y Y Y Y N 
Stability Stable Not very Stable Not very Stable 
Ease of production Variable Variable Difficult Difficult Easy 
Cost Variable Variable Expensive Expensive Inexpensive 
            
Table 1.1 Comparison of current vaccination strategies with DNA vaccination technology. Adapted from Kowalczyk and Ertl (1999) and  
     Hasan et al. (1999). 
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monitor, as it is possible that the attenuated organism may revert back to a virulent form 
and cause disease when administered.  On a safe side, people with compromised immune 
systems are generally not given live vaccines.   
 
1.7.1.3 Toxoid 
Some bacteria - for example those that cause tetanus and diphtheria - produce a 
toxin that is largely responsible for the disease. For this type of bacterial infection, the 
toxin can be used in a modified form as the vaccine. A toxoid is an inactivated toxin that 
is made by treating toxins with heat or chemical such as formalin, a solution of 
formaldehyde and sterile water, but still retains the ability to stimulate the immune 
system to make antitoxins.  Because it is not a live vaccine, a person's immunity tends to 
wane with time, which is why booster doses are required.  One of the most common 
vaccines is the tetanus vaccine.  The first tetanus toxoid was produced in 1924 and was 
used successfully to prevent tetanus in the armed services during World War II.  
Prompted by outbreaks after World War II, the World Health Organization (WHO) 
sponsored trials of diphtheria toxoid in Romania (Pappenheimer, 1984).  In the mid-
1940s, tetanus vaccine was combined with diphtheria toxoid and inactivated pertussis 
bacteria to make the combination DTP vaccine for routine childhood immunization. In 
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1.7.1.4 Conjugated Vaccine 
Conjugate vaccines are so-called because their production involves the 
conjugation of the polysaccharide antigen with a protein from a second type of organism 
that immature immune system can recognize.  The bacteria for which conjugated 
vaccines are designed have an important structural feature in common. They are 
surrounded by a thick and slippery capsule, which determines the extent of their 
virulence. The capsule is made of carbohydrate and provides an antigenic target for 
recognition by the immune system.  However, as carbohydrate antigens are T-cell 
independent, the antigen is not processed by antigen presenting cells, and B cells are able 
to make antibodies without help from T cells, protection wanes rapidly within two years 
from vaccination (Wald et al., 1981).  This conjugation will in turn convert the T- cell 
independent carbohydrate antigen into a T-cell dependent antigen, with all the associated 
benefits in terms of immunological response (Overturf & American Academy of 
Pediatrics, 2000).  Various protein carriers have been used for conjugation, including 
diphtheria and tetanus toxoid.   
 The three most common causes of bacterial meningitis - Neisseria meningitidis 
(the meningococcus), Streptococcus pneumoniae (the pneumococcus) and Haemophilus 
influenzae type B - are all capsulated.  Past attempts to make vaccines against these 
pathogens using traditional methods have been less successful than for other diseases, 
and these diseases provide the best examples of the application of conjugation to vaccine 
technology.  
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1.7.1.5 Subunit Vaccine 
 Subunit vaccines, also known as "component" vaccines, contain only the 
antigenic fragment, rather than the whole microbe.  Subunit vaccines can be made from 
isolated proteins, bacteria, or a combination thereof, from wild type organism as well as 
from those produced by genetic engineering.  They are usually well tolerated with low 
reactogenicity, and are not able to multiply or revert to pathogenicity (Ellis, 2004).  As 
such, subunit vaccines can be developed eliminating many of the safety issues 
characteristic of attenuated vaccines while maintaining epitopes critical to inducing a 
protective immune response (Byrd et al., 2005).    Subunit vaccines are capable of 
inducing systemic as well as mucosal immune responses, and function by eliciting 
primarily an antibody and inducing immunological memory.  Likewise, it has been 
shown that certain subunit vaccines can induce cell-mediated immunity when 
administered with certain adjuvant or via certain delivery systems (Ellis, 2004). 
As typified by the Hepatitis B vaccine, in which a component of a virus is cloned, 
over-expressed, and purified form a recombinant microorganism and delivered as a 
subunit vaccine in combination with an adjuvant (Isaka et al., 2001; Vandepapeliere et 
al., 2005).  One of the highly efficient adjuvant is a bacterial DNA containing cytosine-
phosphate-guanosine (CpG) motifs (Krieg, 2002).  The adjuvanticity of CpG DNA, 
which result from the binding of the CpG-rich DNA to Toll-like receptors, is associated 
with the induction of both pro-inflammatory and Th1-inducing cytokines and 
chemokines, and the induction of Major Histocompatibility Complex (MHC) and co-
stimulatory molecules on antigen presenting cell (APC).  The resulting immune responses 
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in mice are Th1 dominated with high levels of cytotoxic T lymphocytes, interferon-γ 
(IFN-γ) production and IgG2a antibody production.  
 
1.7.1.6 DNA Vaccine 
DNA vaccines, also known as ‘genetic’, nucleic acid’ or ‘polynucleotide’ 
vaccines, deliver genes encoding protein antigens into host cell, enabling antigens 
production to occur in vivo (Davis, 1997).  Generally, in DNA vaccination, direct 
parenteral injection of the plasmid DNA results in the in vivo synthesis of the encoded 
protein with post-translational modification similar to those that occur during natural 
infection and the most commonly studies routes for administration of DNA vaccines have 
been intramuscular (Donnelly et al., 2003).  However, it is believed that majority of the 
DNA injected intramuscularly is degraded by extracellular deoxyribinucleases (Kawabata 
et al., 1995).  Carrier-mediated delivery may provide protection from degradation by 
introducing DNA directly into target cells.  For instances, the gene gun delivery system 
allows direct injection of DNA into the cytosol of host cells, which often results in higher 
levels of antigen-specific stimulated immunity (Bennett et al., 1999; Belperron et al., 
1999; Yoshida et al., 2000). 
The feasibility of DNA vaccines lies in the fact that they can be constructed easily 
within a short time frame and produced at large-scale.  In addition, the ability to 
genetically manipulate DNA offers the advantage of vaccines designed to produce co-
stimulatory molecules, or that are able to target protein production to specific cell 
compartment.  DNA vaccines can also be manipulated to express multiple antigens 
(Garmony et al., 2005).  Even though studies have demonstrated that DNA vaccines are 
able to induce cellular immune responses, it has also been reported that DNA vaccines 
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may induce relatively poor humoral immune responses and also lacks potency in humans 
following intramuscular administration (Donnelly et al., 2003).  Nevertheless, DNA 
vaccine vectors have already been shown to have potential for immunization against 
Yersinia pestis and Bacillus anthracis (Price et al., 2001; Williamson et al., 2002; 
Grosfeld et al., 2003). 
 
1.7.2 Vaccine Delivery 
Many vaccine candidates are highly purified, sometimes monomeric antigens and 
as a result, not very immunogenic.  As such, the application of new strategies to develop 
effective delivery vehicles is essential in modern vaccine design by facilitating the 
efficient delivery of target antigens.  A variety of antigen delivery systems have been 
developed, including various inert systems as well as different live-attenuated bacterial or 
viral vector systems, to optimize the presentation of antigens.  
 
1.7.2.1 Recombinant Vector Vaccines 
Live recombinant vector vaccines are constructed by inserting antigenic genes 
into live, infectious, but non-disease-causing viruses or bacteria such as vaccinia virus or 
Bacille Calmette-Guerin (Rezende et al., 2005; Drexler et al., 2004).  The viruses or 
bacteria are used as vectors, or carriers, to deliver harmless genes from another disease 
causing organism into the cells of the body.  The recombinant vector expresses proteins 
from the inserted genes within the human body and these proteins stimulate immune 
response against the pathogen. 
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1.7.2.1.1 Viral Vectors 
Recombinant viruses represent a particularly promising avenue of vaccine 
research, both for improving existing vaccines and for developing new ones.  This 
process normally involves taking a proven safe and efficacious vaccine virus, such as 
vaccinia or adenovirus, and modifying its genome to include genes coding for 
immunogenic proteins from other pathogens.  The recombinant viral vectors enter cells 
and allow the proteins from foreign pathogens to be generated inside the cells and be 
presented to the immune system in the same way that proteins from a virus-infected cell 
would be (Souza et al., 2005).  Virus-derived vectors offer several potential advantages 
over traditional vaccine technologies. These include, most notably, high-level production 
of protein antigens directly within cells of the immunized host, potential adjuvant effects 
of the viral delivery system itself and the possibility of efficient delivery of antigen 
directly to components of the immune system, such as antigen-presenting cells.  In order 
to be utilized as a vaccine carrier, the ideal viral vector should be safe and enable 
efficient presentation of required pathogen specific antigens to the immune system.   
Vaccinia virus is now commonly used to make recombinant vector vaccines as 
vaccinia virus is relatively large and has ample room to accommodate additional genetic 
materials.  Concerns about the safety of vaccinia virus have been addressed by the 
development of vectors based on attenuated viruses.  One of them, modified vaccinia 
virus Ankara (MVA) can be considered as current vaccinia virus strain of choice for 
clinical investigation (Drexler et al., 2004).  Currently, recombinant MVA-based 
constructs are developed as vaccines for a variety of diseases.  Progress has been made 
towards the clinical assessment of MVA-based vectors in the treatment of HIV 
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infections, malaria, measles, or cancer, either alone or in combination with DNA vaccines 
(Allen et al., 2000; Drexler et al., 1999; Schneider et al., 1998; Weidinger et al., 2001).   
 The popularity of adenovirus (Ad) as a recombinant viral vector is largely due to 
the successful and safe immunization of millions of US military recruits with live enteric-
coated capsules containing unattenuated Ad serotypes 4 and 7 in an attempt to prevent 
outbreaks of respiratory diseases caused by Ad. The safety of these vaccinations has been 
well documented (Top Jr et al., 1971). So far, no significant side effects or illnesses 
related to the use of these vaccines have been reported.  
 
1.7.2.1.2 Virus-like particles 
 Also known as pseudovirus, virus-like particles (VLP) are self-assembling, non-
replicating viral core structures, often from non-enveloped viruses, that are produced 
through recombination in vitro.  VLP are cheap and easily generated, as well as highly 
immunogenic.  In addition, VLP can also be used as carriers or adjuvants for foreign 
antigens expressed recombinantly on the surface of the pseudovirus, and for DNA 
vaccines carried within VLP (Garcea & Gissmann, 2004).  VLP are especially useful 
from a mucosal vaccine point of view as they offer opportunity to use the natural route of 
transmission of the present virus for the delivery of vaccine.  Successful use of VLP has 
been reported from several mucosal viral pathogens including papilomavirus, calicivirus 
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1.7.2.1.3 Bacterial Vector 
 Among the many live bacterial vectors developed, there are two main categories, 
those based on attenuated pathogens and those that use commensally bacteria.  Antigen 
delivery directly to mucosal sites via non-pathogenic commensally bacterial vectors 
could provide a significant advantage over some of the more traditional vaccines in that 
live bacteria are capable of stimulating sustained systemic as well as local immune 
responses (Liljeqvist & Stahl, 1999).  In addition, commensally bacteria are also able to 
colonize the niche invaded by the pathogen and stimulate an immune response at their 
portal of entry to prevent infection.  This ability in combination with the facts that 
bacteria are easily administered, are cost efficient and are well tolerated, makes live 
commensally bacteria attractive vehicles for subunit vaccine delivery (Medina & 
Guzman, 2001).  In addition, the antigens can be tailored to be expressed intracellularly, 
anchored on the cell surface or be secreted into the medium (Reveneau et al., 2002).  
Generally, these expression systems use the conserved pathway that all Gram-positive 
bacteria utilize to export and anchor protein on the cell surface (Medaglini et al., 2001; 
Schneewind et al., 1992).  
One such promising commensally bacterium is the Lactobacillus spp., a normal 
inhabitant of the gastrointestinal tract.  Recombinant Lactobacillus spp. has been 
engineered to produce C fragment of tetanus toxin, Streptococcus pnuemoniae antigens 
and protective antigen of Bacillus anthracis (Shaw et al., 2000; Reveneau et al., 2002; 
Oliveira et al., 2003; Zegers et al., 1999).  Immunization studies using recombinant 
Lactobacillus spp. so far have been rather encouraging. 
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 Similarly, studies have been conducted to test the feasibility of using attenuated 
Salmonella spp. to carry antigenic domains of Hepatitis B virus and TGEV (transmissible 
gastroenteritis coronavirus) (Schodel et al., 1994; Smerdou et al., 1996).  
 
1.7.2.2 Transgenic Plant 
 Transgenic plants have been increasingly utilized for the expression of 
immunogenically relevant antigens since the application was first reported by Mason et 
al. (1992).  Since then, plant transgenics and biotechnology have been used to produce 
proteins with potential human and animal pharmaceutical value (Ma et al., 2003, Sala et 
al., 2003).  This biotechnological strategy has the enormous advantage of not requiring 
fermentation control systems under strict conditions of biosafety and sterility, which 
makes this technology particularly attractive for its simplicity and low cost.  More 
importantly, production of vaccine antigens in plants overcomes the risk of contamination 
with animal pathogens.   
In addition to the utilization of plants as bioreactors for the production of vaccine 
antigens, plants also provide an adequate system for oral delivery of recombinant 
immunogens by including them in the diet.  A number of viral and bacterial antigens 
produced in plants have already demonstrated their immunogenicity when orally 
administered, though the expression level was relatively low.  Among them include 
Escherichia coli heat-labile enterotoxin, cholera toxin B subunit, foot and mouth disease 
virus and rotavirus enterotoxin (Haq et al., 1995; Arakawa et al., 1998; Wigdorovitz et 
al., 1999; Yu & Langridge, 2001).  This approach is particularly relevant for enteric 
pathogens, because oral immunization may be able to elicit appropriate immune 
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mechanisms for the induction of protective responses.  Although this expression system 
constitutes an interesting alternative to conventional methodologies, the main 
disadvantage is the low concentration of the expressed antigen, requiring multiple 




Microencapsulation is a technology by which solid or liquid materials are 
transferred onto spherical particles and protect an antigen from chemical and enzymatic 
degradation in the body.  This technology is especially useful for delivery of vaccines 
like subunit vaccines as subunit antigens alone are usually weak immunogens and require 
adjuvant or carrier system to induce protective immunity (Ellis, 2004).  The use of 
subunit vaccines like antigen-encapsulated microspheres can act to effectively deliver 
specific antigens so as to optimize their immunological response. 
 
1.7.2.3.1 Liposome 
 Liposomes are spherical, self-enclosed structures of varying size consisting of a 
lipid bilayer and an aqueous inner compartment that are generated in vitro (Felnerova et 
al., 2004).  They have enormous versatility with regards to composition, size, 
physicochemical, and immunological characteristics.  The two key problems of 
immunotherapy, biodistribution and targeting, can be addressed at least partially solved 
by the use of liposome formulations.  A liposome can protect the antigen from the 
environment until controlled release occurs at the target site.  The lipid membrane and its 
                                                                                   CHAPTER 1 
                                                                                                         LITERATURE REVIEW 
 28
surface are versatile enough to allow the integration of specific targeting and release 
device.  Molecules such as monoclonal antibodies, ligands for cellular receptors or 
specific peptide sequences can be attached to liposomal surface to provide specific 
binding (Brignole et al., 2003).  However, an unfavourable characteristic of liposomes is 
their potential for unspecific interaction with macromolecules and cellular surfaces, 
resulting in short half-life.  This interaction can be reduced by coating the surface of 
liposome with inert molecules to form a spatial barrier (Allen et al., 2002).  
  
1.7.2.3.2 Virosomes 
 Virosomes are liposomal formulations that involved viral envelope proteins 
anchored in their lipid membrane and offer the same versatility with regard to lipid 
composition as liposome.  Virosomes were not only found suitable as vaccines against 
parental virus, but were further exploited as carrier systems for unrelated vaccine 
antigens.  Additional antigens can be included in virosomal vaccine formulations through 
direct incorporation into membrane, adsorption to the virosomal surface, chemical 
coupling to a hydrophobic anchor (Felnerova et al., 2004).   These virus-like particles 
have proven to be effective immunogens with unique adjuvant properties (Moser et al., 
2003).  The most advanced virosomal systems for targeted delivery and release are the 
immunopotentiating reconstituted influenza virosomes (Moser et al., 2003; Gluck & 
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1.7.2.3.3 Microspheres  
 Microspheres are spherical polymeric particles with diameters of 1 to 1000 μm, 
prepared from various polymers such as poly (ortho-esters), poly (anhydrides), poly 
(phosphazenes), with polyglycolic- (PLG) and polylactic acids and poly (lactic-co-
glycolic acid) (PLGA) being the most promising (Heller, 1985; Leong et al., 1986; 
Lakshmi et al., 2003; Gupta et al., 1998).  Besides acting as an adjuvant by increased 
uptake by antigen presenting cells, they permit sustained release of antigen over time 
(Morris et al., 1994).  Smaller size microspheres (less than 10 μm) are often more 
immunogenic than larger sized ones due to the preferable uptake of smaller microspheres 
by the Membranous epithelial cells (M cells) in the Peyer’s patches of the 
intestine. (Eldridge et al.,1991).  Among biodegradable polymers, PLGA is well 
documented for its safety, being biocompatible and approved for human usage (Frazza & 
Schmitt, 1971).  
 
1.7.3 Route of Vaccination 
Vaccines can be administered either through injection or oral consumption.  A 
major advantage of mucosal administration of vaccine antigens is that both mucosal and 
systemic immune responses are normally induced, while parenteral immunization is 
ineffective for induction of mucosal immunity (Jackson et al., 1993).  There are important 
practical-logistic reasons to try to replace some of the existing injectable vaccines used to 
prevent systemic infections with orally administered vaccines.  Oral vaccines would be 
easier to administer than parenteral vaccines.  They would carry less risk of transmitting 
the type of infections like hepatitis B and HIV infections, which are associated with the 
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use of injectable vaccines in several parts of the world.  Oral vaccines can also be 
expected to have greater acceptability than injectable vaccines by causing no sore arms, 
etc. Oral administration could also lead to simplified manufacturing vaccine, there by 
increasing the potential for local vaccine production in developing countries.  
 
1.7.4 Immunity 
Immune responses to vaccines are influenced by the route of immunization 
(injection or oral), the form of the antigen (live, killed, soluble, peptide subunit, 
particulate, etc.) and the presence in the vaccine of biologically active elements that 
mediate specific tissue tropisms.  There is now substantial evidence supporting the 
existence of at least two immune systems, a peripheral immune system and a mucosal 
immune system (Ogra et al., 1994).  These systems operate separately but simultaneously 
in most species including humans.   Protective immunity acquired during convalescence 
is usually referred to as systemic immunity, which might be a combination of mucosal 
and peripheral immunity or be dominated by an incomplete form of immunity dictated by 
a specific pathogen (Salgame et al., 1991; Mosmann and Sad, 1996).  
The way antigens are acquired by individual lymphatic tissues affects the 
outcome of an immune response.  For example, the same antigen may produce 
qualitatively different immune responses in lymph nodes, spleen or Peyer's patches 
(Anderson et al., 1990).  Generally, the stimulation of the immune system systemically 
either via injection or blood-borne routes result in production of protective antibody 
especially antigen specific IgG and T cells only within the sterile, internal environment of 
the body.  On the other hand, stimulation of the mucosal immune response can result in 
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production of protective B and T cells in both mucosal and systemic environments so that 
infections are aborted before they get systemic into the body (McCluskie & Davis, 1999; 
Ogra et al., 2001).  The nature of serum and secretory immune responses induced after 
immunization by conventional live attenuated or killed vaccines is summarized in Table 
1.2. 
Table 1.2 Nature of immunologic reactivity after systemic or mucosal immunization with 
conventional live or inactivated vaccines.  Adapted from Kiyono et al. (1996). 
  Response to immunization by  
 indicated route and type of vaccine 
 Systemic  Mucosal 
Features of response Live Killed  Live  Killed 
Immunologic response similar to 
natural infection ± -  + - 
Development of systemic immune 
response + +  + ± 
Persistence of systemic immune 
response ± ±  + - 
Development of secretory immune 
response ± ±  + ± 
Persistence of secretory immune 
response ± -  + ± 
Development of secretory 
immunity in other mucosal sites 
and milk 
+ -  + ± 
Protection against mucosal natural 
reinfection ± -  + + 
Protection against systemic disease 
after natural reinfection + +  + ± 
          +, Always; ±, occasional or inconsistent; -, absent. 
 
                                                                                   CHAPTER 1 
                                                                                                         LITERATURE REVIEW 
 32
1.7.4.1 Mucosal Immunity 
Mucous membranes line the gastrointestinal tract, the respiratory tract, and the 
urogenital tract and represent the most important portal of entry for human pathogens.  
The mucosal surfaces are protected from pathogens by non-specific mechanisms such as 
the production of mucus forming a physical barrier, and substances such as lysozyme, 
lactoferri and lactoperoxidase, which kill microorganisms or inhibit their replication 
(Brandtzaeg, 1995).  Specific defense mechanisms at the mucosal site include cellular (T 









Figure 1.1 Current mucosal delivery systems, mucosal inductive sites and the concept of Th1- 
and Th2-type immune responses.  Following uptake in the inductive site, the antigen can 
influence the nature of CD4+ Th cell responses, which in turn regulate cell mediated immunity 
and the isotype of mucosal vesus serum antibody responses.  Adapted from Kiyono et al. (1996). 
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In order to elicit a mucosal antibody response, viral antigens must reach the 
organized mucosa-associated lymphoid tissue, which includes the gut-associated 
lymphoid tissue in the intestine or bronchus-associated lymphoid tissue in the lung.  
Areas that contain clusters of follicles (30 or more) in the submucosal region of the 
intestines are called Peyer's patches, which are organized centers collecting antigen from 
macrophages that migrate from the mucosal area.  The intraluminal surface of Peyer’s 
patches are covered with a follicle-associated epithelium, a one-cell-layer complex 
composed of columnar epithelial cells, globlet cells and M cells (Owen, 1977; Wolf et 
al., 1981).  M cells endocytose antigens from the surface of the mucosa and exocytose 
them to the underlying dendritic and macrophage populations, which express MHC Class 
II molecules.  These immune cells process and present the antigen to CD4+ T cells and 
naive B cells destined to become cytokine producing cells and plasma cells, respectively, 
in mucosal immunity (Owen & Nemanic, 1978; Panja & Mayer, 1994). 
 The adhesion molecule, mucosal addressin cellular adhesion molecule-1 
(MAdCAM-1), is located on the high endothelial venule of Peyer’s patches and regulates 
trafficking of naïve T and B cells into and through the mucosal immune system 
(Brandtzaeg et al., 1999; Berlin et al., 1993).  It is this interaction of T and B cells and 
the balance of cytokines, which controls IgA production for transport and mucosal 
protection.  Transport of IgA through epithelial cells occurs by a receptor-mediated 
process via a polymeric immunoglobulin receptor, which is expressed on the basolateral 
membrane of the cell (Mostov, 1994).  Upon binding to the receptor, the IgA-receptor 
complex is endocytosed and carried to the apical membrane of the cell.  The receptor is 
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then cleaved between its external and intramembranous domains and release the IgA into 
the secretions of the lumen.   
1.7.4.1.1 Secretory IgA 
The principal antibody involved in mucosal immunity is secretory IgA (Russell et 
al., 1997).  IgA is the most abundant immunoglobulin with approximately 75% of the 
antibody-producing cells in the body manufacturing IgA, the majority of which is 
released into the gastrointestinal fluid, saliva, tears, urine and other secretions 
(Brandtzaeg, 1994).  Up to 40 mg/Kg body weight of IgA is manufactured and secreted 
daily in humans, which is many orders of magnitude greater than that of all other 
immunoglobulin isotypes (Brandtzaeg, 1994).  In general, IgA does not mediate strong 
inflammatory responses but favors the principle of immune exclusion rather than 
destroying action (Stokes et al., 1975).  Secretory IgA prevents absorption of pathogens 
or their toxic products at the mucosal epithelium, which allows them to be flushed away 
in the stream of secreted fluids and mucous washing over the epithelial membranes.  In 
addition, IgA may also facilitate transport of pathogens and toxins out of the body by 
causing them to be conveyed into bile and other exocrine secretions (Mazanec et al., 
1993).  Antigen-specific IgA has recently been shown to neutralize viral pathogens 
during transport across M cells of Peyers patches, where non-degradative endosomal 
transport might otherwise deliver a pathogen into the host (Owen and Jones, 1974; Neutra 
and Kraehenbuhl, 1994, Mazanec, 1992).  Secretory IgM and IgG, mainly derived from 
serum, also appear at the mucosal sites, but to a lesser extend (Wagner et al., 1987; Ogra 
et al., 1974).   
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1.7.4.2 Cytokines 
 Cytokines are small-to-medium-sized proteins, or glycoproteins, produced by 
cells in response to a variety of inducing stimuli.  Majority of the cytokines are directly 
mitogenic for their target cells.  They are secreted by their producer cells and are mostly 
directly mitogenic for their target cells (Clemens, 1991a).  Cytokines that are produced 
by or act upon cells of the immune system are known as lymphokines.  Factors 
commonly referred to lymphokines include interferon-γ and the interleukins.  The generic 
name ‘interleukin’ was proposed in 1979 for factors produced and released by activated T 
lymphocytes that act on other lymphocytes to produce biological effects.  In fact, the 
group of interleukins also includes species produced by cells of other hematopoietic 
lineages, such as monocytes.  Interleukins act as intercellular signaling agents between 
lymphocytes.  A brief detail of the biological activities associated with individual 
cytokines is illustrated in table 1.3.  
Table 1.3 Cytokines and biological activities. 
Cytokine     Biological activities 
    
Interferon-α & β        
(IFN-α & β) 
  
All interferons induce antiviral activity in a wide variety of
cell types.  They are multifunctional and pleiotropic
regulators of immune functions. Stimulators of differentiation
in many cells. 
Interferon-γ (IFN-γ) 
  
Antiviral activity.  Factor involved in macrophage activation.
Inducer of class II MHC antigens. Costimulator for
proliferation of B lymphocytes. Enhances IgG2a secretion by
B cells. 
Tumour necrosis factor   
α &  β (TNF α & β) 
  
Multifunctional and pleiotropic stimulators of cellular 
responses.  Inducers of certain cytokines and cell adhesion
molecules.  Regulators of proliferation/differentiation in
lymphocytes and haemopoietic progenitors. 
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Activates T cells. Induces growth factors and inflammatory 
mediators.  Synergises with certain haemopoietic growth
factors.  Highly pleiotropic.  Induces fever. 
Interleukin-2 (IL-2) 
  
Stimulates proliferation of Th cells,
proliferation/differentiation of CTL, and also acts on NK
cells, B cells and macrophages.  Induces other cytokines. 
Interleukin-3 (IL-3) 
  
In combination with lineage-restricted cytokines, stimulates 
early growth of granulocyte, monocyte, erythroid and
megakaryocyte precursor cells.  Also supports mast cell
growth.   
Interleukin-4 (IL-4) 
  
Stimulates or aids proliferation of B cells and mast cells.
Promotes B-cells Ig class switching and induces IgE 
secretion.  Induces class II MHC on B cells and macrophages.
Generation Th2 cell subset from naïve Th0 cell population. 
Interleukin-5 (IL-5) 
  
Induces proliferation and differentiation of eosinophil
progenitors.  Possible differentiation factor for B cells and Ig
class switching (IgA). 
Interleukin-6 (IL-6) 
  
Stimulates terminal differentiaion of B cells.  Enhances Ig
secretion by B cells.  Cofactor for haemopoietic colony 
growth and thymocytes.  Stimulates hepatocytes to produce
acute phase proteins 
Interleukin-7 (IL-7) 
  
Supports growth of immune T and B lymphocytes.
Costimulatory activity on mature T cells 
Interleukin-8 (IL-8) 
  
A member of the chemokine superfamily.  Chemotactic for
neutrophils and T cells.  Activates neutrophils, but not
lymphocytes and monocytes 
Interleukin-9 (IL-9) 
  
Sustains antigen-independent growth of certain Th cells. 
Enhances mast cell proliferative response to IL-2 
Interleukin-10 (IL-10) 
  
Inhibits cytokines synthesis (e.g. IFN-γ) by Th1 cells and 
cytotoxic T lymphocytes.  Suppresses antigen-dependent 
proliferation of Th1 cells.  Enhances B-cell proliferation and 
Ig synthesis. 
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Stimulates cytokines synthesis (e.g. IFN-γ) by T cells and 




Induces proliferation and of activated B cells (but not resting
B cells).  Inhibits Ig secretion by mitogen-stimulated B cells. 
Interleukin-18 (IL-18) 
    
Induce production of IFN-γ by T-cells and enhaces NK cell 
cytotoxicity. 
         Adapted from Meager T. (1998).  
Intestinal epithelial cells (IEC) are known to have an important role in the 
transport of IgA produced by local lamina propria lymphocytes into the external 
secrestions (Brandtzaeg, 1985).  IEC have been shown to produce several immunological 
important cytokines such as IL-6, TGF-β, IL-8 and TNF-α upon stimulation by bacteria, 
bacterial products, or inflammatory cytokines (Panja et al., 1995; Koyama & Podolsky, 
1989; Eckmann et al., 1993; McGee et al., 1995).  This implies that IEC plays an 
important role in the mucosal immune response, where IEC have been suggested to be 
capable of regulating B and T cell response via secreted cytokines (McGee et al., 1995).   
 
1.7.4.2.1 Control of Virus Infections 
 The body combats invading viruses in many ways, including immune and non-
immune pathways, and cytokines are essential to co-ordinate these effects.  In particular, 
sequences upstream of the IFN genes switch on transcription in response to viruses and 
IFNs directly induce a state of resistance to viral replication in a wide variety of target 
cells (Taylor & Grossberg, 1990).  In contrast to IFN-γ which is induced by mitogenic or 
antigenic stimulation of T lymphocytes, IFNα and β can be induced directly by viruses 
                                                                                   CHAPTER 1 
                                                                                                         LITERATURE REVIEW 
 38
following infection of host cells.  Viruses also induce other cytokines, particularly TNFs 
and IL-2, but these cytokines do not induce an anti-viral state in cells.  Production of new 
viral particles in an infected cell requires protein synthesis.  Among the novel proteins 
synthesized by IFN-treated cells are two enzymes that can regulate protein synthesis (De 
Maeyer & De Maeyer-Guignard, 1988).  One of these enzymes, 2’5’-oligoadenylate 
synthetase, uses ATP to synthesize short oligomers of up to 12 adenylate residues, which 
allosterically activate a latent ribonuclease, RNase L, which degrades viral and cellular 
mRNA and ribosomal RNA.  The other enzyme is a phosphokinase, which 
phosphorylates initation factor eIF-2, a protein required for all polypeptide chain 
initation.  Phosphorylated eIF-2 inhibits initiation of viral and cellular protein synthesis 
(Clemens, 1991b).  
 
1.8 CORONAVIRUSES 
Coronaviruses are enveloped and spherical in shape, with a diameter of 120-160 
nm and contain a single molecule of linear, positive sense, single-stranded sRNA.  The 
viral genomic RNA is the largest viral RNA genome known, ranging from 27.6 to 31 kb, 
and functions as an mRNA that is infectious (Figure 1.2).   
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Figure 1.2 Genome organization of SARS coronavirus.  (Adapted from Lio and Goldman, 2004). 
The virions contains approximately 7-10 functional genes, 4 or 5 of which encode 
structural proteins.  Coronavirus contains a large surface glycoprotein (spike), an integral 
membrane protein (M), which is integrated in the virus envelope, a small membrane 
protein (E) and a nucleocapsid protein (N).  The spike protein is large, ranging from 1160 
to 1452 amino acids, and in some coronaviruses, is cleaved into S1 and S2 subunits.  The 
spike protein, a glycoprotein with a globular and stem region, is responsible for 
attachment to cells, hemagglutination, membrane fusion, and induction of neutralizing 
antibodies.  In some coronaviruses such as murine hepatitis virus (MHV), a second layer 
of peplomers formed by the hemagglutinin esterase (HE) has also been observed.  The M 
protein contains 225-260 amino acids and is the main inducer of α-interferon.  Together 
with the E protein (80-109 amino acids), the M protein plays an essential role in 
coronavirus particle assembly.  The N protein (377-455 amino acids), on the other hand, 
is a highly basic phosphoprotein that modulates viral RNA synthesis, binds to the viral 
RNA and forms a helical nucleocapsid (Figure 1.3).  
                                                                                   CHAPTER 1 








Figure 1.3 Arrangement of the structural proteins and viral RNA within an infectious virus 
particle of the coronavirus. (Adapted from Holmes, 2003.)  
Coronaviruses, with a relatively restricted host ranges infects birds and a number 
of mammals, including humans via respiratory, fecal-oral and mechanical transmission.  
They exhibit a marked tropism for epithelial cells of the respiratory and enteric tracts, but 
other organs including liver, kidney, heart and eyes can be affected too.  These viruses 
can be divided into three antigenic groups according to serotypes.  Group I and group II 
contain mammalian viruses.  The porcine transmissible gastroenteritis virus, canine and 
feline coronavirus, and feline infectious peritonitis virus constitute Group I; porcine 
hemagglutinating encephalomyelitis virus and bovine coronavirus make up Group II that 
contain a hemagglutinin esterase gene homologous to that of Influenza C virus (Lai & 
Holmes, 2001).  Coronavirus of group I use the aminopeptidase N as receptor for cell 
entry while those of group II use receptors members of the biliary glycoprotein subfamily 
of the carcinoembryonic antigen family (Yokomori & Lai, 1992; Tresnan et al., 1996).  
Group III contains only avian viruses, which includes infectious bronchitis virus and 
turkey coronavirus. 
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1.8.1 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS  
Severe acute respiratory syndrome (SARS), also called atypical pneumonia, is a 
human severe respiratory infectious disease that emerges recently in Asia, North America 
and Europe.  SARS is characterized by severe pulmonary infection with a high degree of 
transmissibility and mortality (Chan-Yeung and Yu, 2003; Lew et al., 2003; Riley et al., 
2003).  First evident in Guangdong province of China around November 2002, SARS 
quickly became a global outbreak, affecting more 35 countries and regions in the world 
across five continents.  By the end of June 2003, there were 8,450 cases and 810 deaths 
(www.cdc.gov/mmwr/mguide_sars.html), with an estimated mortality rates of 13.2 % for 
patients younger than 60 years and 43.3 % for patients aged 60 years or older (Donnelly 
et al., 2003).  
A novel virus, named as SARS coronavirus (SARS-CoV), was identified as the 
etiological agent and was subsequently confirmed by fulfillment of Koch’s postulates 
(Peiris et al., 2003; Ksiazek et al., 2003; Drosten et al., 2003; Fouchier et al., 2003).   
Like other coronaviruses, SARS-CoV is a single stranded, positive-sense RNA virus with 
a genome of approximately 29,727 nucleotides and is organized into 13 to 15 open 
reading frames (ORFs) (Groneberg et al., 2005; Rota et al., 2003; Thiel et al., 2003).  
The virion is 80-140 nm in diameter, consisting of a nucleocapsid (N) core surrounded by 
an envelope containing three membrane proteins, spike (S), membrane (M) and envelope 
(E), with 20-40 nm complex surface projections surrounding the periphery (Rota et al., 
2003; Ksiazek et al., 2003).  S protein is thought to be involved with receptor binding, E 
protein plays a role in viral assembly, M is important for budding, and N protein is 
associated with viral RNA packaging (Holmes, 2003).  Phylogenetic analysis of the 
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SARS-CoV has demonstrated that this new pathogen is distinct from the three known 
serological groups of coronaviruses (Drosten et al., 2003; Ksiazek et al., 2003).  
However, in a recent study of the replicase gene, SARS-CoV was classified as an early 
split-off of group 2 coronaviruses, which includes human HCV-OC43, mouse hepatitis 
virus and bovine coronavirus (Snijder et al., 2003).  This was further supported by the 
conserved cysteine distribution pattern of the major surface spike glycoprotein 
(Eickmann et al., 2003).  Despite the evolutionary overlap between SARS-CoV and 
Group II coronavirus genome sequences, the SARS genome lacks a gene for 
hemagglutinin-esterase (HE) protein, which is common to a majority of Group II 
coronaviruses (Groneberg et al., 2005). 
The putative natural reservoir of SARS-CoV has been reported to be the 
Himalayan or masked palm civet, Paguma larvata (order Carnivora, family Viverridae).  
However, additional virological and serological evidence suggests that raccoon dog and 
Chinese ferret badger (order Carnivora, families Canidae and Mustelidae, respectively) 
may also be naturally infected with SARS-CoV (Guan et al., 2003).  As the SARS-CoV 
polymerase gene has a recombination breakpoint, suggesting multiple genetic origins for 
this molecule, these evolutionary mechanisms may have facilitated the adaptation of the 
animal-borne SARS-CoV ancestor to the human host (Rest & Mindell, 2003).  The 
modes of SARS-CoV transmission include shedding of the virus from respiratory tract 
via droplets, close contact, and formites.  The incubation period of SARS ranges from 2 
to 26 days, with a mean incubation of 6.4 days (Chan-Yeung & Xu, 2003; Yu, 2004).     
Unlike the known human HCoV-299E and OC43, which infect the upper 
respiratory tract and cause common cold, the new SARS-CoV predominantly causes 
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infection in the lower respiratory tract, causing lung lesions with high morbidity and 
mortality (Lee et al., 2003; Tsang et al., 2003).  Infection is usually characterized by 
high-grade fever and chills, myalgia, headache, subsequently by a dry non-producive 
cough and shortness of breath, loss of appetite and dyspnea, and may progress to 
generalized interstitial infiltrates in the lung (Booth et al., 2003; Hui et al., 2003).  
Gastrointestinal involvement is also common, with more than 20% of patients presenting 
with watery diarrhea (Leung et al., 2003). 
 
1.8.1.1 SARS-CoV Spike Protein 
The S glycoprotein of SARS-CoV, a 1,255-amino-acid type I integral membrane 
glycoprotein, is the prominent protein present in the viral membrane and present as the 
typical spike structure found on the viral surface.  The S glycoprotein consists of a leader 
(amino acid 1 to 14), an ectodomain (amino acid 15 to 1190), a membrane-spanning 
domain (amino acid 1191 to 1227), and a short intracellular tail (amino acid 1227 to 
1255) (Rota et al., 2003).  Sequences analysis of SARS-CoV revealed that the full-length 
S protein has 23 potential N-linked glycosylation sites, and the glycoslation of this 
surface protein is a high-mannose structure (Rota et al., 2003; Krokhin et al., 2003).  
Unlike many other coronaviruses, such as mouse hepatitis virus (MHV) in which 
the S protein is post-translationally cleaved into S1 and S2 subunit, no typical cleavage 
motif has been identified in the SARS-CoV S protein (Frana et al., 1985; Luytjes et al., 
1987; Rota et al., 2003).  Nonetheless, its S1 and S2 domains were predicted by sequence 
alignment with other coronavirus S proteins (Spiga et al., 2003; Rota et al., 2003).  
Because S protein is not cleaved, defining the exact location of the boundary between S1 
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and S2 is difficult; presumably it is somewhere between residues around 672 and 758 
(Xiao et al., 2003; Li et al., 2003).  S1 forms the bulbous globular head and is responsible 
for cell attachment.  Its amino acid sequence is less conserved than S2, which forms the 
membrane-anchored stalk region and is responsible for membrane fusion (Duquerroy et 
al., 2005).  The S1 domain (residues 12-672) of SARS-CoV S protein mediates virus 
binding with angiotensin-converting enzyme 2 (ACE2), a metallopeptidase that has been 
identified as a functional receptor for SARS-CoV (Li et al., 2003; Prabakaran et al., 
2004).  The S2 domain (residues 681-1255), which contains a putative fusion peptide and 
two heptad repeat (HR1 and HR2) regions, is responsible for fusion between viral and 
target cellular membranes (Spiga et al., 2003; Rota et al., 2003).  
Mapping of the receptor-binding domain have been ongoing.  In particular, 
Babcock et al. (2004) have determined that the first 510 amino acids of the SARS-CoV S 
glycoprotein contain the entire ligand-binding domain.  Amino-terminal truncation of the 
first 510 residues of S protein further demonstrated that amino acids 270 to 510 contain 
the minimal receptor-binding domain of the SARS-CoV S glycoprotein.  It was also 
found that independently folded fragments as short as 193 residues can specifically bind 
receptor molecules (Babcock et al., 2004).   
 
1.8.1.2 Immunogenicity 
Besides mediating the initial stages of viral entry, the S protein of SARS-CoV is 
also known to be responsible for inducing host immune responses and virus 
neutralization by antibodies (Buchholz et al., 2004).  Recent studies have shown that S 
protein is one of the major antigens eliciting immune responses during infection where 
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sera from convalescent SARS patients also neutralized the virus (Hofmann et al., 2004; 
Lu et al., 2004; He et al., 2004).  The entry of SARS-CoV into cells can also be inhibited, 
when the antibodies specific for S protein compete with ACE2 for binding to the S 
glycoprotein, thus preventing virus-receptor interaction (Sui et al., 2004). 
Several candidate vaccines such as DNA and vaccinia virus-based vaccines that 
express full-length S protein or soluble fragments including the whole ectodomain and 
fragments containing the receptor-binding domain induced SARS-CoV-specific 
neutralizing antibodies and protective immunity against SARS-CoV challenge (Gao et 
al., 2003; Yang et al., 2004; Bisht et al., 2004).  These reports highlight the potential for 
developing peptide-based vaccine candidate if neutralizing epitopes of S could be 
identified. 
 
1.8.2 TRANSMISSIBLE GASTROENTERITIS CORONAVIRUS 
First isolated in 1946, Transmissible gastroenteritis coronavirus (TGEV), a 
member of the genus Coronavirus, family Coronaviridae, order Nidovirales, is an 
enteropathogenic coronavirus that causes a highly contagious enteric disease in swine of 
all ages (Doyle & Hutchings, 1946; Cavanagh, 1997).  Within this family, TGEV forms 
an antigenic cluster with feline infectious peritonitis virus, feline enteric coronavirus, 
canine coronavirus and porcine respiratory coronavirus (Sanchez et al., 1990).  The first 
clinical signs of TGEV in pigs are a roughening of the haircoat, shivering, vomiting and 
extreme thrist.  This is followed by a severe, watery diarrhea that has a very putrid, 
characteristic odor, where the pigs will become dehydrated, weak and die within 2 to 5 
days (NebGuide).  While older animals generally recover, the mortality rate in piglets 
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under the age of 2 weeks old approaches 100% (Siddell et al., 1983; Saif & Wesley, 
1992).  The enzootic form of the disease is becoming a major problem in swine nurseries 
(Saif & Wesley, 1999).  It has been estimated to cost US pig producers about 100 million 
dollars annually due to death or poor growth of infected pigs (Wesley & Woods, 2001).   
The viral genome consists of a single-stranded, positive-sense 28.5 kb RNA and is 
constructed of three major structural proteins: a phosphorylated nucleoprotein (N protein) 
and two glycoproteins, the membrane (M) and the spike (S) protein with 382, 262 and 
1431 amino acids respectively (Saif & Wedley, 1982; Kapke & Brian, 1986; Laude et al., 
1987; Rasschaert & Laude, 1987).  The S protein has a membrane-anchoring domain and 
is highly glycosylated.  It is also thought to be the viral attachment protein which 
interacts with the cell receptor, porcine aminopeptidase N (APN) (Schultze et al., 1996; 
Krempl et al., 1997). As the major inducer of TGEV-neutralizing antibodies, the S 
protein has been used mainly for the induction of protective immunity to TGEV (Delmas 
et al., 1986; Jim´enez et al., 1986; Laude et al., 1992).  
Passive immunity is of primary importance in providing neonatal piglets with 
immediate protection against TGEV infection (Saif & Wesley, 1992).  The protection of 
suckling piglets against TGEV infection is based on the uptake of specific lactogenic 
antibodies, mainly of the IgA class, in the milk of the TGEV immune sows.  The 
induction of lactogenic immunity can be stimulated by presentation of selected antigens 
to the immune system in gut associated lymphoid tissues (Wesley et al., 1988; 
Montgomery et al., 1974). 
 
 
                                                                                   CHAPTER 1 
                                                                                                         LITERATURE REVIEW 
 47
1.8.2.1 TGEV Spike Protein 
The S protein is 1431 residues long, highly glycosylated, with a membrane-
anchoring domain near its carboxy-terminus and a globular domain assumed to 
correspond to its amino-terminal half (Rasschaert & Laude, 1987).   
The surface S protein initiates the infection by binding to the cell surface and also 
mediates the subsequent fusion between the viral and cellular membranes.  The S protein 
has two binding activities.  Binding to aminopeptidase N has been reported to occur 
between residues 522 and 744, and is required for the initiation of infection (Godet et al, 
1994; Delmas et al., 1992).  Aminopeptidase N is an ectoenzyme abundantly expressed at 
the apical membrane of the enterocytes and serves as a receptor for TGEV.   In addition, 
S protein has a salic acid binding activity which enables TGEV to recognize terminal 
salic acid residues on glycoproteins and glycolipids, allowing TGEV to agglutinate 
erythrocytes (Schultze et al., 1996).  Studies with mutants of TGEV indicated that 
residues with a short stretch of amino acid (145 to 209) are important for recognition of 
salic acids (Krempl et al., 1997; Krepml et al., 2000), where point mutations of the 
residues resulted in the loss of both the hemagglutinating activity and enteropathogenicity 
(Krempl et al., 1997).   
Neutralizing antibodies against the virus are directed mainly to the S glycoprotein, 
and relevant epitopes in neutralization have been mapped into the N-terminal domain of 
this protein (Garwes et al., 1978; Jim’enez et al., 1986; Correa et al., 1988).  In this 
protein, four antigenic sites (A, residues 538-591; B, residues 97-144; C, residues 49-52 
and D, residues 378-395) have been defined by mutual competition of monoclonal 
antibodies (Correa et al., 1988; Delmas et al., 1986; Gebauer et al., 1991).  Epitopes 
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critical for neutralization were found to cluster in the immunodominant A, and D sites, 
and to a minor extend site B (Delmas et al., 1986; Jim’enez et al., 1986).  Sites A, B and 
D have been found to be highly conserved among TGEV strains, whereas antigenic 
variation was observed on site C epitope (Enjuanes et al., 1992).  Site A and B have been 
demonstrated to be conformational and glycosylation dependent, while sites C and D are 
continuous and glycosylation independent, although a small effect of glycosylation has 
been observed in site D (Correa et al., 1988; Correa et al., 1990; Posthumus et al., 1990a; 
Posthumus et al., 1990b; Gebauer et al., 1991).  Site A being the major inducer of 
neutralizing antibodies has been divided into three antigenic subsites: Aa, Ab and Ac, 
with subset Ab being the most antigenic (Correa et al., 1988; De Diego M et al., 1992).   
 
1.8.2.2 Vaccines Developed Against TGEV 
To date, genetically engineered and attenuated agents have been utilized for the 
development of vaccines against TGEV.  The ability of Salmonella typhimurium to 
colonize the intestinal tract has prompted the development of Salmonella typhimurium as 
a bivalent vector to induce an immune response against both Salmonella and TGEV 
(Smerdou et al., 1996).  When attenuated Salmonella vaccine constructs expressing 
TGEV S protein were orally fed to mice, TGEV-neutralizing antibodies was detected in a 
significant number of immunized animals (Chen & Schifferli, 2003).   
In addition, transgenic plants expressing the S protein were also created.  Extracts 
from potato tubers or arabidopsis expressing the N-terminal domain of the S glycoprotein 
that were inoculated intraperitoneally or orally to mice developed serum IgG specific for 
TGEV (Gomez et al., 2000, Gomez et al., 1998). Antigens from transgenic tobacco 
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plants also induced TGEV-specific immune responses in pigs as determined by virus 
neutralization and ELISA (Tuboly et al., 2000).   
Recombinant adenoviruses and baculoviruses expressing either fragments or the 
full-length TGEV S protein were used to study the induction of antibodies in hamster and 
swine.  In particular, Torres et al. has constructed ten adenovirus recombinants 
expressing either full length or truncated amino-terminal fragments of the S protein 
(Torres et al., 1995).  These recombinants induced immune responses in both hamsters 
and swine, which neutralized infectivity, though higher titers of antibodies was induced 




Development of less invasive and more readily administered vaccines has become 
a priority for public health agencies, and new vaccine formulation and delivery 
technologies have emerged.  There is great interest in the use of mucosal membranes for 
noninvasive vaccine administration, especially when the mucosal surfaces of the 
gastrointestinal and respiratory tracts represent the principal portals of entry for most 
pathogens.  However, most vaccines licensed for use in humans and animals are injected 
intramuscularly or subcutaneously.  The mucosal immune responses induced by 
parenteral immunization are generally weaker, are more variable, and last for a briefer 
time than do mucosally induced responses (McGhee et al., 1992; Liu et al., 1998; Kaul et 
al., 1998; McCluskie et al., 2002; Goonetilleke et al., 2003).  As such, the focus of this 
study is to determine the feasibility of using bacteria and yeast as vectors for the delivery 
of coronavirus antigens via the intragastric route. 
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Hence, the specific objectives of this study are as follow: 
a) To analyze the adhesion capabilities of Lactobacillus casei Shirota, Saccharomyces 
boulardii, Saccharomyces cerevisiae and Pichia pastoris on mucosal surfaces. 
b) To select one of the yeasts for development into an oral vaccine carrier. 
c) To engineer L.casei Shirota and the selected yeast to express an antigenic fragment of 
Transmissible Gastroenteritis coronavirus spike protein. 
d) To conduct immunization studies and compare the efficacy of using prokaryotic and 
eukaryotic vectors for oral delivery of the coronavirus antigen. 
e) To generate oral vaccine for Severe Acute Respiratory Syndrome coronavirus using 
the suitable vector (Lactobacillus spp. or yeast). 
 
                                                                                   CHAPTER 2 
                                                                                                              MATERIALS & METHODS 
 51
2.0 MATERIALS AND METHODS 
2.1 ADHESION STUDIES 
2.1.1 Bacteria and Yeast Strains 
The bacteria and yeast used in this study are given in Table 2.1.  Lactobacillus 
casei Shirota was cultured in MRS medium (Merck, Germany) at 37 oC with 5 % CO2.  
Saccharomyces boulardii, Saccharomyces cerevisiae and Pichia Pastoris GS115 were 
cultured in Yeast Extract Peptone Dextrose medium [(YPD) (Appendix 1)] at 30 oC with 
shaking at 200 rpm.  
Table 2.1 Bacterial and yeast strains used in adhesion study.      
Strain Abbreviations Characteristics  Source 
Lactobacillus casei 
Shirota 





S.boulardii Probiotic yeast consumed 







S.cerevisiae Baker’s yeast used to 
ferment dough when 
baking bread. 










2.1.2 Adhesion Studies in Vivo 
2.1.2.1 Preparation of Fluorogenic dye 
Five-(and 6-) carboxyfluorescein diacetate succinimidyl ester [(cFDA-SE) 
(Molecular Probes, USA)] is a non-fluorescent membrane-permeable ester which non-
specific prokaryotic and eukaryotic intracellular esterases convert to a fluorescent 
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derivative, that is in turn covalently linked to intracellular proteins via the probe’s 
succinimidyl group (Weston & Parish, 1990).  cFDA-SE was prepared as previously 
described by Logan and co-workers (1998), with slight modifications.  In brief, a 3.6 mM 
stock solution of cFDA-SE was prepared by first dissolving in 20 μl of di-methyl-
sulphoxide [(DMSO) (Merck, Germany)] and further diluting in 1ml of reagent grade 
ethanol.  This was then filter-sterilized with 0.2 μm Acrodisc (Gelman, USA) before 
being aliquoted and stored at –20oC.   
 
2.1.2.2 Labeling of Lactobacillus spp. and Yeast with Fluorescent Probe   
Overnight culture of Lactobacillus spp. or yeast were inoculated into fresh broth 
(Appendix 1) and incubated at the appropriate temperature (37 oC for Lactobacillus spp. 
and 30 oC yeast.  The log-phase cultures were centrifuged at 3000 x g for 10 min, 
whereafter the pellet was washed twice in sterile PBS (Appendix 5).  The pellet were then 
adjusted to give a cell concentration of 1010 CFU ml-1 prior to labeling with 50 μM 
cFDA-SE at 37 oC with shaking for 20 min.  Pelleting the cells and washing twice in PBS 
to remove excess cFDA-SE terminated fluorescent labeling.  Labeled LcS and yeast were 
resuspended in PBS (Appendix 5) to the desired concentration and viewed under 
conventional optical-fluorescence microscope (Olympus 1X81, Japan) with excitation 
wavelength of 480 nm and emission wavelength of 518 nm to check for labeling.  The 
labeled organisms were also inoculated into fresh culture media and allowed to replicate 
for a few generations where the median fluorescence intensities were determined via flow 
cytometric analysis (Section 2.1.2.4) before proceeding further. 
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2.1.2.3 Feeding of Mice with Labeled LcS or Yeast 
Seven-week-old female BALB/c mice were obtained from the Laboratory 
Animals Centre, National University of Singapore, and maintained at the University’s 
Animal Holding Unit of the Department of Microbiology. The mice had free access to 
standard mouse diet and water.  For each of the microorganisms investigated, a group of 
15 mice had been orally dosed with approximately 109 cFDA-SE labeled LcS, 
S.boulardii, S.cerevisiae or P.pastoris by orogastric intubation.  Another group of 12 
mice that have been orally fed with sterile PBS served as control.  The food and water 
intake of the experimental and control batches were measured daily.  In addition, the 
daily faeces production was measured and collected for mucin extraction.   Groups of 
three mice were sacrificed on days 1, 2, 3, 4 and 6 post-dosing by CO2 asphyxiation.  The 
duodenum, jejunum, ileum and colon were removed from each animal and individual 
sections were cut longitudinally.  Any visible residual food particles or faecal material 
were removed.  For determination of the intestinal water volume (IV), each intestinal part 
was gently blotted dry (i.e. until no visible water mark remained on the filter) using pre-
weighed filter paper (90 nm Dia, Whatman®, UK), and the increase in the weight of the 
paper being taken as the IV of the respective intestinal portion.  The various intestinal 
parts were then examined for the presence of adhering cFDA-SE labeled LcS.  This was 
accomplished by adding 150 μl of PBS to every 1.0 cm of tissue and dislodging microbes 
from the mucosal surface of the tissues with the aid of a plunger from a syringe (1.0 ml, 
Terumo®, Japan).  Cell extracts were fixed with formaldehyde  (final vol = 0.75 % v/v) 
and filtered using SEFAR NITEX 60 μm polyester mesh filter (SEFAR, USA) to remove 
intestinal cells present in the intestinal extract prior to flow cytometric analysis. 
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2.1.2.4 Flow cytometric analysis   
Enumeration of cFDA-SE-stained LcS, S.boulardii, S.cerevisiae or P.pastoris 
yeast from cell extracts were performed on a Coulter EPICS® ELITE flow sorter (Miami, 
USA) at an excitation wavelength of 488 nm using a 15 mW Argon laser with a 75 mm 
sort sense flow cell at 82.7 kPa sheath pressure.  Upon excitation at the wavelength of 
488 nm in the flow cytometer, cFDA-SE gives a maximal emission signal in green at the 
wavelength of 518 nm.  Data were recorded in the FCS2.0 file format using Coulter Epics 
Elite (ver 4.01) software, then analyzed and converted into plots using WinMDI (ver 2.8) 
software (J.Trotter, Scripps Research Inst., La Jolla, CA, USA).  The sample volume was 
estimated from the counts of the reference glass beads included in the sample. 
 
2.1.2.5 Mucus extraction from fecal material 
Mucus was isolated from murine feces by extraction and dual ethanol 
precipitation with modification from Miller and Hoskins (1981).  In short, fecal samples 
collected daily were diluted 4 times in PBS containing protease inhibitors (1mM 
phenylmethysulfonyl fluoride, 2 mM iodoacetamide and 10 mM EDTA), and slowly 
stirred for 1 hr at 4 oC.  The suspension was centrifuged at 15, 000 x g at 4 oC for 30 min 
and the supernatant collected.  Absolute ethanol was added to the supernatant to a final 
concentration of 70 %.  This was then centrifuged at 10, 000 x g at 4 oC for 30 min and 
the precipitate were collected.  The pellet was dissolved in milli-Q water and again 
precipitated with ethanol (70 % v/v) whereafter the extracted mucus was lyophilised.  
The dry weight of the mucus was then measured and the amount of mucus in the feces 
was calculated.   
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2.1.3 Adhesion Studies In Vitro 
Fifty milliliters overnight culture of LcS, S.boulardii, S.cerevisiae or P.pastoris 
were centrifuged at 5000 x g for 8 min and washed once with sterile PBS.  The pellet was 
resuspended in sterile PBS and 109 cfu of LcS, S.boulardii, S.cerevisiae or P.pastoris was 
added to confluent HT-29 or Caco-2 cells grown on coverslips (Section 2.12.5).  The 
bacteria or yeast and cell mixture was incubated at 37 oC with 5 % CO2 for 1 hr to allow 
adhesion to take place.  The culture media was then removed and the coverslips were 
gently rinsed twice with 1.5 ml PBS (Appendix 5), after which the coverslips were fixed 
and processed for viewing by scanning electron microscopy (Section 2.14). 
 
2.2 MOLECULAR CLONING TECHNIQUES 
2.2.1 Bacterial and Yeast Strains 
The bacteria and yeast used in this study are given in Table 2.2.  Escherichia coli 
TOP10, DH10β and JM105 were culture in Luria Bertani [(LB) (Appendix 1)] broth at 37 
oC with shaking at 200 rpm, while LcS was cultured in MRS medium (Merck, Germany) 
at 37 oC with 5 % CO2.  P.pastoris was cultured in Yeast Extract Peptone Dextrose 
medium [(YPD) (Appendix 1)] at 30 oC with shaking. Recombinant E.coli, LcS or 
P.pastoris harboring plasmids with antibiotic resistant genes were grown in the respective 
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Table 2.2 Bacteria and yeast strains used in the study.      
Strain Abbreviation Characteristics  Source 
One Shot® TOP10 
Escherichia coli 
F- mcrA (mrr-hsdRMS-
mcrBC) 80lacZ M15 
lacX74 recA1 ara 139 (ara-
leu)7697 galU galK rpsL 
(StrR) endA1 nupG 
TOP10 Ampicillin sensitive 








DH10β Escherichia coli 
F- mcrA (mrr-hsdRMS-
mcrBC) 80lacZ M15 
lacX74 recA1 endA1 ara
139 (ara-leu)7697 galU 
galK λ-rpsL (StrR) nupG 
DH10β Ampicillin sensitive 
(Amps); bacterial host 
for pLP500 and 
construction of clones 




JM105 Escherichia coli 
F' traD36 proA+ proB+ lacIq 
delta(lacZ)M15 delta(pro-lac) 
hsdR4 sbcB15 rpsL thi endA1 
lambda- 
JM105 Ampicillin sensitive 
(Amps); bacterial host 
for pGEX-4T-3 
clones of TGEV 
spike gene fragment 
ATCC, USA 




expression host and 
oral vaccine delivery 






Pichia pastoris GS115     
his4-  
 
P.pastoris Zeocin sensitive 
(ZeoS); expression 
host and oral vaccine 
delivery vehicle of 
TGEV Spike protein 
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2.2.2 Cloning and Expression Vectors 
The following table (Table 2.3) shows the list of cloning and expression vectors 
that were used in this study.   
Table 2.3 Molecular vectors and related information. 
 
 
Zeor : Zeocin resistance gene; Kanr : Kanamycin resistance gene; Ampr : Ampicillin 
resistance gene; Eryr : Erythromycin resistance gene. 
 
pCR®-XL-TOPO® is a TA cloning vector that not only enable fast and efficient 
cloning of Taq-amplified PCR products, but also facilitates subsequent cloning of the 
Plasmid Purpose Source 
pCR®-XL-TOPO® 
Shuttle vector to facilitate 
cloning DNA fragment into 
Lactobacillus expression 





vector for heterologous 
protein expression under 
control of constitutive 
lactate dehygrogenase (ldh) 









P.pastoris expression vector 
for recombinant protein 
expression under control of 
constitutive GAP promoter. 





fusion vectors under the 
control of tac promoter 
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gene of interest into the desired expression vector.  The restriction map and complete 
sequence is shown in Appendix 2. 
pLP500 which mediates the expression and secretion of foreign protein under the 
control of the constitutive lactate dehygrogenase (ldh) promoter, was kindly given by 
Prof. Pouwels PH of TNO-Nutrition and Food Research Institute, Netherlands.  A very 
useful feature of pLP500 is that the plasmid is able to replicate not only in Lactobacillus 
spp., but also in some strains of E.coli.  All elements needed for these specific functions, 
promoter, ribosome binding region, translation initiation sequences, secretion signal 
sequence and terminal sequence, are separated by unique restriction sites, facilitating the 
use of these plasmids in the directed expression of cloned genes.  Immediately 
downstream from the translation initiation region, a multiple cloning sites sequence 
harboring a few unique restriction sites was introduced to allow cloning of heterologous 
gene sequences.  The restriction map and complete sequence of pLP500 is shown in 
Appendix 2. 
pGAPZαC uses the GAP promoter of glyceraldehyde-3phosphate dehydrogenase 
(GADPH) to constitutively express recombinant protein in P.pastoris.  Recombinant 
proteins can be expressed as fusions to the N-terminal peptide encoding the 
Saccharomyces cerevisiae α-factor secreting signal for constitutive and secretable 
expression of protein of interest. The restriction map and complete sequence of pLP500 is 
shown in Appendix 2. 
pGEX-4T-3 is a Glutathione S-transferase (GST) fusion vector that allows protein 
of interest to be tagged with GST for easy purification.  The restriction map and complete 
sequence is shown in Appendix 2. 
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2.2.3 Restriction Digestion of DNA 
 Enzymes from New England Biolabx Inc. (USA) were used for the enzymatic 
digestion of inserts or plasmids in buffers and conditions as specified by the 
manufacturer.  In general, an appropriate amount of DNA and the corresponding 10x 
restriction buffer were dispensed into microcentrifuge tubes and made up to the correct 
volume with double glass distilled water [(dgd) (Megapure, Corning, USA)].  A ratio of 
2-4 units of restriction endonuclease per µg of substrate DNA was employed, thereafter 
the contents were mixed by flicking the reaction tube and incubated at 37 ºC for 2 hr.  
The total enzyme added must not exceed one tenth of the total volume, as the enzyme 
preparations used in this study contained 50 % glycerol, which in excess affect the 
activities of the enzymes.  The digestion results were interpreted by running the digestion 
mix on agarose gel.  
 
2.2.4 Ligation and Transformation 
 One unit of T4 DNA ligase (New England Biolabs, USA) was used in a total 
reaction volume of 20 µl.  The DNA concentration in the ligation mix was about 70-80 
µg/ml and the vector:insert ratio was 1:2.  Both vector and the insert were cleaved with 
the same set of restriction endonucleases to generate complementary sticky ends to 
facilitate ligation.  The reaction was carried out at 16 ºC for at least 2 hr in 1x T4 DNA 
ligase reaction buffer.  The ligation mixture was used directly to transform competent 
E.coli cells.  The ligated vector (10 µl) was added to 50 µl of E.coli competent cells and 
incubated on ice for 30 min.  The cells were the heat-shock at 42 ºC for 1 min, after 
which the transformation mixture was returned immediately onto ice for 2 min.  For the 
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recovery of the transformed cells, 1 ml of LB broth (Appendix 1) was added to the cells 
and incubated at 37 ºC with shaking (200 rpm) for 1 hr.  The cells were the plated on pre-
warmed LB agar plate (Appendix 1) with the appropriate selective marker and incubated 
overnight at 37 ºC for the selection of clones.  
 
2.2.5  Agarose Gel Electrophoresis 
To prepare a 1.0 % agarose gel, 1.0 g of agarose (Sigma, USA) was mixed with 
100 ml of 1x TBE buffer (Appendix 2) in a 250 ml conical flask and heated in a 
microwave to dissolve the agarose.  After cooling to about 45 ºC, ethidium bromide 
[(EtBr)(1μg/ml)(Sigma, USA)] was added and mixed, after which the agarose-EtBr 
mixture was poured into a gel tray assembled within a gel box on a leveled platform and 
the comb placed into position.  The gel was allowed to set at room temperature for         
30 min.  The solidified gel was then submerged in the Bio-Rad Wide Mini-sub Cell GC 
tank filled with 1x TBE buffer (Appendix 2).  Ten to twenty µl of DNA samples were 
mixed with gel loading buffer (Appendix 2) before loading into the wells.  Ten μl of 1 kb 
or 100 bp DNA ladder (New England Biolabs, USA; Promega, USA) was also loaded as 
a relative molecular size reference.  The sample was then electrophorized at 120 Volts for 
30 min.  The DNA bands were then visualized and photographed under UV trans-
illuminator using ChemiGenius2 Bio imaging system (Syngene, UK).  
 
2.2.6 DNA Purification from Agarose Gel  
DNA electrophoretically separated on agarose gel was extracted using QIAquick 
II Gel Extraction Kit (Qiagen, Germany) accordingly to the manufacturer’s protocol.  
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Briefly, the DNA band of interest was excised from the gel using a clean scalpel and 
placed into a sterile eppendorf tube where 10 μl of Capture Buffer was added for every 
10 mg of gel slice.  The tube was vortexed vigorously and incubated at 60 oC until the gel 
was completely dissolved (~10 min).  The dissolved sample was transferred to the 
QIAquick spin column placed in a collection tube, which was incubated at room 
temperature for 1 min.  After incubation, the sample was centrifuged at 15, 000 x g for 30 
sec.  The flow-through was discarded and 500 μl of Wash Buffer was added.  The 
column was then centrifuged at 15, 000 x g for 30 sec and the spin column was 
transferred to a sterile 1.5 ml eppendorf tube.  For the elution of DNA, 50 μl of nuclease 
free water was added directly to the top of the glass fiber matrix in the spin column, and 
incubated at room temperature for 1 min.   The purified DNA was recovered by 
centrifugation at 15, 000 x g for 1 min, and stored at -20 ºC. 
 
2.2.7  Plasmid Isolation and Purification 
Well-defined colonies were picked from the culture plate and inoculated into 5 ml 
of LB broth (Appendix 1) containing appropriate concentration of antibiotic (100 μg/ml 
of ampicillin or 50 μg/ml of kanamycin) in sterile 15 ml tubes.  The tubes were incubated 
at 37 °C with shaking at 200 rpm overnight.  The plasmids were then isolated following 
the procedures of the Wizard® Plus SV Miniprep DNA Purification System (Promega, 
USA). 
Briefly, the cells were harvested by centrifugation at 8000 x g for 5 min and the 
pellet was resuspended in 250 μl of Cell Resuspension Solution and transferred to a 
sterile eppendorf tube.  The cells were first lysed with 250 μl of Cell Lysis Solution, and 
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10 μl of Alkaline Protease Solution was added to inactivate endonucleases and other 
proteins released by the lysed cells.  The reaction mixture was then neutralized with 350 
μl of Wizard® Plus SV Neutralization Solution and was centrifuged at 8000 x g.  The 
cleared lysate was transferred to a Spin Column, and washed twice with 750 μl and 250 
μl of Column Wash Solution previously diluted with 95 % ethanol (Merck, Germany).   
The spin column was then transferred to a sterile 1.5 ml eppendorf tube and the plasmid 
DNA was eluted with 100 μl of nuclease free water.   
 
2.3  GENERATION OF RECOMBINANT LCS EXPRESSING TGEV SPIKE 
PROTEIN FRAGMENT 
2.3.1 Complementary DNA (cDNA) Synthesis of TGEV gene 
RNA sample extracted from TGEV (Section 2.13.5) was first reverse transcripted 
into cDNA.  The reaction mixture consisted of 2 μl of 10 x Reaction Buffer, 4 μl of       
25 mM MgCl2, 2 μl of Deoxynucleotide Mix, 1 μl of gene specific reverse primer, 1 μl 
RNAse inhibitor, 0.8 μl Superscript Reverse Transcriptase (Invitrogen, USA), and 8.2 μl 
of RNA sample.  The mixture was briefly vortexed and pulsed before being incubated at 
25 oC for 10 min and then 42 oC for 60 min.  The cDNA was then stored at –20 oC. 
2.3.2 Amplification of TGEV Spike Gene 
2.3.2.1 Primers Sequences and Related Information 
The sequence, size and Tm of the primers used for the cloning of TGEV-S gene 
into pLP500 are listed in Table 2.4. 
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Table 2.4 Primers used in this part of study. 
Primer Sequence Size Tm Polarity
   5’                                                                   3’  (nts) (oC)   
Tgeplp-FI CGGGATCCAATGCCATTGATTTATGGAGACAA 29 76 Forward
Tgeplp-RII CGGCTAGCTTAGACCTAACAGTTCACTG 28 70 Reverse
pLP5005’ GCATGCACATAAGAAAGGATGAT 23 58 Forward
 
2.3.2.2 Polymerase Chain Reaction (PCR) 
Two μl of the cDNA was used for the amplification of TGEV Spike gene via 
PCR.  The primers Tgeplp-FI and Tgeplp-RII were synthesized to specifically amplify a 
2.3 kb N-terminal fragment (nucleotides 30-2293) of the TGEV spike gene (rTGEV-S) 
that encompasses all the major antigenic domains of the spike protein (Figure 2.1, 
GenBank accession number: AF302263).  The 8-bp overhang contains a BamHI 
restriction site in Tgeplp-FI, and a 8-bp overhang coding NheI in Tgeplp-RII for cloning 
procedures.  The reaction mixture consisted of 37.5 μl of dgd water, 5 μl of 10x reaction 
buffer, 4 μl of dNTPs (5mM), 0.5 μl of forward primer (50 pmol/μl), 0.5 μl of reverse 
primer (50 pmol/μl), 0.5 μl of DNA Polymerase (Qiagen, Germany) and 2 μl DNA 
template.  The reaction mixture was vortexed before it was amplified in a PCR machine 
(Hybaid PCR ExpressTM, Hybraid Ltd).  This mixture was heated to 94 oC for 5 min, and  
then amplified for 30 cycles, each consisted of 94 oC for 30 sec, 55 oC for 30 sec and 72 
oC for 2 min, which enabled repetitive DNA denaturation, primer hybridization and 
primer extension, respectively.  An extra step of 72 oC for 7 min allowed final extension 
to occur and a holding step at 4 oC.   
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DEFINITION - Porcine transmissible gastroenteritis virus spike protein S mRNA 
 































                 1 atgaaaaaat tatttgtggt tttggtcgta atgccattga tttatggaga caattttcct 
       61 tgttctaaat tgactaatag aactataggc aaccattgga atctcattga aacctttctt 
      121 ctaaactata gtagtaggtt accacctaat tcagatgtgg tgttaggtga ttattttcct 
      181 actgtacaac cttggtttaa ttgcattcgc aataatagta atgaccttta tgttacattg 
      241 gaaaatctta aagcattgta ttgggattat gctacagaaa acatcacttg gaatcacaaa 
      301 caacggttaa acgtagtcgt taatggatac ccatactcca tcacagttac aacaacccgc 
      361 aattttaatt ctgctgaagg tgctattata tgcatttgta agggctcacc acctactacc 
      421 accacagaat ctagtttgac ttgcaattgg ggtagtgagt gcaggttaaa ccataagttc 
      481 cctatatgtc cttctaattc agaggcaaat tgtggtaata tgctgtatgg cctacaatgg 
      541 tttgcagatg cggttgttgc ttatttacat ggtgctagtt accgtattag ttttgaaaat 
      601 caatggtctg gcactgttac acttggtgat atgcgtgcga ctacattaga aaccgctggc 
      661 acgcttgtag acctttggtg gtttaatcct gtttatgatg tcagttatta tagagttaat 
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      721 aataaaaatg gtattaccgt agtttccaat tgcactgatc aatgtgctag ttatgtggct 
      781 aatgttttta ctacaaagcc aggaggtttt ataccatcag attttagttt taataattgg 
      841 ttccttctaa ctaatagctc cacgttggtt agtggtaaat tagttaccaa acagccgtta 
      901 ttagttaatt gcttatggcc agtccctagc tttgaagaag cagcttctac attttgtttt 
      961 gaaggtgctg gctttgatca atgtaatggt gctgttttaa ataacactgt agacgtcatt 
     1021 aggtttaacc ttaattttac tacaaatgta caatcaggta agggtgccac agtgttttca 
     1081 ttgaacacaa cgggtggtgt cactcttgaa atctcatgtt ataatgatac agtgagtgac 
     1141 tcgagctttt tcagttacgg tgaaattccg ttcggcgtaa ctgatggacc acggtactgt 
     1201 tacgtactct ataatggcac agctcttaag tatctaggaa cattaccacc tagtgtcaag 
     1261 gagattgcta ttagtaagtg gggccatttt tatattaatg gttacaattt ctttagcaca 
     1321 tttcctattg attgtatatc ttttaatttg accactggtg atagtgacgt tttctggaca 
     1381 atagcttaca catcgtacac tgaagcatta gtacaagttg aaaacacagc tattacaaag 
     1441 gtgacgtatt gtaatagtta cgttaataac attaaatgct ctcaacttac tgctaatttg 
     1501 aataatggat tttatcctgt ttcttcaagt gaagttggtc ttgtcaataa gagtgttgtg 
     1561 ttactaccta gcttttacac acataccatt gttaacataa ctattggtct tggtatgaag 
     1621 cgtagtggtt atggtcaacc catagcctca acattaagta acattacact accaatgcag 
     1681 gacaagaaca ccgatgtgta ctgtattcgt tctgaccaat tttcagttta tgttcattct 
     1741 acttgcaaaa gttctttatg ggacaatatt tttaagcgaa actgcacgga cgttttagat 
     1801 gccacagctg ttataaaaac tggtacttgt cctttctcat ttgataaatt gaacaattac 
     1861 ttaactttta acaagttctg tttgtcgttg agtcctgttg gtgctaattg taagtttgat 
     1921 gtagctgccc gtacaagaac caatgatcag gttgttagaa gtttgtatgt aatatatgaa 
     1981 gaaggagaca acatagtggg tgtaccgtct gataatagtg gtttgcacga tttgtcagtg 
     2041 ctacacctag attcctgcac agattacaat atatatggta gaactggtgt tggtattatt 
     2101 agacaaacta acaggacgct acttagtggc ttatattaca catcactatc aggtgatttg 
     2161 ttagggttta aaaatgttag tgatggtgtc atctactctg taacgccatg tgatgtaagc 
     2221 gcacaagcag ctgttattga tggcaccata gttggggcta tcacttccat taacagtgag 
     2281 ctgttaggtc taacacattg gacaacaaca cctaattttt attactactc tatatataat 
     2341 tacacaaatg ataggattcg tggcactgca attgacagta atgatgttga ttgtgaacct 
     2401 gtcataacat attctaacat aggtgtttgt aaaaatggtg cttgggtttt tattaacgtc 
     2461 acacattctg atggagacgt gcaaccaatt agcactggta atgtcacgat acctacaaac 
     2521 tttaccatat ccgtgcaagt cgaatacatt caggtttaca ctacacccgt gtcaatagac 
     2581 tgttcaagat atgtttgtaa tggtaaccct aggtgtaaca aattgttaac acaatacgtt 
     2641 tctgcatgtc aaactattga gcaatcactt gcaatgggtg ccagacttga aaacatggag 
     2701 gttgattcca tgttgtttgt ttctgaaaat gcccttaaat tggcttctgt cgaagcattc 
     2761 aatagttcag aaactttaga tcctatttac aaagaatggc ctaatatagg tggttcttgg 
     2821 ctagaaggtc taaaatatat acttccgtcc gataatagca aacgtaagta tcgttcagct 
     2881 atagaggact tgctttttga taaggttgta acatctggtt taggtacagt tgatgaagat 
     2941 tataaacgtt gtacaggtgg ttatgacata gctgacttag tatgtgctca atactataat 
     3001 ggcatcatgg tgctacctgg tgtggctaat gctgacaaaa tgactatgta cacagcatcc 
     3061 cttgcaggtg gtataacatt aggtgcactt ggtggaggcg ccgtggctat accttttgca 
     3121 gtagcagttc aggctagact taattatgtt gctctacaaa ctgatgtatt gaataaaaac 
     3181 cagcagatcc tggctagtgc tttcaatcaa gctattggta acattacaca gtcatttggt 
     3241 aaggttaatg atgctataca tcaaacatca cgaggtcttg ccactgttgc taaagcattg 
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     3301 gcaaaagtgc aagatgttgt caacacacaa gggcaagcat taagccacct aacagtacaa 
     3361 ttgcaaaata atttccaagc cattagtagt tctattagtg acatttataa taggcttgat 
     3421 gaattgagtg ctgatgcaca agttgacagg ctgatcacag gaagacttac agcacttaat 
     3481 gcatttgtgt ctcagactct aaccagacaa gcggaggtta gggctagtag acaacttgcc 
     3541 aaagacaagg ttaatgaatg cgttaggtct cagtctcaga gattcggatt ctgtggtaat 
     3601 ggtacacatt tgttttcact cgcaaatgca gcaccaaatg gcatgatctt ctttcacaca 
     3661 gtgctattac caacggctta tgaaactgtg actgcttggg caggtatttg tgctttagat 
     3721 ggtgatcgca cttttggact tgtcgttaaa gatgtccagt tgactttgtt tcgtaatcta 
     3781 gatgacaagt tctatttgac ccccagaact atgtatcagc ctagagtggc aactagttct 
     3841 gattttgttc aaattgaagg gtgcgatgtg ctgtttgtta atgcaactgt aagtgatttg 
     3901 cctagtatta tacctgatta tattgatatt aatcagactg ttcaagacat attagaaaat 
     3961 tttagaccaa attggactgt acctgagttg acatttgaca tttttaacgc aacctattta 
     4021 aacctgactg gtgaaattga tgacttagaa tttaggtcag aaaagctaca taacactact 
     4081 gtagaacttg ccattcttat tgacaacatt aacaatacat tagtcaatct tgaatggctc 
     4141 aatagaattg aaacctatgt aaaatggcct tggtatgtgt ggctactaat aggcttagta 
     4201 gtaatatttt gcataccatt actgctattt tgctgttgta gtacaggttg ctgtggatgc 
     4261 ataggttgtt taggaagttg ttgtcactct atatgcagta gaagacaatt tgaaaattac 
     4321 gaacctattg aaaaagtgca cgtccattaa 
 
Figure 2.1 Porcine transmissible gastroenteritis virus spike protein S mRNA sequences 
(GenBank accession number AF302263) downloaded from NCBI website 
(http//:www.ncbi.nlm.nih.gov).  The sequences included in the forward primer (Tgeplp-FI) with a 
start codon ATG (underlined) at the 5’ end, and the sequences included in the reverse primer 
(Tgeplp-RII) with stop codon TAA (underlined) at the 3’ end, were in bold, respectively.  
 
 
2.3.3 Construction of Recombinant pLP500 Harboring TGEV Spike Gene 
Fragment  
The amplified rTGEV-S was first subcloned into pCR®-XL-TOPO® vector using 
TOPO® XL PCR Cloning Kit (Invitrogen, USA) accordingly to manufacturer’s 
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2.3.3.1 Subcloning of rTGEV-S into pCR®-XL-TOPO® Vector 
In brief, 4 μl of gel purified rTGEV-S and 1 μl of pCR®-XL-TOPO® vector were 
incubated for 5 min at room temperature, after which 1 μl of 6X TOPO® Cloning Stop 
Solution was added and mixed for several seconds.  The mixture was pulse spun before 
being transformed into One Shot® cell (Invitrogen, USA).  Two μl was transferred into a 
vial of One Shot® cell, and incubated on ice for 30 min.  Heat shock was carried out at 42 
°C for 30 sec, after which the transformation mix was incubated on ice for 2 min before 
250 μl of SOC medium (Appendix 1) was added.  After 1 hr of incubation at 37 °C, 100 
μl of the transformation mix was spread on a pre-warmed LB plate (Appendix 1) 
containing 50 μg/ml kanamycin (Appendix 1) and incubated overnight at 37 °C for the 
selection of clones. 
2.3.3.2 Cloning of rTGEV-S into pLP500 
Five μl of the plasmids isolated from Section 2.3.3.1 was digested with BamHI 
and NheI (New Englands Biolabs, UK) as described in Section 2.2.3.  The digested 
samples were separated on agarose-EtBr gel.  The 2.3 kb rTGEV-S was excised from the 
gel and purified using QIAquick II Gel Extraction Kit (Qiagen, Germany) as in Section 
2.2.6 and ligated to pLP500 (pre-digested with BamHI and NheI) to generate recombinant 
vector pLP500/rTGEV-S.  
 
2.3.4 Preparation of Competent E.coli Cells for Chemical Transformation 
   A 100 ml DH10β E.coli culture was incubated at 37 °C until OD600 = 0.5.  The 
cells were placed on ice for 10 min before being centrifuged for 5 min at a speed of 4000 
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rpm.  The supernatant was removed and the pellet was resuspended with 50 ml of cold 
0.1M CaCl2.  The cells were incubated on ice for 45 min, spun and resuspended in 8 ml 
of 0.1M CaCl2.  Two ml of sterile glycerol was added before the cells were aliquoted and 
kept at -80 °C for long term storage. 
 
2.3.5 Generation of Recombinant L.casei Shirota Expressing rTGEV-S 
2.3.5.1 Transformation of pLP500/rTGEV-S into E.coli 
Ten μl of the ligation mixture (Section 2.3.3.2) was added to 50 μl of DH10β 
E.coli competent cells and incubated on ice for 30 min.  This was followed by heat shock 
at 42 °C for 1 min, after which the cells were placed on ice for another 2 min.  One 
hundred μl of transformed cells was then plated out on pre-warmed LB plate containing 
100 μg/ml of ampicillin and incubated overnight at 37 °C for the selection of clones.  
Well-defined colonies were picked from the plate and grown in LB containing ampicillin 
(Appendix 1). The plasmids were then isolated following the procedures of the Wizard® 
Plus SV Miniprep DNA Purification System (Promega, USA) as mention in Section 
2.2.7, and glycerol stocks (20 % v/v) of the bacterial cultures were also prepared and 
stored at –80 °C. 
 
2.3.5.2 Confirmation of Transformants 
 Restriction digestion analysis of the vectors isolated from Section 2.3.5.1 was 
conducted to determine if the plasmids contain rTGEV-S insert.  Five μl of the vector 
was digested with BamHI and NheI.  The digestion mixtures were vortexed and incubated 
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at 37 °C for 2 hr.  The digested DNA was then electrophoresized in 1.0 % agarose-EtBr 
gel at 120 Volts for 30 min and DNA bands were then visualized and photographed.   
Nucleotide sequencing was also performed to verify if the rTGEV-S was 
appropriately inserted in the vector.  The sequencing reaction was performed using the 
specific forward primer, pLP5005’, that primed the pLP500 vector backbone sequence 
(Table 2.4), and ABI PRISM BigDye™ Terminator Cycle Sequencing Ready Reaction 
Kit (Applied Biosystem, USA).  The composition of the sequencing reaction, sequencing 
profiles and purification of the extension product was performed as recommended by the 
manufacturer’s protocol.  In brief, the precipitation reaction was carried out by adding 80 
µl of freshly prepared precipitation solution (3.0 µl of 3 M sodium acetate (pH 4.6); 62.5 
µl of non-denatured 95 % ethanol; 14.5 µl of dgd water) to each tube of vector to be 
sequenced.  The precipitation mixture was mixed by vortexing briefly and left to stand at 
room temperature for 15 min.  The DNA was then pelleted by centrifuging at 14, 000 rpm 
for 20 min at room temperature.  The supernatant from each of the tubes were removed 
carefully, after which 250 µl of 70 % ethanol was added.  The mixture was vortex briefly 
and centrifuge for 5 min at 14, 000 rpm.  The supernatant was then carefully removed and 
left to air dry for 15 min at room temperature.  The precipitated extension product was 
stored in -20 oC until they were sent for electrophoresis.  
 
2.3.5.3 Preparation of Competent Cells for Electroporation 
Hundred ml of MRS medium was inoculated with 10 ml of overnight culture of 
LcS and incubated at 37 oC in a CO2-enriched atmosphere.  The cells were harvested 
during log phase (about 4-5 hr incubation) by centrifugation of the culture at 9500 rpm 
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for 10 min at room temperature.  The cell pellet was resuspended in chilled washing 
buffer (Appendix 2) and spun down at 5000 rpm for 10 min.  The washing step was 
repeated once before resuspending the cells in electroporation buffer (Appendix 2) and 
adjusted to a concentration of 1010-1011 cells/ml.  The exact number of cells per ml was 
determined by plating them on MRS agar. Aliquots (100 μl) of the electroporation 
competent LcS were stored at -20 oC 
 
2.3.5.4 Electroporation 
 Transformation of LcS with pLP500/rTGEV-S was carried out by electroporation. 
0.5 µg of the recombinant plasmid was added into 100 µl of LcS competent cell (Section 
2.3.5.3).  The electroporation mixture was transferred to an electroporation cuvette with a 
0.2 cm gap width (Bio-Rad, USA).  One single pulse was applied with the Bio-Rad Gene 
Pulser (Bio-Rad, USA) and pulse controller under the following conditions: potential 2.5 
kV; capacity, 25 µF; resistance, 200 Ω.  One ml of MRS broth (Merck, Germany) was 
added to the cells immediately after the pulse.  The cell suspension was then transferred 
to a sterile eppendorf tube and incubated at 37 °C for 3 hr.  The cells were pelleted and 
resuspended in 100 µl of MRS medium, before being plated on MRS agar (Merck, 
Germany) with erythromycin (5 µg/ml, Appendix 1).  The MRS plates were incubated at 
37 °C with 5 % CO2, for 48-72 hr until colonies were formed. 
 
2.3.5.5 Analysis of the Transformants 
To confirm that the LcS colonies with Eryr phenotype were true transformants, 
plasmids were extracted from the transformants using method described by Posno (1991) 
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with slight modifications.  In brief, 3 ml overnight culture of the transformants were 
centrifuged and resuspended in 400 µl of lysis buffer (Appendix 2).  After 2 hr of 
incubation at 37 °C, the cells were pelleted and resuspended in 400 µl of 20 mM Tris-Cl 
(pH 8.0), and lysed with 1 % (v/v) sodium dodecyl sulfate (SDS).  High molecular weight 
DNA was denatured by the addition of 35 µl of 1.0 N NaOH and incubating the mixture 
at room temperature for 10 min.  The lysate was then neutralized by addition of 70 µl of 2 
M Tris-Cl (pH 7.0).  A final concentration of 0.5 M NaCl was added, before the lysate 
was extracted once with phenol and once with phenol-chloroform (1:1).  Nucleic acid 
was precipitated with 1 volume of isopropanol and leaving the mixture at -20 °C for at 
least 1 hr.  The nucleic acid pellet was washed once with 70 % ethanol before being 
dissolved in 30 µl of TE buffer with 50 µg of RNaseA (Qiagen, Germany) per ml and 
incubated at 37 °C for 15 min.  The extracted plasmids were analyzed for the presence of 
rTGEV-S insert via PCR (Section 2.3.2.2) using the cloning primers. 
 
2.3.6 Expression of rTGEV-S Protein 
Overnight culture of recombinant LcS harboring the pLP500 encoding rTGEV-S 
(LcS-rTGEV-S) was inoculated into 100 ml of MRS broth and incubated at 37 °C with 
shaking at 200 rpm.  As the vector pLP500 used in this study is a constitutive vector that 
expresses heterologous protein in a secretable form, supernatant from LcS-rTGEV-S was 
harvested at 12 hr and concentrated ten times using Ultrafree-CL PBGC Biomax-10 
(Millipore, USA).  The concentrated supernatant was analyzed with 10 % Sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by 
immunoblotting as described in Section 2.6 and 2.7. 
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2.4 GENERATION OF RECOMBINANT P.PASTORIS EXPRESSING TGEV 
SPIKE PROTEIN FRAGMENT 
2.4.1 Amplification of TGEV Spike Gene 
2.4.1.1 Primers Sequences and Related Information. 
The sequence, size and Tm of the primers used for the cloning of TGEV spike 
gene fragment into pGAPZαC are listed in Table 2.5. 
Table 2.5 Primers used in this part of study. 
Primer Sequence Size Tm Polarity
   5’                                                                   3’  (nts) (oC)   
pGAPtge-FI GGAATTCGCCATTGATTTATGGAGACAA 28 73 Forward
pGAPtge-RII GCTCTAGAGTTAGACCTAACAGTTCACTG 29 78 Reverse
α-factor TACTATTGCCAGCATTGCTGC 21 53 Forward
 
2.4.1.2 Polymerase Chain Reaction (PCR) 
A 2.3 kb TGEV spike gene fragment (PrTGEV-S, nucleotides 33-2288) was 
amplified from 2 μl of TGEV cDNA, synthesized in Section 2.3.1, with the aid of the 
primers pGAPtge-FI and pGAPtge-RII.  The 7-bp overhang contains an EcoRI restriction 
site in pGAPtge-FI, and a 8-bp overhang coding XbaI in pGAPtge-RII for cloning 
procedures and PCR was carried out as described in Section 2.3.2.2.  
 
2.4.2 Cloning of TGEV Spike Gene Fragment into pGAPZαC  
Twenty μl of PrTGEV-S generated in Section 2.4.1.2 was cleaved with EcoRI and 
XbaI (New Englands Biolabs, UK) and ligated with EcoRI and XbaI digested pGAPZαC 
to generate recombinant vector pGAPZαC/PrTGEV-S. 
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2.4.3 Transformation of pGAPZαC/PrTGEV-S into E.coli 
Ten μl of the vector mixture was transformed into 50 μl of DH10β E.coli 
competent cells as described in Section 2.2.4.  One hundred μl of transformed cells was 
then plated out on pre-warmed Low Salt LB plate (Appendix 1) with 25 μg/ml of zeocin 
and incubated overnight at 37 °C for the selection of clones.  Well-defined colonies were 
picked from the plate and grown in Low Salt LB medium containing zeocin.  The 
plasmids were then isolated following the procedures of the Wizard® Plus SV Miniprep 
DNA Purification System (Promega, USA) as mention in Section 2.2.7, and glycerol 
stocks (20 % v/v) of the bacterial cultures were also prepared and stored at –80 °C. 
 
2.4.4 Confirmation of Transformants 
 To verify if the transformants harbour the recombinant pGAPZαC/PrTGEV-S 
vector, PCR was performed on the isolated vectors using the primers pGAPtge-FI and 
pGAPtge-RII.  
Nucleotide sequencing was also performed to check if the insert was in-frame 
with the α-factor secretion signal.  The sequencing reaction was performed using the α-
factor sequencing primer (Table 2.5) and ABI PRISM BigDye™ Terminator Cycle 
Sequencing Ready Reaction Kit (Applied Biosystem, USA).  The composition of the 
sequencing reaction, sequencing profiles and purification of the extension product was 
performed as recommended by the manufacturer’s protocol.  Precipitation of the 
extension product was performed as described in Section 2.3.5.2.  The precipitated 
extension product was stored in -20 oC until they were sent for electrophoresis.  
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2.4.5 Generation of Recombinant P.pastoris Expressing rTGEV-S 
2.4.5.1 Linearization of Recombinant Vector 
The recombinant vector was linearized to permit homologous recombination 
between transforming DNA and regions of homology within the genome (Cregg et al., 
1985, 1989) to generate stable transformants of P.pastoris.  Gene insertion events occurs 
at the GAP promoter locus as a result of a single crossover event between the locus and 
the PGAP region on pGAPZαC, leading to the insertion of one or more copies of the vector 






Figure 2.2 Insertion of plasmid 5’ to the intact GAP promoter locus. 
 Five µg of pGAPZαC/PrTGEV-S was linearized with AvrII, which cuts once in 
the GAP promoter region to linearize the vector.  The digest was electrophoresized to 
ensure complete linearization of vector and purified using QIAquick II Gel Extraction Kit 
(Qiagen, Germany) as described in Section 2.2.6. 
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2.4.5.2 Transformation of pGAPZαC/PrTGEV-S into P.pastoris 
 Transformation of the linearized vector into P.pastoris was carried out using 
Pichia EasyComptm Kit (Invitrogen, USA), following manufacturer’s instructions. The 
following provides the protocol in brief. 
2.4.5.2.1 Preparation of Competent P.pastoris  
 Ten ml of overnight culture of P.pastoris was diluted to an OD600 of 0.2 in 10 ml 
of YPD and grown at 30 °C with shaking until the OD600 reached 0.6-1.0.  The cells were 
centrifuged at 500 x g for 5 min at room temperature, where the pellet was resuspended 
in 10 ml of Solution I from Pichia EasyComptm Kit (Invitrogen, USA).  The cells were 
pelleted again and resuspended in 1 ml of Solution I before being aliquoted into 
microcentrifuge tubes and stored at -80 °C. 
2.4.5.2.2 Transformation of competent P.pastoris 
 Three µg of linearized pGAPZαC/PrTGEV-S was added to 50 µl of competent 
P.pastoris GS115 cells, after which 1 ml of Solution II from Pichia EasyComptm Kit 
(Invitrogen, USA) was added to the transformation mixture and mixed by flicking the 
tube.  The transformation reaction was incubated at 30 °C for 1 hr, where the 
transformation mixture was mixed by flicking the tube every 15 min.  The cells were then 
heat shocked at 42 °C for 10 min and split into 2 microcentrifuge tubes, where 1 ml of 
YPD medium (Appendix 2) was added to each tube.  The cells were incubated at 30 °C 
for 1 hr to allow expression of zeocin resistance.  The cells were then centrifuged at 3000 
x g for 5 min at room temperature and resuspended in 1 ml of Solution III from Pichia 
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EasyComptm Kit (Invitrogen, USA).  The cells were pelleted again before being 
resuspended in 100 µl of Solution III and plated onto YPD plates with 100 µg/ml zeocin 
(Appendix 1).  The plates were incubated at 30 °C for 2 to 4 days until colonies appeared. 
 
2.4.5.3 Analysis of the Transformants 
2.4.5.3.1 Total DNA isolation form P.pastoris 
 One ml of overnight culture of transformant was centrifuged at 7000 rpm for 1 
min, after which the pellet was resuspended in 200 µl of Breaking buffer (Appendix 2).  
A single scoop of 400 μ glass beads (BioSpec Products Inc., USA) was added to the cells, 
followed by 200 µl of Phenol/Chloroform (1:1 v/v).  The lysis mixture was vortexed 
continuously for 5 min and centrifuged at 14000 rpm for 5 min, after which the aqueous 
DNA phase was transferred to a new microcentrifuge tube.  This step was repeated before 
500 µl of absolute ethanol was added and the mixture was centrifuged at 14, 000 rpm for 
10 min.  The DNA pellet was washed with 500 µl of 70 % ethanol before being 
resuspended in 200 µl of 0.3 M NaAc.  The DNA was precipitated again with 500 µl of 
absolute ethanol, washed with 500 µl 70 % ethanol and air dried before resuspended in 
50 ul of dgd water.  The samples were stored at -20 °C until ready for usage. 
 
2.4.5.3.2 PCR of Total DNA 
 In order to determine if the insert PrTGEV-S has integrated into the transformant 
genome, PCR of the DNA isolated from the P.pastoris transformants was conducted 
using the primers pGAPtge-FI and pGAPtge-RII.  The generated products were analyzed 
on a 1.0 % agarose-EtBr gel. 
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2.4.6 Expression of PrTGEV-S Protein 
Overnight culture of the recombinant P.pastoris (PP/PrTGEV-S) was grown from 
which 0.1 ml was used to inoculate 50 ml of YPD medium in a 250 ml flask.  The culture 
was incubated at 30 °C in a shaking incubator.  One ml of the expression culture was 
transferred to a 1.5 ml microcentrifuge tube on Day 1, 2, 3 and 4 post-inoculation.  The 
culture was centrifuged and the supernatant was transferred to a separate tube.  The 
supernatants were snap frozen in liquid nitrogen before being stored at -80 °C, until ready 
for the analysis of protein expression through Western blotting (Section 2.6 & 2.7).  
 
2.5 GENERATION OF RECOMBINANT P.PASTORIS EXPRESSING SARS CoV 
SPIKE PROTEIN FRAGMENT 
2.5.1 Amplification of SARS CoV Spike Gene 
 Babcock and coworkers (2004) reported that amino acids 270 to 510 were the 
receptor-binding region of Severe Acute Respiratory Syndrome Coronavirus (SARS 
CoV) spike protein.  More importantly, antibodies raised against recombinant protein 
containing amino acid residues 318-510 of the SARS spike protein were able to induce 
highly potent neutralizing antibody responses against SARS CoV. As such, gene 
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2.5.1.1 Primers Sequences and Related Information 
The sequence, size and Tm of the primers used for the cloning of the receptor-
binding region of SARS CoVspike gene into pGAPZαC are listed in Table 2.6. 
Table 2.6 Primers used in this part of study. 
Primer Sequence Size Tm Polarity
   5’                                                                   3’  (nts) (oC)   
RBD-SSF1 GGGGTACCTACAATCACAGATGCT 25 58 Forward
RBD-SSR1 GCTCTAGATCAGTGGATAATTTTGGT 27 70 Reverse
α-factor TACTATTGCCAGCATTGCTGC 21 53 Forward
 
2.5.1.2 Polymerase Chain Reaction (PCR) 
With the aid of the primers, RBD-SSF1 and RBD-SSR1, a 720 bp fragment of 
SARS CoV receptor-binding domain (nucleotides 810-1530) of spike gene (SARS-S-
RBD) was amplified from pCR-XL-TOPO-S, a vector encoding the SARS CoV spike 
gene, kindly provided by Associate Professor Vincent Chow of Department of 
Microbiology, National University of Singapore.  Both primers were designed to contain 
an 8-bp overhang that encodes a KpnI restriction site in RBD-SSF1, and XbaI in RBD-
SSR1 for cloning procedures. PCR was carried out as described in Section 2.3.2.2.  
The same approach of cloning and generation of recombinant PrTGEV-S 
encoding P.pastoris (Section 2.4.3 to 2.4.6) was employed for the generation of 
recombinant P.pastoris expressing SARS-S-RBD (PP/SARS-S-RBD).  Expression of the 
SARS-S-RBD protein was determined as in Section 2.4.7. 
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2.6 SODIUM-DODECYL SULFATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE) 
The discontinuous Laemmli gel system (Laemmli, 1970) was used for 
electrophoresis of proteins in this study.  The electrophoresis apparatus used was from 
Mini-Protean®II Electrophoresis Cell (Bio-Rad, USA). 
A 10 % separation gel (Appendix 3) was cast between two glass plates.  The gel 
mixture was poured to about 1.5 cm below the comb bottom.  Seventy percentage ethanol 
was layered over the gel mixture to ensure a straight meniscus and to exclude oxygen 
which inhibits gel polymerization reaction.  The gel is allowed to polymerize for 
approximately 45 min before the ethanol was decanted and washed with dgd water to 
flush out the residual polyacrylamide.  Stacking gel (Appendix 3) was then layered over 
the separation gel with comb in position and allowed to polymerize for 30 min.  The 
comb was removed and the gel assembly was immersed into the electrophoresis chamber 
filled with running buffer (Appendix 3). 
Prior to loading, 25 μl of each protein sample was boiled for 1 min with 5 μl of 
loading dye (Appendix 3). Six μl of the prestained protein marker (New England Biolabs, 
UK) was treated as mentioned before.  Electrophoresis was carried out using constant 
current of 20 mA for approximately 1.5 hr.   
After electrophoresis, the gel was removed from the glass plates and soaked in 
staining solution (Appendix 3) for 1 hr.  The gel was then rinsed briefly to remove the 
excess stain and immersed in destaining solution (Appendix 3), until the protein bands 
could be clearly visualized. 
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2.7 IMMUNOBLOTTING 
For the immunoblotting of proteins, the gel was transferred into a blotting cell.  
The 0.45 μm nitrocellulose membrane (Bio-Rad, USA), filter paper and sponge for 
transblot sandwich were presoaked in transfer buffer (Appendix 4).  The separation gel 
was placed between a wet nitrocellulose membrane and a piece of pre-wet filter paper.   
The set-up was sandwiched between two pieces of sponge in the transblot cell.  The cell 
was immersed into the transfer chamber filled with transfer buffer with the nitrocellulose 
membrane side adjacent to the positive electrode.  The transfer was carried out at 90 
Volts for 2 hr in a cold room.   
After the transfer, the blot was blocked in PBS containing 5 % skim milk for 1 hr, 
after which the blot was washed thrice with wash buffer (Appendix 4) for 5 min each.   
Primary antibodies (Table 2.7), diluted in PBS, was added to the blot and incubated 
overnight at 4 °C on an orbital shaker (Bellco, USA). 
The immunoblot was washed with three times with wash buffer, before incubated 
with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies 
(Table 2.7).  The secondary antibody was diluted in PBS and incubation was carried out 
at room temperature for 1 hr. 
After the incubation period, the blot was washed thrice for 10 min each time.  
Visualization of the immunolabeled bands was then carried out using SuperSignal West 
Pico Chemiluminescent Substrate chemiluminescence reagent (Pierce Biotechnology, 
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2.7.1 Antibodies Used For Immunoblotting 





















































HRP: Horseradish peroxidase 
The convalescence swine serum against TGEV was obtained from pigs that were 
inoculated by oral route with 105 TCID50 of TGEV Miller Strain and challenged 
intramuscularly 45 days post-inoculation.  For the detection of specific antibody binding, 
horseradish peroxidase (HRP)-conjugated anti-swine IgG (ZYMED Laboratories Inc., 
USA) diluted at 1:10,000 were used. 
 
2.8 IMMUNIZATION OF MICE 
 Groups of three female BALB/c mice (8 weeks old) were immunized orally either 
with recombinant rTGEV-S expressor LcS (LcS-rTGEV-S), PrTGEV-S or SARS-S-RBD 
expressing P.pastoris (PP/PrTGEV-S and PP/SARS-S-RBD).  Control non-expressor 
strain (harboring empty vector) or sterile PBS (Appendix 5) was also administrated as 
controls.  Freshly cultured bacteria were harvested and washed twice with sterile PBS 
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(pH 7.2).  Oral doses of 2 x 109 cells (0.1 ml of the suspension) were administered on 
three consecutive days at days 0, 1 and 2.  A booster immunization was given at days 14, 
15 and 16 and a second booster was given at days 28, 29 and 30.  Tail bleeding and 
lavaging was performed at the appropriate timing to collect sera and intestinal fluid from 
the mice.  Mice were then sacrificed, where the Peyer’s patches and/or the cervical lymph 
node (CLN) were aseptically removed. 
 
2.8.1 Collection of Intestinal Secretions 
Lavaging of mice was performed as following the method used by Elson et al. 
(1984) with slight modifications.  In brief, four doses of 0.5 ml of lavage solution [25mM 
NaCl, 40 mM Na2SO4, 10 mM KCl, 20 mM NaHCO3, and 48.5 mM polyethylene glycol 
(average MW = 3350)] were given intragastrically at 15 min intervals.  Thirty minutes 
after the last dose of lavage solution, the mice were given 0.1 mg of pilocarpine (Alcon-
Couvreur, Belgium) intraperitoneally.  A discharge of intestinal contents occurred 
regularly over the next 10-20 min.  The collected intestinal discharges were transferred to 
15 ml centrifuge tubes and the volume brought up to 6 ml with PBS.  The samples were 
vortexed vigorously before being centrifuged at 6000 x g for 10 min for the clarification 
of the intestinal content, of which 3 ml of the supernatant was transferred to a round-
bottomed polycarbonate centrifuge tube.  The secretions were further clarified by 
centrifugation at 14, 000 x g at 4 °C for 20 min after the addition of 30 µl of 100 mM 
phenlymethylsulfonyl fluoride [(PMSF) (Sigma, USA)] in 95 % ethanol. Two microliters 
of the clarified secretions were removed, to which 20 µl of 100 mM PMSF in 95 % 
ethanol and 20 µl of 1 % sodium azide (Sigma, USA) were added.  The samples were 
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then left to stand for 15 min, after which 100 µl of fetal calf serum serum was added to 
provide an alternate substrate for any remaining proteases.  The intestinal lavages were 
stored at -20 °C until assay.     
 
2.9 LARGE SCALE EXPRESSION OF TGEV SPIKE PROTEIN  
A 1.3 kb N-terminal fragment of TGEV spike protein, expressed as a GST fusion 
protein (TGEV-S-GST), was used for the analytical studies of the recombinants 
LcS/rTGEV-S and PP/PrTGEV-S generated. 
 
2.9.1. Polymerase Chain Reaction (PCR) 
The sequence, size and Tm of the primers used for the cloning of N-terminal 
fragment of TGEV spike gene into pGEX-4T-3 are listed in Table 2.8. 
Table 2.8 Primers used in this part of study. 
Primer Sequence Size Tm Polarity
   5’                                                                                     3’ (nts) (oC)   
pGEXF1 CCGGAATTCTGTTTATGATGTCAGTTATTAT 31 77 Forward
pGEXR1 ACGCGTCGACATTATCAGACGGTACACCCAC 31 84 Reverse
 
Amplification of an N-terminal fragment (nucleotides 690-2010) of the TGEV 
spike gene was carried out using the primers, pGEXF1 and pGEXR1.  Both primers were 
designed to contain a 9-bp overhang, which encodes an EcoRI restriction site in 
pGEXF1, and a 10-bp overhang that encodes SalI in pGEXR1 for cloning procedures. 
PCR was carried out as described in Section 2.3.2.2.  
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2.9.2 Cloning of TGEV Spike Gene Fragment into pGEX-4T-3  
Twenty μl of TGEV gene fragment generated in Section 2.9.1 was cleaved with 
EcoRI and SalI (New Englands Biolabs, UK) and ligated with EcoRI and SalI digested 
pGEX-4T-3, downstream of GST gene.  
Transformation of the vector mixture into JM105 E.coli competent cell was 
carried out as in Section 2.2.4.  One hundred μl of transformed cells was then plated out 
on pre-warmed LB plate (Appendix 1) containing 100 μg/ml of ampicillin and incubated 
overnight at 37 °C for the selection of clones.  Well-defined colonies were picked from 
the plate and grown in LB medium (Appendix 1) containing 100 μg/ml of ampicillin. The 
plasmids were then isolated following the procedures of the Wizard® Plus SV Miniprep 
DNA Purification System (Promega, USA) as mention in Section 2.2.7, and glycerol 
stocks (20 % v/v) of the bacterial cultures were also prepared and stored at –80 °C. 
 
2.9.3 Induction of TGEV-S-GST 
Overnight culture of transformant was diluted 1:10 in 50 ml of fresh LB medium 
and incubated at 37 °C until OD600 reached 0.6-0.8.  Protein expression was induced with 
1 mM of Isopropyl-ß-D-thiogalactopyranosid [(IPTG) (Sigma, USA)] and incubating the 
transformants at 37 °C for 3 hr.  The cells were then pelleted by centrifuging at 6000 rpm 
for 5 min at 4 °C.  The supernatant was removed and kept for analysis, while the insoluble 
protein fraction was extracted via sonication of the pellet on ice.  The cell extract was then 
centrifuged at 13, 000 rpm for 20 min at 4 °C, where the supernatant was kept and the 
insoluble fraction was resuspended with 1.5 ml of 1 M urea before being sonicated again.  
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The insoluble protein fractions were then further extracted consecutively with 1 M, 6 M, 8 
M urea and 0.01 % SDS (Appendix 2).   
 
2.9.4 Purification of TGEV-S-GST 
Two hundred microliters of Glutathione Sepharose 4B (Amersham Biosciences, 
England) was washed thrice with 3 ml of chilled PBS.  Cell lysate containing the fusion 
protein was then added to the beads and incubated at 4 °C for 1 hr with gentle agitation.  
The matrix was then transferred to a disposable column.  Unbound proteins were 
removed by washing the column twice with chilled PBS.  Finally, the purified proteins 
were eluted by adding reduced glutathione (Amersham Biosciences, England) to the 
column and the eluates were collected.  All samples were kept at -80 °C until ready to be 
analyzed by SDS-PAGE (Section 2.6). 
 
2.10 ELISA 
 Polystyrene microtitre plates were coated overnight at 4 oC with 1 μg of SARS-
Associated Coronavirus Spike mosaic recombinant protein S(M) [(SARS-S(M)(Virogen, 
USA)] or affinity purified TGEV-S-GST.  The coating antigen, TGEV-S-GST, was 
extracted from cell lysate of recombinant E.coli harboring and expressing a 1.3 kb amino 
terminal fragment of S protein in the form of GST-fusion protein (TGEV-S-GST), and 
purified by passing the cell lysate through Glutathione Sepharose 4B affinity column 
(Amersham Biosciences, England).  Serum or intestinal lavage samples were diluted two 
fold and used as primary antibodies.  Bound antibodies were detected using horseradish 
peroxidase conjugated goat anti-mouse IgA or IgG (ZYMED Laboratories Inc., USA), 
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followed by colour development using O-phenylene diamine dihydrochloride (Sigma, St. 
Louis, USA) as substrate.  The plate was read using an ELISA TouchScreen plate reader 
(Tecan, Austria), running in Magellan2 software, at the wavelength of 490 nm.  For the 
determination of relative levels of IgG subclasses, anti-murine IgG1 and IgG2a 
conjugated with horseradish peroxidase (ZYMED Laboratories, USA) were substituted 
for anti-mouse IgG horseradish peroxidase. 
 
2.11 CYTOKINE PROFILING 
2.11.1 Preparation of Peyer’s Patches and Cervical Lymph Node for In Vitro Re-
stimulation 
Single-cell suspensions of the Peyer’s patches (PP) and/or cervical lymph node 
(CLN) were prepared by mechanical dissociation.  The cells were resuspended and 
adjusted to 4 x 106 cells/ml in RPMI with 10 % heat-inactivated FCS (Appendix 5).  The 
PP and CLN cells from mice immunized orally with LcS-rTGEV-S or PP/PrTGEV-S 
were cultured in the presence of 5 μg of TGEV-S-GST, while cells isolated from mice 
fed with PP/SARS-S-RBD were re-stimulated with 5 μg of SARS-S(M).  The T-cell 
mitogen concanavalin A [(5 μg/ml)(Vector Laboratories, USA)] was added to positive 
control wells while an equal volume of RPMI medium was added to the negative control 
wells.  The culture supernatants were harvested on days 2, 3, 4 and 5 after restimulation 
to determine the kinetics of production of different cytokines.  All supernatants were 
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2.11.2 Cytokine Assay 
The level of IL-2, IL-4, IL-5 and IFN-γ in the culture supernatants was 
determined using Bio-PlexTM Cytokine Assays (Bio-Rad, USA), following 
manufacturer’s instruction.  In brief, required wells of a 96-well filter plate were pre-wet 
with 150 μl of Bio-Plex assay buffer.  The buffer was then removed by vacuum filtration 
using MultiScreen Vacuum Manifolds (Millipore, USA) and the bottom of the filter plate 
was blotted to dry with a clean paper towel.  Fifty microliters of multiplex beads (anti-
cytokine conjugated) was added per well and the buffer was removed by vacuum 
filtration.  The beads in each well were washed twice with 100 μl of Bio-Plex wash buffer 
before 50 μl of the culture supernatant (Section 2.11.1) was added to each well.  The filter 
plate was sealed with plate sealing tape, wrapped in aluminum foil to protect the beads 
from light and incubated at room temperature on a shaker at 1100 rpm for the first 30 sec, 
then at 300 rpm for 30 min.  The buffer was then removed and the beads were washed 
thrice with 100 μl of Bio-Plex wash buffer before 25 μl of 50 x Bio-Plex detection 
antibody was then added to each well.  The plate was sealed and covered with aluminum 
foil, and incubated at room temperature on a shaker at a speed of 1100 rpm for the first 
30 sec, then 300 rpm for 30 min.  The buffer was first removed, after which the beads 
were washed thrice with 100 μl of Bio-Plex wash buffer.  The beads were then 
resuspended with 125 μl of Bio-Plex assay buffer and the plate was shook at 1100 rpm 
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2.12 CELL CULTURE TECHNIQUES 
All solutions and media for cell culture were made using chemicals of ultrapure 
grades and dgd.  All cell cultures and media preparation works were performed under 
aseptic conditions in a laminar flow cupboard (Gelman Sciences, Australia) or biohazard 
hood (Nuaire, USA).  Prepared media were stored in sterile glass bottles with screwed 
capped with non-toxic silicone rubber washers.   
Cells used in this study were grown in sterile plastic tissue culture flasks (25 cm2, 
75 cm2 or 175 cm2), 6-well, 24-well or 96-well tissue culture plates from Falcon (USA).  
Cells were either cultured in humidified incubator (Nuaire, USA) with carbon dioxide (5 
%) or dry incubator at 37 °C. 
 
2.12.1 Cell Lines 
Cell lines that were used in this study were listed in the Table 2.9. The culture 
media, passage level and origin of the cell lines are indicated. 
Table 2.9 Cell lines and related information. 
Cell Line Type of cell 
line 




ST cell, Swine 
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2.12.2 Media for Cell Culture  
Cell culture media supplemented with 10 % fetal calf serum was used as the 
growth medium (Appendix 5) for the respective cell lines (Section 2.12.1).  The pH of the 
medium was adjusted to 7.2 - 7.4 with sodium bicarbonate (Appendix 5). 
 
2.12.3 Cultivation and Propagation of the Cell Lines 
New flasks of cells were sub-cultured from confluent monolayer at a ratio of 1:8 
(for 25 cm2 flask) and 1:4 (for 75 cm2 and 175 cm2 flask).  The growth medium 
(Appendix 5) was first discarded, after which the monolayer was then rinsed twice with 
about 5 ml of phosphate-buffered saline (PBS - Appendix 5).  The cell was rinsed with 
trypsin-versene (ATV - Appendix 5) and incubated with fresh ATV for 3 min at 37 °C 
for the detachment of the cell monolayer from the flask.  Appropriate amounts of the 
growth media (depending on the size of the flask), were added to the cell suspension to 
inactivate the enzymatic activity of the ATV. Cell aggregates were dispersed by pipetting 
to give a single cell suspension.  The suspended cells were then distributed into new 
tissue culture flasks. The cells were then incubated at 37 °C.  The monolayer would reach 
confluence in 3 to 4 days and was used for all the experiments. 
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2.12.4 Cultivation of Cells in 6-Well, 24-Well and 96-Well Tissue Culture Tray 
A confluent cell monolayer in a 25 cm2 tissue culture flask was used to seed a 6-, 
24-, or 96-well tray (Falcon, USA).  The cell monolayer was treated as previously 
described (Section 2.11.3) and the cell suspension was made up to a final volume of 30 
ml using cell culture medium (Appendix 5).  Five ml, 1 ml and 300 µl aliquot of this 
suspension was transferred into each well of the 6-, 24- and 96-well tray, respectively.  
The trays were then incubated at 37 °C in the humidified incubator (Nuaire, USA) with 
carbon dioxide (5 %).  The monolayers were confluent within 3 days and ready for use. 
 
2.12.5 Cultivation of Cells on Glass Coverslips 
Cells were grown on coverslip for scanning electron microscopy (Section 2.14).   
 
2.12.5.1 Pretreatment of Coverslips  
Glass coverslips of 13 mm in diameter (ARH, UK) were washed in 95 % ethanol 
for 30 min and then boiled in dgd water for about 15 min.  The coverslips were then dried 
overnight at 37 °C and dry heat sterilized in a hot air oven at 160 °C for 2 hr. 
 
2.12.5.2 Culture of Cells on Coverslips 
The individual coverslip was aseptically placed in a 24-well tissue culture tray.  A 
confluent cell monolayer in a 25 cm2 flask was used to propagate the cells as described in 
Section 2.12.4.  The cells were subcultured into the wells at a ratio of 1:25 using cell 
culture medium (Appendix 5).  The trays were incubated at 37 °C in a humidified 
incubator supplemented with 5 % carbon dioxide until they were about 50 % confluent. 
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2.12.6 Storage of Cells 
A confluent cell monolayer in 25 cm2 tissue culture flask was was treated as for 
propagation of cell line in Section 2.12.4.  The cell suspension was spun in a sterile 15 ml 
centrifuge tube at 800 x g for 10 min, after which the pellet was resuspended in 2 ml of 
preserving medium (Appendix 5).  One ml aliquot of this suspension (about 1 x 107 
viable cells) was dispensed into cryovials with screw caps (Iwaki, Canada).  These vials 
were placed in Cryo-freezing container [(1 °C/min) (Nalgene, USA)] in the -80 °C 
freezer overnight.  The vials were then stored in liquid nitrogen.   
The frozen cell lines were regenerated for experiments by fast thawing at 37 °C in 
a water bath.  The cell suspension was then transferred into a sterile 10 ml centrifuge tube 
that contained 4 ml of cell culture medium (Appendix 5) for the specific cell line to dilute 
the dimethyl sulphoxide (DMSO) in the preserving medium that would be toxic to the 
cells.  The cell suspension was then pelleted by centrifuging at 800 x g for 10 min. The 
supernatant (preserving medium) was discarded and the cell pellet was resuspended in 5 
ml of fresh growth medium (Appendix 5) of the specific cell line.  This suspension was 
transferred into a 25 cm2 tissue culture flask and was incubated at 37 °C overnight.  
Growth medium was changed the following day and the cells were allowed to grow to 
confluency. 
 
2.13  INFECTION OF CELLS 
2.13.1 Viruses 
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The viruses used in this study are given in Table 2.10.  The viruses were 
propagated in either ST cells or Vero cells throughout this study and would be herein 
referred by the abbreviations given below.   
Table 2.10 Viruses and related information. 



























vector particles  
- MLV(SARS) 












2.13.2 Infection of Cell Monolayers 
Cell culture medium of the 3 days old confluent cell monolayer was discarded and 
the monolayer was washed with 5 ml of virus diluent (Appendix 6).  Different volumes of 
virus suspension [Multiplicity Of Infection (M.O.I.) of 10] used were: a) 0.2 ml for a 25 
cm2 flask, b) 0.6 ml for a 75 cm2 flask and c) 1.5 ml for a 175 cm2 flask.  The flask was 
incubated at 37 °C for 1 hr and rocked every 15 min to ensure even infection.  After 1 hr, 
unabsorbed virus was washed off with 5 ml of maintenance medium [(MEM) (Appendix 
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6)] and an appropriate volume of MEM was added to the flask.  The infected ST cells 
were then incubated at 37 °C until the appropriate harvest time (Table 2.10). 
Mock-infected controls used in this study were prepared as abovementioned 
except that an appropriate amount of virus diluent (Appendix 9) was used instead of the 
virus.  
 
2.13.4 Neutralization Assay 
2.13.4.1 Plaque Neutralization Assay 
Intestinal fluids and serum samples from mice were evaluated using plaque 
neutralization assay.  Fifty µl of the samples in 2-fold serial dilutions (from 1:2 to 1:256 
or 1:512) were prepared in microcentrifuge tubes.  Virus, adjusted to 5 x 104 PFU in 50 
μl of virus diluent (Appendix 6) was added to the tube containing serially diluted serum 
or intestinal lavage.  The antibody-virus mixture was mixed by vortexing for 30 sec, 
pulsed centrifuged and incubated at 37 oC for an hour.  A 24-well plate with confluent 
monolayers of cells (prepared as described in Section 2.12.4) was used for virus 
infection.  The cell monolayer was rinse once with virus diluent (Appendix 6), after 
which 100 μl of the antibody-virus mixture was added to the appropriate wells.  The 
plates were left at 37 oC for another hour, and rocked at 15 min intervals.  After 
incubation, the inoculum was removed and the cell monolayer was rinsed once with virus 
diluent.  Overlay medium (Appendix 6) was added to the wells and the plate was 
incubated at 37 °C for 4-6 days. The overlay medium was then discarded, after which the 
wells were washed thrice with sterile PBS and virus plaques were stained with 0.5 % 
crystal violet/25 % formaldehyde solution (Appendix 6) for 30 min at room temperature. 
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Differences in the number of plaques formed between treatments were examined for the 
level of significance by Student’s t-test after analysis of variance. 
 
2.13.4.2 Fluorescent Focus Assay 
MLV(SARS), adjusted to 5 x 104 PFU in 50 μl of virus diluent (Appendix 6), was 
added to 50 µl of lavage and serum samples from mice in 2-fold serial dilutions (from 1:2 
to 1:256 or 1:512).  The antibody-virus mixture was mixed by vortexing for 30 sec, 
pulsed centrifuged and incubated at 37 oC for 1 hr to enhance virus absorption.  Confluent 
Vero cells in 24-well microtiter plate (prepared as described in Section 2.12.4) was rinse 
once with virus diluent (Appendix 6), after which 100 μl of the antibody-virus mixture 
was added to the appropriate wells.  In contrast to infection with authentic virus, 
transduction with SARS CoV S protein-pseudotyped murine leukemia virus 
[MLV(SARS)] into Vero cells was carried out by spinning the plate at 800 x g at 31 °C 
for 1 hr.  The transduced cells were then incubated at 37 °C in 5 % CO2 for 24 hr.  The 
supernatant was replaced with fresh culture medium and further incubated for another 48 
hr.  The plaque neutralization efficiency of the pseudovirus was analyzed using 
fluorescence focus assay.  The titers of individual serotypes (FFU/ml) were determined 
by counting the number of fluorescent foci in the well with an inverted fluorescence 
microscope with suitable filters for fluorescein isothiocyanate at 1000× magnification. 
 
2.13.5 Extraction of Virus RNA Molecules 
 Viral RNA extraction procedure was carried out using QIAmp® Viral RNA 
extraction kit from Qiagen, USA, following manufacturer’s instruction.  In brief, 140 μl 
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of virus supernatant (approximately 5 x 108 PFU/ml) were added to 560 µl of Buffer 
AVL containing carrier RNA in a 1.5 ml microcentrifuge tube.  The mixture was 
incubated at 25 ºC for 10 min, followed by the addition of 560 µl of absolute ethanol.  
The solution was then transferred to the QIAmp spin column and spun at 6000 x g for 1 
min.  The filtrate was discarded and the spin column was spun again at 6000 x g for 1 
min after adding 500 µl of Buffer AW1.  The above step was repeated with the addition 
of Buffer AW2.  Viral RNA was eluted from the spin column by adding 60 µl of Buffer 
AVE and spun at 6000 x g for 1 min.  The viral RNA was stored at -80 ºC until use. 
 
2.14 BIO-IMAGING VIA SCANNING ELECTRON MICROSCOPY (SEM) 
The cells on the coverslip were fixed with a primary fixative (2 % glutaraldehyde 
– Appendix 7) at room temperature for 1 hr and washed twice with 0.1 M sodium 
cacodylate buffer (Appendix 7) where the coverslip was soaked in the buffer for 5 min 
during each wash.  The cells were then post-fixed with secondary fixative (1 % osmium 
tetroxide - Appendix 7) for 1 hr at 4 °C.  Excess fixatives were removed by rinsing and 
soaking the samples twice for 5 min in 0.1 M sodium cacodylate buffer before 




Ethanol Concentrations Dehydration Time 
50 % 15 min 
75 % 15 min 
                                                                                   CHAPTER 2 
                                                                                                              MATERIALS & METHODS 
 96
95 % 15 min 
100 % 20 min (3x) 
 
The dehydrated cells on the coverslips were then critical point dried with CO2 and 
mounted onto SEM stubs before being sputter-coated with 70 nm gold films. Coated 
samples were then viewed under the scanning electron microscope (JEOL 5660, Japan). 
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3.0 ADHESION STUDIES 
3.1 INTRODUCTION 
In order for probiotic microorganisms, like lactobacilli and yeast, to function as 
oral vaccine delivery vehicle, the ability of the microorganisms to adhere to the intestinal 
tract is crucial.  To date, limited studies have been performed to investigate the 
colonization capability of lactobacilli and yeast.  As such, the present work aims to 
determine the adhesion and colonization capacity of Lactobacillus casei Shirota (LcS), 
and three other yeasts, S.boulardii, S.cerevisiae and P.pastoris.  In vitro adhesion of 
lactobacilli was not performed in this study as the ability of lactobacilli to adhere to 
intestinal cells in vitro has been previously elucidated (Morita et al., 2002; Coconnier et 
al., 1992; Lee & Puong, 2002).  In vitro interactions between the yeasts and human 
intestinal cell lines were first studied using scanning electron microscope, while the 
ability of exogenously administered lactobacilli and yeasts to adhere to the mucosal cells 
and to multiply in murine intestinal tract were determined in vivo.  L.casei Shirota and 
yeasts fluorescently labeled with five (and 6)-carboxyfluorescein diacetate, succinimidyl 
ester (cFDA-SE), were individually fed to mice and the intestinal segments were 
extracted from mice sacrificed various days post feeding.  The adhesiveness of each 
organism on the mucosa surface was then determined via flow cytometry analysis of the 





                                                                                   CHAPTER 3 
                                                                                RESULTS 
 98
3.2 IN VITRO ADHESION STUDIES USING SCANNING ELECTRON 
MICROSCOPY 
  To date, few studies have been performed to determine the adhesion capability of 
yeast to intestinal cells.  As a preliminary study, S.boulardii, S.cerevisiae and P.pastoris 
were assessed for their abilities to adhere to human enterocyte-like Caco-2 cells and to 
bind to mucus produced by the human mucus-secreting HT-29 cell in culture.  In vitro 
adhesion of Lactobacillus spp. was not carried out as previous studies have already 
confirmed that interactions do exist between lactobacilli and cultured human intestinal 
cells (Morita et al., 2002; Coconnier et al., 1992; Lee & Puong, 2002).    
Attachment of yeasts to the intestinal cell surfaces was characterized by scanning 
electron microscopic examination.  Scanning electron micrographs clearly illustrated that 
binding of the yeasts to Caco-2 occurred at the mucosal surface of the cultured intestinal 
epithelial cells (Figure 3.1).  In particular, P.pastoris was seen to interact with the brush 
border of the differentiated Caco-2 cells (Figure 3.1C).  Adhesiveness of each of the 
yeasts was assessed by enumerating the number yeast cell attached to 20 randomly 
chosen Caco-2 cells (Appendix 8d).  Similar attachment were observed with S.boulardii 
and S.cerevisiae (4.1 x 101 and 4.8 x 101 yeasts per cell) while P.pastoris demonstrated 
stronger adhesiveness (7.14 x 102 yeast per cell) to Caco-2 cells when compared to 
Saccharomyces spp.   
S.boulardii, S.cerevisiae and P.pastoris were also observed to adhere to the 
mucus-secreting HT-29 cell line (Figure 3.2).  The number of yeasts adhering to 20 
randomly chosen HT-29 cell were also enumerated (Appendix 8d).  Corresponding to the 
results obtained in the adhesion study performed using Caco-2 cell, a higher level of 
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adhesion to HT-29 cell was observed for P.pastoris (1.12 x 103 yeast per cell), while 
S.boulardii and S.cerevisiae (3.4 x 101 and 4.3 x 101 yeast per cell) demonstrated 
adhesiveness comparable to that in Caco-2 cell.  It is noteworthy that cells of P.pastoris 
conspicuously interacted with the secreted mucus of HT-29 cells (Figure 3.3).  The high 
level of adhesion by P.pastoris obscured the brush border, which was present under the 
biofilm of P.pastoris of HT-29 cells.   
It is apparent from the scanning electron micrographs in Figures 3.1 and 3.2, and 
the enumeration results that P.pastoris exhibited the strongest affinity amongst the three 
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Figure 3.1 Observation by scanning electron microscopy of the adherence of S.boulardii, S.cerevisiae and P.pastoris to human intestinal epithelial 
Caco-2 cells.  Low magnification showing adhesion of (A) S.boulardii (magnification, x2500) and (B) S.cerevisiae (magnification, x3300) to Caco-2 
cells.  Adhesion of (C) P.pastoris onto the brush border of Caco-2 cells (magnification, x2500).  (D) Scanning electron micrograph showing Caco-2 
cells with sparse microvilli (magnification, x2500). 
                                                                                   CHAPTER 3 
                                                                                RESULTS 
 101
 
Figure 3.2 Adhesion of (A) S.boulardii (magnification, x3500), (B) S.cerevisiae (magnification, x2500) and (C) P.pastoris (magnification, x3500) to 
human mucus-secreting HT29 cells observed by scanning electron microscopy.  (D) Scanning electron micrograph of HT29 cells with sparse microvilli 
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Figure 3.3 P.pastoris whole cells interacted with the mucus secreted by the HT29 cells (magnification, x2000 
[A] and x3700 [B]).  (C) High level of adhering P.pastoris formed a biofilm, which obscured the brush border 
(magnification, x2000).   
A B 
C 
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3.3 IN VIVO ADHESION STUDIES 
3.3.1 Murine Intestinal Surface Water and Mucus Content   
Many of the intestinal microorganisms were suspended in a layer of intestinal 
water, coating the intestinal surfaces.  Any ingestion of food and water could potentially 
exert a dilution effect on the intestinal water.  Hence, it is likely that microorganisms that 
remained suspended in the intestinal water and did not adhere to the mucosal surfaces 
would be diluted and washed out from the intestinal surfaces together with the mucus as 
part of the excreta eventually. As such, the dynamics of the mucosal layer determines the 
resident time of the intestinal microbiota.   
For determination of the intestinal water volume, mice were sacrificed where the 
intestinal tracts were extracted and cut longitudinally.  Each intestinal part was gently 
blotted dry using pre-weighed filter paper and the increase in the weight of the paper 
being taken as the volume of intestinal water of the respective intestinal portion.  The 
amounts of intestinal water overlaying the duodenum, jejunum, ileum and colon was 
found to be 34.4 + 2.9, 58.8 + 6.8, 21.6 + 2.2 and 8.0 + 1.0 mg, respectively.  The mice 
consumed 6.6 + 0.7 g of feed and water per animal per day and excreted an average of 1.2 
+ 0.3 g of feces per animal per day.  Since the mucus content of the feces was 0.9 + 0.1 
mg/g-faeces, it could be derived that 1.1 + 0.2 mg mucus was dislodged from the intestine 
surface of a mouse per day. 
 
3.3.2 Analysis of Lactobacillus casei Shirota Adhesion in Murine Intestinal Tract 
The protein dye cFDA-SE has been used to track cells and to analyze cell division 
(Logan et al., 2000; Ueckert et al., 1997).  An in vitro culture of cFDA-SE stained LcS 
                                                                                   CHAPTER 3 
                                                                                RESULTS 
 104
showed that the bacteria could be successfully stained by the protein dye (Figure 3.4).  In 
addition, division of cell was characterized by sequential two-fold reduction in cFDA-SE 
fluorescence (Figure 3.5).  For instance, one cell doubling in number (generation number 
1) resulted in a 1.6-fold reduction in the cellular fluorescence intensity of the dividing 
cells.  A further doubling in cell number (generation number 2) led to a 4.0-fold reduction 
in the initial cellular fluorescence intensity.  There is no indication of leakage of the dye 
and re-staining of cells, which would lead to disproportional changes in cellular 













Figure 3.4 cFDA-SE labelling of LcS.  (a) LcS visualized under transmitted light source.  (b) 
Green fluorescence of LcS stained with cFDA-SE.  (c) Superimposed image of (a) and (b).  (d) 
Unlabelled bacteria do not autofluorescence when the image was captured under cFDA-SE 
excitation wavelength. (Magnification x1000) 
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Figure 3.5 Plot of the residual median fluorescence intensity of an in vitro culture of labeled LcS 
against the generation number.  cFDA-SE labeled LcS was allowed to replicate in vitro where the 
median fluorescence intensities were determined at various generation number of LcS.  Each 
value represents the average of 3 samples and the vertical bars represent the standard deviations. 
 
The rate of wash-out of the lactobacilli from the intestinal mucosal surface was 
estimated from the slope of the plots of the residual concentration of lactobacilli labeled 
with cFDA-SE (total fluorescent cells irrespective of the intensity) extracted from the 
mucosal surface versus the time after orogastric intubation (Figure 3.6).  The half times 
for the wash-out of lactobacilli were determined to be 3.98, 1.55, 1.34, and 2.48 days in 
the duodenum, jejunum, ileum, and colon, respectively. 
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Figure 3.6 Plot of total LcS cell number adhered on various sections of the intestinal tract against 
time after orogastric intubation. Each value represents the average for three samples, and the 
vertical bars indicate standard deviations. 
 
As shown in Figure 3.5, division of LcS resulted in the dilution of the cFDA 
labeled protein by half.  Thus, the doubling times of the lactobacilli adhered on the 
mucosal surfaces were estimated from the residual fluorescence intensities (median) of 
cells extracted at different times after orogastric intubation (Figure 3.7).  The doubling 
times of LcS were 4.10, 4.78, 4.56, and 5.59 days in the duodenum, jejunum, ileum, and 
colon, respectively.  This suggests that LcS is able to divide at comparable rates in all 
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Figure 3.7 Plot of the residual median fluorescence intensity of LcS adhered on various sections 
of the intestinal tract against time after orogastric intubation. The median fluorescence intensity 
of LcS adhering in the ileum on Day 6 could not be determined due to some technical faults with 
the flow sorter during flow cytometric analysis of the sample.  Each value represents the average 
for three samples, and the vertical bars indicate standard deviations. 
 
The fluorescence intensity profiles of the adhered lactobacilli determined on the 
various days after orogastric intubation are summarized in Table 3.1.  The percentage of 
total population of LcS with fluorescence intensity greater than the median on Day 1 was 
found to differ amongst various portion of the intestinal tract.  This gave an indication 
that the bacterial cells were not uniformly labeled by cFDA-SE, and could probably be 
due to the physiological status of the cells at the time of incubation with cFDA-SE.  
Taking the median fluorescence intensities measured on day 1 as the reference, the 
fluorescence intensities are categorized into those that are higher than the median 
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measured on day 1 (expected fluorescence intensity after one cell division), those from 
half of the median intensity down to one-fourth of the median intensity measured on day 
1 (expected fluorescence intensity after two cell divisions), and those lower than one-
fourth of the median intensity measured on day 1 (expected fluorescence intensity after 
three cell divisions).  For example, in the duodenum on day 1, 35.92% of the lactobacilli 
showed fluorescence intensity higher than the median intensity (1.40 × 101 fluorescence 
units/cell), and 36.49% showed an intensity lower than 3.5 × 100 fluorescence units/cell 
(expected fluorescence level after three cell divisions).   
The cell division profiles of the adherent lactobacilli post oral administration were 
also illustrated in Figure 3.8.  It was observed that the percentage of cells that did not 
undergo any cell division decreased over the days post feeding, while the percentage of 
cells that have undergone two or three cell divisions was found to increase.  This gives an 
indication that LcS adhering to various portion of the gastrointestinal tract was able to 
undergo replication.  Using the data from Table 3.1, 44.4% (15.96/35.92) of the labeled 
lactobacilli retained the original fluorescence intensity (no cell division), whereas 13.1% 
of the total labeled lactobacilli had divided at least three times (49.54 − 36.49) on day 6 
in the duodenum.   It was calculated that on day 6 after orogastric intubation, the 
percentages of the lactobacilli that remained non-divided and adhered on the intestinal 
mucosal surfaces were 44.4, 60.5, 37.2, and 56.3% in the duodenum, jejunum, ileum, and 
colon, respectively.  On day 6 after orogastric intubation, 13.1, 3.9, 21.6, and 21.4% of 
the lactobacilli fed had divided at least three times. 
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Table 3.1 Fluorescence intensity profiles of lactobacilli harvested from various sections 
of the intestinal mucosal surface on various days after orogastric intubation of LcS.    
 
Section and %  of the total population with the following fluorescence intensity (mean + SD)a 
Day <1/4 median 1/4-1/2 median 1/2-median >Median 
Duodenum     
1 36.49 ± 3.51 10.13 ± 1.02 17.46 ± 1.98 35.92 ± 2.47 
2 33.04 ± 2.87 15.16 ± 1.48 19.80 ± 1.21 32.00 ± 2.41 
4 37.76 ± 2.69 18.64 ± 1.78 20.02 ± 2.04 23.58 ± 2.84 
6 49.54 ± 3.98 18.31 ± 1.20 16.19 ± 1.18 15.96 ± 1.07 
     
Jejunum     
1 24.23 ± 1.79 12.64 ± 0.84 18.95 ± 1.51 44.18 ± 4.25 
2 28.54 ± 2.07 16.53 ± 1.20 20.97 ± 1.99 33.96 ± 2.89 
4 28.15 ± 2.10 18.06 ± 1.74 21.71 ± 2.10 32.08 ± 3.84 
6 28.14 ± 3.07 24.51 ± 2.86 20.60 ± 2.51 26.75 ± 2.76 
     
Ileum     
1 30.06 ± 2.87 14.73 ± 1.17 15.78 ± 1.72 39.43 ± 3.20 
2 43.57 ± 3.51 24.85 ± 2.71 15.93 ± 1.43 15.65 ± 1.33 
4 47.87 ± 3.82 24.18 ± 2.14 12.57 ± 0.94 15.38 ± 1.14 
6 51.61 ± 4.01 22.90 ± 1.88 10.83 ± 0.76 14.66 ± 1.21 
     
Colon     
1 40.70 ± 3.14 14.38 ± 1.13 21.05 ± 1.45 23.87 ± 1.71 
2 37.74 ± 2.41 24.33 ± 2.03 25.00 ± 2.17 12.93 ± 0.72 
4 65.00 ± 4.95 14.36 ± 1.24 7.12 ± 0.49 13.52 ± 1.00 
6 62.14 ± 3.45 16.57 ± 1.52 7.86 ± 0.84 13.43 ± 1.17 
          
 
a The medians of the fluorescence intensities (n = 3) measured on day 1 were 1.40 x 101, 9.33 x 100, 1.87 x 101, and 
2.23 x 101 U/cell in the duodenum, jejunum, ileum and colon respectively.  <1/4 median, lower than one-fourth of the 
median fluorescence intensity measured on day 1; 1/4-1/2 median, one-fourth to one-half of the median intensity; 1/2-
median, half of median to median intensity; >median, higher then median intensity. 
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Figure 3.8 Plots showing the division profiles of total population of adhering LcS.  Each value 
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3.3.3 Analysis of Saccharomyces boulardii Adhesion in Murine Intestinal Tract  
Similarly, cFDA-SE was also utilized to analyze the ability of S.boulardii to 
adhere to murine intestinal cells.  S.boulardii labeled with cFDA-SE was cultured in vitro 
to determine if the replication of the yeast will result in halving of the fluorescence 
intensity.  Results had shown that the yeast could be successfully stained by the protein 
dye (Figure 3.9) and the division of cell was characterized by sequential two-fold 
reduction in cFDA-SE fluorescence (Figure 3.10).  One cell doubling in number 
(generation number 1) resulted in a 1.6-fold reduction in the cellular fluorescent intensity 
of the dividing cells.  A further doubling in cell number (generation number 2) led to a 
4.1-fold reduction in the initial cellular fluorescent intensity.  There is no indication of 
leakage of the dye and re-staining of cells, which would lead to disproportional changes 











Figure 3.9 cFDA-SE labelling of S.boulardii.  (a) S.boulardii visualized under transmitted light 
source.  (b) Green fluorescence of S.boulardii stained with cFDA-SE.  (c) Superimposed image of 
(a) and (b).  (d) Unlabelled yeast does not autofluorescence when the image was captured under 
cFDA-SE excitation wavelength. (Magnification x1000). 
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Figure 3.10 Plot of the residual median fluorescent intensity of an in vitro culture of labeled 
S.boulardii against the generation number.  cFDA-SE labeled S.boulardii was allowed to replicate in 
vitro where the median fluorescence intensities were determined at various generation number.  Each 
value represents the average of 3 samples and the vertical bars represent standard deviations. 
 
As shown in Figure 3.11, the adherence of yeast cells after oral feeding took place 
mainly in the duodenum (81.5 % of total adhering S.boulardii on day 1).  The rate of 
wash-out of S.boulardii from the intestinal mucosal surface was estimated from the slope 
of the plots of the residual concentration of the yeast labeled with cFDA-SE (total 
fluorescent cells irrespective of the intensity) extracted from the mucosal surface versus 
the time after orogastric intubation (Figure 3.11).  The half times for the wash-out of 
S.boulardii were determined to be 2.64, 3.02, 5.35, and 66.02 days in the duodenum, 
jejunum, ileum, and colon, respectively. 
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Figure 3.11 Plot of total S.boulardii cell number adhered on various sections of the intestinal 
tract against time after orogastric intubation. Each value represents the average for three samples, 
and the vertical bars indicate standard deviations. 
 
The time taken by adhering S.boulardii to replicate in murine intestinal tract were 
estimated from the residual fluorescence intensities (median) of cells extracted at 
different times after orogastric intubation (Figure 3.12). The doubling times of 
S.boulardii were found to be 1.33, 2.61, 10.91, and 20.83 days in the duodenum, jejunum, 
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Figure 3.12 Plot of residual median fluorescence intensity of S.boulardii adhered on various 
sections of the intestinal tract against time after orogastric intubation. Each value represents the 
average for three samples, and the vertical bars indicate standard deviations. 
 
Table 3.2 summarizes the fluorescence intensity profiles of the adhered 
S.boulardii determined on the various days after orogastric intubation.  On day 1, 38.66% 
of the yeast showed a fluorescence intensity higher than the median intensity (1.22 × 101 
fluorescence units/cell) in the duodenum, and 33.15% showed an intensity lower than 
3.05 × 100 fluorescence units/cell (expected fluorescence level after three cell divisions).   
The cell division profiles of the adherent yeast post oral administration were 
illustrated in Figure 3.13.  Interestingly, the percentages of S.boulardii that did not under 
go cell division remained constantly high in the ileum and colon.  This gives an 
indication that the yeast adhering to ileum and colon could not replicate.  As for the cells 
attached to duodenum and jejunum, there is a gradual reduction in the percentages of cell 
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that did not undergo division, which was complimented by a general increase in the 
percentages of cells that have replicated at least once.  Based on the data obtained from 
Table 3.2, 35.5% (13.72/38.66) of the labeled S.boulardii retained the original 
fluorescence intensity (no cell division), whereas 16.3% of the total labeled yeast had 
divided at least three times (49.48 − 33.15) on day 6 in the duodenum.   It was calculated 
that on day 6 after orogastric intubation, the percentages of S.boulardii that remained 
non-dividing and adhering on the intestinal mucosal surfaces were 35.59, 53.4, 91.5, and 
96.6% in the duodenum, jejunum, ileum, and colon, respectively.  On day 6 after 
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Table 3.2 Fluorescence intensity profiles of S.boulardii harvested from various sections 
of the intestinal mucosal surface on various days post orogastric intubation.  
 
Section and % of the total population with the following fluorescence intensity  (mean + SD)a 
Day <1/4 median 1/4-1/2 median 1/2-median >Median 
Duodenum     
1 33.15 ± 3.19 11.58 ± 1.01 16.61 ± 1.88 38.66 ± 2.90 
2 35.49 ± 3.75 13.34 ± 1.08 19.38 ± 1.13 31.79 ± 3.40 
4 40.03 ± 3.63 16.52 ± 1.16 20.87 ± 1.42 22.58 ± 2.17 
6 49.48 ± 4.35 17.28 ± 1.48 19.52 ± 1.60 13.72 ± 1.65 
     
Jejunum     
1 24.87 ± 2.41 13.80 ± 1.75 17.44 ± 1.79 43.89 ± 3.74 
2 27.22 ± 1.19 14.80 ± 1.84 19.45 ± 1.77 38.53 ± 3.32 
4 27.91 ± 3.05 17.37 ± 2.42 22.81 ± 1.84 31.91 ± 3.44 
6 38.85 ± 2.21 19.31 ± 1.17 18.41 ± 2.08 23.43 ± 2.56 
     
Ileum     
1 9.12 ± 0.99 11.82 ± 1.02 10.78 ± 1.75 68.28 ± 4.66 
2 9.83 ± 1.09 12.95 ± 1.91 11.54 ± 1.38 65.68 ± 2.92 
4 12.55 ± 1.10 13.62 ± 1.24 10.74 ± 1.21 63.09 ± 3.53 
6 17.10 ± 0.84 11.99 ± 1.20 8.44 ± 1.19 62.47 ± 2.95 
     
Colon     
1 8.23 ± 1.23 10.08 ± 1.05 9.53 ± 1.29 72.16 ± 4.73 
2 12.19 ± 1.19 9.26 ± 0.25 8.11 ± 1.17 70.44 ± 4.16 
4 11.24 ± 1.23 9.65 ± 1.36 8.01 ± 1.41 71.10 ± 3.96 
6 14.33 ± 1.68 8.28 ± 1.37 7.70 ± 1.20 69.69 ± 5.13 
          
 
a The medians of the fluorescence intensities (n = 3) measured on day 1 were 1.22 x 101, 4.72 x 100, 2.6  x 100, and 
2.21 x 100 U/cell in the duodenum, jejunum, ileum and colon respectively.  <1/4 median, lower than one-fourth of the 
median fluorescence intensity measured on day 1; 1/4-1/2 median, one-fourth to one-half of the median intensity; 1/2-
median, half of median to median intensity; >median, higher then median intensity. 
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Figure 3.13 Plots showing the division profiles of total population of adhering S.boulardii.  Each 
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3.3.4 Analysis of Saccharomyces cerevisiae Adhesion in Murine Intestinal Tract 
An in vitro culture of fluorescently labeled S.cerevisiae was analyzed to 
determine if the replication of the yeast would result in halving of the fluorescence 
intensity.  The yeast was observed to be successfully tag with cFDA-SE when viewed 
under fluorescent microscope (Figure 3.14).  Results had shown that division of cell was 
characterized by sequential two-fold reduction in cFDA-SE fluorescence (Figure 3.15).  
There is no indication of leakage of the dye and re-staining of cells, which would lead to 













Figure 3.14 cFDA-SE labelling of S.cerevisiae.  (a) S.cerevisiae visualized under transmitted 
light source.  (b) Green fluorescence of S.cerevisiae stained with cFDA-SE.  (c) Superimposed 
image of (a) and (b).  (d) Unlabelled yeast does not autofluorescence when the image was 
captured under cFDA-SE excitation wavelength. (Magnification x1000). 
  a b 
  c d 
                                                                                   CHAPTER 3 













Figure 3.15 Plot of the residual median fluorescent intensity of an in vitro culture of labeled 
S.cerevisiae against the generation number.  cFDA-SE labeled S.cerevisiae was allowed to replicate in 
vitro where the median fluorescence intensities were determined at various generation number.  Each 
value represents the average of 3 samples and the vertical bars represent standard deviations. 
 
The rate of wash-out of S.cerevisiae from the intestinal mucosal surface was 
estimated from the slope of the plots of the residual concentration of yeast labeled with 
cFDA-SE (total fluorescent cells irrespective of the intensity) extracted from the mucosal 
surface versus the time after orogastric intubation (Figure 3.16).  The half times for the 
wash-out of S.cerevisiae were determined to be 1.25, -4.46, 1.70, and 1.84 days in the 
duodenum, jejunum, ileum, and colon, respectively.  The negative wash-out half time 
obtained for S.cerevisiae in the jejunum was attributable to the increase in cell number 
various days post feeding.  The increase in the number of S.cerevisiae in the jejunum 
could either be due to the replication of the adhering yeast or contributed by the re-
adherence of yeast detached from the duodenum.  It could be observed from Figure 3.17 
that the median fluorescence intensity of S.cerevisiae adhering to the jejunum remained 
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relatively constant from Day 1 to 6 post administrations.  This implied that the adhering 
S.cerevisiae has not undergone replication, as division of the cells would result in a 
decrease in the fluorescence intensity.  Hence, the increase in number of S.cerevisiae in 
the jejunum is more likely due to the reattachment of the detached cells from the 














Figure 3.16 Plot of total S.cerevisiae cell number adhered on various sections of the intestinal 
tract against time after orogastric intubation. Each value represents the average for three samples, 
and the vertical bars indicate standard deviations. 
 
The doubling times of S.cerevisiae adhering to different portions of murine 
intestinal tract were estimated from the residual fluorescence intensities (median) of cells 
extracted at different times after orogastric intubation (Figure 3.17).    The doubling times 
of S.cerevisiae were 1.67, 9.10, 0.45, and 0.85 days in the duodenum, jejunum, ileum, 
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Figure 3.17 Plot of residual median fluorescence intensity of S.cerevisiae adhered on various 
sections of the intestinal tract against time after orogastric intubation. Each value represents the 
average for three samples, and the vertical bars indicate standard deviations. 
 
Analysis of the fluorescence intensities of adherent S.cerevisiae various days after 
orogastric intubation was conducted.  The fluorescence profiles were summarized and 
represented in Table 3.3.  For example, on day 1, 42.15% of the yeast showed a 
fluorescence intensity higher than the median intensity (3.17 × 101 fluorescence 
units/cell) in the duodenum, and 25.05% showed an intensity lower than 7.93 × 100 
fluorescence units/cell (expected fluorescence level after three cell divisions).   
As illustrated by the cell division profiles of the adhered S.cerevisiae (Figure 
3.18), the percentage of S.cerevisiae that did not under go cell division was constantly 
high in the jejunum. More than half of the cells that were attached to the jejunum did not 
replicate and only a small fraction of cell has undergone cell division.  Replication of 
S.cerevisiae was observed in the duodenum, ileum and colon, as indicated by a gradual 
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reduction in the percentages of cell that did not undergo division, and an increase in the 
percentages of cells that have replicated at least once.  Based on the data obtained from 
Table 3.3, 44.5% (18.76/42.15) of the labeled S.cerevisiae retained the original 
fluorescence intensity (no cell division), whereas 16.6% of the total labeled yeast had 
divided at least three times (41.57 − 25.02) on day 6 in the duodenum.   On day 6 after 
orogastric intubation, the percentages of S.cerevisiae that remained non-divided and 
adhered on the intestinal mucosal surfaces were 44.5, 93.3, 24.0, and 30.6% in the 
duodenum, jejunum, ileum, and colon, respectively.  On day 6 after orogastric intubation, 
16.6, 0.27, 34.23, and 26.09% of the yeast fed had divided at least three times. 
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Table 3.3 Fluorescence intensity profiles of S.cerevisiae harvested from various sections 
of the intestinal mucosal surface on various days post orogastric intubation.  
 
Section and % of the total population with the following fluorescence intensity  (mean + SD)a 
Day <1/4 median 1/4-1/2 median 1/2-median >Median 
Duodenum     
1 25.02 ± 3.45 14.15 ± 1.45 18.68 ± 2.69 42.15 ± 3.86 
2 28.62 ± 2.48 16.35 ± 1.11 19.74 ± 1.21 35.29 ± 3.05 
4 34.85 ± 3.71 18.41 ± 1.98 20.67 ± 3.00 26.07 ± 2.69 
6 41.57 ± 2.52 19.71 ± 2.01 20.96 ± 2.34 18.76 ± 1.85 
     
Jejunum     
1 11.32 ± 1.34 11.74 ± 0.82 11.33 ± 1.91 65.61 ± 2.79 
2 10.40 ± 1.14 10.75 ± 1.29 12.08 ± 1.67 66.77 ± 2.97 
4 10.49 ± 0.98 11.68 ± 1.49 15.42 ± 0.76 63.95 ± 2.56 
6 11.59 ± 1.35 11.19 ± 2.09 16.00 ± 1.31 61.22 ± 2.84 
     
Ileum     
1 28.99 ± 3.07 18.36 ± 2.12 19.48 ± 1.56 33.17 ± 2.63 
2 43.62 ± 4.58 16.42 ± 2.71 18.32 ± 2.27 21.64 ± 3.16 
4 56.84 ± 3.78 16.14 ± 1.98 14.96 ± 1.96 12.06 ± 1.66 
6 63.22 ± 4.52 15.56 ± 1.48 13.51 ± 1.42 7.97 ± 1.49 
     
Colon     
1 30.45 ± 3.01 16.47 ± 1.42 17.47 ± 1.93 35.61 ± 3.47 
2 36.03 ± 3.50 18.23 ± 1.64 18.83 ± 1.66 26.97 ± 2.91 
4 48.46 ± 4.14 17.44 ± 1.65 17.37 ± 1.99 16.73 ± 1.46 
6 56.54 ± 4.22 16.40 ± 1.92 16.17 ± 1.33 10.89 ± 1.44 
          
 
a The medians of the fluorescence intensities (n = 3) measured on day 1 were 3.17 x 101, 1.87 x 101, 4.06  x 100, and 
6.05 x 100 U/cell in the duodenum, jejunum, ileum and colon respectively.  <1/4 median, lower than one-fourth of the 
median fluorescence intensity measured on day 1; 1/4-1/2 median, one-fourth to one-half of the median intensity; 1/2-
median, half of median to median intensity; >median, higher then median intensity. 
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Figure 3.18 Plots showing the division profiles of total population of adhering S.cerevisiae.  Each 
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3.3.5 Analysis of Pichia pastoris Adhesion in Murine Intestinal Tract 
An in vitro culture of cFDA-SE stained P.pastoris had shown that the yeast could be successfully 
labeled by the protein dye (Figure 3.19) and the division of cell was characterized by sequential two-fold 
reduction in cFDA-SE fluorescence (Figure 3.20).  There is no indication of leakage of the dye and re-














Figure 3.19 cFDA-SE labelling of P.pastoris.  (a) P.pastoris visualized under transmitted optical 
view.  (b) Green fluorescence of P.pastoris stained with cFDA-SE.  (c) Superimposed image of 
(a) and (b).  (d) Unlabelled yeast does not autofluorescence when the image was captured under 
cFDA-SE excitation wavelength. (Manification x1000). 
 
  a  b
  c  d
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Figure 3.20 Plot of the residual median fluorescent intensity of an in vitro culture of labeled 
P.pastoris against the generation number.  cFDA-SE labeled P.pastoris was allowed to replicate in vitro 
where the median fluorescence intensities were determined at various generation number.  Each value 
represents the average of 3 samples and the vertical bars represent the standard deviations. 
 
The wash-out rate of P.pastoris adhered to intestinal mucosal surface was 
estimated from the slope of the plots of the residual concentration of yeast labeled with 
cFDA-SE (total fluorescent cells irrespective of the intensity) extracted from the mucosal 
surface versus the time after orogastric intubation (Figure 3.21).  The half times for the 
wash-out of P.pastoris were determined to be 2.85, 2.21, -28.80, and –5.97 days in the 
duodenum, jejunum, ileum, and colon, respectively.  The negative half times for the 
wash-out of P.pastoris in the ileum and colon were due to the increase in cell number 
various days post feeding.  As mentioned in the previous section, an increase in cell 
number might not be due to the replication of the adhering yeast.  The re-adherence o 
cells detached from the upper portion of the intestine could also result in an increase in 
cell number further down the intestinal tract.  As observed in Figure 3.22, the median 
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fluorescence intensity of P.pastoris adhering to the ileum increased over the days, while 
the median fluorescence intensity of those attached to the colon decreased over the days.  
An increase in cell number, accompanied by a decrease in median fluorescence intensity, 
implied the occurrence of cell division.  Hence, P.pastoris that adhered to the colon had 
undergone replication.  As for the increase in number of yeast in the ileum, there was a 
corresponding increase in the median fluorescence intensity of the adhering P.pastoris.  
This gave an indication that yeast detached from the upper portion of the intestinal tract 











Figure 3.21 Plot of total P.pastoris cell number adhered on various sections of the intestinal tract 
against time after orogastric intubation. Each value represents the average for three samples, and 
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As each division of the yeast resulted in the halving of fluorescence intensity, the 
doubling times of P.pastoris adhered on the mucosal surfaces were estimated from the 
residual fluorescence intensities (median) of cells extracted at different times after 
orogastric intubation (Figure 3.22).  The doubling times of P.pastoris were 1.54, 1.97, -
77.32, and 2.76 days in the duodenum, jejunum, ileum, and colon, respectively.  The 
negative doubling time of P.pastoris in the ileum was due to the increase in the residual 
median fluorescence intensity of adhering yeast over the days in the ileum.  As explained 
earlier, this increase in fluorescence intensity was resulted from the reattachment of 










Figure 3.22 Plot residual median fluorescence intensity of P.pastoris adhered on various sections 
of the intestinal tract against time after orogastric intubation. Each value represents the average 
for three samples, and the vertical bars indicate standard deviations. 
 
The fluorescence intensity profiles of the adhered P.pastoris determined on the 
various days after orogastric intubation have been illustrated in Table 3.4.  On day 1, 
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40.50% of the yeast showed a fluorescence intensity higher than the median intensity 
(1.77 × 101 fluorescence units/cell) in the duodenum, and 26.69% showed an intensity 
lower than 4.43 × 100 fluorescence units/cell (expected fluorescence level after three cell 
divisions).   
The cell division profiles of the adherent P.pastoris post oral administration were 
also illustrated in Figure 3.23.  The percentage of P.pastoris that adhered to the ileum but 
did not replicate was constantly high in comparison to those that were attached to other 
portions of the intestinal tract.  This is in agreement to the observations that the increase 
in number of P.pastoris in the ileum was contributed by the re-adhesion of detached yeast 
rather than the replication of the adhering P.pastoris in the ileum.  The percentages of 
cells that have undergone 1 or 2 cell divisions were uniformly low throughout the days, 
while those that have undergone 3 cell divisions were increasing, giving an indication 
that the adhering yeast were constantly dividing.  Based on the data obtained from Table 
3.2, 44.9% (18.22/40.50) of the labeled P.pastoris retained the original fluorescence 
intensity (no cell division), whereas 20.2% of the total labeled yeast had divided at least 
three times (46.89 − 26.69) on day 6 in the duodenum.   It was calculated that on day 6 
after orogastric intubation, the percentages of P.pastoris that remained non-divided and 
adhered on the intestinal mucosal surfaces were 44.9, 45.2, 94.9, and 49.4% in the 
duodenum, jejunum, ileum, and colon, respectively.  On day 6 after orogastric intubation, 
20.2, 23.7, 3.7, and 13.7% of the yeast fed had divided at least three times. 
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Table 3.4 Fluorescence intensity profiles of P.pastoris harvested from various sections of 
the intestinal mucosal surface on various days post orogastric intubation. 
 
Section and % of the total population with the following fluorescence intensity  (mean + SD)a 
Day <1/4 median 1/4-1/2 median 1/2-median >Median 
Duodenum     
1 26.69 ± 2.90 15.45 ± 1.20 17.36 ± 1.50 40.50 ± 3.73 
2 27.04 ± 2.65 17.18 ± 1.92 19.52 ± 1.82 36.26 ± 2.47 
4 38.47 ± 3.86 19.51 ± 1.94 17.35 ± 1.88 24.67 ± 2.51 
6 46.89 ± 4.10 18.36 ± 1.30 16.52 ± 2.45 18.22 ± 1.75 
     
Jejunum     
1 23.09 ± 1.63 13.54 ± 1.62 18.62 ± 1.51 44.75 ± 3.77 
2 29.97 ± 3.27 15.21 ± 1.39 19.98 ± 1.29 34.84 ± 2.07 
4 39.05 ± 2.47 16.86 ± 1.86 20.76 ± 1.87 23.33 ± 2.35 
6 46.75 ± 3.21 14.59 ± 1.54 18.44 ± 1.49 20.22 ± 2.06 
     
Ileum     
1 20.34 ± 1.44 13.13 ± 1.42 15.45 ± 0.73 51.08 ± 3.66 
2 20.04 ± 2.68 16.08 ± 1.77 18.36 ± 1.66 45.52 ± 3.45 
4 21.12 ± 2.28 14.58 ± 1.66 12.62 ± 1.59 51.68 ± 4.35 
6 24.03 ± 2.59 14.00 ± 2.30 13.51 ± 1.96 48.46 ± 3.79 
     
Colon     
1 25.22 ± 2.83 12.40 ± 2.10 13.92 ± 1.71 48.46 ± 4.30 
2 26.39 ± 2.63 15.65 ± 1.58 16.40 ± 2.01 41.56 ± 2.87 
4 31.52 ± 3.39 16.61 ± 1.57 18.19 ± 1.91 33.68 ± 2.78 
6 38.91 ± 2.48 17.68 ± 2.12 19.48 ± 2.44 23.93 ± 1.99 
          
 
a The medians of the fluorescence intensities (n = 3) measured on day 1 were 1.77 x 101, 1.27 x 101, 1.17 x 101, and 
6.96 x 100 U/cell in the duodenum, jejunum, ileum and colon respectively.  <1/4 median, lower than one-fourth of the 
median fluorescence intensity measured on day 1; 1/4-1/2 median, one-fourth to one-half of the median intensity; 1/2-
median, half of median to median intensity; >median, higher then median intensity. 
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Figure 3.23 Plots showing the division profiles of total population of adhering P.pastoris.  Each 
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4.0 DEVELOPMENT OF ORAL VACCINE AGAINST 
TRANSMISSIBLE GASRTOENTERITIS CORONAVIRUS 
(TGEV) 
4.1 INTRODUCTION 
TGEV, an enteropathogenic coronavirus, causes acute diarrhea in newborn pigs 
with a mortality rate that is close to 100%.  Oral vaccination, which allows the 
neutralization of pathogens at the point of infection, would be useful in the development 
of protective measures against TGEV infection.  In this part of the study, the feasibility of 
using prokaryotic lactobacilli and eukaryotic yeasts as a mode of delivery of TGEV 
antigen was investigated.  In the previous chapter, we have showed that LcS and the three 
strains of yeast were able to adhere to the intestinal cells.  In particular, P.pastoris 
demonstrated the highest adhesiveness both in vitro and in vivo when compared to 
S.boulardii and S.cerevisiae.  Hence, LcS and P.pastoris were genetically engineered to 
constitutively express and secrete an N-terminal fragment of TGEV spike protein.  
Immunization studies of the recombinant LcS and P.pastoris were carried out using 
BALB/c mice.  The neutralization ability of the induced antibodies against TGEV were 
determined, while the cytokine production profiles of cells of the Peyer’s patches 
extracted from the immunized mice were also characterized.  
 
4.2 GENERATION OF TGEV-S-GST  
A 1.3 kb gene fragment encoding the N-terminal portion of TGEV spike protein 
was generated from first strand cDNA synthesized from the TGEV genomic RNA 
(Figure 4.1) and cloned into pGEX-4T-3, downstream of GST gene.  The selected gene 
                                                                                   CHAPTER 4 
                                                                                RESULTS 
 133
fragment consisted of the two immunodominant A and D sites, where epitopes critical for 
neutralization were found to be clustered within (Delmas et al., 1986; Jim’enez et al., 
1986).  Plasmids isolated from positively selected transformants were analyzed for the 
presence of TGEV spike insert via restriction digestion.  As shown in Figure 4.2, the 
presence of a band that is approximately 1.3 kb in size indicated that recombinant E.coli 
harboring TGEV spike gene fragment have been successfully constructed.  Nucleotide 
sequencing of the recombinant vectors showed that the TGEV insert were cloned in-
frame to the sequence encoding GST in the vector. 
Induction of TGEV-S-GST protein by the recombinant E.coli was carried out for 
3 hr using 1 mM IPTG, for the optimal expression of the recombinant protein.  The 
recombinant protein consisting of the N-terminal fragment of TGEV spike protein (44 
kDa) fused to the C-terminal of GST protein (26 kDa), would have a molecular weight of 
70 kDa.  The supernatant and different fractions of the insoluble proteins extracted using 
various concentrations of urea and 0.01% SDS were separated on 10% SDS-PAGE and 
visualized by Coomassie Blue staining (Figure 4.3).  It could be observed from Figure 
4.3A that the highest amount of TGEV-S-GST protein was extracted using 6M urea.  The 
protein fraction solubilized using 6M urea was then re-folded by extensive buffer 
exchange and further purified by running the extract through a column containing 
glutathione sepharose 4B.  As apparent from Figure 4.3B, TGEV-S-GST protein was 
relatively pure after the affinity purification step.  The purified form of TGEV-S-GST 
protein was then included as positive control in subsequent Western blots or used as 
coating antigen in ELISA for the analytical studies of the recombinant LcS or P.pastoris 
that were developed as oral vaccine carriers against TGEV.       
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Figure 4.1 Agarose gel electrophoresis of PCR amplified TGEV spike gene fragment to be 










Figure 4.2 Restriction digested plasmids extracted from E.coli transformants electrophorized on 
agarose gel.  Lane: 1 and 2, a 1.3 kb band corresponded to the TGEV spike gene insert was 
cleaved from the vector using EcoRI and Sal1, which corresponded to the 5.0 kb band.  Lane M1 
denotes 1 kb DNA ladder while lane M2 denotes 100 bp DNA ladder. 
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Figure 4.3 Expression and purification of TGEV-S-GST protein by recombinant E.coli after 
IPTG induction.  (A) Over-production of TGEV-S-GST protein analyzed on 10% SDS-PAGE 
and visualized by Coomassie Blue staining.  Lanes: 1-4, cell extract solubilized with 1M, 6M, 8M 
urea and 0.01% SDS respectively; 5, cell-free extract. (B) Re-folded and column purified TGEV-
S-GST was observed to be relatively pure. 
   
4.3 L.CASEI SHIROTA AS ORAL VACCINE CARRIER AGAINST TGEV 
4.3.1 Generation of Recombinant LcS Expressing rTGEV-S Protein  
In order to generate recombinant LcS expression vector harboring TGEV spike 
gene, the genes encoding an N-terminal fragment of the TGEV spike protein was 
amplified from first strand cDNA synthesized from the viral genomic RNA by RT-PCR 
reverse transcription. 
To obtain the rTGEV-S insert, primers Tgeplp-FI and Tgeplp-RI were used to 
amplify the region between nucleotides 33-2286 of TGEV spike gene (Figure 4.4).  This 
insert encompasses all the four major antigenic domains of the spike gene.  The design of 
oligonucleotides for PCR was based on the sequences of the TGEV spike gene at the start 
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and end of nucleotides 33-2286.  The restriction sites of BamHI and NheI, which were 
not present in the TGEV spike gene sequence to be amplified, were included onto the 








Figure 4.4 Agarose gel electrophoresis of PCR products of rTGEV-S, amplified from cDNA 
synthesized from viral genomic RNA.  Lane M denotes 1 kb DNA ladder. 
 
Numerous attempts to clone rTGEV-S directly into Lactobacillus spp. expression 
vector had failed.  The insert was therefore subcloned into pCR®-XL-TOPO® vector via 
TA cloning (Figure 4.5).  Taq polymerase-amplified rTGEV-S was directly inserted into 
the linearized vector with single 3´-thymidine (T) overhangs and transformed into One 
Shot® cell.  The 2.3 kb insert was then cleaved from plasmid isolated from transformant 
positively selected on LB plates containing 50 μg/ml kanamycin (Figure 4.6).   
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Figure 4.5 Schematic diagram of the construction of recombinant Lactobacillus spp. expression 
vector harboring rTGEV-S gene fragment.  Taq polymerase amplified rTGEV-S gene fragment 
was subcloned into pCR®-XL-TOPO® via TA cloning.  The insert rTGEV-S was cleaved from 
pCR®-XL-TOPO® using BamH1 and Nhe1 and religated to pLP500 to generate the recombinant 
pLP500/rTGEV-S. 
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A rTGEV-S 
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Figure 4.6 Electrophoretogram of BamHI and NheI digested pCR®-XL-TOPO® vector in which 
rTGEV-S have been subcloned.  Lane: 1, a 2.3 kb band corresponded to the insert was cleaved 
from the vector, which corresponded to the 3.5 kb band.  Lane M denotes 1 kb DNA ladder. 
 
The cleaved insert was purified prior to cloning into Lactobacillus spp. expression vector pLP500 
and transformed into E.coli DH10β competent cells.  pLP500 is a plasmid with endogenous regulation 
elements from Lactobacillus, downstream of the secretion signal of prt P gene of L. casei for secretable 
protein expression.  Transformants selected on LB agar plate containing 100 μg/ml ampicillin were 
checked for the presence of insert rTGEV-S via restriction digestion of the isolated plasmids (Figure 4.7).  
A 2.3 kb band was obtained for two of the plasmids extracted from the transformants, indicating that 
recombinant pLP500 vector harboring the insert rTGEV-S have been successfully constructed.  One of the 
resulting plasmid was verified by sequence analysis, indicating that rTGEV-S has been cloned in frame 
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Figure 4.7 Electrophoretogram of BamHI and NheI digested plasmids isolated from E.coli 
DH10β transformants.  Lanes: 1 and 2, a 2.3 kb band corresponding to the expected size of 
rTGEV-S was generated, indicating that both plasmids were recombinant clones of rTGEV-S; 3, 
only a single band (7.2 kb) was obtained giving an indication that recirculation of pLP500 could 
have taken place.  Lane M denotes 1 kb DNA ladder. 
 
  
After the initial construction, screening and confirmation of the presence of the 
TGEV spike gene fragment in the recombinant plasmid in E.coli, pLP500/rTGEV-S was 
then electroporated into LcS.  Transformants appeared after 48 hr of incubation on MRS 
agar plates containing erythromycin (5 µg/ml).  The gene coding for the resistance to 
erythromycin was encoded by the pE194 portion of the pLP500 plasmid (Appendix 2).  
Ampicillin resistance could not be used for the selection of LcS transformants as 
proteolytic degradation of secreted β-lactamases occur in lactobacilli (Sibakov et al., 
1991; Pouwels & Leer et al., 1993).  PCR analysis of the isolated vectors using the 
primers Tgeplp-FI and Tgeplp-RI identified five recombinant LcS harboring 
pLP500/rTGEV-S (Figure 4.8) of which one of the recombinant LcS was denoted as LcS-
rTGEV-S 
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Figure 4.8 PCR of recombinant pLP500/rTGEV-S extracted from LcS transformants. Lanes: 1, 
pLP500 (negative control); 2-6, plasmids isolated from transformants.  Lane M denotes 1 kb 
DNA ladder. 
 
The expression of rTGEV-S protein by LcS-rTGEV-S was analyzed by 
immunoblot assay using recombinant LcS harboring either pLP500/rTGEV-S or the 
empty vector and wild type LcS as the control (Figure 4.9).  Western blot analysis of 
concentrated supernatant from overnight culture of LcS-rTGEV-S revealed a protein 
band (75 kDa) corresponding to the expected molecular weight of the rTGEV-S protein 
(lane 3).     
As the supernatant had to be concentrated ten times before a distinct protein band 
could be seen, the expression of rTGEV-S protein by the recombinant LcS was 
apparently inefficient.  Nevertheless, the reactivity of the 75 kDa band with a polyclonal 
TGEV-specific convalescence swine serum gave an indication of the immunogenicity of 
the expressed protein.  In contrast, no signal was detected in culture medium and culture 
supernatants of control strain harboring pLP500 or wild type LcS (lanes 2, 4 and 5).  
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Samples of purified recombinant TGEV spike protein (TGEV-S-GST, 70 kDa) was also 









Figure 4.9 Expression of rTGEV-S protein from LcS-rTGEV-S.  Concentrated supernatants from 
overnight cultures of LcS-rTGEV-S (lane 3), LcS-pLP500 (lane 4) or LcS (lane 5) were separated 
by SDS-PAGE 10% and transferred electrophoretically to nitrocellulose membrane before being 
incubated with convalescent swine anti-TGEV serum at a dilution of 1:1000.  Antibodies bound 
to the 75 kDa rTGEV-S protein were detected with HRP-conjugated anti-swine IgG antibodies.  
Lanes; 1, purified recombinant TGEV-S-GST protein (positive control); 2, MRS broth (negative 
control). 
 
4.3.2 Immune responses induced by intragastric immunization of LcS-rTGEV-S 
To investigate the levels of in vivo immune responses generated by the 
Lactobacillus spp. vaccine (LcS-rTGEV-S), three 8 weeks old female BALB/c mice were 
orally immunized with LcS-rTGEV-S.  As shown in Figure 4.10, mice receiving three 
doses of LcS expressing rTGEV-S protein on days 0-2 were primed for a secondary 
response to rTGEV-S protein following booster oral administrations on days 14-16 and 
28-30.  BALB/c mice were chosen as the model as it was utilized by Liu et al. to evaluate 
the immunogenicity of TGEV DNA vaccine (Liu et al., 2001).   
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Figure 4.10 Schematic diagram showing the oral vaccination regime of recombinant LcS to 
BALB/c mice.       indicates oral administration of 2 x 109 cfu LcS-rTGEV-S to each mice on the 
specific days indicated;      indicates the specific days in which lavaging and bleeding of the 
vaccinated mice were performed.    
 
 
Immunological responses of the oral fed mice to rTGEV-S protein were 
determined by probing blots of ten-fold concentrated LcS-rTGEV-S supernatant with 
intestinal lavages and sera obtained from these mice.  IgA is the most abundant 
immunoglobulin that is released into the gastrointestinal fluid, saliva, tears, urine and 
other secretions (Brandtzaeg, 1994), while IgG constitute the major type of 
immunoglobulin in the serum.  For this reason, the presence of antibodies against 
rTGEV-S protein in the lavages and sera were determined using goat anti-mouse IgA or 
IgG conjugated with HRP respectively.  As shown in figure 4.11, intestinal IgA in 
intestinal lavage and serum IgG bound to the 75kDa rTGEV-S protein where as no band 
was observed on membranes probed with preimmune lavage and serum.  The detection of 
a 75 kDa rTGEV-S band on the respective membranes blotted with intestinal lavages and 
sera, indicated that both mucosal and systemic immune responses against TGEV were 
elicited.   
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Figure 4.11 Production of rTGEV-S protein specific intestinal IgA and serum IgG in mice fed 
with LcS-rTGEV-S.  Western blot was performed using intestinal lavages (lane 2) and sera (lane 
4) from mice orally fed with LcS-rTGEV-S.  Controls of preimmunized samples of intestinal 
lavage (lane 1) and serum (lane 3) were also included.   
 
The local immunological response was further studied by measuring the anti-
rTGEV-S IgA response in murine intestinal lavages post intragastric immunization with 
LcS-rTGEV-S.  The concentration of mucosal IgA antibodies against rTGEV-S protein in 
the intestinal lavages was determined via ELISA, using purified TGEV-S-GST protein as 
coating antigen.  Results were expressed as titers that were determined by expression of 
the test samples to a standard curve generated by serial dilution of commercially 
purchased IgA of known titer.  As shown in figure 4.12, there was no substantial 
difference in mucosal IgA levels between experimental group and control groups prior to 
intervention while oral immunization of rTGEV-S protein expressing LcS elicited an 
antigen-specific mucosal IgA response.  The IgA titer of the rTGEV-S protein specific 
response in BALB/c mice following immunization with recombinant LcS was detectable 
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as rapidly as day 18 (1.29 ± 0.24 ng/ml of lavage), raising to titers of 3.98 ± 0.18 ng/ml of 
lavage and 3.63 ± 0.19 ng/ml of lavage by day 32 and day 48 respectively.  Since an 
approximate volume of 2 ml of intestinal lavage was extracted from each mouse, the 
maximum amount of IgA in the entire intestinal tract, based on the highest titer detected 
on day 32, would be 7.96 ± 0.36 ng.  From the estimation of a previous study (Lee et al., 
2004), it was derived that the intestinal water covering the surface of the entire 
gastrointestinal tract of mice adds up to 122.8 ± 3.2 mg.  As such, the maximum titer of 
IgA induced by oral administration of recombinant LcS amounted to 64.82 ± 2.93 ng/ml 














Figure 4.12 rTGEV-S protein specific local IgA responses in murine intestinal lavage after 
intragastric immunization.  Groups of three mice received three consecutive doses of 109 cfu of 
LcS-rTGEV-S, three times at two weeks interval.  Control mice received 109 CFU of LcS 
containing pLP500 while a naïve group received buffer (PBS) dose.  Intestinal lavages that were 
collected 2 days after the first boost, 2 and 18 days after the second boost, were analyzed via 
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Likewise, serum concentration of rTGEV-S protein specific IgG from immunized 
mice were also determined.  All animals that were orally fed with rTGEV-S protein 
expressing LcS sero-converted after the first boost (Figure 4.13A).  Elicitation of TGEV 
specific serum IgG was found to be prompter and stronger on comparison to the 
induction of mucosal IgA in the intestine as the concentration of serum IgG was 4.7 time 
higher that of intestinal IgA on day 18.  A titer of 6.03 ± 0.32 ng/ml of serum of rTGEV-
S protein specific IgG was attained after the first boost which continued to increase to a 
level of 8.38 ± 0.18 ng/ml after the second boost.  The subclasses of rTGEV-S protein 
specific IgG induced by the LcS-rTGEV-S vaccine were also determined.  As shown in 
Figure 4.13B, most of the IgG responses generated from oral immunization with LcS-
rTGEV-S was of IgG2a isotype (ratio of IgG2a to IgG1, 2.27).  As a study by Finkelman 
and coworkers (1990) indicated that the production of IgG1 type is induced by Th2-type 
cytokines and the IgG2a isotype is regulated by Th1-type cytokines.  The result of the 
serum isotype analysis suggested that LcS-rTGEV-S induces stronger T-helper-cell-type 
1 (Th1) immune responses.  No significant induction of anti-rTGEV-S antibodies was 
observed in the control groups of mice that received PBS or LcS harboring the empty 
vector (Figures 4.12 & 4.13).   
Taken together these results, the recombinant LcS generated in this study was 
able to elicit both TGEV specific systemic and mucosal antibody responses upon oral 
administration. 
Plaque reduction assays were performed to further determine the neutralizing 
ability of the antibody against TGEV.  The percentage of inhibition was expressed as a 
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percentage of plaques obtained in reduction assay with anti-rTGEV-S intestinal lavages 
or sera with respect to intestinal lavages or sera obtained from control mice fed with PBS.   
Results demonstrated that anti-rTGEV-S IgA or IgG conferred statistically significant 
neutralizing effects (p<0.05) on TGEV infection (Figure 4.14).  A near 15% ± 0.77% 
reduction in the number of plaques was consistently observed when plaque reduction 
assays were carried out using two to eight folds diluted intestinal lavages or sera from 
LcS-rTGEV-S fed mice.  The inhibitory effect decreased gradually on further dilutions 
and reached a level similar to that of the control non-expressor strain at dilutions 1:128 
and 1:64 of intestinal lavages and sera, respectively. 
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Figure 4.13 Anti-rTGEV-S serum IgG titers induced after intragastric immunization with 
recombinant LcS.  (A) Total sera from groups of three mice immunized orally with 109 cfu of 
LcS (rTGEV-S expressor or control non-expressor strains) were tested for the presence of 
rTGEV-S specific IgG by ELISA, using TGEV-S-GST as the coating antigen.  Negative control 
sera from mice fed with PBS were also assayed.  (B) Serum IgG1 and IgG2a antibodies specific 
to the rTGEV-S protein were shown in samples collected 2 days after the second boost.  Bars 
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Figure 4.14 Inhibition of viral plaque formation by (A) intestine lavages (Day 48) and (B) sera 
(Day 48) prepared from mice fed with recombinant LcS.  Maximum reduction in number of 
plaques, expressed as a percentage of plaques obtained for the negative control samples, using 
(A) intestinal lavages or (B) sera collected from mice fed with rTGEV-S-expressing LcS was 
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4.3.3 Kinetics of cytokine production by Peyer’s patches from mice orally 
immunized with LcS-rTGEV-S 
Cellular immune responses can be determined through the pattern of cytokine 
production from cells of the Peyer’s patches of mice immunized with LcS-rTGEV-S.  
Cells from the Peyer’s patches, that represent the intestine inductive sites from where 
cells migrate to the mesenteric lymph node then to the lamina propria, were isolated two 
weeks after the second booster doses.  The level of IL-2, IFN-γ, and IL-4, IL-5, as being 
representative of Th1 and Th2 responses, in the supernatant of Peyer’s patches cell 
culture were examined at different times after in vitro re-stimulation with TGEV-S-GST 
protein.  The viability and ability of the cells from the Peyer’s patches were assessed.  As 
shown in Figure 4.15, the cells were capable of being stimulated in vitro and to produce 
cytokines upon re-stimulation with concanavalin A.   
When re-stimulated with TGEV-S-GST protein, cells of the Peyer’s patches 
isolated from mice immunized with LcS-rTGEV-S produced a mixed Th1/Th2-like 
cytokine profile including IL-2, IFN-γ, IL-4 and IL-5 (Figure 4.16). With respect to the 
level of cytokine production, highest amount of IFN-γ (1320.61 ± 55.19 pg/ml) was 
produced by the sensitized cells from the Peyer’s patches.  However, IL-2 production 
peaked earlier than IFN-γ, IL-4 and IL-5 production.  Maximum production of IL-2 
(375.55 ± 22.85 pg/ml) was attained on day 2, while highest concentration of IFN-γ, IL-4 
and IL-5 (1320.61 ± 55.19 pg/ml; 539.55 ± 37.54 pg/ml; 405.35 ± 27.62 pg/ml) were 
detected on day 4 or day 5.  As for the cells from control mice that received the native 
LcS, no significant cytokine titers could be detected after in vitro re-stimulation with 
TGEV-S-GST protein.  Residual production from in vivo priming was also evaluated in 
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wells incubated without antigen in the presence of RPMI only.  The results presented 
here indicated that oral administration of mice with recombinant LcS expressing rTGEV-















Figure 4.15 IL-2, IFN-γ, IL-4 and IL-5 production by Peyer’s patches cells from mice 
immunized orally with LcS-rTGEV-S or LcS after re-stimulated with concanavalin A.  Readings 
are the actual increment in cytokine concentrations after off setting the background cytokine 
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Figure 4.16 Kinetics of Th1 (IL-2 and IFN-γ) and Th2 (IL-4 and IL-5) cytokines production by Peyer’s patches cells from mice 
immunized with LcS-rTGEV-S and LcS.  Cells were removed 2 weeks after the second boost and re-stimulated in vitro with TGEV-S-
GST or cultured in the presence of RPMI medium only.  Results shown are the mean values and standard errors of triplicates means.    
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4.4 P.PASTORIS AS ORAL VACCINE CARRIER AGAINST TGEV 
4.4.1 Generation of Recombinant P.pastoris (PP) Expressing PrTGEV-S Protein 
The insert PrTGEV-S was obtained by amplifying the region between nucleotides 
33-2286 of TGEV first strand cDNA using primers pGAPtge-FI and pGAPtge-RII 
(Figure 4.17).  This insert encompasses all the four major antigenic domains of the spike 
gene.  The design of oligonucleotides for PCR was based on the sequences of the TGEV 
spike gene at the start and end of nucleotides 33-2286.  The restriction sites of EcoRI and 
XbaI, which were not present in the TGEV spike gene sequence to be amplified, were 











Figure 4.17  Agarose gel electrophoresis of PCR amplified PrTGEV-S (2.3 kb).  Lane M denotes 
1 kb DNA ladder. 
 
PrTGEV-S was cloned into P.pastoris expression vector pGAPZαC and 
transformed into E.coli DH10β competent cells.  pGAPZαC uses the GAP promoter to 
constitutively express recombinant proteins that are fused to the N-terminal peptide 
encoding the S.cerevisiae α-factor secretion signal in P.pastoris.  Positively selected 
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transformants on LB agar plate containing 25 μg/ml zeocin were then screened for the 
presence of PrTGEV-S by performing PCR on the isolated plasmids using the cloning set 
of primers (Figure 4.18).  A 2.3 kb band which corresponded to the expected size of 
PrTGEV-S was generated from the PCR of all the five plasmids isolated from the 
transformants, hence indicating that recombinant pGAPZαC vector harboring the insert 
PrTGEV-S have been successfully constructed.  Nucleotide sequencing conducted on one 
of the recombinant vector verified that PrTGEV-S has been cloned in frame with the 












Figure 4.18 PCR screening of plasmids isolated from transformants.  Lanes: 1-5, a 2.3 kb band 
corresponding to the expected size of PrTGEV-S was amplified from each plasmid.  Lane M 
denotes 1 kb DNA ladder. 
 
 pGAPZαC/PrTGEV-S was linearized with AvrII prior to transformation into 
P.pastoris to allow homologous recombination between the insert and regions of 
homology within the genome (Cregg et al., 1985; Cregg et al., 1989).   Such integrants 
show extreme stability even in the absence of selective pressure.  PCR analysis of the 
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total DNA extracted from the yeast transformants showed that PrTGEV-S has been 
inserted into the genome of two P.pastoris transformants (Figure 4.19).  Non-specific 









Figure 4.19 Electrophoretogram of PCR products amplified from genomic DNA isolated from 
P.pastoris transformants.  Lanes: 1 & 2, a 2.3 kb band corresponding to the expected size of 
PrTGEV-S was amplified from total DNA extracted from yeast transformed with 
pGAPZαC/PrTGEV-S; 3, PCR of genomic DNA isolated from yeast transformed with empty 
vector.  Lane M denotes 1 kb DNA ladder. 
 
Immunoblot assay was then performed to check for the expression and 
immunogenicity of PrTGEV-S protein (Figure 4.20).  Supernatant from overnight culture 
of recombinant P.pastoris (PP/PrTGEV-S) subjected to Western blotting revealed a 
protein band (90 kDa) significantly larger than the expected molecular weight of 
PrTGEV-S protein (lane 4).  The increase in molecular weight (15 kDa) of the expressed 
PrTGEV-S protein could be attributable to glycosylation of the protein in P.pastoris 
expression system, where the N-glycosylation pathway of the yeast mirrors the pathway 
in typical mammalian cells (Bretthauer & Castellino, 1999).  Nevertheless, the ability of 
polyclonal TGEV-specific convalescence swine serum to probe to the expressed 
PrTGEV-S protein gave an indication that the glycosylated protein has retained its 
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immunogenicity.  As observed in the immunoblot, no signal was detected in the culture 
supernatants of the control PP/pGAPZαC or wild type P.pastoris, as well as in the culture 
medium (lanes 2, 3 and 5 respectively).  Purified TGEV-S-GST (70 kDa) was also 










Figure 4.20 Expression of PrTGEV-S protein from P.pastoris transformants.  Supernatants from 
overnight cultures of P.pastoris (lane 2), PP/pGAPZαC (lane 3) or PP/PrTGEV-S (lane 4) were 
separated by 10% SDS-PAGE and transferred electrophoretically to nitrocellulose membrane 
before being incubated with convalescent swine anti-TGEV serum at a dilution of 1:1000.  Bound 
antibodies were detected with HRP-conjugated anti-swine IgG antibodies.  Lanes; 1, purified 
recombinant TGEV-S-GST protein (positive control); 5, MRS broth (negative control). 
 
4.4.2 Immune responses induced by intragastric immunization of PP/PrTGEV-S 
BALB/c mice orally dosed with 2 x 109 cfu of recombinant PP/PrTGEV-S on 
days 0-2 were primed for a secondary response to PrTGEV-S protein following booster 
oral administrations on days 14-16 and 28-30 (Figure 4.21).   
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Figure 4.21 Schematic diagram showing the oral vaccination regime of PP/PrTGEV-S to 
BALB/c mice.       indicates oral administration of the recombinant P.pastoris to each mice on the 
specific days indicated;   indicates the specific days in which lavaging and bleeding of the 
vaccinated mice were performed.    
 
Elicitation of immune responses to PrTGEV-S protein in the mice was determined 
by probing blots of PP/PrTGEV-S supernatant with intestinal lavages and sera extracted 
from these mice.  Antibody binding was determined using goat anti-mouse IgA and IgG 
conjugated with HRP for the detection of IgA in the lavages and IgG in the sera 
respectively.  The detection of a 90 kDa band, corresponding to the molecular weight of 
the expressed PrTGEV-S protein, on the respective membranes blotted with intestinal 
lavages and sera, indicated that both PrTGEV-S protein specific mucosal and systemic 
immune responses were elicited (Figure 4.22).   
Further studies on the local and systemic immune responses against PrTGEV-S 
protein were also performed.  The appropriate concentration of anti-PrTGEV-S IgA and 
IgG in intestinal lavages and sera was determined via ELISA, using purified TGEV-S-
GST protein as capturing antigen.  Results were expressed as titers that were determined 
by expression of the test samples to a standard curve generated by serial dilution of 
commercially purchased IgA or IgG of known titer.   
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Figure 4.22 Immunogenicity of induced intestinal IgA and serum IgG specific for PrTGEV-S 
protein.  Western blot was performed using intestinal lavages (lane 1) and sera (lane 3) from mice 
orally fed with PP/PrTGEV-S.  Controls of preimmunized samples of intestinal lavage (lane 2) 
and serum (lane 4) were also included.  The PrTGEV-S protein (90 kDa) in the supernatant of 
PP/PrTGEV-S was detected by intestinal IgA (lane 1) and serum IgG (lane 3), respectively.  
However, no band was observed on membranes probed with preimmune lavage and serum. 
 
As shown in Figure 4.23, mice immunized with pGAPZαC and PBS control did 
not show significant PrTGEV-S protein specific antibody production, while oral 
administration of PP/PrTGEV-S elicited a rapid and strong antigen-specific mucosal IgA 
response in the immunized mice.  The antibody titer against the protein PrTGEV-S in 
BALB/c mice following immunization with PrTGEV-S protein expressing P.pastoris 
reached a high level of 4.51 ± 0.17 ng/ml of lavage on day 18.  Since an approximate 
volume of 2 ml of intestinal lavage was extracted from each mouse, the maximum 
amount of IgA in the entire intestinal tract would be 9.02 ± 0.34 ng.  From an estimation 
of a previous study (Lee et al., 2004), the intestinal water covering the surface of the 
entire gastrointestinal tract of mice adds up to 122.8 ± 3.2 mg.  It was then derived that 
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the maximum titer of IgA induced by oral administration of PP/PrTGEV-S would be 















Figure 4.23 PrTGEV-S protein specific local IgA response in murine intestinal lavage after 
intragastric immunization.  Groups of three mice received three consecutive doses of 109 
PP/PrTGEV-S, three times at two weeks interval.  Control mice received 109 CFU of 
PP/pGAPZαC while a naïve group received buffer dose.  Intestinal lavages that were collected 2 
days after the first boost, 2 and 16 days after the second boost, were analyzed via ELISA, using 
TGEV-S-GST as the coating antigen.  Bars represent the mean IgA titer ± S.E.M in each group. 
 
Results from ELISA demonstrated that all mice that were orally fed with 
PP/PrTGEV-S sero-converted by day 18 (Figure 4.24A).  The level of PrTGEV-S protein 
specific IgG remained relatively constant from day 18 (9.41 ± 0.44 ng/ml of serum) to 
day 48 (9.51 ± 0.32 ng/ml of serum).  The serum IgG isotypes of PrTGEV-S protein 
specific antibodies induced by PP/PrTGEV-S were shown in Figure 4.24B.  The 
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The result of the serum isotype analysis suggested that PP/PrTGEV-S induced more T-
helper-cell-type 1 (Th1) immune responses.  No significant induction of anti-PrTGEV-S 
antibodies was observed in the control groups of mice that received PBS or 
PP/pGAPZαC (Figures 4.23 & 4.24).   
Results obtained in this part of the study have shown that the recombinant 
P.pastoris harbouring PrTGEV-S was able to induce TGEV specific systemic and 
mucosal immune responses when orally fed to mice.  Even though a stronger serological 
response (IgG) was elicited, prompt induction of mucosal IgA was observed as the 
concentration of PrTGEV-S protein specific IgA after the first boost reached a level 
similar to those after the second boost. 
The ability of the induced antibodies to confer protection against TGEV infection 
was then determined via plaque reduction assay.  The percentage of inhibition was 
expressed as a percentage of plaques obtained in reduction assay with anti-rTGEV-S 
intestinal lavages or sera with respect to intestinal lavages or sera obtained from control 
mice fed with PBS.  As observed in Figure 4.25, incubation of anti-PrTGEV-S IgA or 
IgG with TGEV conferred statistically significant and potent neutralizing effects 
(p<0.05).  TGEV infection was strongly inhibited by both anti-PrTGEV-S IgA and IgG 
up to the dilution of 1:32 of lavages or sera from PP/PrTGEV-S fed mice respectively.  It 
is commendable that anti-PrTGEV-S IgA and IgG conferred a near 100% inhibition of 
TGEV infection, up to dilutions of 1:4 and 1:8 respectively.  The inhibitory effect 
decreased gradually on further dilutions and reached a level similar to that of the control 
non-expressor strain at dilutions 1:512 of intestinal lavages.   
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Figure 4.24 Humoral immune responses after intragastric immunization with recombinant 
P.pastoris (PP/PrTGEV-S).  (A) Total sera from groups of three mice immunized orally with 109 
cfu of P.pastoris (PrTGEV-S protein expressor or control non-expressor strains) were tested for 
the presence of PrTGEV-S protein specific IgG by ELISA, using TGEV-S-GST as the coating 
antigen.  (B) Serum IgG1 and IgG2a antibodies specific to PrTGEV-S protein were shown in sera 
collected 2 days after the second boost.  Negative control sera from mice fed with PBS were also 
assayed.  Bars represent the mean IgG titer ± S.E.M in each group. 
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Figure 4.25 Inhibition of viral plaque formation by (A) intestine lavages (Day 48) and (B) sera 
(Day 48) prepared from mice orally fed with PP/PrTGEV-S and P.pastoris.  Maximum reduction 
in number of plaques, expressed as a percentage of plaques obtained for the negative control 
samples, using (A) intestinal lavages or (B) sera collected from mice fed with PrTGEV-S-
expressing P.pastoris was 66.79 ± 2.11 % and 72.20 ± 2.37 % respectively.  Results are mean 
values and standard errors of triplicates. 
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4.4.3 Kinetics of cytokine production by Peyer’s patches from mice orally 
immunized with PP/PrTGEV-S 
The level of cytokines released by the Peyer’s patches cell reflects the direction 
and magnitude of the immune responses.  Therefore, supernatant from Peyer’s patches 
cell cultures stimulated with TGEV-S-GST in vitro were harvested and the release of IL-
2, IFN-γ, IL-4 and IL-5 were assessed at different times after re-stimulation.  The 
capacity of Peyer’s patch cells to be stimulated in vitro and to produce cytokines was 
confirmed by production of cytokines in the presence of concanavalin A (Figure 4.26). 
Residual production from in vivo priming was evaluated in wells incubated with 
RPMI only.  Cell from control mice that received the native P.pastoris did not produce 
any significant cytokine titers after in vitro re-stimulation with TGEV-S-GST.  Cells of 
the Peyer’s patches from mice immunized with recombinant P.pastoris produced a mixed 
Th1/Th2-like cytokine profile including IL-2, IFN-γ, IL-4 and IL-5 (Figure 4.27).  
However, the results obtained indicated that the oral vaccine (PP/PrTGEV-S) resulted in 
the induction of stronger Th1-type cellular immune responses and the levels of Th1 (IL-2 
and IFN-γ)-type cytokines were significantly higher than that of Th2 (IL-4 and IL-5)-type 
cytokines.  IFN-γ production was the highest among the four cytokines being studied (IL-
2, 455.01 ± 34.65 pg/ml; IL-4, 375.21 ± 19.62 pg/ml; IL-5, 273.35 ± 22.41 pg/ml), 
reaching a concentration of 1402.67 ± 24.68 pg/ml on day 4 after re-stimulation, while 
IL-2 production was found to peak earlier than IFN-γ, IL-4 and IL-5 production.  Highest 
concentration of IL-2 was produced on day 3 as compared to IFN-γ, IL-4 and IL-5, where 
the maximum concentrations of the cytokines were only produced on day 4 or day 5.  
Nevertheless, the cytokine profiling study have shown that oral administration of mice 
                                                                                   CHAPTER 4 
                                                                                RESULTS 
 163
with recombinant P.pastoris expressing PrTGEV-S protein resulted in the induction of 
specific and potent Th1 and Th2-type cellular immune responses in the Peyer’s patches 












Figure 4.26 IL-2, IFN-γ, IL-4 and IL-5 production by Peyer’s patches cells from mice 
immunized orally with PP/PrTGEV-S or P.pastoris after re-stimulated with concanavalin A.  
Readings are the actual increment in cytokine concentrations after off setting the background 


















































































































































































































Figure 4.27 Kinetics of Th1 (IL-2 and IFN-γ) and Th2 (IL-4 and IL-5) cytokine production by Peyer’s patches cells from mice immunized 
with PP/PrTGEV-S and P.pastoris.  Cells were removed 2 weeks after the second boost and re-stimulated in vitro with TGEV-S-GST or 
cultured in the presence of RPMI medium only.  Results shown are the mean values and standard errors of triplicates means.      
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5.0 DEVELOPMENT OF ORAL VACCINE AGAINST SEVERE 
ACUTE RESPIRATORY SYNDROME CORONAVIRUS  
(SARS CoV) 
5.1 INTRODUCTION 
SARS CoV is a highly contagious respiratory illness that first infected people in 
parts of Asia, North America, and Europe, affecting 8,450 people by the end of June 
2003.  During the SARS outbreak, the spread of the disease was primarily controlled by 
strict quarantine protocols and patient-isolation measures, as well as by broad-spectrum 
antibiotics and antiviral regimens, where a combination of corticosteroid and ribavirin 
therapy was given (So et al., 2003; Tsang & Zhong, 2003; Tsang et al., 2003; Centre for 
Disease Control and Prevention, 2003).  There is, however, considerable skepticism over 
the use of these drugs in SARS and there is currently no consistently effective anti-SARS 
CoV therapy (Cyranoski, 2003).   
Comparison studies from the previous chapter have demonstrated that P.pastoris 
as an oral vaccine delivery vehicle, allowed eukaryotic modification of the expressed 
antigen.   As a result, the antigen specific mucosal IgA and serum IgG induced confer 
strong protection against viral infection.  As such, in this final part of the study, 
P.pastoris was chosen over LcS for the development of oral vaccine against SARS CoV.   
 
5.2 GENERATION OF RECOMBINANT P.PASTORIS (PP) EXPRESSING 
SARS CoV SPIKE RECEPTOR-BINDING DOMAIN PROTEIN 
A 720 bp fragment of SARS CoV receptor-binding domain (SARS-S-RBD), 
spanning within the region of nucleotides 810-1530 of SARS CoV spike gene, was 
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amplified from pCR-XL-TOPO-S, a vector encoding the full length SARS CoV spike 
gene, with the aid of the primers RBD-SSF1 and RBD-SSR1 (Figure 5.1).  The 
restriction sites of KpnI and XbaI, which were not present in the SARS spike gene 
sequence to be amplified, were tagged onto the primers for cloning of the SARS-S-RBD 
into the expression vector (Table 2.6). 
The insert, SARS-S-RBD, was cloned into P.pastoris expression vector 
pGAPZαC and transformed into E.coli DH10β competent cells.  Transformants that were 
positively selected on LB agar plate containing 25 μg/ml zeocin were assessed for the 
presence of SARS-S-RBD by conducting PCR on the isolated plasmids using the cloning 
set of primers (Figure 5.2).  Recombinant pGAPZαC vector harboring the insert SARS-S-
RBD have been successfully constructed since a 720 bp band that corresponded to the 
expected size of SARS-S-RBD was amplified from all isolated plasmids.  Results from 
nucleotide sequencing performed on one of the vectors showed that SARS-S-RBD was 
inserted in frame with the secretion signal sequences of the vector.  The plasmid was then 
denoted as pGAPZαC/SARS-S-RBD. 
  In order to generate stable recombinants, pGAPZαC/SARS-S-RBD 
was linearized and transformed into P.pastoris so as to allow homologous recombination 
between the insert and regions of homology within the genome (Cregg et al., 1985; Cregg 
et al., 1989).   PCR analysis of the total DNA was extracted from the P.pastoris 
transformants showed that SARS-S-RBD has been inserted into the genome of the four 
P.pastoris transformants (Figure 5.3).  Non-specific amplification was not observed in 
the genome of P.pastoris transformed with pGAPZαC [(PP/pGAPZαC) (lane 1)].   
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Figure 5.1 Agarose gel electrophoresis of PCR products of SARS-S-RBD, amplified from pCR-















Figure 5.2 PCR screening of plasmids isolated from transformants.  Lanes: 1-3, a 720 bp band 
corresponding to the expected size of SARS-S-RBD was amplified from each plasmid.  The faint 
bands at the lower end of lanes 1-3 were likely to be primer-dimers.  Lane M denotes BenchTop 1 
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Figure 5.3 Electrophoretogram of PCR products amplified from genomic DNA isolated from 
P.pastoris transformants.  Lanes: 2-5, a 720 bp band corresponding to the expected size of SARS-
S-RBD was amplified from total DNA extracted from yeast transformed with pGAPZαC/SARS-
S-RBD; 1, PCR of genomic DNA isolated from yeast transformed with empty vector.  Lane M 
denotes BenchTop1 kb DNA ladder. 
 
It could be observed that SARS-S-RBD could only be weakly amplified from the 
total DNA isolated from one of the recombinant P.pastoris (lane 3).  On comparison of 
the total DNA extracted from all the transformants using gel electrophoresis, it was noted 
that equivalent amount of DNA were extracted from each recombinant (Figure 5.4).  As 
such, the variation in the amount of SARS-S-RBD amplified could not be attributed to 
the difference in concentration of total DNA utilized during PCR.  More likely, the insert 
might have been integrated into other regions of the genome, resulting in instability of the 
integrant and subsequent loss of the insert.  In view of this, subsequent studies were 
performed using the recombinant P.pastoris from which SARS-S-RBD could be strongly 
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Figure 5.4 Agarose gel electrophoresis for the comparison of the amount of total DNA extracted 
from four P.pastoris transformants.  Lanes 1-4, genomic DNA from which PCR analysis was 
performed to check for the insertion of SARS-S-RBD in lane 2-5 of Figure 5.3 respectively.  
Lane M denotes BenchTop 1 kb DNA ladder. 
 
To visualize the synthesis of SARS-S-RBD protein by recombinant P.pastoris, 
culture medium was harvested from overnight culture of PP/SARS-S-RBD.  Total 
secreted proteins were separated on 10 % SDS-PAGE and analyzed by Western blotting 
using SARS CoV convalescent human serum (Figure 5.5).  Two distinct bands of 24 kDa 
and 62 kDa reacted strongly with the convalescence serum (lane 2).  Previous studies 
showed that proteins expressed under P.pastoris expression system generally produce 
two forms of the same protein (Calabozo et al., 2003; Farn´os et al., 2005).  One of which 
corresponds to the expected size of the actual protein while the other with a higher 
molecular-mass, corresponded to glycosylated product.  Hence, the 62 kDa band 
probably correspond to glycosylated SARS-S-RBD protein while the 24 kDa band is 
probably the unglycosylated SARS-S-RBD protein since the unglycosylated SARS-S-
RBD protein has a similar molecular weight.   
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Figure 5.5 Expression of SARS-S-RBD protein from P.pastoris transformants.  Supernatants 
from overnight cultures of PP/SARS-S-RBD (lane 2), PP/pGAPZαC (lane 3) or P.pastoris (lane 
4) were separated by 10 % SDS-PAGE and transferred electrophoretically to nitrocellulose 
membrane before being incubated with SARS CoV human convalescent serum at a dilution of 
1:500.  Bound antibodies were detected with HRP-conjugated anti human IgG antibodies.  Lanes; 
1, SARS-S(M) (positive control); 5, MRS broth (negative control). 
 
The ability of polyclonal SARS-specific convalescence human serum to probe to 
the expressed SARS-S-RBD protein gave an indication that both the glycosylated and 
nonglycosylated protein retained antigenic authenticity.  As observed in the immunoblot, 
the convalescence serum did not react with proteins present in the culture supernatants of 
the control PP/pGAPZαC or wild type P.pastoris, as well as in the culture medium (lanes 
3, 4 and 5, respectively).  The positive control included in the analysis of the expression 
of SARS-S-RBD protein by the recombinant P.pastoris (PP/SARS-S-RBD) was different 
from the positive control used in the previous chapter (TGEV-S-GST).  Commercially 
available SARS-Associated Coronavirus Spike mosaic recombinant protein S(M) 
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[(SARS-S(M), 45 kDa (Virogen, USA)], was also utilized as the positive control in this 
part of the study (lane 1).   
 
5.3 IMMUNE RESPONSES INDUCED BY INTRAGASTRIC 
IMMUNIZATION OF PP/SARS-S-RBD 
Immunological responses of mice inoculated with three doses of 2 x 109 cfu of 
PP/SARS-S-RBD on days 0-2 and primed for a secondary response with booster doses on 






Figure 5.6 Schematic diagram showing the oral vaccination regime of PP/SARS-S-RBD to 
BALB/c mice.        indicates oral administration of 2 x 109 cfu PP/SARS-S-RBD to each mice on 
the specific days indicated;   indicates the specific days in which lavaging and bleeding of the 
vaccinated mice were performed.    
 
Intestinal lavages and sera extracted from these mice were checked for reactivity 
to SARS-S-RBD protein in the supernatant harvested from overnight culture of 
PP/SARS-S-RBD.  As shown in figure 5.7, both intestinal IgA in intestinal lavage and 
serum IgG were able detect the glycosylated (62 kDa) and nonglycosylated (24 kDa) 
forms of SARS-S-RBD protein.  The detection of the SARS-S-RBD protein bands on the 
respective membranes blotted with intestinal lavages and sera indicated that both mucosal 
and systemic immune responses against SARS CoV were elicited.  Non-specific binding 
Day   0    1    2 14   15   16 28  29  30 
 48    18   32 
  1st Boosters  2nd Boosters
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Figure 5.7 Immunogenicity of induced intestinal IgA and serum IgG specific for SARS-S-RBD 
protein.  Western blot was performed using intestinal lavages (lane 1) and sera (lane 3) from mice 
orally fed with PP/SARS-S-RBD.  Controls of preimmunized samples of intestinal lavage (lane 2) 
and serum (lane 4) were also included.  Intestinal IgA in intestinal lavage and serum IgG bound to 
the SARS-S-RBD protein where as no band was observed on membranes probed with preimmune 
lavage and serum. 
 
The serum and intestinal antibody responses in the mice were further examined by 
performing ELISA, using SARS-S(M) as the target antigen.  The level of anti-SARS-S-
RBD IgG and IgA in sera and intestinal lavages were expressed as titers that were 
determined by expression of the test samples to a standard curve generated by serial 
dilution of commercially purchased IgA or IgG of known titer. 
Eighteen days after the first vaccination with recombinant PP/SARS-S-RBD, the 
immunized mice had produced a rapid and strong antigen-specific mucosal IgA response 
(Figure 5.8).  The anti-SARS-S-RBD IgA titer was 4.48 ± 0.36 ng/ml of lavage on day 18 
and remained relatively constant after the second boost from day 32 to 48.  No substantial 
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difference in mucosal IgA levels between experimental group and control groups was 
observed prior to intervention.  It could also be derived that the maximum amount of IgA 
in the entire intestinal tract was 8.96 ± 0.72 ng, since an approximate volume of 2 ml of 
intestinal lavage was extracted from each mouse.  On the basis that the intestinal water 
covering the surface of the entire gastrointestinal tract of mice is 122.8 ± 3.2 mg (Lee et 
al., 2004), the maximum titer of IgA induced by oral administration of PP/SARS-S-RBD 









Figure 5.8 SARS-S-RBD protein specific local IgA response in murine intestinal lavage 
after intragastric immunization.  Groups of three mice received three consecutive doses of 109 
PP/SARS-S-RBD, three times at two weeks interval.  Control mice received 109 CFU of 
PP/pGAPZαC while a naïve group received buffer dose.  Intestinal lavages that were collected 2 
days after the first boost, 2 and 16 days after the second boost, were analyzed via ELISA, using 
SARS-S(M) as the coating antigen.  Bars represent the mean IgA titer ± S.E.M in each group. 
 
Mice immunized orally with PP/SARS-S-RBD developed high IgG serological 
responses (Figure 5.9A).  All animals receiving three consecutive vaccine doses and the 
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which was significantly greater than the antibody titers generated following inoculation 
with PBS or PP/pGAPZαC.  With the administration of the second booster doses, the IgG 
antibody level remained at a constant level of 9.49 ± 1.01 to 9.45 ± 0.86 ng/ml of serum 
from day 32 to day 48.  Even though the application of a second boost did not further 
stimulate stronger serological responses, the high level of SARS-S-RBD protein specific 
IgG induced by day 18 indicated that the recombinant P.pastoris was able to elicit strong 
and rapid responses in mice when being orally vaccinated.  The subclasses of SARS-S-
RBD specific IgG induced by the P.pastoris vaccine were also determined.  As shown in 
Figure 5.9B, most of the IgG responses generated from oral immunization with 
PP/SARS-S-RBD were of IgG1 isotype (ratio of IgG2a to IgG1, 0.50), indicating that 
PP/SARS-S-RBD induced a stronger type 2 (Th2)-like immune responses. 
The capacity of PP/SARS-S-RBD to induce neutralizing antibodies, which would 
be effective to confer protection against SARS CoV infection, was determined.  Since 
SARS CoV-related work with the involvement of live virus can only be conducted in 
biosafety level 3 or higher containment facilities, it was not possible to use SARS CoV as 
the target virus as such containment facilities was not available in the department.  SARS 
CoV S protein-pseudotyped murine leukemia virus [MLV(SARS)] (Giroglou et al., 
2004), a relatively safe surrogate for native SARS CoV with a tropism restricted to the 
same cell types and host species as SARS CoV was instead utilized in the plaque 
reduction assay.  The MLV(SARS) displayed properties of MLV with infectivity of cell 
and tissue tropism mediated solely by SARS CoV spike protein, as the spike protein, with 
a partially deleted cytoplasmic tail, was incorporated into the envelop of MLV particles.  
MLV(SARS) was produced by co-transfection of 293T cells with plasmids encoding C-
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terminally truncated SARS CoV spike protein, MLV proteins and eGFP (enhanced green 
fluorescence protein).  The pseudotype viruses released into the supernatant were then 
collected where infection of MLV(SARS) can be carried out by transduction of 
MLV(SARS) into Vero cells.   Neutralization assays were performed by incubating 
concentrated pseudotypes (5 x 104 PFU) with serial dilutions of serum or intestinal lavage 
at 37 oC for 1 hr, after which the antibody-virus mixture was transduced into Vero cells.  
The percentage of eGFP-positive cells, as an indicator of MLV(SARS) infected cells, was 
enumerated under fluorescence microscope at 72 hr post-transduction.  The percentage of 
inhibition of fluorescence- forming unit (FFU) was expressed as a percentage of 
fluorescence cell obtained in the neutralization assay with anti-SARS-S-RBD intestinal 
lavages or sera with respect to intestinal lavages or sera obtained from control mice fed 
with PBS.   
As presented in Figure 5.10, relatively high titers of neutralizing antibodies 
(p<0.05) were observed in the serum of mice orally administered with PP/SARS-S-RBD.  
To determine the neutralization activities in secretions, intestinal lavages were analyzed 
for neutralization activities.  Strong neutralizing activities (p<0.05) were also detected in 
the intestinal lavages extracted from mice immunized with PP/SARS-S-RBD.  Inhibition 
of MLV(SARS) infection was close to 100 % by both anti-SARS-S-RBD IgA and IgG up 
to the dilution of 1:8 of lavages or sera respectively.  It is noteworthy that even at the 
dilution of 1:32, anti-SARS-S-RBD IgA and IgG in the intestinal lavage and serum could 
block more than 50 % of the viral infection.  The inhibitory effect decreased gradually on 
further dilutions and reached a level similar to that of the control non-expressor strain at 
dilution 1:512 of intestinal lavages and sera.   
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Figure 5.9 Anti-SARS-S-RBD serum IgG titers induced after intragastric immunization 
with PP/SARS-S-RBD.  (A) Total sera from groups of three mice immunized orally with 109 
P.pastoris (SARS-S-RBD protein expressor or control non-expressor strains) were tested for the 
presence of SARS-S-RBD protein specific IgG by ELISA, using SARS-S(M) as the coating 
antigen.  (B) Serum IgG1 and IgG2a antibodies specific to the SARS-S-RBD protein were shown 
in samples collected 2 days after the second boost.  Negative control sera from mice fed with PBS 
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Figure 5.10 Inhibition of MLV(SARS) infection by (A) intestine lavages and (B) sera prepared 
from mice fed with PP/SARS-S-RBD.  Maximum reduction in FFU, expressed as a percentage of 
the FFU obtained for the negative control samples, using (A) intestinal lavages or (B) sera 
collected from mice fed with SARS-S-RBD-expressing P.pastoris was 71.99 ± 2.44 % and 78.56 
± 2.07 % respectively.  Results are mean values and standard errors of triplicates. 
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5.3.1 Kinetics of cytokine production by Peyer’s patches and cervical lymph node 
from mice orally immunized with PP/SARS-S-RBD 
Since SARS CoV causes an acute respiratory illness, virus-specific memory T 
cells may need to be present in the airway to undergo rapid activation and differentiation 
upon acute infection.  As such, the presence of antigen-specific T cells in cervical lymph 
nodes (CLN) was also determined.  The SARS-S-RBD protein specific cytokine 
production by cells from both the Peyer’s patches and CLN of mice orally inoculated 
with PP/SARS-S-RBD was examined.  The level of IL-2, IFN-γ, IL-4 and IL-5 produced 
by cells of the lymphoid tissue cultures were assessed at different times after in vitro re-
stimulation with SARS-S(M).  The capacity of lymphoid cells to be stimulated in vitro 
and to produce cytokines was confirmed by production of cytokines in the presence of 
concanavalin A (Figure 5.11).   
As seen in Figure 5.12 and 5.13, cells of the Peyer’s patches and CLN of mice 
immunized with PP/SARS-S-RBD produced a mixed Th1/Th2-like cytokine profile, 
whereby both Th1 (IFN-γ and IL-2) and Th2 (IL-4 and IL-5)-type cytokines were 
produced by the re-stimulated cells.  In general, it could be observed that much larger 
amounts of IL-4 and IL-5 as compared to IL-2 and IFN-γ were produced when the cells 
of the Peyer’s patches and CLN were re-stimulated in vitro with SARS-S(M).  The 
highest concentration of cytokines produced by cells of the Peyer’s patches were 250.12 
± 23.45 pg/ml for IL-2 on day 4, 135.62 ± 24.06 pg/ml for IFN-γ on day 4, 1188.67 ± 
60.25 pg/ml for IL-4 on day 5 and 1449.88 ± 64.70 pg/ml for IL-5 on day 4.  As for the 
cells of the CLN, maximum amount of cytokines detected were 134.99 ± 11.68 pg/ml for 
IL-2 on day 4, 82.02 ± 5.57 pg/ml for IFN- γ on day 4, 462.20 ± 30.65 pg/ml for IL-4 on 
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day 5 and 535.94 ± 16.69 pg/ml for IL-5 on day 4.  These results indicated that oral 
vaccination of recombinant P.pastoris expressing SARS-S-RBD protein resulted in the 
induction of Th2-biased immune responses in the immunized mice.  However, the 
concentrations of all four cytokines in the CLN culture were generally lower than those in 
the culture of the Peyer’s patches.  The level of cytokines produced by cells from the 
Peyer’s patches was 1.2 to 4.1 times higher than that from the cells of CLN.  
Nevertheless, the ability of cell from the CLN to produce both Th1 and Th2 associated 
cytokines gave an indication that oral vaccination of mice with PP/SARS-S-RBD was 
able to induce sensitized T cell not only within the intestine milieu, but also in a distal 
lymphoid tissue which is more closely associated with the immune protection of the nasal 
organs. 
Cervical lymph node and Peyer’s patches cells from control mice inoculated with 
native P.pastoris did not produce any significant cytokine titers after in vitro re-
stimulation with SARS-S(M).  However, it was noticed that a higher basal level of all the 
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Figure 5.11 IL-2, IFN-γ, IL-4 and IL-5 production by cells from Peyer’s patches (A) and CLN 
(B) of mice immunized orally with PP/SARS-S-RBD or P.pastoris after re-stimulated with 
concanavalin A.  Readings are the actual increment in cytokine concentrations after offsetting the 
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 Figure 5.12 Kinetics of Th1 (IL-2 and IFN-γ) and Th2 (IL-4 and IL-5) cytokine production by Peyer’s patches cells from mice immunized with 
PP/SARS-S-RBD and P.pastoris.  Cells were removed 2 weeks after the second boost and re-stimulated in vitro with SARS-S(M) or cultured in 
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Figure 5.13 Kinetics of Th1 (IL-2 and IFN-γ) and Th2 (IL-4 and IL-5) cytokine production by CLN cells from mice immunized with 
PP/SARS-S-RBD and P.pastoris.  Cells were removed 2 weeks after the second boost and re-stimulated in vitro with SARS-S(M) or 
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6.0 DISCUSSION 
Mucosal surfaces in the gastrointestinal, urogenital, and respiratory tracts provide 
portals of entry for pathogens.  It is therefore important to develop vaccines that induce 
protective mucosal immune responses where initial infection and replication of the 
pathogen occurred.  Although parental vaccination is usually highly effective in eliciting 
a protective systemic immune response, it is not necessarily effective against mucosal 
infections (Mesteck, 1987; Mc Ghee et al., 1992).  
With the widespread threat of many emerging pathogenic viruses (such as SARS 
CoV, Hantan and influenza viruses) to human life, challenges have been spawned to 
develop safe anti-viral vaccine for preventive use.  Ideally, the new generation of 
vaccines to be developed to combat mucosal pathogens should meet a number of 
prerequisites.  They should be safe, cheap, stable, and easy to administer, preferably 
given orally in a single dose.  The oral route of administration is a most convenient route 
of vaccination as compared with the more frequently used parenteral routes mainly 
because of a less stringent criteria for application and education of trained healthcare 
workers.  More importantly, oral administration of antigens might stimulate the natural 
route of infection and be a more effective method of immunization (Staats et al., 1994).  
The scientific consensus at this point of time is that live vaccines are potential candidates 
for single oral immunization.   
For vaccines to be able to exert long-term protective effects, it is important that 
the vector is able to continuously express the antigen of interest within the mucosal 
surfaces.  This can be achieved using live vaccine delivery vehicles, capable of adhering 
to the mucosal surfaces, hence permitting continuous expression of antigen.  The use of 
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attenuated pathogen is particularly interesting, being powerful tool to present antigens, 
since they can induce specific immune responses against heterologous antigen and 
simultaneous protection against the pathogen.  Various attenuated mutants have been 
produced and tested, such as Listeria monocytogenes, Salmonella typhimurium, Shigella 
flexneri and Mycobacterium bovis (Shata et al., 2000; Dietrich et al., 2001; Medina & 
Guzman, 2001).  Although these attenuated strains have been extensively engineered to 
minimize their pathogenicity, they maintian certain invasive and virulence properities 
(Fischetti et al., 1996).  To circumvent some of the safety and environmental issues 
inherent to the wide-scale dissemination of engineered pathogens, it will be more feasible 
to develop non-pathogenic vectors as vaccine vectors.  In this study, the focus was on the 
development of a mucosal delivery system for the gastrointestinal tract.  The potential of 
using Lactobacillus spp. (LcS) and yeast (S.boulardii, S.cerevisiae and P.pastoris), as the 
respective candidates of prokaryotic and eukaryotic carriers, were investigated.   
The rationale behind the selection of Lactobacillus spp. and yeast as the 
investigative candidate in this study, is that both organisms have been used from time 
immemorial in the production of food and have been consumed widely by humans and 
animals (Sharpe, 1981; van der Aa Kuhle et al., 2005).   In addition, many lactobacilli 
and yeasts have been shown to exert beneficial probiotic effects (Havenaar & Huis in’t 
Veld, 1993; Broussard & Surawicz, 2004).  The first protective immune response for 
lactobacilli expressing C fragment of tetanus toxin was obtained when total cell-free 
extracts of L.casei expressing the toxin fragment at the cell surface were injected 
subcutaneously (Maassen et al., 1999).  Subsequently, L.casei and L.plantarum strains 
have been developed as delivery vectors for tetanus toxin fragment C, Helicobacter 
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pylori urease B and the protective antigen of Bacillus anthracis to induce high 
immunological response, equivalent to those using Specol as an adjuvant (Pouwels et al., 
1996; Zegers et al., 1999; Shaw et al., 2000; Corthesy et al., 2005).  As such, amongst 
the numerous species and strains of lactobacilli, LcS was selected in this study for 
development of an oral vaccine carrier against coronaviruses.   
At the moment, S.boulardii is the only yeast commercialized as probiotic in 
human medicine.  As several taxonomy studies have indicated that S.boulardii is closely 
related to S.cerevisiae, this leads to the question whether S.cerevisiae possess probiotic 
properties as well (Mitterdorfer et al., 2002a,b; van der Aa Ku¨hle & Jespersen, 2003).  
As for the P.pastoris, though not commonly used in the food industry, it has been 
permitted by U.S. Food and Drug Administration as a food additive in feed formulation 
for animals (U.S. Food and Drug Administration).  More importantly, Pichia expression 
system is an excellent host for the production of heterologous proteins and have been 
proven capable of generating post-translational modifications that are more similar to 
human proteins modifications than Saccharomyces cerevisiae (Cregg et al., 1987; 
Romanos et al., 1992; Ilgen et al., 2004).  A number of human glycoproteins expressed in 
P.pastoris have been shown to have retained the native structure and biological properties 
(Caputo et al., 1999; Gupta & Dighe, 1999; Lerner et al., 1999).  Proteins synthesized by 
P.pastoris have also been applied in various industries, such as for the production of 
caseinomacropeptide, a peptide with growth-inhibitory activity against oral opportunistic 
pathogens and puroindolines, a functional component of wheat endosperm used for 
bread-making (Dubreil et al., 1998; Kim et al., 2005).  
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Very few yeasts have been studied as possible biotherapeutics.  Despite the fact 
that S.boulardii is one of the first and currently the only yeast commercialized in human 
medicine, the adhesive properties of S.boulardii on intestinal surface have only been 
examined in few cases (Tasteyre et al., 2002; Ouwehand et al., 1999 & 2000; van der Aa 
Kühle et al., 2005).  The adhesive capacity of a strain can be examined in vitro by the use 
of intestinal cell lines.  For this purpose, different human intestinal epithelial cell lines 
have been employed such as Caco-2 (Tuomola & Salminen, 1998; Kimoto et al., 1999; 
Greene & Klaenhammer, 1994), T84 (Dahan et al., 2003) and HT29 (Gopal et al., 2001), 
which are all derived from colon adenocarcinoma (Adlerberth et al., 1996).  In this study, 
the two well-characterized cultured colon carcinoma cell lines, Caco-2 and HT29, were 
selected to study the in vitro adhesion capability of S.boulardii, S.cerevisiae and 
P.pastoris.  The advantages of these two cellular models are that they expresses 
morphological and functional differentiation in vitro and show characteristics of mature 
enterocytes, including polarization, a functional brush border, and apical intestinal 
hydrolases (Pinto et al., 1982 & 1983).  Caco-2 and HT29 cells forms two clearly 
distinguishable domains, an apical membrane and a basolateral membrane separated by 
tight junctions (Simon & Fuller, 1985).  The apical surface (brush border) contains 
peptidases and disaccharidases while the basolateral domain contains several peptide 
receptors involved in controlling intestinal hydroelectrolytic secretion (Hauri, 1988; 
Hauri et al., 1985; Pinto et al., 1982 & 1983; Laburthe & Amiranoff, 1990).  Since the 
binding of microorganisms to mucosal cells involves the interaction of bacterial ligands 
with specific eukaryotic receptors, human intestinal Caco-2 and HT29 cells are probably 
the best available models to study intestinal attachment of yeasts. 
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Scanning electron microscopic examination revealed the ability of S.boulardii, 
S.cerevisiae and P.pastoris to adhere to Caco-2 and HT29 cells (Figures 3.1 & 3.2).  
Congruent to the present study, Kuhle et al. (2005) and Ouwehand et al. (1999) observed 
that S.boulardii isolated from pharmaceutical product were able to adhere to human 
intestinal mucus and a primary neonatal piglet jejunum cell line, IPEC-J2.  However, 
only a few of the food-borne S.cerevisiae possessed noteworthy adhesiveness with strains 
from blue veined cheeses, as the most adhesive (Kuhle et al., 2005).  In this study, 
P.pastoris demonstrated highest adhesiveness (7.14 x 102 yeast per cell) when compared 
to the other two yeasts, which showed similar adhesiveness to Caco-2 (4.1 x 101 and 4.8 
x 101 yeast per cell) and HT29 (3.4 x 101 and 4.3 x 101 yeast per cell) cells.  The amount 
of P.pastoris attached to the cell surface of Caco-2 was 15 to 17 times higher than those 
of S.boulardii and S.cerevisiae, while the number of P.pastoris adhering to HT29 cells 
was 26 to 33 times the number of adhering S.boulardii and S.cerevisiae.  Interestingly, 
P.pastoris seemed to have a stronger affinity to HT29 cells as the number of P.pastoris 
adhering to HT29 cells was 1.6 times higher than that adhering to Caco-2 cells.  Besides 
direct adherence to epithelial cells to colonize a mucosal surface, microorganisms may 
adhere to mucous (Coconnier et al., 1992; Bernet et al., 1994).  Scanning electron 
micrographs have revealed that P.pastoris interacts not only with the brush border of the 
cell, the yeast cells were also observed to interact conspicuously with the secreted mucus 
(Figure 3.3).  It is therefore likely that the increased adhesiveness to HT29 cells was 
attributable to the binding of P.pastoris to the mucous, forming an additional platform for 
the adherence of P.pastoris to the intestinal cells.   
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Even though numerous adhesion studies performed using food-derived 
lactobacilli and human isolates indicated the ability of lactobacilli to adhere to human 
intestinal cell lines (Jacobsen et al., 1999; Baccigalupi et al., 2005).  Chauviere et al. 
(1992) observed that not all strains of Lactobacillus spp. developed this adhesiveness to 
human intestinal cells in vitro.  Strains like L.acidophilus BG2FO4 and HN017, 
L.johnsonii La1, L.rhamnosus DR20, L.casei subsp. rhamnosus and LcS were found to be 
able to adhered to enterocyte-like Caco-2 cells (Coconnier et al., 1992; Bernet et al., 
1994; Hudault et al., 1997; Tuomola & Salminen, 1998; Forestier et al., 2001; Gopal et 
al., 2001; Kankaanpaa et al., 2001; Lee & Puong, 2002; Morita et al., 2002; Lee et al., 
2003).  Since the ability of LcS to adhere to intestinal cell lines have already been 
demonstrated, in vitro adhesion assay of LcS was not included in the current study.  In 
view of the fact that the adhesion of Lactobacillus spp. to human intestinal cells was a 
discriminative parameter, showing pronounced variation among the strains, including 
variations depending on the cell culture used (Chauviere et al., 1992; Sarem et al., 1996; 
Tuomola & Salminen, 1998; Jacobsen et al., 1999), determination of the adhesiveness of 
LcS in vivo will better correlate to the ability of LcS to colonize the intestinal tract.    
As Hautefort et al. (2000) have pointed out that in vitro adhesion to intestinal 
cells is not sufficient to ensure the persistence of lactic acid strains in the digestive tract 
of mice, it is not very clear if results obtained in the in vitro adhesion assays for 
S.boulardii, S.cerevisiae and P.pastoris can be extrapolated to in vivo environments.  It is 
therefore necessary to determine if the in vitro adhesiveness of LcS, S.boulardii, 
S.cerevisiae and P.pastoris is applicable in vivo, so as to better elucidate which of the 
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investigated microorganisms will be more suitable for oral vaccine delivery purposes 
with regard to their persistence in the intestinal tract. 
As the fluids present at the mucosal are constantly motile, it is likely that 
microorganisms which remained suspended in the intestinal water and did not adhere to 
the mucosal surfaces would be diluted and washed out from the intestinal surfaces 
quickly.  The layer of intestinal water in mice where intestinal microorganisms were 
suspended amounted to 0.33 to 0.89% (wt/wt) of the daily feed and water consumption 
(in small intestine) and 0.67% (wt/wt) of daily fecal excretion (in colon).  That is, there 
were more than 100 volume changes in the intestinal water content per day.  One volume 
change in intestinal water would dilute the organisms suspended in it by half.  Hence, 
intestinal microorganisms that did not adhere on mucosal surfaces would be diluted to an 
undetectable level soon after a single feeding.  The probability of an orally administered 
microorganism interacting with antigen sampling inductive cells may be increased if the 
carrier is able to persist in the environment.  This persistence may be achieved by direct 
adherence to the epithelial cells or to the mucous.   
The observation that the average half time for the wash-out of LcS, S.boulardii, 
S.cerevisiae and P.pastoris fed ranged from -28.80 to 66.02 days in the various parts of 
the animal intestine suggests that the lactobacilli and yeasts were able to compete with 
the indigenous microorganisms for adhesion on the mucosal surface along the full stretch 
of the intestinal tract.  A negative value in the half time for wash-out indicates an 
increment in the number of adhering cell.  The wash-out half times of LcS and the yeasts 
varied within the different segments of the intestinal tract, indicating that the affinity for 
adhesion of LcS, S.boulardii, S.cerevisiae and P.pastoris differed.  The affinity for 
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adhesion were in the order of duodenum > colon > jejunum > ileum for LcS (half times 
for wash-out were 3.98, 2.48, 1.55, and 1.34 days respectively), colon > ileum > jejunum 
> duodenum for S.boulardii (half times for wash-out were 66.02, 5.35, 3.02 and 2.64  
days respectively), jejunum > colon > ileum > duodenum for S.cerevisiae (half times for 
wash-out were -4.46, 1.84, 1.70 and 1.25 days respectively), and ileum > colon > 
duodenum > jejunum for P.pastoris (half times for wash-out were -28.80, -5.97, 2.85 and 
2.21 days respectively).   
A study using human fecal samples demonstrated that the half time for the wash-
out of Lactobacillus rhamnosus GG from the intestinal tract was about 1 day (Goldin et 
al., 1992).  The current study showed that the wash-out half times for LcS in the animal 
model ranged from 1.34 to 3.98 days, indicating that LcS have a stronger affinity to 
murine intestinal tract than Lactobacillus rhamnosus GG.  Martins et al. (2005) observed 
that several strains of S.cerevisiae were not capable of colonizing the digestive tract of 
germ-free mice, and only one particular strain, S.cerevisiae 905, was detected in the feces 
with a level never fell below 106 cfu/g.  Since the intestinal microorganisms in a fecal 
sample are diluted by fecal material, their counts could reach the limits of detection when 
the organism could still be detected on intestinal mucosal surfaces (Alander et al., 1999; 
Cesena et al., 2001).  Moreover, the organism count of a fecal sample does not allow the 
differentiation of growth and colonization in the various sections of the intestine.  Hence, 
the study of fecal samples has limitations in evaluating growth and colonization by 
lactobacilli and yeasts.  
Disparate to the results obtained from the in vitro adhesion assay where P.pastoris 
was seen to be the most adhesive strain, S.boulardii appeared to have a higher affinity to 
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the different segments of murine intestinal tract, as the half times for wash-out were 
generally longer than those for S.cerevisiae and P.pastoris.  The higher adhesiveness 
displayed by S.boulardii was expected as S.boulardii has been widely documented as 
probiotic yeast.  Interestingly, S.cerevisiae and P.pastoris that failed to remain adhered to 
the upper segments of the gastrointestinal tract were able to reattach to the lower regions 
of the intestine.  As observed by a concurrent increment in the number of adhering yeast 
cells and the median fluorescence intensity of S.cerevisiae and P.pastoris in the jejunum 
and ileum respectively, 25.8 % of the S.cerevisiae detached from the duodenum 
readhered to the jejunum, while 9.5 % of P.pastoris detached from the duodenum and 
jejunum were able to reattach to the ileum.  About 1.1 mg of mucus per day was 
dislodged from intestinal surfaces and could be recovered in the feces of the mice. 
Microorganisms adhered on mucosal surface would have dislodged together with mucus, 
and a fraction of the dislodged bacteria might have been released and readhered onto the 
newly exposed mucosal surface.  The higher readhesion percentage of S.cerevisiae could 
be due to the binding of the detached S.cerevisiae onto those attaching to the jejunum.  
Yeast flocculation, commonly seen in S.cerevisiae, is a spontaneous aggregation of cells 
and is mediated by mannose chains present on the yeast cell surface which react with 
neighboring cells via N-terminal domains of the proteins encoded by dominant 
flocculation genes (Miki et al., 1982; Kobayashi et al., 1998).  The increase in number of 
P.pastoris in the ileum was likely a result of the reattachment of detached yeast cells onto 
the enterocytes as there has been no clear evidence in the literature, showing flocculation 
of P.pastoris.   
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As there has been no previous study on the adhesion of P.pastoris, the mechanism 
by which P.pastoris adhered to various portion of the intestinal tract was uncertain.  It is 
possible that the adhesion of P.pastoris to the intestinal surfaces occurred by hydrophobic 
interactions since studies have suggested that S.cerevisiae CBS 7764 isolated from the 
intestine of rainbow trout adhere to fish intestinal mucus via hydrophobic interactions 
(Andlid et al., 1998).  However, adhesion of the yeasts can also be mediated by 
glycoprotein structures since flocculation of yeast cells have been known to be enhanced 
by carbohydrate binding domain on the cell surface (Javadekar et al., 2000; Jin et al., 
2001).  There has been diverse speculations on the adhesion mechanism of Lactobacillus 
spp..  It has been suggested that besides a polysaccharide located at the bacterial surface, 
adherence of Lactobacillus acidophilus was also mediated by a second factor, a 
proteinaceous compound that was secreted into the culture medium (Hood & Zottola, 
1989; Coconnier et al., 1992).   For some Lactobacillus spp., adhesion to human cells has 
been ascribed to an adhesion promoting protein with a molecular mass of 29 kDa highly 
homologous to a collagen-binding protein from Lactobacillus reuteri NCBI 11951 and to 
a basic surface protein from Lactobacillus fermentum BR11 (Heinemann et al., 2000).  A 
recent study by Baccigalupi et al. (2005) indicated that at least two small (less than 3 
kDa) factors, that were loosely associated with the cell wall, were involved in mediating 
the in vitro adhesion of Lactobacillus fermentum to Caco-2 cells.  On the other hand, LcS 
was shown to possess multiple surface adhesions and up to four adhesins could bind to 
the mucosal surface at any time (Lee et al., 2000).  Despite the extensive research that 
has been undertaken, the molecular basis and the exact mechanism of lactobacilli 
adhesion is still not completely understood. 
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It is interesting that the medians of the fluorescence intensities of LcS and yeasts 
measured on day 1 in various sections of the intestine were not the same (Figure 3.7, 
3.12, 3.17 and 3.22).  The differences in the fluorescence intensity of the original LcS and 
yeasts population were probably due to the physiological status of the cells at the time of 
incubation with cFDA-SE.  Various quantities of cFDA-SE might have been taken up by 
the cells, converted to the fluorescent derivative, and covalently linked to intracellular 
proteins with different efficiencies.  This observation suggests that lactobacilli and yeasts 
in different physiological states preferentially adhere to the various sections of the 
intestinal tract.  This may have implications for the preparation of vaccine carriers for 
selective adhesion on specific sections of the intestinal tract, so as to be more efficient in 
delivering the antigen of interest to the site of infection.  As such, the medians of the 
fluorescence intensity profiles of LcS, S.boulardii, S.cerevisiae and P.pastoris 
determined on day 1 were taken as the first generation (original population).  In the 
various sections of the intestine, 37.2 to 60.5 % of the original population of LcS that had 
adhered onto the intestinal surface remained attached and undivided on day 6 after 
orogastric intubation (Table 3.1).  However, more than 90 % of the yeasts that were 
attached to the jejunum, ileum or colon remained undivided on day 6.  In particular, 91.5 
and 96.6 % of S.boulardii did not undergo cell replication 6 days after attachment to the 
ileum and colon respectively.  The lower percentage of non-dividing LcS in the intestinal 
tract could be due to the presence of a larger proportion of viable lactobacilli, as report 
has suggested that ingested LcS were able to survive intestinal transit (Donnet-Hughes et 
al., 1999; Yuki et al., 1999).  The cells that had remained undivided on day 6 could have 
lost their viability after passing through the stomach and intestinal tract but still retained 
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their adhesion capability.  Studies have shown that non-viable probiotic organisms 
retained their ability to adhere to intestinal mucus, even though the adhesiveness has been 
compromised to varying degree (Ouwehand et al., 2000).  Among the dividing cells, 3.9 
to 21.6 % of the total adhered LcS have undergone three cell divisions on day 6 after 
orogastric intubation, while 6.1 to 16.3 % of S.boulardii, 0.27 to 34.23 % of S.cerevisiae 
and 3.7 to 23.7 % of P.pastoris were found to be in their fourth generation.  This study 
has clearly demonstrated that a large part of the LcS, S.boulardii, S.cerevisiae and 
P.pastoris fed were able to grow and divide in the intestinal environment; however, the 
rate of cell division were low. 
Doubling time is the time required for a cell population to double either the 
number of cells or the active cell mass.  Doubling time varies with organism and 
environment and can range from 20 minutes for a fast growing organism under ideal 
conditions, to hours and days for less than ideal conditions or for slow growing 
organisms.  The average doubling times of the lactobacilli measured in the duodenum, 
jejunum, ileum, and colon were 4.10, 4.78, 4.56, and 5.59 days, respectively. These 
values are low compared with doubling times of the bacterium cultured in MRS medium 
under aerobic (1.7 h) and anaerobic (1.2 h) conditions.  The average doubling times for 
for S.boulardii, S.cerevisiae and P.pastoris were 1.33, 1.67 and 1.54 days in the 
duodenum, 2.61, 9.10 and 1.97 days in jejunum, 10.91, 0.45 and –77.32 days in the 
ileum, and 20.83, 0.85 and 2.76 days in the colon.  The negative doubling time of 
P.pastoris in the ileum was due to the reattachment of P.pastoris detached from the 
duodenum and jejunum, resulting in an increase in the median fluorescence intensity of 
the adhering yeast.  Similar to LcS, the doubling time of S.boulardii, S.cerevisiae and 
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P.pastoris were slow compared to a doubling time of 3.4 h and 3.5 h under aerobic and 
anaerobic conditions (Porthur et al., 2000).  Since the nutritional composition of the feed 
for mice is well balanced and rich, it is the intestinal content and conditions that 
suppressed the growth of the lactobacilli and yeasts. 
The process of washing out of a microorganism from the intestinal mucosal 
surface can be described by the following relationship: wash-out rate = specific growth 
rate − dilution rate.  The dilution factor involves the rate at which the intestinal content 
passes through and the ability of the organism to adhere to the mucosal surface.  The 
effective dilution rate could be estimated from the values of the wash-out rate and the 
specific growth rate, which were determined experimentally.  For example, in the 
duodenum, the average wash-out rates of LcS and S.boulardii were ln2/3.98 or 0.17 day−1 
and ln2/2.64 or 0.26 day-1 respectively, and the specific growth rates were ln2/4.10 or 
0.17 day−1 and ln2/1.33 or 0.52 day−1 respectively.  Thus, the calculated effective dilution 
rates for LcS and S.boulardii in the duodenum were 0.34 day−1 and 0.78 day−1.  In order 
to persist on a mucosal surface (i.e., wash-out rate = 0), the lactobacilli and yeast would 
need to grow and divide at an average specific growth rate that equals to the effective 
dilution rate.  This specific growth rate represents a doubling time of 2.04 and 0.88 days 
for LcS and S.boulardii respectively in the environment of the duodenum.  In order to 
permanently colonize the jejunum, ileum, and colon, LcS would need to divide at 
doubling times of 1.17, 1.03 and 1.72 days respectively, while S.boulardii would have to 
divide at doubling times of 1.40, 3.59 and 15.83 days respectively.  These doubling time 
are 2.0 to 4.4 times faster than the actual doubling time for the lactobacilli in the 
intestine.  This indicated that for LcS to persist in the intestinal tract, the lactobacilli 
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would have to double its population at a time that is 2.0 to 4.4 times faster than the 
current doubling times.  In comparison, S.boulardii would only have to achieve doubling 
times that is 1.3 to 3.0 times shorter than the original doubling time to be able to colonize 
the intestinal tract for a significant period of time. 
 For S.cerevisiae and P.pastoris to persist in the intestinal tract, the yeasts must 
have doubling times shorter than 0.71, 0.36 and 0.58 days in the duodenum, ileum and 
colon for S.cerevisiae, and 1.00, 1.04 and 5.13 days in the duodenum, jejunum and colon 
for P.pastoris.  These represented doubling times which are 1.3 to 2.3 times and 0.5 to 
1.9 times the actual doubling time for S.cerevisiae and P.pastoris respectively.  The 
doubling times required by S.cerevisiae and P.pastoris to permanently colonize the 
jejunum and ileum respectively were not calculated as the actual doubling time of 
S.cerevisiae and P.pastoris in the jejunum and ileum could not be accurately determined.  
As mentioned earlier, the increment in the number of S.cerevisiae and P.pastoris in the 
jejunum and ileum due to the readherence of S.cerevisiae detached from the duodenum, 
and reattachment of P.pastoris detached from the duodenum and jejunum, resulted in the 
derivation of negative wash-out times of S.cerevisiae and P.pastoris in the jejunum and 
ileum respectively. 
The adhesion study suggests that in addition to direct competition between 
intestinal microorganism for adhesion, the rate of growth and division, or generation 
time, determine the ability of these organisms to colonize and persist on mucosal surfaces 
of the intestinal tract.  In this study, we have demonstrated the ability of LcS, S.boulardii, 
S.cerevisiae and P.pastoris to adhere to various portions of murine intestinal tract.  
Permanent adhesion of vaccine carrier is not a crucial criteria as prolonged stimulation of 
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the immune system might in turn result in the development of tolerance to the antigen of 
interest (Mowat & Weiner, 1999).  Since LcS was shown to be able to adhere to the 
intestinal tract for a reasonable period of time, recombinant LcS expressing coronavirus 
antigen was generated to determine its feasibility as a vaccine delivery vehicle.  Among 
the three yeast strains, P.pastoris was chosen to be further analyzed as this yeast has 
shown more potential to be developed as an oral vaccine carrier.  In particular, P.pastoris 
was capable of readhering and replicating in certain segments of the gastrointestinal tract.  
These can be beneficial as the readhesion and replication of P.pastoris will allow the 
maintenance of a significant number of vaccine carriers in the intestinal tract, long 
enough for the effective elicitation of immunological responses to the delivered antigen.  
On top of these, P.pastoris also offers an additional advantage over S.cerevisiae in that it 
is capable of generating post-translational modifications that are more similar to human 
proteins modifications than S.cerevisiae (Cregg et al., 1987).   
 Interest in the expression of heterologous genes in Lactobacillus spp. has been 
increased in the recent years, as techniques for the genetic manipulation of strains, many 
of which were previously believed to be refractory to genetic transformation, have been 
developed.  To date, only a few systems have been described using Lactobacillus spp. as 
a carrier for expressing heterologous vaccine antigens in a form that can be presented to 
and processed by the immune system of the mammalian host (Zegers et al., 1999; Shaw 
et al., 2000; Reveneau et al., 2002).  Key features of cloning vectors for the delivery of 
antigens involve promoter sequences that allow either constitutive or inducible 
expression.  Well-known inducible expression systems are the nisin-inducible expression 
system (Kleerebezem et al., 1997; Pavan et al., 2000), and systems based on sugar 
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metabolism with promoters that are regulated by catabolite repression such as xylose 
promoter (Lokman et al., 1997).  On the other hand, there has been limited development 
of constitutive expression system of Lactobacillus spp..  To our best knowledge, the only 
constitutive expression system was developed by Pouwels et al. (1996), where 
recombinant protein have been constitutively expressed under the constitutive promoter 
of L.casei L-(+)-lactate dehydrogenase gene.  In addition, these vectors can contain 
secretion and anchor signals that allow expression of proteins in different cellular 
compartments (Reveneau et al., 2002, Pouwels et al., 2001).  Mostly, plasmid-based 
expression systems are used for their ease of manipulation.  However, integrated systems 
offer the benefit of greater genetic stability of the immunization strain, but this could 
compromise the expression levels of the antigen to be delivered.  In contrast to the great 
interest of the scientific community in developing Lactobacillus strains as vaccine 
vehicles, the potential of using yeast, which is also commonly utilized in food processes, 
remained unexplored.  Since the idea of developing live bacterial or yeast as antigen 
delivery vector is on the basis of the ability of the vaccine carrier to produce the antigen 
incessantly, hence conferring long-term protection, constitutive and secretable expression 
systems have been selected for the expression of TGEV spike protein fragment by both 
LcS and P.pastoris.  Ideally, the secreted antigen will be sampled by cells of the mucosal 
immune system to induce a specific mucosal immune response, and will also be 
transported from the lumen across the epithelial barrier to stimulate a specific systemic 
immune response as well.    
In this study, we engineered for the first time, a Lactobacillus spp. to express a 
coronaviral protein, rTGEV-S, into the external mileu.  This N-terminal fragment of the 
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TGEV spike protein encompasses all the four major antigenic sites (A, B, C and D) of the 
virus, of which epitopes critical for neutralization were found to be clustered within 
(Delmas et al., 1986; Jimenez et al., 1986; Correa et al., 1988; Gebauer et al., 1991).  In 
swine testicular cells, the receptor binding sites of TGEV are mapped within site A and 
D, since monoclonal antibodies specific for these sites inhibit the binding of the virus to 
the cells (Sune et al., 1990).  At the same time, P.pastoris that constitutively expresses 
and secrete the same recombinant coronaviral protein (PrTGEV-S) was also generated.  
The use of recombinant Lactobacillus spp. and yeast as a coronavirus vaccine candidate 
also offer major advantages over the existing immunization strategies.  Vaccine delivery 
using bacterial and yeast vectors does not involve the usage of attenuated or chimeric 
viruses, hence excluding the possibility of potential risk of the virus undergoing 
recombination, changing of tropism and resulting in increased pathogenicity.   
A 75 kDa band corresponded to the expected size of rTGEV-S protein was 
detected in the supernatant of overnight recombinant LcS culture, when probed with 
convalescent swine serum (Figure 4.9).  The expressed rTGEV-S protein could only be 
detected when the supernatant was concentrated ten-fold.  Likewise, a study by Oliveira 
et al. (2003) indicated that secretion of recombinant protein by L.casei was only detected 
when the supernatant was concentrated.  As suggested Oliveira and coworkers, the low 
level of rTGEV-S protein being secreted by recombinant LcS could be due to the 
inefficient processing of the expressed protein.  The partially processed protein might 
have remained attached to the cell surface, thus resulting in low level of protein being 
secreted into the supernatant.  On the other hand, a protein band with a molecular weight 
significantly higher (90 kDa) than then expected size of PrTGEV-S protein (75 kDa) was 
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detected in the supernatant of overnight culture of recombinant P.pastoris using 
convalescent swine serum (Figure 4.20).  Since P.pastoris is capable of generating post-
translational modifications, resulting in proteins which are correctly folded and secreted 
into the medium, the increase in molecular weight of PrTGEV-S protein is likely 
contributed by glycosylation of the expressed protein (Romanos et al., 1992; Cregg et al., 
1993; Ilgen et al., 2004).  Nevertheless, the ability of the polyclonal anti-TGEV 
antibodies in the convalescent swine serum to bind to rTGEV-S or PrTGEV-S protein 
bands indicated that both recombinant LcS and P.pastoris were able to express and 
secrete TGEV spike protein fragment without compromising its antigenic properties. 
The hallmark of the mucosal immune system is the production of IgA as IgA is 
the predominant antibody at the mucosal surface that is locally produced at a level that 
exceeds that of all of other immunoglobulins.  Therefore, it is likely that to be effective, 
an oral vaccine will have to induce a specific intestinal IgA response.  Both recombinant 
LcS and P.pastoris were shown to be able to elicit mucosal and systemic humoral 
responses after oral immunization in mice.  The mucosal and systemic immune responses 
elicited by the recombinant P.pastoris was significantly prompter and stronger than the 
immune responses induced by the recombinant LcS (Figures 4.12, 4.13, 4.23 & 4.24).  
High level of PrTGEV-S specific IgA and IgG were already induce on day 18 by 
recombinant P.pastoris, reaching concentrations that were relatively close to the 
maximum level of IgA and IgG observed in the study (Figure 4.23 & 4.24A).  In 
particular, the concentration of rTGEV-S specific IgA elicited by recombinant LcS was 
only 16 % of the highest level IgA attained (Figure 4.12).  The discrepancies in the 
immunological responses of mice to the LcS and P.pastoris oral vaccines could be 
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attributable to the differential expression level of TGEV spike protein fragment.  As 
observed in in vitro culture of recombinant LcS and P.pastoris, the recombinant TGEV 
spike protein fragment might be more efficiently expressed and secreted by P.pastoris 
adhering to the intestinal tract, resulting in a more rapid dissemination of PrTGEV-S 
protein to sensitize the mucosal inductive sites in the intestinal tract.  Inevitably, a 
prompter immune response specific for PrTGEV-S protein could be elicited. 
The oral immunization regime used, which consisted of three sets of three 
successive daily doses of the experimental vaccine, was adapted from the procedure of 
Challacombe (1983), who found that this pattern of immunization was consistently 
effective when particulate oral vaccines were used to immunize mice.  Three successive 
daily doses of recombinant strains were required in order to ensure that systemic antibody 
response to rTGEV-S or PrTGEV-S proteins can be elicited in all mice receiving 
recombinant LcS or P.pastoris intra-gastrically.  In additional to mucosal rTGEV-S and 
PrTGEV-S specific IgA responses, the presence of rTGEV-S and PrTGEV-S specific IgG 
antibodies in the serum of orally immunized mice indicated that this regime also induced 
rTGEV-S and PrTGEV-S specific immune responses in the systemic compartment.  
Although Lactobacillus spp. have been known to possess adjuvant properties (Meydani & 
Ha, 2000; Marteau, 2002), recombinant LcS being used as a vaccine carrier in this study 
did not induce a stronger systemic response in comparison to that elicited by recombinant 
P.pastoris.  Mice administered with wild type LcS showed antibody levels similar to the 
control groups that received PBS only.  As suggested by Maassen and coworkers (2000) 
who found that many of the Lactobacillus strains did not affect the systemic humoral 
immune responses, LcS may act very similarly to natural gut commensals of the mice and 
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hence, do not disturb the existing immune status.  Nevertheless, the subclasses of 
rTGEV-S or PrTGEV-S specific IgG induced by the oral vaccines were also determined.  
Most of the IgG responses generated by oral immunization with LcS-rTGEV-S or 
PP/PrTGEV-S were of IgG2a isotype (Figures 4.13B & 4.24B). 
Although mucosal IgA has been known to be an important effector molecule to 
protect mucosal surfaces, the contribution to mucosal protection by the cellular immune 
system should not be underestimated.  Cell-mediated immunity occurs before the 
induction of antibodies and forms an early line of defense against viral infections.  Since 
previous study has indicated that the production of IgG1 isotype is induced by Th2-type 
cytokines, and that the IgG2a isotype is regulated by Th1-type cytokines (Finkelmann et 
al., 1990; Gemmell et al., 2004), it could be presumed from a higher IgG2a level that 
both recombinant LcS and P.pastoris induced a more prominent type 1 response.  In 
order to have a better understanding of the cellular immune responses induced by the 
recombinant LcS and P.pastoris, the specific cytokine responses were assessed in the 
Peyer’s patches of mice after oral immunization.  As the Peyer’s patches represent the 
inductive sites after oral administration, from which sensitized lymphocytes migrate to 
the mesenteric lymph nodes, then to the lamina propria, it is of particular importance to 
assess the immune responses elicited in the Peyer’s patches to determine the effectiveness 
of the oral vaccines to induce cell-mediated immunity. 
It was observed that the immunized animals displayed strong cell-mediated 
immune responses.  A specific Th1/Th2-like cytokine response was observed after in 
vitro re-stimulation of Peyer’s patches cells from mice orally immunized with 
recombinant LcS or P.pastoris (Figure 4.16 & 4.27).  In accordance with the fact that 
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higher levels of IgG2a (Figures 4.13B & 4.24B) were induced by both LcS-rTGEV-S and 
PP/PrTGEV-S, a stronger Th1-like cytokines response, as measured by the Th1-type 
cytokines, IFN-γ and IL-2, were elicited (Figures 4.16 & 4.27).  In particular, high levels 
of IFN-γ were induced by the sensitized cells of Peyer’s patches of mice orally 
immunized with recombinant LcS or P.pastoris.  The strong interferogenic activity 
exhibited by cells of the Peyer’s patches could be attributed to the nature of the delivered 
antigen, where TGEV has been reported to be a potent inducer of interferon (La 
Bonnardiere & Laude, 1981; Riffault et al., 1997).  Interferon gamma, a prototypical 
Th1-type cytokine, is produced predominantly by CD4 Th1 cells and CD8 T cells.  The 
level of IFN-γ expressed by cells of the Peyer’s patches reflects the magnitude of the T 
cell response.  Since after in vitro re-stimulation, cytokines are most likely to be produced 
by T cells, it can be concluded that TGEV-specific lymphocytes were present in the 
intestine after oral immunization of mice with recombinant LcS or P.pastoris, capable of 
constitutive expression of TGEV spike protein fragment. 
Interestingly, even though IFN-γ is known to down regulate Th2-type responses 
(McGhee et al., 1989), the findings in this study indicated that the production of Th2-type 
cytokines (IL-4 and IL-5) were elicited and maintained in the mice orally dosed with 
recombinant LcS or P.pastoris (Figures 4.16 & 4.27).  Since IL-4, a prototypical Th2-
type cytokine, have been shown to play a dominant role in B cell-mediated immune 
responses (Agadjanyan et al., 1999), the induction of Th2 cytokine producing cells may 
contribute to the induction of TGEV-specific IgA and IgG responses in both the mucosal 
and systemic compartment of immunized mice.   
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When developing vaccines, it is crucial that the vaccines are capable of conferring 
protection against viral infection.  As such, the evaluation of their protective immunity 
are warranted.  In order to confirm the efficacy of the induced antibodies in inhibiting 
TGEV infection, intestinal lavages and sera from mice orally immunized with rTGEV-S 
protein expressing LcS or PrTGEV-S protein expressing P.pastoris were tested for their 
ability to inhibit the infection of ST cells in plaque reduction neutralization assay.  Sera 
and intestinal lavages collected from mice administered with recombinant LcS or 
P.pastoris demonstrated statistically significant inhibition of plaque formation by TGEV 
(Figures 4.14 & 4.25).  However, the protection conferred by lavages and sera from mice 
fed with recombinant LcS were very much less efficient than those conferred by lavages 
and sera from mice fed with recombinant P.pastoris.  The maximum reduction in the 
number of plaques using intestinal lavages and sera collected from mice orally 
immunized with recombinant LcS were lower that 15 %.  These inhibition efficiencies 
were only 19 to 22 % of the maximum plaque inhibition by the lavages and sera of mice 
fed with the recombinant P.pastoris, which showed a reduction close to 100 % at lower 
dilutions.  The poor protective immunity conferred by recombinant LcS could be due to 
the lack of post-translational modifications in the prokaryotic expression system.  The 
native TGEV S glycoprotein is usually highly glycosylated (Rasschaert & Laude, 1987).  
In particular, antigenic sites A and B, which have been included in the recombinant 
rTGEV-S protein, have been demonstrated to be conformational and glycosylation 
dependent (Correa et al., 1988; Correa et al., 1990; Posthumus et al., 1990a; Posthumus 
et al., 1990b; Gebauer et al., 1991).  As such, the lack of correlation between antibody 
levels measured by ELISA and neutralizing antibody titers is not surprising as 
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neutralizing antibodies probably represent a subset of the total antibody, and the levels of 
neutralizing antibodies may be related to the availability of neutralizing epitopes on the 
expressed antigen.  The expressed rTGEV-S protein might not be functional due to the 
lack of post-translational modifications, especially when glycosylation is crucial for the 
immunogenicity of site A, the major inducer of neutralizing antibodies (Correa et al., 
1988; De Diego M et al., 1992).  Interestingly, despite the lack of post-translational 
modifications in prokaryotic expression system, the 75 kDa fragment of rTGEV-S protein 
expressed by LcS was recognized by convalescent swine serum, indicating that the 
expressed protein possessed certain degree of immunogenicity, albeit not strong enough 
to elicit significant immune protection. 
Since P.pastoris has been demonstrated to be an extremely efficient expression 
system that generate recombinant proteins which are post-translationally modified and 
typically correctly folded (Cregg et al., 1987; Romanos et al., 1992; Ilgen et al., 2004), it 
is likely that the high inhibitory percentage of TGEV plaque formation was due to the 
proper processing of the expressed product.  In agreement, Gomez and coworkers (1998) 
have developed arabidopsis transgenic plants expressing N-terminal domain of TGEV 
spike protein that elicited neutralizing antibodies when used to immunize mice.  On the 
other hand, inoculation of animals with recombinant E.coli expressing glycoprotein S did 
not induce neutralizing antibodies or confer protection in vivo (Hu et al., 1996).  In 
another study, the use of plant as an oral vaccine delivery vehicle would only result in 
short-term induction of the immune system against the expressed antigen and hence, 
requires consistent and frequent feeding of mice with the transgenic plant if long-term 
effect is desired.  In contrast, the development of a delivery system like P.pastoris that is 
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able to adhere and colonize the intestinal tract permits continuous expression of antigen 
in the intestine, resulting in extended protection of the vaccinated subject from viral 
infection.   
 To this point, the results have provided evidence, favoring the choice of 
P.pastoris over LcS as vaccine delivery vehicle for coronaviruses.  Oral immunization of 
mice with recombinant P.pastoris expressing PrTGEV-S protein induced strong humoral 
and cellular immune responses.  These responses were characterized by high levels of 
specific mucosal IgA and systemic IgG, neutralizing antibodies, as well as high levels of 
IL-2, IFN-γ, IL-4 and IL-5 producing cells in the Peyer’s patches of immunized mice, 
which were good indicators of effective immunization strategy. 
 The emergence of SARS that resulted in a pandemic in 2003 spurred a flurry of 
interest in the development of antiviral strategies against SARS CoV.  Because of the 
threat of a reemerging epidemic, much effort has been placed on the development of a 
prophylatic vaccine against the pathogenic SARS CoV (Bisht et al., 2004; Bukreyev et 
al., 2004; Chen et al., 2005; Johnston, 2004; Weingartl et al., 2004; Yang et al., 2004). 
The fact that high titers of virus neutralizing antibody to SARS CoV are found in sera of 
patients recovering from infection and those infected with the virus show improvement 
after passive antibody administration suggests a SARS CoV vaccine is feasible (Pearson 
et al., 2003; Sui et al., 2004; Oxford et al., 2005).  Currently, the development of SARS 
vaccine are focussed essentially on the utilization of two different types of SARS CoV 
derived immunogens, inactivated whole virus and recombinant SARS CoV structural 
proteins.  Although Takasaka et al. (2004) have reported that subcutaneous 
administration of UV-inactivated SARS CoV viron elicits high level of humoral 
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immunity, there remains the threat of introducing live virus into the environment from 
partially inactivated vaccine, as there are no validated and effective inactivation measures 
developed yet.   
Current efforts on SARS CoV vaccine have very much been focussed on the 
development of recombinant vectored or recombinant subunit vaccines, utilizing 
recombinant nucleocapsid or S proteins as the antigen.  Of the structural proteins that 
compose SARS CoV, the S glycoprotein is probably the most significant target for 
neutralization (Buchholz et al., 2004).  Li and coworkers (2003) identified angiotensin-
converting enzyme 2 (ACE2) as a functional receptor for SARS CoV.  This finding was 
further confirmed by several other research groups (Xiao et al., 2003; Wang et al., 2004; 
Mossel et al., 2005).  The interaction between ACE2 and SARS CoV S glycoprotein was 
further explored to elucidate the structure and function of ACE2 (Prabakaran et al., 
2004).  ACE2 was found to interact with an independently folded receptor binding 
domain (RBD), which is a 193 residue fragment [S(318-510)] of the SARS CoV S 
protein (Wong et al., 2004).  Since the RBD of SARS CoV alone exhibited potent 
antiviral activity by blocking S protein mediated infection, the ACE2-binding site of the 
S glycoprotein has become an attractive target for vaccine design.  Chen et al. (2005) 
have introduced the S protein into the deletion III region of the live attenuated modified 
vaccinia virus Ankara vector and the recombinant virus generated elicited potent 
neutralization antibodies in mice, rabbits and monkeys.  On the other hand, mice 
immunized with a plasmid containing the S protein developed neutralizing antibodies and 
cell-mediated responses resulting in a six-fold reduction in viral titer (Yang et al., 2004).  
The demonstration that S proteins of several CoVs (TGEV, porcine epidemic diarrhea 
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virus, and infectious bronchitis virus) are immunogenic when administered orally in 
animals (Zhou et al., 2003; Bae et al., 2003; Lamphear et al., 2004; Tuboly et al., 2000) 
have led us to test yeast derived SARS antigen by this route. 
 In the present study, a 720 bp fragment of SARS CoV S glycoprotein, encoding 
the receptor-binding domain of SARS CoV was introduced into the genome of 
P.pastoris.  As suggested by the results presented earlier, P.pastoris being a more 
appropriate vaccine carrier for coronaviruses was selected for the delivery of SARS-S-
RBD protein.  P.pastoris is an eukaryotic expression system with high efficiency and 
proteins expressed by this system can get appropriate post-translational modifications, 
including glycosylation (Kukuruzinska et al., 1987; Grinner & Tschopp, 1989; Romanos 
et al., 1992).  Recombinant SARS-S-RBD protein was successfully expressed by 
P.pastoris, and the expressed SARS-S-RBD protein was similar to the native protein in 
its immune response.  This can be demonstrated by the reaction of recombinant SARS-S-
RBD protein with SARS-positive sera in Western blotting, which revealed two distinct 
protein bands in the supernatant of overnight culture of recombinant P.pastoris (Figure 
5.5).  The smaller protein band corresponding to the expected size of SARS-S-RBD 
protein represents the unglycosylated protein while the larger protein protein band is 
likely to be the glycosylated SARS-S-RBD protein.  The ability of recombinant 
P.pastoris to generate glycosylated SARS-S-RBD protein is crucial as recent evidence 
has determined that virus neutralization is sensitive to deglycosylation of the S protein 
(Song et al., 2004).  Interestingly, the increment in molecular weight of SARS-S-RBD 
protein due to glycosylation of the expressed protein was much higher than that of the 
glycosylated PrTGEV-S protein.  One could reason that the variation in the increment of 
                                                                                   CHAPTER 6 
                                                                                                                    DISCUSSION & CONCLUSION 
 209
size of the glycoprotein could possibly be due to the presence of different number of 
glycosylation sites, resulting in the different extend of glycosylation.  In a study where 
glycosylation variants of β-lactoglobulin with different number of glycosylation sites 
were produced by P.pastoris, the extent of glycosylation were found to vary among the 
mutants (Kalidas et al., 2001).  It has been predicted that the S protein of SARS CoV 
contains 23 potential N-glycosylation sites (Krokhin et al., 2003).  However, mass 
spectrometric analysis of the S protein confirmed the existence of 12 glycosylation sites 
in this protein, while another study by Ying et al. (2004) revealed that only 4 
glycosylation sites were present.  On the other hand, no literature specifying the number 
of glycosylation sites in the S protein of TGEV is available.  As such, no comparison 
could be made between the number of glycosylation sites within the PrTGEV-S and 
SARS-S-RBD protein in order to elucidate the reason for the discrepancies in the 
increment of size of the recombinant proteins.  
In this study, oral immunization of PP/SARS-S-RBD induced SARS-S-RBD 
specific humoral responses, characterized by strong and persistent SARS-S-RBD specific 
IgA and IgG levels in the intestinal lavages and sera from immunized mice (Figures 5.8 
& 5.9).  The level of antigen specific IgA and IgG induced by P.pastoris, in the delivery 
of PrTGEV-S or SARS-S-RBD proteins were highly similar.  These, together with the 
strong mucosal and systemic immunological responses elicited against PrTGEV-S and 
SARS-S-RBD proteins demonstrated the stability and suitability of P.pastoris as an oral 
vaccine delivery vehicle for coronaviruses.  Interestingly, in contrast to a higher level of 
IgG2a isotype induced by PP/PrTGEV-S, the SARS-S-RBD specific isotype was 
predominantly IgG1 (Figure 5.9B).  The decreased ratio of IgG2a/IgG1 in mice orally fed 
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with P.pastoris expressing SARS-S-RBD protein suggests a shift toward a Th2-type 
response in immunized animals.  The type of immune response is known to be important 
in achieving maximum protection against various pathogens, such as respiratory syncytial 
virus (Kim et al., 1969; Srikiatkhachorn & Braciale, 1997).  The level of IgG1 antibody 
is often associated with Th2 cells (Finkelmann et al., 1990; Gemmell et al., 2004).  The 
Th2 cells produce more IL-4, expanding Th2 cells which support the associated immune 
responses.  The production of IL-4 support IgG1 subclass and antibodies such as IgE and 
IgA are also produced during a Th2 dominated response (McGhee et al., 1999).  In 
accordance to a more dominant IgG1 isotype induced by oral immunization of mice with 
PP/SAR-S-RBD, a stronger Th2-like cytokine response was elicited.  The Th2 biased 
response was quite unexpected as IFN-γ, a typical Th1-type cytokine, was reported to be 
elevated in the acute phase sera of Taiwan SARS patients (Huang et al., 2005).  In 
addition, when a combination of whole killed SARS CoV and DNA vaccine containing a 
plasmid encoding the full-length SARS CoV S protein were used to immunize mice, a 
Th1 dominated immune response was induced (Zakhartchouk et al., 2005).  However, by 
database analysis, Wang et al. (2004) identified two T cell epitopes, S978 and S1203, in 
SARS CoV S protein which are localized in the S2 protein of SARS CoV.  The SARS 
CoV specific peptides S978 and S1203 were found to induce a high frequency of IFN-γ 
secreting T cell response, indicating that the IFN-γ-related cytokine storm in SARS 
patients and the Th1 dominated responses induced by the SARS CoV vaccines (DNA and 
whole killed virus) might be contributed significantly by the T cell epitopes in the S2 
fragment of SARS CoV S glycoprotein.  This might provide an explanation for the less 
dominant Th1-like cytokines responses in the Peyer’s patches and CLN of mice orally 
                                                                                   CHAPTER 6 
                                                                                                                    DISCUSSION & CONCLUSION 
 211
immunized with P.pastoris expressing SARS-S-RBD protein, since the delivered antigen 
encompasses only the RBD within the S1 fragment of SARS CoV S glycoprotein.  In 
accordance to our findings, injection of plant-derived S1 fragment of the SARS-CoV S 
protein resulted in a shift toward Th2-type response in mice (Pogrebnyak et al., 2005). 
The specific cytokine responses were assessed both in the Peyer’s patches and 
CLN of mice after oral ingestion of P.pastoris expressing SARS-S-RBD protein.  It is of 
particular importance to assess the cell mediated immune responses in the CLN after 
immunization by the oral route since SARS CoV is a respiratory pathogen and the 
immune responses are expected to be stronger at the sites of induction than at distant 
sites.  Indeed, the amount of IL-4 and IL-5 produced by the re-stimulated cells of the 
Peyer’s patches were generally higher than the concentrations of these cytokines 
produced by the re-stimulated cells of the CLN of mice immunized with PP/SARS-S-
RBD.  Several studies reported that gut associated lymphoid tissue can stimulate the 
common mucosal immune system, in which immune cell stimulated at one site migrate to 
other sites through the systemic (blood and lymph) circulation (Tilney, 1971; Rudzik et 
al., 1975; McCluckie et al., 2001).  The ability of cells of the CLN to generate a mixed 
Th1/Th2-like cytokine response when re-stimulated with SARS-S(M) indicated that oral 
immunization with PP/SARS-S-RBD resulted in dissemination of cytokine producing 
cells from the mucosal tissue to the CLN.  This further substantiates the potential use of 
P.pastoris for the oral delivery of antigens to elicit specific immunological responses at 
sites close to or distant from the immunization site.  However, at present, the available 
data are insufficient to allow conclusions about effectiveness of PP/SARS-S-RBD as 
SARS CoV vaccine to be made.  
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 Spike specific monoclonal and polyclonal antibodies that neutralize the virus have 
been developed (Berry et al., 2004; Zhang et al., 2004) and passive transfer of immune 
serum into naive mice protected them from infection with SARS CoV (Subbarao et al., 
2004).  These suggest that neutralizing antibody alone can prevent viral infection.  As 
such, it is crucial to determine the neutralizing activity of the antibodies elicited by 
SARS-S-RBD protein.  In contrast to plaque reduction neutralization assay utilized to 
analyze the inhibitory effects of antibodies elicited by PP/PrTGEV-S against TGEV 
infection, fluorescent focus assay was performed using intestinal lavages and sera from 
mice orally immunized with PP/SARS-S-RBD to determine the protective effects 
conferred by SARS-S-RBD specific intestinal IgA and serum IgG to inhibit infection of 
Vero cells.  As SARS CoV is a highly hazardous pathogen in which only trained and 
experienced personnel is suited to work with, the next best alternative is to utilize murine 
leukemia virus particle pseudotyped with SARS CoV S protein (Giroglou et al., 2004).  
MLV(SARS) offers a retroviral pseudotype-based assay that facilitates the accurate 
determination of neutralizing antibody responses to SARS CoV without the use of 
replication competent virus.  Cells infected with MLV(SARS) will fluoresce under 
fluorescence microscope as the pseudotyped virus was co-transfected with eGFP as a 
marker during its construction.  The number of FFU can then be enumerated and 
expressed as a percentage of fluorescence cell obtained in the neutralization assay with 
anti-SARS-S-RBD intestinal lavages or sera with respect to intestinal lavages or sera 
from control mice.  The recombinant P.pastoris expressing SARS-S-RBD elicited potent 
neutralizing antibodies when orally administered to mice (Figure 5.10).  The anti-SARS-
S-RBD IgA and IgG (up to dilution of 1:8) were capable of almost completely inhibiting 
                                                                                   CHAPTER 6 
                                                                                                                    DISCUSSION & CONCLUSION 
 213
infection of Vero cell by MLV(SARS).  Of note, more that 50 % of infection by 
MLV(SARS) were blocked by  anti-SAR-S-RBD IgA and IgG in the intestinal lavage 
and serum at a dilution of 1:32.  In agreement, rabbits and mice immunized with RBD 
produced high titer of neutralizing antibodies against SARS CoV (He et al., 2004).  It is 
likely that the S protein-based oral vaccine induced potent neutralizing antibodies that 
prevented the virus from entering the Vero cells by binding to the virions to block their 
interaction with ACE2.  More importantly, van den Brink et al. (2005) showed that one 
human monoclonal antibody (CR3014) specific for RBD of one of the SAR CoV strains 
can effectively bind to most RBDs of the early and late SARS CoV strains.  These data 
suggest that antibodies directed against RBD of a SARS CoV isolate may neutralize 
infection by a broad spectrum of SARS CoV strains. 
 The data obtained in our attempt to generate an oral vaccine against SARS CoV 
have demonstrated the feasibility of utilizing P.pastoris as an oral delivery vehicle for the 
coronavirus.  Oral immunization of mice with PP/SAR-S-RBD induced strong humoral 
and cellular immune responses.  These responses were characterized by high levels of 
SARS-S-RBD specific serum IgG and secretory IgA, neutralizing antibodies, and IFN-γ 
producing cells both in the Peyer’s patches and CLN.  Thus, PP/SARS-S-RBD can act as 
a potent oral vaccine to induce both humoral and systemic responses, as well as both 
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6.1 CONCLUSION 
6.1.1 Adhesion Studies 
• All the three yeasts (S.boulardii, S.cerevisiae and P.pastoris) demonstrated in vitro 
adhesiveness to human intestinal Caco-2 and HT29 cells, where P.pastoris appeared 
to have a stronger affinity to the intestinal cells in comparison to S.boulardii and 
S.cerevisiae.   
• In agreement, in vivo adhesion studies conducted on the Balb/c mice revealed that 
S.boulardii, S.cerevisiae and P.pastoris were able to adhere and replicate in various 
segments of murine gastrointestinal tract.   
• P.pastoris was selected over the other two yeasts for further development into oral 
vaccine carrier against coronavirus as P.pastoris was found to be better equipped with 
the ability to re-adhere and replicate in certain segments of the gastrointestinal tract. 
At the same time, in vivo adhesion analysis of LcS showed that the lactobacilli was 
able to compete with the indigenous microorganisms for adhesion on the mucosal 
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6.1.2 Development of Oral Vaccine Against TGEV 
• Recombinant LcS and P.pastoris capable of constitutively expressing and 
secreting an N-terminal fragment that encompassed the major antigenic domains 
of TGEV S protein were generated.  The recombinant proteins (rTGEV-S and 
PrTGEV-S protein) expressed by LcS-rTGEV-S and PP/PrTGEV-S were showed 
to have retained their authentic antigenicities.   
• More importantly, oral immunization of mice with LcS-rTGEV-S or PP/PrTGEV-
S elicited antigen specific mucosal and systemic humoral responses against the 
delivered antigens.  However, the antibodies induced by the recombinant LcS 
conferred modest protection against TGEV infection in the plaque reduction 
assays conducted.  This is in opposed to the strong inhibitory effects exerted by 
the antibodies induced by PP/PrTGEV-S.  
• The low protective ability of the antibodies elicited by LcS-rTGEV-S was 
attributed to the lack of post-translational modifications of the delivered rTGEV-S 
protein in prokaryotic expression system, where some of the antigenic sites within 
the rTGEV-S protein were reported to be dependent on glycosylation.   
• Nevertheless, mice immunized with either LcS-rTGEV-S or PP/PrTGEV-S 
displayed strong cell-mediated immune responses, where Th1-type dominated 
responses were elicited.  Our findings indicated that P.pastoris served as a better 
oral vaccine carrier against coronaviruses, while Lactobacillus spp. is more 
suitable for the delivery of antigens in which post-translational modifications is 
not crucial for the immunogenicity of the antigens. 
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6.1.3 Development of Oral Vaccine Against SARS CoV 
• Earlier results indicated that P.pastoris is a highly potential candidate for the 
delivery of coronavirus antigen via the oral route.  In view of this, P.pastoris was 
developed into an oral vaccine carrier for the delivery of SARS CoV antigen in 
the final part of the study.   
• Recombinant P.pastoris was engineered to express and secrete a fragment of the 
S glycoprotein of SARS CoV (SARS-S-RBD).  The recombinant protein 
contained the RBD of SARS CoV, found to be essential for the generation of 
protective immunological responses against the coronavirus.    PP/SARS-S-RBD 
was demonstrated to be able to express the recombinant protein without 
compromising its antigenic properties.  
• Mice orally immunized with PP/SARS-S-RBD developed strong mucosal and 
systemic immune responses against SARS-S-RBD.  The antibodies elicited 
demonstrated potent neutralizing activity against a SARS CoV pseudotyped virus 
particle, MLV(SARS). 
• A Th2 dominated cell-mediated response was elicited both in the Peyer’s patches 
and CLN of immunized animals, indicating that oral immunization of PP/SARS-
S-RBD is able to induce cellular responses at sites close to and distant from the 
site of immunization. 
• Findings obtained in this part of study further substantiate the potential of 
utilizing P.pastoris or even other yeast strains as oral vaccine delivery vehicles 
against viral antigens. 
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APPENDIX 1 
MATERIALS FOR BACTERIAL AND YEAST CULTURE 
 
Materials Required for Bacterial Culture 
(a) Luria-Bertani (LB) Broth, pH 7.0 
Items Amount Source 
Bacto-tryptone 10.0 g BD Biosciences, USA 
Bacto-yeast extract 5.0 g BD Biosciences, USA 
NaCl 10.0 g Merck, Germany 
 
The above components were dissolved in 1.0 liter of dgd.  The solution was autoclaved 
at 121 ºC for 15 min (Hirayama, Japan).  Storage was at 4 °C. 
 
(b) Luria-Bertani (LB) Agar 
Items Amount Source 
Bacto-tryptone 10.0 g BD Biosciences, USA 
Bacto-yeast extract 5.0 g BD Biosciences, USA 
NaCl 10.0 g Merck, Germany 
Agarose 10.0 g Oxoid, UK 
 
The above components were dissolved in 1.0 liter of deionised water.  The solution was 
autoclaved at 121 ºC for 15 min (Hirayama, Japan) and cooled to 60 °C before pouring 
plates.  Storage was at 4 °C. 
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(c) Low Salt (LB) Agar 
Items Amount Source 
Bacto-tryptone 10.0 g BD Biosciences, USA 
Bacto-yeast extract 5.0 g BD Biosciences, USA 
NaCl 5.0 g Merck, Germany 
Agarose 10.0 g Oxoid, UK 
 
The above components were dissolved in 1.0 liter of deionised water.  The solution was 
autoclaved at 121 ºC for 15 min (Hirayama, Japan) and cooled to 60 °C before pouring 
plates.  Storage was at 4 °C. 
 
(d) SOC media 
Items Amount  Source 
Bacto-Tryptone 2.0 g BD Biosciences, USA 
Bacto -Yeast extract 0.5 g BD Biosciences, USA 
NaCl 0.58 g Merck, Germany 
KCl 0.25 g Merck, Germany 
MgCl2 2.03 g Merck, Germany 
MgSO4 2.46 g Merck, Germany 
Glucose 1.8 g Merck, Germany 
 
The above components were dissolved in 1.0 liter of dgd.  The solution was autoclaved 
at 121 ºC for 15 min (Hirayama, Japan).  Storage was at 4 °C. 
 
(e) Antibiotics 
Ampicillin was prepared as stock solution of 100 mg/ml in dgd and diluted to100 μg/ml 
as the working concentration.  Kanamycin was prepared as stock solution of 50 mg/ml in 
dgd and diluted to 50 μg/ml as the working concentration. Zeocin was prepared as stock 
solution of 10 mg/ml in dgd and diluted to 100 μg/ml as the working concentration. 
Erythromycin was prepared as stock solution of 25 mg/ml in ethanol and diluted to 5 
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μg/ml as the working concentration.   All the antibiotic solutions were filtered through a 
0.22 µm filter and stored at -20 °C prior to use.   
 
Materials Required for Yeast Culture 
(f) YPD Media 
Items Amount Source 
Bacto-Peptone 20.0 g BD Biosciences, USA 
Bacto-yeast extract 10.0 g BD Biosciences, USA 
Dextrose 20.0 g Merck, Germany 
 
The above components were dissolved in 1.0 liter of dgd.  The solution was autoclaved 
at 121 ºC for 15 min (Hirayama, Japan).  Storage was at 4 °C. 
 
(g) YPD Agar 
Items Amount Source 
Bacto-Peptone 20.0 g BD Biosciences, USA 
Bacto-yeast extract 10.0 g BD Biosciences, USA 
Dextrose 20.0 g Merck, Germany 
Agarose 10.0 g Oxoid, UK 
Agar 10.0 g Oxoid, UK 
 
The above components were dissolved in 1.0 liter of deionised water.  The solution was 
autoclaved at 121 ºC for 15 min (Hirayama, Japan) and cooled to 60 °C before pouring 
plates.  Storage was at 4 °C. 
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APPENDIX 2 
MATERIALS FOR MOLECULAR CLONING 
 
Materials Required for DNA Agarose Gel Electrophoresis 
(a) 1 x Tris-Borate-EDTA Buffer (TBE) 
The stock solution of 10x TBE buffer was purchased from the National University 
Medical Institute (NUMI) Store.  Ten ml of the 10x TBE buffer was added to 90.0 ml of 
deionized water to obtain the 1 x TBE buffer. 
 
(b) 1.5 % Agarose Gel 
Items Amount Source 
Agarose 20.0 g Seakem, USA 
10 x TBE 25.0 ml Prepared by NUMI Store 
Ethidium Bromide (10 
mg/ml) 
12.5 μl Sigma, USA 
 
The above mixture was topped up to 250.0 ml (excluding ethidium bromide) with dgd 
and the mixture was boiled for 3 min in a microwave oven.  The solution was allowed to 
cool to 60 °C followed by the addition of ethidium bromide.  The solution was mixed 
well before pouring into the agarose gel apparatus in the fume cardboard. 
 
(c) DNA Loading Buffer 
Items Amount Source 
Bromophenol Blue 25.0 mg Sigma, USA 
Sucrose 4.0 g Merck, Germany 
Dgd 10.0 ml Corning, USA 
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Materials for Recombinant Fusion Protein Extraction 
 
(d) GST- Lysis buffer 
Items Amount Source 
Tris-HCl 7.88 g Sigma, USA 
Magnesium chloride 0.1 g Sigma, USA 
Triton X-100 (v/v) 0.1 ml Sigma, USA 
PMSF 5.0 ml Appendix 5 (e) 
DTT 0.78 g Sigma, USA 
 
The above materials were dissolved in 1.0 litre of dgd water.  The pH was adjusted to 7.2 
using either 1 M HCl or 1 M NaOH. Storage was at room temperature. 
(e) Urea + 0.01% SDS 
Items Amount Source 
Urea 30 g  Sigma, USA 
SDS 0.1 g Sigma, USA 
Triton X-100 (v/v) 0.1 ml Sigma, USA 
PMSF 5.0 ml Appendix 5 (e) 
DTT 0.78 g Sigma, USA 
 
Materials for Electroporation of LcS 
 
(f) Washing Buffer 
 
Items Amount Source 
KH2PO4-K2HPO4 50 mM Sigma, USA 
Sucrose 0.3 M Sigma, USA 
MgCl2 1 mM Sigma, USA 
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(g)  Electroporation Buffer 
 
Items Amount Source 
Sucrose 952 mM Sigma, USA 
MgCl2 3.5 mM Sigma, USA 
 
The solution was then sterilized by filtration through 0.22 μm filter unit (Sterivex G-S, 
Millipore, USA). 
 
Materials for DNA Isolation from Yeast Cells 
 
(h)       Breaking Buffer 
 
Items Amount Source 
Triton X-100 (v/v) 20 ml Sigma, USA 
SDS 10 ml Sigma, USA 
Na Cl 100 mM Sigma, USA 
Tris-Cl 10 mM Sigma, USA 
EDTA 1 mM Sigma, USA 
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APPENDIX 3 
MATERIAL FOR SODIUM DODECYL SULPHATE - POLYACRYLAMIDE 
GEL ELECTROPHORESIS (SDS-PAGE) 
 
(a) Stacking Gel 
 
Items Amount  Source 
30 % Acrylamide & 0.8 % 
bis-acrylamide 
1.67 ml Merck, Germany 
0.5 M Tris buffer pH 6.8 2.5 ml Merck, Germany 
10 % SDS 0.1 ml Merck, Germany 




20.0 μl Merck, Germany 
10 % Ammonium 
persulphate 
50.0 μl Merck, Germany 
 
The chemicals were added in the above order. 
 
 
(b) Separation Gel (12% SDS-PAGE) 
 
Items Amount  Source 
30 % Acrylamide & 0.8 % 
bis acrylamide 
12.0 ml Merck, Germany 
1 M Tris buffer pH 8.8 11.25 ml Merck, Germany 
10 % SDS 0.3 ml Merck, Germany 




40.0 μl Merck, Germany 
10 % Ammonium 
persulphate 
80.0 μl Merck, Germany 
 
The chemicals were added in the above order. 
 
 
(c) Dye Mixture (Stock Solution) 
 
Items Amount  Source 
Bromophenol blue 0.1g Sigma, USA 
Glycerol 1.0 ml Analar, UK 
0.5 M Tris buffer, pH 6.8 10.0 ml Merck, Germany 
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(d) SDS-Sample Buffer 
 
A 1ml cocktail of dye mixture [see Appendix 5 (c)] stock solution were mixed with 100 
mg of dithioerythritol (Biorad, USA).  To every 25.0 μl of sample, 5.0 μl of these 
cocktail were added.  After mixing the sample with cocktail, the mixture was boiled for 1 
min in a water bath before loading onto the gel. 
 
(e) Running Buffer (pH 8.9) 
 
Items Amount  Source 
Tris 6.0 g Merck, Germany 
Glycine 28.7 g Merck, Germany 
SDS 2.0 g BioRad, USA 
 
The above was dissolved in 1 litre of dgd to make a 2x concentrated solution.  From this 
concentrated solution, 250.0 ml were diluted to 500.0 ml and used as the top chamber 
buffer.  The remaining stock solution were diluted to 4 litres and used as the bottom 
chamber buffer. 
 
(f) Gel Fixing Solution 
 
Items Amount (ml) Source 
Glycerol 25.0 Merck, Germany 
Glacial acetic acid  25.0 Merck, Germany 
Deionised water 450.0 Elga, UK 
 
This solution was prepared fresh before usage. 
 
 
(g) X-Ray Film Developer  
 
Items Amount (ml) Source 
X-ray Film Developer 100.0 Kodak, USA 
Deionised water 900.0 Elga, UK 
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(h) X-Ray Film Fixer  
 
Items Amount (ml) Source 
X-ray Film Fixer 100.0 Kodak, USA 
Deionised water 900.0 Elga, UK 




MATERIAL FOR IMMUNOBLOTTING 
 
(a) Transfer Buffer 
 
Items Amount  Source 
Tris (hydroxymethyl)-
aminoethane 
3.0 g Merck, Germany 
Glycine 14.40 g Merck, Germany 
Methanol 200.0 ml Merck, Germany 
Dgd 800.0 ml Elga, UK 
 
 
(b) 5% Skim Milk Blocking Solution 
 
Items Amount  Source 
Skim milk powder 5.0 g Diploma, Singapore 
PBS 100.0 ml  Appendix 1 (d) 
 
 
(c) 0.1 % Bovine Serum Albumin (BSA)/PBS 
 
0.1 ml of BSA (CSL, Australia) was added into 100.0 ml of PBS [see Appendix 1 (d)].  
The solution was prepared fresh. 
 
(d) 10% Bovine Serum Albumin (BSA)/PBS 
 
1.0 ml of BSA (CSL, Australia) was added into 100.0 ml of PBS [see Appendix 1 (d)].  
The solution was prepared fresh. 
 
(e) 20 mM Phenylmethylsulfonyl Fluoride (PMSF) 
Items Amount  Source 
Phenylmethylsulfonyl 
fluoride 
0.35 g Sigma, USA 
 
The PMSF is dissolved in dgd to a final volume of 100.0 ml by stirring overnight. 
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 APPENDIX 5  
 
MATERIALS FOR CELL CULTURE 
 
All materials prepared for cell culture were either sterile or sterilised.  Double glass 
distilled water [(dgd) (Corning, USA)] was used for all dilutions. 
(a) Growth Medium, M199 for Vero cells (pH 7.2 - pH 7.4), filter sterilised. 
 
Items Amount  Source 
Medium M199  1 packet (commerical) CSL, Australia 
NaHCO3 2.2 g Merck, Germany 
Foetal calf serum 100.0 ml GIBCO BRL, New Zealand 
Dgd 900.0 ml Corning, USA 
 
 
(b) Growth Medium, RPMI for single cell suspension of Peyer’s patches and 
cervical lymph nodes, (pH 7.2 - pH 7.4), filter sterilised. 
 
Items Amount  Source 
RPMI   1 packet (commerical) CSL, Australia 
NaHCO3 2.0 g Merck, Germany 
Foetal calf serum 100.0 ml GIBCO BRL, New Zealand 
Dgd 900.0 ml Corning, USA 
 
The solution was then sterilized by filtration through 0.22 μm filter unit (Sterivex G-S, Millipore, USA). 
All cell culture media were screened for microbial contamination before the addition of serum. 
 
(c) Growth Medium, MEM for ST cells (pH 7.2 - pH 7.4), filter sterilised. 
 
 
Items Amount  Source 
MEM  900 ml of the 1 liter 
solution 
GIBCO BRL, New Zealand 
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(d) Growth Medium, EMEM for Caco-2 cells (pH 7.2 - pH 7.4), filter sterilised. 
 
 
Items Amount  Source 
Medium M199  900 ml of the 1 liter 
solution 
CSL, Australia 








Items Amount  Source 
McCoy’s 5a 900 ml of the 1 liter 
solution 
CSL, Australia 
Foetal calf serum 100.0 ml GIBCO BRL, New Zealand 
 
 
  The sera supplemented media were kept at 4 °C.  The cell culture media were warmed 
up in water bath to the temperature suitable for cell culture before use. 
 
(f) Phosphate Buffered Saline (PBS) 
 
Items Amount (g) Source 
NaCl 8.0 Merck, Germany 
KCl 0.2 Merck, Germany 
Na2HPO4 1.15 Merck, Germany 
KH2PO4 0.2 Merck, Germany 
 
The above materials were dissolved in 1 litre of dgd water.  The pH was adjusted to 7.2 
using either 1 M HCl or 1 M NaOH.  The solution was aliquoted and sterilised at 15 
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(g) Trypsin-Versene (ATV) Solution (10x concentrate) 
 
Items Amount  Source 
NaCl 80.0 g Merck, Germany 
KCl 4.0 g Merck, Germany 
D-glucose 10.0 g Analar, UK 
NaHCO3 5.8 g Merck, Germany 
Trypsin 5.0 g Difco, New Zealand 
Versene (EDTA) 2.0 g Sigma, USA 
dgd 1000.0 ml Corning, USA 
 
The mixture was heated to 37 °C with occasional shaking for 3 to 4 hr to dissolve the 
trypsin.  The solution was then sterilised by filtration through 0.22 μm filter unit 
(Sterivex G-S, Millipore, USA).  To use, 10.0 ml of this solution was added to 90.0 ml of 
sterile dgd to give 1x ATV solution. 
 
(h)  Preservation Medium 
 
Items Amount (ml) Source 
Dimethylsulphoxide 
(DMSO) 
1.0 Sigma, USA 
Foetal calf serum 1.0 GIBCO BRL, New Zealand 
Growth medium  7.0 Appendix 5 (a-d) 
 
 
(i) 0.4% Phenol Red Solution 
 
0.8 g of phenol red powder (Merck, Germany) was dissolved in a mortar using 1 M 
NaOH.  The NaOH was also used to adjust the pH of the solution.  The solution was 
made up to 200.0 ml with dgd.  Working concentration of 0.1 % was made by diluting in 
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(j) 0.04 % L-Glutamine Solution 
 
Items Amount  Source 
L-glutamine 5.85 g Merck, Germany 
NaCl 1.70 g Merck, Germany 
Dgd 200.0 ml Corning, USA 
 
 
(k) 3 % Sodium Bicarbonate - 0.01 % Phenol Red Solution 
 
Items Amount  Source 
NaHCO3 30.0 g  Merck, Germany 
0.4 % phenol red solution 250.0 ml Appendix 5 (i) 
Dgd 975.0 ml Corning, USA 
 
 
(l) 0.5 % Trypan Blue Solution 
 
Items Amount  Source 
Trypan blue 0.5 g Merck, Germany 
PBS 100.0 ml Appendix 5 (f) 
 
The solution was autoclaved at 121 ºC for 15 min (Hirayama, Japan).  The solution was 
filtered before use. 
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APPENDIX 6 
MATERIALS FOR VIRUS INFECTION, GROWTH OF VIRUS AND PLAQUE 
ASSAY 
 
(a) Maintenance Medium (MEM) - pH 7.2-7.4 
 
9.57 g of MEM (Minimal Essential Medium) powder was dissolved in 995.0 ml of dgd 
with 5.0 ml of 0.4 % Phenol Red solution [Appendix 5 (i)].  Ninety mls of the solution 
was aliquoted into 100.0 ml glass bottles and sterilised at 15 Ib/in2 pressure for 20 min.  
Storage was at 4 °C.  MEM was warmed to the required temperature before adding to 
cells. 
The complete MEM was prepared as follow: 
 
Items Amount (ml) Source 
MEM 90.0 From above 
10% BSA 1.0 CSL, Australia 
L-glutamine 1.0 Appendix 5 (j) 
3% Sodium bicarbonate 2.0 Appendix 5 (k) 
 
 
(b) Virus Diluent (pH 7.2 - 7.4) 
 
Items Amount (ml) Source 
Hank's BSS (10x 
concentrate) 
10.0 CSL, Australia 
10% Bovine serum albumin 1.0 CSL, Australia 
Dgd 87.0 Corning, USA 
3% Sodium bicarbonate 1.0 Appendix 5 (k) 
 
The solution was then sterilised by filtration through 0.22 μm filter unit (Sterivex G-S, 
Millipore, USA).  Storage was at 4 °C.  Virus diluent was warmed to room temperature 
before use. 
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(c) Overlay Medium (pH 7.2 - 7.4) 
 
Items Amount  Source 
Medium M199   1 packet (commerical) CSL, Australia 
NaHCO3 2.2 g Merck, Germany 
Foetal calf serum 20.0 ml GIBCO, New Zealand 
Dgd 500.0 ml Corning, USA 
2 % w/v 
Carboxymethylcellulose 
(CMC) 
500.0 ml Behring Diagnostic, USA 
 
The solution was then sterilised by filtration through 0.22 μm filter unit (Sterivex G-S, 
Millipore, USA) before mixing with CMC (sterilising at 15 Ib/in2 pressure for 15 min).  
Storage was at 4 °C. Overlay medium is warmed to the required temperature before 
adding to cells. 
 
(d) 0.5 % Crystal Violet / 25 % Formaldehyde Solution 
 
Items Amount  Source 
Crystal violet 5.0 g Sigma, USA 
37 % Formaldehyde 
solution 
300.0 ml Merck, Germany 
PBS 200.0 ml See Appendix 5 (f) 
 
 
(e) 0.02 M Tris (hydroxymethyl)-aminoethane buffer, pH 7.4 
 
 
Items Amount  Source 
Tris-base 0.24 g Merck, Germany 
NaCl 0.87 g Merck, Germany 
 









MATERIALS FOR BIO-IMAGING  
 
Materials for Indirect Immunofluorescence Microscopy 
 
(a) Ammonium Chloride - PBS Solution 
 
Ammonium chloride (Merck, Germany) was prepared fresh by dissolving in PBS [see 
Appendix 5 (f)] to give a final concentration of 0.265 g/100.0 ml. 
 
(b) 0.1 % Bovine Serum Albumin (BSA) 
 
0.1 ml of BSA (CSL, Australia) was added into 100.0 ml of PBS [Appendix 5 (f)].  The 
solution was prepared fresh. 
 
(c) DABCO Mountant 
 
4.5 g of DABCO (Sigma, USA) was dissolved in 180.0 ml of glycerol (Merck, Germany) 
and stirred gently while heating.  This was made up to 200.0 ml with PBS [see Appendix 
5 (f)]. 
 
Materials for Processing of Samples for Tranmission Electron Microscopy 
(d) 0.4 M Sodium Cacodylate Stock 
 
Items Amount  Source 
Sodim cacodylate 8.56 g Merck, Germany 
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(e) 0.2 M Sodium Cacodylate Stock (pH 7.4) 
 
Items Amount (ml) Source 
0.4 M Sodim cacodylate 50.0 Appendix 7 (d) 
0.1 M HCl 25.2 Merck, Germany 
0.1 M CaCl2 (1.1 g in 100 
of dgd 
2.0 Merck, Germnay 
 
 
(f) 10 % Paraformaldehyde in 0.1 M Cacodylate buffer (pH 7.4) 
 
Items Amount  Source 
Paraformaldehyde powder 10.0 Merck, Germany 
0.2 M Sodium cacodylate 
buffer (pH 7.4) 
50.0 ml Appendix 7 (e) 
 
Paraformaldehyde powder was first dissolved in the buffer by heating to 65 ºC.  A few 
drops of 1 M NaOH solution were added to clear the solution.  The solution was cooled 
before making up to 100.0 ml with the buffer. 
 
(g) 2.5 % Glutaradehyde, 2.0 % Paraformaldehyde in 0.1 M Cacodylate Buffer, 
pH 7.4 
 
Items Amount  Source 
0.2 M Cacodylate buffer 50.0 ml Appendix 7 (e) 
10 % Paraformaldehyde 
solution 
20.0 ml Appendix  7 (f) 
25 % Glutaraldehyde 10.0 ml Merck, Germany 
CaCl2 0.01 g Merck, Germany 
Dgd 20.0 ml Elga, UK 
 
(h) 1 % Osmium Tetroxide in 0.1 M Cacodylate Buffer, pH 7.4 
Items Amount  Source 
Osmium tetroxide (packed 
in ampoule) 
1.0g Taab, UK 
0.2 M Sodium cacodylate 
buffer (pH 7.4) 
100.0 ml Appendix 7 (e) 
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To prepare the solution, the ampoule was opened in a brown glass bottle with the buffer 
inside.  The mixture was swirled to ensure that the osmium tetroxide dissolved totally.  
The solution was aliquoted into 5.0 ml bottle and stored at -20 °C. 
 
(i) Ryter Kellenburger Buffer Stock Solution 
Items Amount  Source 
Sodium veronal 2.9 g Analar, UK 
Sodium acetate (hydrated) 1.9 g Analar, UK 
NaCl 3.4 g Merck, Germany 
Dgd  100 ml Elge, UK 
 




DATA FOR CHAPTER 3 
 
(a) Average food and water intake per mouse per day 
Food intake per mouse per day (g) 
3.74 1.93 5.27 
4.58 5.63 3.43 
3.40 4.43 3.90 
3.40 4.80 4.43 
4.23 5.30 3.97 
4.12 4.67 4.60 
3.93 3.50 4.40 
3.77 5.10 4.07 
4.53 4.33 4.02 
3.90 4.60 3.33 
Avg Food 
intake (g) 
Std dev Avg H2O 
intake (g) 
Avg food & water 
intake (g) 
4.18 0.73 2.42 6.60 
 
(b) Fecal volume excreted per mouse per day 
Fecal vol per mouse per day (g)  
1.13 0.93 1.04 
1.32 1.64 1.02 
1.08 1.88 0.63 
1.24 1.50 1.00 
0.77 1.44 1.30 
0.83 1.13 1.28 
0.90 1.40 1.34 
0.76 1.23 1.29 
2.02 1.01 1.18 
Avg fecal vol (g) Std dev 
1.20 0.32 
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  Total length(cm) Length used(cm) IV (g) IV/ tissue (g) 
Day 1 Mouse 1 7.0 5.0 0.0440 0.0616 
 Mouse 2 6.0 6.0 0.0459 0.0459 
 Mouse 3 6.5 6.5 0.0370 0.0370 
      
Day 2 Mouse 1 7.5 7.5 0.0380 0.0380 
 Mouse 2 8.0 6.5 0.0334 0.0411 
 Mouse 3 5.5 5.5 0.0456 0.0456 
      
Day 4 Mouse 1 5.5 5.5 0.0288 0.0288 
 Mouse 2 6.5 5.0 0.0154 0.0200 
 Mouse 3 6.0 6.0 0.0351 0.0351 
      
Day 6 Mouse 1 6.5 6.5 0.0395 0.0395 
 Mouse 2 8.5 6.0 0.0230 0.0326 
 Mouse 3 7.5 6.0 0.0244 0.0305 
      
Day 7 Mouse 1 7.5 6.0 0.0249 0.0311 
 Mouse 2 6.0 6.0 0.0134 0.0134 
 Mouse 3 8.0 6.0 0.0161 0.0215 
      
Control  Mouse 1 7.5 6.8 0.0242 0.0267 
 Mouse 2 8.5 6.5 0.0294 0.0384 
    Avg 0.0344 
    Std dev 0.0029 
      
Jejunum 
  Total length(cm) Length used(cm) IV (g) IV/ tissue (g) 
Day 1 Mouse 1 9.3 5.0 0.0141 0.0262 
 Mouse 2 15.0 8.5 0.0481 0.0849 
 Mouse 3 11.0 11.0 0.0360 0.0360 
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Day 2 Mouse 1 13.0 6.0 0.0037 0.0080 
 Mouse 2 11.0 6.5 0.0438 0.0741 
 Mouse 3 12.0 7.0 0.0259 0.0444 
      
Day 4 Mouse 1 6.5 6.0 0.0315 0.0341 
 Mouse 2 13.5 6.0 0.0338 0.0761 
 Mouse 3 10.3 6.0 0.0387 0.0664 
      
Day 6 Mouse 1 11.5 6.0 0.0604 0.1158 
 Mouse 2 13.0 6.0 0.0678 0.1469 
 Mouse 3 12.0 6.5 0.0304 0.0561 
      
Day 7 Mouse 1 9.0 6.0 0.0319 0.0479 
 Mouse 2 13.0 6.0 0.0191 0.0414 
 Mouse 3 10.0 6.0 0.0186 0.0310 
      
Control  Mouse 1 8.0 7.5 0.0117 0.0125 
 Mouse 2 13.0 6.0 0.0467 0.1012 
    Avg 0.0588 
    Std dev 0.0068 
      
Ileum 
  Total length(cm) Length used(cm) IV (g) IV/ tissue (g) 
Day 1 Mouse 1 10.5 8.5 0.0269 0.0332 
 Mouse 2 13.5 11.0 0.0065 0.0080 
 Mouse 3 10.0 10.0 0.0096 0.0096 
      
Day 2 Mouse 1 8.5 6.0 0.0560 0.0793 
 Mouse 2 9.0 6.5 0.0097 0.0134 
 Mouse 3 6.0 6.0 0.0006 0.0006 
      
Day 4 Mouse 1 8.0 6.0 0.0035 0.0047 
 Mouse 2 9.5 6.0 0.0014 0.0022 
 Mouse 3 13.5 6.0 0.0052 0.0117 
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Day 6 Mouse 1 9.0 6.0 0.0170 0.0255 
 Mouse 2 13.0 6.5 0.0045 0.0090 
 Mouse 3 15.0 6.5 0.0100 0.0231 
      
Day 7 Mouse 1 9.5 6.0 0.0009 0.0014 
 Mouse 2 15.0 6.0 0.0120 0.0300 
 Mouse 3 13.0 6.0 0.0059 0.0128 
      
Control  Mouse 1 8.5 5.5 0.0242 0.0374 
 Mouse 2 10.0 6.5 0.0294 0.0452 
    Avg 0.0216 
    Std dev 0.0080 
      
Colon 
  Total length(cm) Length used(cm) IV (g) IV/ tissue (g) 
Day 1 Mouse 1 6.5 5.0 0.0055 0.0072 
 Mouse 2 7.0 6.0 0.0048 0.0056 
 Mouse 3 5.6 5.6 0.0039 0.0039 
      
Day 2 Mouse 1 6.0 6.0 0.0029 0.0029 
 Mouse 2 6.5 6.5 0.0048 0.0048 
 Mouse 3 6.0 6.0 0.0067 0.0067 
      
Day 4 Mouse 1 6.0 6.0 0.0050 0.0050 
 Mouse 2 5.5 6.0 0.0061 0.0056 
 Mouse 3 6.8 6.0 0.0047 0.0053 
      
Day 6 Mouse 1 6.0 6.0 0.0033 0.0033 
 Mouse 2 7.5 6.0 0.0026 0.0033 
 Mouse 3 7.0 6.0 0.0057 0.0067 
      
Day 7 Mouse 1 6.5 6.0 0.0249 0.0270 
 Mouse 2 6.0 6.0 0.0134 0.0134 
 Mouse 3 6.5 6.0 0.0161 0.0174 
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Control  Mouse 1 7.5 6.0 0.0242 0.0303 
 Mouse 2 6.5 6.0 0.0294 0.0319 
    Avg 0.0106 
    Std dev 0.0099 
 
(d) Average number of yeast cell adhering to human intestinal cells 
Average no. of yeast attached per cell  
  Caco-2 HT29 
S.boulardii 4.10E+01 3.40E+01 
S.cerevisiae 4.80E+01 4.30E+01 
P.pastoris 7.14E+02 1.12E+03 
 
(e) Median fluorescence intensities and the corresponding generation number of 




Hr Median fluorescence intensity (units/cell) Average Std dev 
0 3.50E+02 3.30E+02 3.70E+02 3.50E+02 2.00E+01 
2 2.60E+02 2.80E+02 2.90E+02 2.77E+02 1.53E+01 
4 1.40E+02 1.60E+02 1.80E+02 1.60E+02 2.00E+01 
6 6.80E+01 6.30E+01 7.10E+01 6.73E+01 4.04E+00 
        
  CFU/ml Average Generation No. 
0 2.36E+05 2.29E+05 2.40E+05 2.35E+05 0.00 
2 3.39E+05 3.27E+05 3.19E+05 3.28E+05 0.48 
4 5.85E+05 6.06E+05 5.96E+05 5.96E+05 1.34 
6 1.04E+06 9.60E+05 1.20E+06 1.07E+06 2.18 
      
S.boulardii 
Hr 
Median fluorescence intensity 
(units/cell) Average Std dev 
0 3.70E+02 4.00E+02 3.60E+02 3.77E+02 2.08E+01 
2 2.00E+02 2.20E+02 2.30E+02 2.17E+02 1.53E+01 
4 1.40E+02 1.60E+02 1.30E+02 1.43E+02 1.53E+01 
6 8.70E+01 9.20E+01 8.60E+01 8.83E+01 3.21E+00 
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  CFU/ml Average Generation No. 
0 3.24E+05 3.39E+05 3.48E+05 3.37E+05 0.00 
2 5.92E+05 5.74E+05 6.02E+05 5.89E+05 0.81 
4 1.05E+06 9.76E+05 9.98E+05 1.01E+06 1.58 
6 1.36E+06 1.51E+06 1.39E+06 1.42E+06 2.08 
      
      
S.cerevisiae 
Hr 
Median fluorescence intensity 
(units/cell) Average Std dev 
0 3.70E+02 4.00E+02 3.80E+02 3.83E+02 1.53E+01 
2 2.60E+02 2.20E+02 2.90E+02 2.57E+02 3.51E+01 
4 1.40E+02 1.50E+02 1.70E+02 1.53E+02 1.53E+01 
6 9.20E+01 9.60E+01 8.90E+01 9.70E+01 3.51E+00 
        
  CFU/ml Average Generation No. 
0 3.24E+05 3.10E+05 3.19E+05 3.18E+05 0.00 
2 5.57E+05 5.77E+05 5.63E+05 5.66E+05 0.83 
4 9.07E+05 9.19E+05 9.03E+05 9.10E+05 1.52 
6 1.27E+06 1.33E+06 1.36E+06 1.32E+06 2.05 
      
P.pastoris 
Hr 
Median fluorescence intensity 
(units/cell) Average Std dev 
0 4.00E+02 3.90E+02 3.80E+02 3.90E+02 1.00E+01 
2 2.60E+02 2.50E+02 2.80E+02 2.63E+02 1.53E+01 
4 1.30E+02 1.50E+02 1.00E+02 1.27E+02 2.52E+01 
6 8.30E+01 9.60E+01 8.90E+01 8.93E+01 6.51E+00 
        
  CFU/ml Average Generation No. 
0 2.89E+05 2.96E+05 3.01E+05 2.95E+05 0.00 
2 4.87E+05 4.95E+05 4.73E+05 4.85E+05 0.72 
4 9.29E+05 9.16E+05 9.03E+05 9.16E+05 1.63 
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(f) Number of LcS, S.boulardii, S.cerevisiae and P.pastoris adhered to different 
segments of murine gastrointestinal tract 
 
L.casei Shirota 
Day Duo 1 Duo 2 Duo 3 Avg Duo Std dev 
1 4.98E+03 7.01E+03 6.12E+03 6.04E+03 1.02E+03
2 4.12E+03 3.71E+03 5.88E+03 4.57E+03 1.15E+03
4 3.06E+03 2.98E+03 4.71E+03 3.58E+03 9.77E+02
            
  Jej 1 Jej 2 Jej 3 Avg Jej Std dev 
1 1.52E+04 1.64E+04 2.01E+04 1.72E+04 2.59E+03
2 5.98E+03 7.09E+03 4.69E+03 5.92E+03 1.20E+03
4 6.13E+03 3.90E+03 5.63E+03 5.22E+03 1.17E+03
            
  Ileum 1 Ileum 2 Ileum 3 Avg Ileum Std dev 
1 5.71E+04 7.99E+04 6.97E+04 6.89E+04 1.14E+04
2 1.80E+04 1.68E+04 1.21E+04 1.56E+04 3.09E+03
4 1.75E+04 1.08E+04 1.55E+04 1.46E+04 3.42E+03
        
  Colon 1 Colon 2 Colon 3 Avg Colon Std dev 
1 3.58E+04 2.84E+04 2.58E+04 3.00E+04 5.17E+03
2 2.44E+04 1.54E+04 2.07E+04 2.02E+04 4.53E+03
4 1.34E+04 8.80E+03 1.68E+04 1.30E+04 4.01E+03
      
S.boulardii 
Day Duo 1 Duo 2 Duo 3 Avg Duo Std dev 
1 6.27E+05 7.25E+05 6.54E+05 6.69E+05 5.06E+04
2 5.09E+05 4.61E+05 4.79E+05 4.83E+05 2.42E+04
3 3.48E+05 3.67E+05 2.99E+05 3.38E+05 3.51E+04
4 2.48E+05 3.61E+05 3.02E+05 3.04E+05 5.65E+04
        
  Jej 1 Jej 2 Jej 3 Avg Jej Std dev 
1 9.19E+04 1.09E+05 7.04E+04 9.05E+04 1.94E+04
2 8.59E+04 6.91E+04 7.97E+04 7.82E+04 8.50E+03
3 4.78E+04 7.31E+04 5.22E+04 5.77E+04 1.35E+04
4 4.44E+04 3.88E+04 5.32E+04 4.55E+04 7.26E+03
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  Ileum 1 Ileum 2 Ileum 3 Avg Ileum Std dev 
1 4.02E+04 2.76E+04 3.93E+04 3.57E+04 7.03E+03
2 3.82E+04 4.05E+04 4.31E+04 4.06E+04 2.45E+03
3 1.97E+04 3.18E+04 2.09E+04 2.41E+04 6.67E+03
4 1.89E+04 2.67E+04 2.71E+04 2.42E+04 4.62E+03
        
  Colon 1 Colon 2 Colon 3 Avg Colon Std dev 
1 2.07E+04 2.54E+04 3.14E+04 2.58E+04 5.36E+03
2 3.28E+04 4.37E+04 5.27E+04 4.31E+04 9.97E+03
3 3.31E+04 2.69E+04 1.59E+04 2.53E+04 8.71E+03
4 1.87E+04 3.18E+04 2.46E+04 2.50E+04 6.54E+03
      
S.cerevisiae 
Day Duo 1 Duo 2 Duo 3 Avg Duo Std dev 
1 2.74E+06 1.93E+06 2.27E+06 2.31E+06 4.10E+05
2 6.55E+05 7.65E+05 9.13E+05 7.78E+05 1.29E+05
3 9.06E+05 7.08E+05 7.44E+05 7.86E+05 1.06E+05
4 5.42E+05 4.13E+05 3.59E+05 4.38E+05 9.42E+04
            
  Jej 1 Jej 2 Jej 3 Avg Jej Std dev 
1 5.55E+05 7.18E+05 1.19E+06 8.22E+05 3.32E+05
2 1.15E+06 9.96E+05 1.30E+06 1.15E+06 1.51E+05
3 9.83E+05 1.17E+06 8.84E+05 1.01E+06 1.45E+05
4 1.60E+06 1.10E+06 1.22E+06 1.31E+06 2.63E+05
            
  Ileum 1 Ileum 2 Ileum 3 Avg Ileum Std dev 
1 5.16E+05 4.07E+05 6.52E+05 5.25E+05 1.23E+05
2 4.91E+05 5.84E+05 7.21E+05 5.99E+05 1.15E+05
3 2.43E+05 2.82E+05 3.58E+05 2.94E+05 5.84E+04
4 1.94E+05 1.05E+05 1.63E+05 1.54E+05 4.51E+04
        
  Colon 1 Colon 2 Colon 3 Avg Colon Std dev 
1 7.94E+05 7.79E+05 6.79E+05 7.51E+05 6.23E+04
2 3.80E+05 3.85E+05 2.33E+05 3.33E+05 8.66E+04
3 2.31E+05 1.04E+05 1.40E+05 1.58E+05 6.55E+04
4 6.96E+04 6.05E+05 5.00E+04 2.42E+05 3.15E+05
                                                                                   APPENDIX 
 317
      
Pichia pastoris 
Day  Duo 1 Duo 2 Duo 3 Avg Duo Std dev 
1 1.04E+06 1.09E+06 9.92E+05 1.04E+06 5.12E+04
2 1.07E+06 9.89E+05 1.05E+06 1.04E+06 4.19E+04
3 5.15E+05 5.37E+05 4.59E+05 5.04E+05 4.02E+04
4 5.31E+05 4.75E+05 4.99E+05 5.02E+05 2.81E+04
        
  Jej 1 Jej 2 Jej 3 Avg Jej Std dev 
1 7.56E+05 6.86E+05 7.32E+05 7.25E+05 3.58E+04
2 6.51E+05 7.43E+05 7.03E+05 6.99E+05 4.61E+04
3 4.62E+05 4.13E+05 4.39E+05 4.38E+05 2.45E+04
4 3.91E+05 3.47E+05 1.10E+05 2.83E+05 1.51E+05
        
  Ileum 1 Ileum 2 Ileum 3 Avg Ileum Std dev 
1 6.45E+05 6.02E+05 6.76E+05 6.41E+05 3.72E+04
2 6.46E+05 5.91E+05 5.75E+05 6.04E+05 3.72E+04
3 7.15E+05 7.36E+05 7.51E+05 7.34E+05 1.81E+04
4 7.11E+05 6.57E+05 6.99E+05 6.89E+05 2.84E+04
        
  Colon 1 Colon 2 Colon 3 Avg Colon Std dev 
1 3.81E+05 4.92E+05 4.18E+05 4.30E+05 5.65E+04
2 7.52E+05 7.10E+05 7.33E+05 7.32E+05 2.10E+04
3 6.89E+05 5.40E+05 6.42E+05 6.24E+05 7.62E+04
4 6.49E+05 5.79E+05 5.99E+05 6.09E+05 3.61E+04
 
(g) Residual median fluorescence intensities of cFDA-SE labeled LcS, 
S.boulardii, S.cerevisiae and P.pastoris adhering to different segments of 
murine intestinal tract 
 
L.casei Shirota 
  Control = 2.10E+00       
Day  Duo 1 Duo 2 Duo 3 Avg Std dev 
1 1.49E+01 1.21E+01 1.51E+01 1.40E+01 1.68E+00
2 1.20E+01 1.53E+01 9.80E+00 1.24E+01 2.77E+00
4 7.10E+00 6.50E+00 8.10E+00 7.23E+00 8.08E-01 
6 5.20E+00 6.00E+00 7.20E+00 6.13E+00 1.01E+00
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  Control = 1.80E+00       
  Jej 1 Jej 2 Jej 3 Avg Std dev 
1 9.95E+00 7.80E+00 1.02E+01 9.33E+00 1.33E+00
2 6.30E+00 7.20E+00 8.20E+00 7.23E+00 9.50E-01 
4 6.50E+00 7.30E+00 4.90E+00 6.23E+00 1.22E+00
6 3.50E+00 5.00E+00 4.20E+00 4.23E+00 7.51E-01 
            
  Control =  2.00E+00       
  Ileum 1 Ileum 2 leum 3 Avg  Std dev 
1 7.20E+00 5.90E+00 5.00E+00 6.03E+00 1.11E+00
2 5.80E+00 4.50E+00 3.70E+00 4.67E+00 1.06E+00
4 4.20E+00 3.50E+00 3.10E+00 3.60E+00 5.57E-01 
            
  Control = 2.30E+00       
  Colon 1 Colon 2 Colon 3  Avg  Std dev 
1 1.98E+01 2.50E+01 2.21E+01 2.23E+01 2.61E+00
2 1.47E+01 1.58E+01 1.20E+01 1.42E+01 1.96E+00
4 1.51E+01 1.47E+01 1.53E+01 1.50E+01 3.06E-01 
6 1.27E+01 1.46E+01 8.70E+00 1.20E+01 3.01E+00
            
S.boulardii 
  Control = 2.26E+00       
Day Duo 1 Duo 2 Duo 3 Avg Std dev 
1 1.29E+01 1.17E+01 1.19E+01 1.22E+01 6.54E-01 
2 9.61E+00 7.72E+00 7.56E+00 8.30E+00 1.14E+00
4 6.16E+00 4.87E+00 5.03E+00 5.35E+00 7.03E-01 
6 3.65E+00 2.06E+00 1.98E+00 2.56E+00 9.42E-01 
            
  Control = 2.16E+00       
  Jej 1 Jej 2 Jej 3 Avg Std dev 
1 5.76E+00 4.63E+00 3.78E+00 4.72E+00 9.93E-01 
2 3.63E+00 4.76E+00 2.43E+00 3.61E+00 1.17E+00
4 3.50E+00 3.31E+00 2.51E+00 3.11E+00 5.25E-01 
6 1.51E+00 2.83E+00 2.05E+00 2.13E+00 6.64E-01 
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  Control =  1.85E+00       
  Ileum 1 Ileum 2 leum 3 Avg  Std dev 
1 2.38E+00 2.31E+00 3.12E+00 2.60E+00 4.49E-01 
2 2.27E+00 2.20E+00 3.11E+00 2.53E+00 5.06E-01 
4 2.11E+00 1.80E+00 2.82E+00 2.24E+00 5.23E-01 
6 3.12E+00 2.34E+00 1.86E+00 2.44E+00 6.36E-01 
            
  Control = 1.95E+00       
  Colon 1 Colon 2 Colon 3  Avg  Std dev 
1 2.96E+00 2.14E+00 1.52E+00 2.21E+00 7.22E-01 
2 2.22E+00 2.12E+00 1.87E+00 2.07E+00 1.80E-01 
4 2.90E+00 1.66E+00 2.01E+00 2.19E+00 6.39E-01 
5 1.87E+00 3.22E+00 9.10E-01 2.00E+00 1.16E+00
            
S.cerevisiae 
  Control = 9.54E+00       
Day Duo 1 Duo 2 Duo 3 Avg Duo Std dev 
1 3.43E+01 2.93E+01 3.17E+01 3.17E+01 2.49E+00
2 1.63E+01 1.46E+01 1.36E+01 1.48E+01 1.33E+00
4 8.32E+00 1.04E+01 1.09E+01 9.88E+00 1.38E+00
6 8.57E+00 8.48E+00 1.04E+01 9.15E+00 1.08E+00
            
  Control = 3.43E+00       
  Jej 1 Jej 2 Jej 3 Avg Jej Std dev 
1 1.94E+01 1.90E+01 1.76E+01 1.87E+01 9.66E-01 
2 1.68E+01 1.22E+01 1.37E+01 1.42E+01 2.36E+00
4 1.39E+01 1.63E+01 1.24E+01 1.42E+01 1.97E+00
6 1.32E+01 1.67E+01 1.48E+01 1.49E+01 1.75E+00
            
  Control = 1.34E+00       
  Ileum 1 Ileum 2 Ileum 3 Avg Ileum Std dev 
1 4.22E+00 5.20E+00 2.75E+00 4.06E+00 1.23E+00
2 2.60E-01 9.10E-01 1.84E+00 1.00E+00 7.94E-01 
4 -7.70E-01 -1.50E-01 6.10E-01 -1.03E-01 6.91E-01 
6 5.80E-01 -4.20E-01 -4.00E-02 4.00E-02 5.05E-01 
            
  Control = 1.41E+00       
  Colon 1 Colon 2 Colon 3 Avg Colon Std dev 
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1 6.65E+00 6.14E+00 5.37E+00 6.05E+00 6.44E-01 
2 -1.20E-01 4.60E-01 4.80E-01 2.73E-01 3.41E-01 
4 -3.00E-02 1.50E-01 1.20E+00 4.40E-01 6.64E-01 
6 1.28E+00 8.00E-02 2.10E-01 5.23E-01 6.59E-01 
            
P.pastoris 
  Control = 2.79E+00       
Day Duo 1 Duo 2 Duo 3 Avg Std dev 
1 1.60E+01 1.79E+01 1.94E+01 1.77E+01 1.72E+00
2 1.36E+01 1.62E+01 1.40E+01 1.46E+01 1.40E+00
4 6.37E+00 7.48E+00 6.00E+00 6.62E+00 7.70E-01 
6 5.03E+00 3.37E+00 5.44E+00 4.61E+00 1.10E+00
        
  Control = 2.98E+00       
  Jej 1 Jej 2 Jej 3 Avg Std dev 
1 1.33E+01 1.26E+01 1.22E+01 1.27E+01 5.67E-01 
2 1.12E+01 9.63E+00 1.05E+01 1.04E+01 7.95E-01 
4 7.38E+00 6.70E+00 5.38E+00 6.49E+00 1.02E+00
6 3.94E+00 4.28E+00 5.01E+00 4.41E+00 5.47E-01 
        
  Control =  2.88E+00       
  Ileum 1 Ileum 2 leum 3 Avg  Std dev 
1 1.28E+01 1.09E+01 1.15E+01 1.17E+01 9.51E-01 
2 1.04E+01 9.68E+00 9.16E+00 9.75E+00 6.23E-01 
4 1.54E+01 1.47E+01 1.41E+01 1.47E+01 6.77E-01 
6 16.68- 1.29E+01 1.12E+01 1.21E+01 1.17E+00
        
  Control = 2.62E+00       
  Colon 1 Colon 2 Colon 3  Avg  Std dev 
1 5.59E+00 7.94E+00 7.36E+00 6.96E+00 1.22E+00
2 4.67E+00 3.94E+00 3.06E+00 3.89E+00 8.06E-01 
4 4.24E+00 3.30E+00 3.55E+00 3.70E+00 4.87E-01 
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(h) Half times for wash-out of LcS, S.boulardii, S.cerevisiae and P.pastoris from 
different segments of murine intestinal tract 
 
In2/Tw  = (In F2 - In F1)/( t2 - t1) 
 Duodenum Jejunum Ileum Colon 
L.casei Shirota 1.90 3.70 3.50 3.80 
S.boulardii 2.64 3.02 5.35 66.02 
S.cerevisiae 1.25 -4.46 1.70 1.84 
P.pastoris 2.85 2.21 -28.80 -5.97 
 
 
(i) Fluorescence intensity profiles of cFDA-SE labeled LcS, S.boulardii, 
S.cerevisiae and P.pastoris in various segments of murine intestinal tract 
 
L.casei Shirota 
Section and Day <1/4 median 1/4-1/2 median 
Duodenum       Average 
Std 
Dev       Average 
Std 
Dev 
1 33.08 36.30 40.10 36.49 3.51 9.21 9.94 11.23 10.13 1.02 
2 32.84 36.01 30.28 33.04 2.87 14.95 16.74 13.78 15.16 1.48 
4 40.45 37.76 35.07 37.76 2.69 16.98 20.50 18.44 18.64 1.78 
6 49.12 53.71 45.78 49.54 3.98 17.11 18.31 19.51 18.31 1.20 
             
  1/2-median >Median 
Duodenum       Average 
Std 
Dev       Average 
Std 
Dev 
1 15.58 19.53 17.26 17.46 1.98 35.72 38.48 33.55 35.92 2.47 
2 21.11 19.59 18.69 19.80 1.21 34.50 31.80 29.70 32.00 2.41 
4 22.15 18.08 19.82 20.02 2.04 23.38 26.51 20.84 23.58 2.84 
6 15.01 16.19 17.37 16.19 1.18 15.75 17.13 14.99 15.96 1.07 
             
  <1/4 median 1/4-1/2 median 
Jejunum       Average 
Std 
Dev       Average 
Std 
Dev 
1 24.04 26.10 22.54 24.23 1.79 12.44 13.58 11.90 12.64 0.84 
2 30.70 26.57 28.35 28.54 2.07 16.32 15.43 17.83 16.53 1.20 
4 26.19 30.36 27.90 28.15 2.10 17.86 19.90 16.42 18.06 1.74 
6 28.14 31.21 25.07 28.14 3.07 21.76 27.47 24.31 24.51 2.86 
                      
  1/2-median >Median 
Jejunum       Average 
Std 
Dev       Average 
Std 
Dev 
1 18.75 20.55 17.54 18.95 1.51 48.53 43.98 40.03 44.18 4.25 
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2 20.77 19.08 23.05 20.97 1.99 33.76 36.95 31.17 33.96 2.90 
4 23.90 19.71 21.51 21.71 2.10 31.88 36.02 28.34 32.08 3.84 
6 20.40 18.19 23.20 20.60 2.51 26.55 29.60 24.09 26.75 2.76 
                      
  <1/4 median 1/4-1/2 median 
Ileum       Average 
Std 
Dev       Average 
Std 
Dev 
1 27.89 29.28 32.98 30.05 2.87 14.53 16.01 13.66 14.73 1.19 
2 40.16 47.18 43.37 43.57 3.51 27.65 24.65 22.24 24.85 2.71 
4 47.75 44.07 51.79 47.87 3.82 22.14 26.41 23.98 24.18 2.14 
6 47.70 51.40 55.72 51.61 4.01 24.87 22.70 21.12 22.90 1.88 
                      
  1/2-median >Median 
Ileum       Average 
Std 
Dev       Average 
Std 
Dev 
1 15.58 17.59 14.16 15.78 1.72 39.23 42.73 36.33 39.43 3.20 
2 17.45 15.73 14.60 15.93 1.43 14.47 15.39 17.08 15.65 1.33 
4 12.57 13.51 11.63 12.57 0.94 16.52 15.38 14.24 15.38 1.14 
6 11.69 10.63 10.17 10.83 0.76 14.66 15.87 13.45 14.66 1.21 
                      
  <1/4 median 1/4-1/2 median 
Colon       Average 
Std 
Dev       Average 
Std 
Dev 
1 43.94 37.66 40.90 40.83 3.14 14.18 13.35 15.60 14.38 1.13 
2 37.58 35.41 40.23 37.74 2.41 26.45 24.13 22.40 24.33 2.03 
4 60.15 64.80 70.05 65.00 4.95 13.12 15.60 14.36 14.36 1.24 
6 61.94 65.69 58.79 62.14 3.45 16.37 15.15 18.18 16.57 1.52 
             
  1/2-median >Median 
Colon       Average 
Std 
Dev       Average 
Std 
Dev 
1 19.71 22.58 20.85 21.05 1.45 22.26 25.68 23.67 23.87 1.72 
2 24.79 22.93 27.27 25.00 2.17 13.75 12.73 12.31 12.93 0.72 
4 7.66 7.02 6.68 7.12 0.49 13.32 14.61 12.64 13.52 1.00 
6 7.76 8.75 7.07 7.86 0.84 14.69 13.23 12.37 13.43 1.17 
 
S.boulardii 
Section and Day <1/4 median 1/4-1/2 median 
Duodenum       Average 
Std 
Dev       Average 
Std 
Dev 
1 33.67 29.73 36.05 33.15 3.19 10.54 11.63 12.56 11.58 1.01 
2 31.70 39.19 35.57 35.49 3.75 12.19 13.51 14.32 13.34 1.08 
4 43.59 36.34 40.17 40.03 3.63 16.09 15.64 17.83 16.52 1.16 
6 49.82 53.64 44.97 49.48 4.35 17.44 15.72 18.67 17.28 1.48 
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  1/2-median >Median 
Duodenum       Average 
Std 
Dev       Average 
Std 
Dev 
1 14.63 18.37 16.82 16.61 1.88 35.87 41.65 38.46 38.66 2.90 
2 19.33 20.53 18.27 19.38 1.13 28.69 35.42 31.25 31.79 3.40 
4 22.43 20.55 19.64 20.87 1.42 22.72 20.35 24.68 22.58 2.17 
6 17.85 19.68 21.04 19.52 1.60 11.99 15.27 13.89 13.72 1.65 
                      
  <1/4 median 1/4-1/2 median 
Jejunum       Average 
Std 
Dev       Average 
Std 
Dev 
1 27.18 22.37 25.06 24.87 2.41 13.65 12.13 15.62 13.80 1.75 
2 27.22 26.03 28.41 27.22 1.19 12.97 16.65 14.79 14.80 1.84 
4 24.49 28.88 30.35 27.91 3.05 14.97 17.32 19.81 17.37 2.42 
6 41.07 36.65 38.83 38.85 2.21 17.99 20.21 19.73 19.31 1.17 
                      
  1/2-median >Median 
Jejunum       Average 
Std 
Dev       Average 
Std 
Dev 
1 15.48 17.85 18.99 17.44 1.79 40.26 43.67 47.73 43.89 3.74 
2 19.45 17.68 21.22 19.45 1.77 41.89 38.45 35.26 38.53 3.32 
4 21.04 22.68 24.72 22.81 1.84 28.56 35.44 31.73 31.91 3.44 
6 20.38 18.62 16.24 18.41 2.08 23.14 26.13 21.03 23.43 2.56 
                      
  <1/4 median 1/4-1/2 median 
Ileum       Average 
Std 
Dev       Average 
Std 
Dev 
1 10.11 9.12 8.14 9.12 0.99 11.91 12.79 10.76 11.82 1.02 
2 10.74 8.62 10.13 9.83 1.09 11.11 14.92 12.83 12.95 1.91 
4 12.61 11.42 13.61 12.55 1.10 12.66 13.18 15.02 13.62 1.24 
6 16.82 16.43 18.04 17.10 0.84 10.73 12.13 13.11 11.99 1.20 
                      
  1/2-median >Median 
Ileum       Average 
Std 
Dev       Average 
Std 
Dev 
1 12.44 8.96 10.93 10.78 1.75 73.02 63.70 68.11 68.28 4.66 
2 10.39 11.15 13.07 11.54 1.38 64.25 69.04 63.75 65.68 2.92 
4 10.23 12.12 9.88 10.74 1.21 65.87 64.28 59.12 63.09 3.53 
6 7.22 8.51 9.60 8.44 1.19 59.66 65.54 62.22 62.47 2.95 
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  <1/4 median 1/4-1/2 median 
Colon       Average 
Std 
Dev       Average 
Std 
Dev 
1 8.29 6.97 9.43 8.23 1.23 8.96 10.23 11.05 10.08 1.05 
2 10.96 13.33 12.28 12.19 1.19 10.33 7.89 9.55 9.26 1.25 
4 9.88 11.57 12.27 11.24 1.23 9.87 10.88 8.19 9.65 1.36 
6 12.66 16.02 14.32 14.33 1.68 9.62 6.89 8.33 8.28 1.37 
             
  1/2-median >Median 
Colon       Average 
Std 
Dev       Average 
Std 
Dev 
1 10.88 9.39 8.32 9.53 1.29 76.88 72.16 67.43 72.16 4.73 
2 8.21 6.89 9.22 8.11 1.17 69.98 66.53 74.82 70.44 4.16 
4 6.44 8.41 9.18 8.01 1.41 71.12 75.05 67.14 71.10 3.96 
6 7.26 6.78 9.05 7.70 1.20 74.68 69.96 64.43 69.69 5.13 
 
S.cerevisiae 
Section and Day <1/4 median 1/4-1/2 median 
Duodenum       Average 
Std 
Dev       Average 
Std 
Dev 
1 21.52 25.12 28.41 25.02 3.45 12.71 14.12 15.61 14.15 1.45 
2 25.98 30.89 28.99 28.62 2.48 17.43 16.41 15.22 16.35 1.11 
4 35.17 30.99 38.38 34.85 3.71 18.39 16.44 20.39 18.41 1.98 
6 39.64 40.64 44.42 41.57 2.52 19.63 21.76 17.74 19.71 2.01 
             
  1/2-median >Median 
Duodenum       Average 
Std 
Dev       Average 
Std 
Dev 
1 16.15 21.51 18.37 18.68 2.69 42.12 46.02 38.31 42.15 3.86 
2 19.87 20.88 18.48 19.74 1.21 32.19 38.28 35.40 35.29 3.05 
4 23.63 20.74 17.63 20.67 3.00 25.96 23.44 28.81 26.07 2.69 
6 18.81 20.61 23.45 20.96 2.34 20.82 17.24 18.23 18.76 1.85 
                      
  <1/4 median 1/4-1/2 median 
Jejunum       Average 
Std 
Dev       Average 
Std 
Dev 
1 9.84 11.64 12.47 11.32 1.34 11.93 10.84 12.44 11.74 0.82 
2 9.17 11.42 10.61 10.40 1.14 11.99 9.42 10.84 10.75 1.29 
4 9.44 10.66 11.37 10.49 0.98 13.37 11.13 10.54 11.68 1.49 
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6 10.03 12.42 12.32 11.59 1.35 11.86 8.84 12.86 11.19 2.09 
                      
  1/2-median >Median 
Jejunum       Average 
Std 
Dev       Average 
Std 
Dev 
1 9.41 13.22 11.35 11.33 1.91 64.63 63.44 68.76 65.61 2.79 
2 10.32 13.65 12.27 12.08 1.67 63.61 67.22 69.49 66.77 2.97 
4 15.32 14.71 16.22 15.42 0.76 63.44 61.68 66.73 63.95 2.56 
6 17.28 16.07 14.66 16.00 1.31 63.83 61.63 58.19 61.22 2.84 
                      
  <1/4 median 1/4-1/2 median 
Ileum       Average 
Std 
Dev       Average 
Std 
Dev 
1 26.46 32.41 28.11 28.99 3.07 20.44 16.20 18.45 18.36 2.12 
2 48.43 43.11 39.32 43.62 4.58 16.92 13.49 18.84 16.42 2.71 
4 52.79 60.28 57.46 56.84 3.78 13.96 16.62 17.84 16.14 1.98 
6 59.22 62.32 68.12 63.22 4.52 15.83 16.89 13.96 15.56 1.48 
                      
  1/2-median >Median 
Ileum       Average 
Std 
Dev       Average 
Std 
Dev 
1 21.15 19.22 18.06 19.48 1.56 33.23 30.52 35.77 33.17 2.63 
2 20.73 16.21 18.02 18.32 2.27 21.49 18.56 24.88 21.64 3.16 
4 15.07 12.95 16.86 14.96 1.96 12.26 10.31 13.62 12.06 1.66 
6 12.33 15.08 13.12 13.51 1.42 9.03 8.61 6.27 7.97 1.49 
                      
  <1/4 median 1/4-1/2 median 
Colon       Average 
Std 
Dev       Average 
Std 
Dev 
1 27.42 30.51 33.43 30.45 3.01 16.11 15.27 18.04 16.47 1.42 
2 36.22 39.43 32.44 36.03 3.50 19.89 16.62 18.19 18.23 1.64 
4 44.38 48.34 52.66 48.46 4.14 15.69 17.64 18.98 17.44 1.65 
6 56.67 60.69 52.26 56.54 4.22 18.13 14.34 16.72 16.40 1.92 
             
  1/2-median >Median 
Colon       Average 
Std 
Dev       Average 
Std 
Dev 
1 17.81 15.40 19.21 17.47 1.93 32.32 39.24 35.26 35.61 3.47 
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2 20.54 18.74 17.22 18.83 1.66 26.74 29.99 24.19 26.97 2.91 
4 15.27 19.22 17.61 17.37 1.99 18.14 16.83 15.22 16.73 1.46 
6 14.71 17.33 16.46 16.17 1.33 10.87 12.33 9.46 10.89 1.44 
 
P.pastoris 
Section and Day <1/4 median 1/4-1/2 median 
Duodenum       Average 
Std 
Dev       Average 
Std 
Dev 
1 26.53 29.67 23.87 26.69 2.90 15.76 14.12 16.46 15.45 1.20 
2 24.31 27.21 29.61 27.04 2.65 15.22 17.26 19.06 17.18 1.92 
4 34.56 42.27 38.58 38.47 3.86 17.61 21.49 19.43 19.51 1.94 
6 42.81 46.84 51.01 46.89 4.10 18.42 19.63 17.04 18.36 1.30 
                      
  1/2-median >Median 
Duodenum       Average 
Std 
Dev       Average 
Std 
Dev 
1 18.71 17.62 15.75 17.36 1.50 36.81 44.27 40.43 40.50 3.73 
2 19.23 21.47 17.86 19.52 1.82 38.67 36.38 33.74 36.26 2.47 
4 15.47 17.37 19.22 17.35 1.88 24.75 27.14 22.13 24.67 2.51 
6 16.74 18.85 13.96 16.52 2.45 16.49 18.21 19.98 18.23 1.75 
                      
  <1/4 median 1/4-1/2 median 
Jejunum       Average 
Std 
Dev       Average 
Std 
Dev 
1 21.30 23.48 24.49 23.09 1.63 13.63 15.11 11.88 13.54 1.62 
2 26.81 33.34 29.76 29.97 3.27 16.38 13.68 15.57 15.21 1.39 
4 37.18 38.11 41.85 39.05 2.47 15.28 18.91 16.38 16.86 1.86 
6 43.68 50.08 46.49 46.75 3.21 16.22 14.37 13.17 14.59 1.54 
                      
  1/2-median >Median 
Jejunum       Average 
Std 
Dev       Average 
Std 
Dev 
1 20.12 18.64 17.11 18.62 1.51 44.56 48.61 41.08 44.75 3.77 
2 20.15 21.17 18.61 19.98 1.29 34.95 36.85 32.71 34.84 2.07 
4 22.67 18.94 20.67 20.76 1.87 25.32 23.92 20.74 23.33 2.35 
6 18.92 16.77 19.64 18.44 1.49 18.16 20.24 22.27 20.22 2.06 
                      
                                                                                   APPENDIX 
 327
  <1/4 median 1/4-1/2 median 
Ileum       Average 
Std 
Dev       Average 
Std 
Dev 
1 18.84 20.47 21.71 20.34 1.44 11.86 14.67 12.87 13.13 1.42 
2 18.12 18.91 23.10 20.04 2.68 14.30 16.11 17.83 16.08 1.77 
4 18.53 22.01 22.82 21.12 2.28 13.12 16.39 14.22 14.58 1.66 
6 26.14 21.14 24.81 24.03 2.59 11.70 16.29 14.02 14.00 2.30 
                      
  1/2-median >Median 
Ileum       Average 
Std 
Dev       Average 
Std 
Dev 
1 15.35 16.22 14.78 15.45 0.73 54.67 47.36 51.22 51.08 3.66 
2 16.91 18.00 20.17 18.36 1.66 41.78 46.22 48.57 45.52 3.45 
4 14.10 12.83 10.94 12.62 1.59 46.92 55.44 52.68 51.68 4.35 
6 15.39 13.66 11.47 13.51 1.96 52.29 44.71 48.37 48.46 3.79 
                      
           
           
  <1/4 median 1/4-1/2 median 
Colon       Average 
Std 
Dev       Average 
Std 
Dev 
1 22.26 25.48 27.91 25.22 2.83 10.32 14.52 12.36 12.40 2.10 
2 25.57 29.33 24.27 26.39 2.63 14.36 15.18 17.42 15.65 1.58 
4 28.21 34.98 31.37 31.52 3.39 14.89 17.96 16.97 16.61 1.57 
6 38.56 41.54 36.62 38.91 2.48 19.86 17.55 15.63 17.68 2.12 
             
  1/2-median >Median 
Colon       Average 
Std 
Dev       Average 
Std 
Dev 
1 12.35 15.74 13.68 13.92 1.71 53.24 47.22 44.92 48.46 4.30 
2 14.28 18.29 16.62 16.40 2.01 41.65 44.38 38.64 41.56 2.87 
4 18.21 16.27 20.09 18.19 1.91 30.98 33.53 36.54 33.68 2.78 
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(j) Doubling times of LcS, S.boulardii, S.cerevisiae and P.pastoris in different 
segments of murine intestinal tract 
 
In2/Td  = (In X2 - In X1)/( t2 - t1) 
 Duodenum Jejunum Ileum Colon 
L.casei Shirota 4.10 4.80 4.60 5.60 
S.boulardii 1.33 2.61 10.91 20.83 
S.cerevisiae 1.67 9.10 0.45 0.85 






















DATA FOR CHAPTER 4 
 
(a) Concentrations of rTGEV-S specific IgA in the intestinal lavages of mice 
orally immunized with LcS-rTGEV-S 
 
 Intestinal IgA (ng/ml) 
 Pre-immune 
serum  
Average SD Day 18 Average SD 
PBS 0.20 0.24 0.05 0.16 0.22 0.06 
 0.24   0.23   
 0.29   0.28   
LcS-rTGEV-S 0.17 0.23 0.06 1.52 1.29 0.24 
 0.24   1.29   
 0.28   1.05   
LcS-pLP500 0.31 0.26 0.06 0.37 0.32 0.04 
 0.20   0.29   
 0.27   0.31   
       
PBS Day 32 Average SD Day 48 Average SD 
 0.16 0.18 0.03 0.35 0.27 0.08 
 0.17   0.26   
LcS-rTGEV-S 0.21   0.19   
 4.15 3.98 0.18 3.81 3.63 0.19 
 3.98   3.65   
LcS-pLP500 3.80   3.44   
 0.21 0.24 0.04 0.29 0.24 0.06 
 0.28   0.18   
 0.24   0.25   
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(b) Concentrations of rTGEV-S specific IgG in the sera of mice orally 
immunized with LcS-rTGEV-S 
 
 Serum IgG (ng/ml) 
 Pre-immune 
serum 
Average SD Day 18 Average SD 
PBS 0.23 0.28 0.06 0.37 0.31 0.06 
 0.27   0.30   
 0.34   0.25   
LcS-rTGEV-S 0.24 0.20 0.04 5.71 6.03 0.32 
 0.19   6.04   
 0.17   6.34   
LcS-pLP500 0.2 0.25 0.05 0.32 0.26 0.06 
 0.29   0.21   
 0.26   0.25   
       
 Day 32 Average SD Day 48 Average SD 
PBS 0.18 0.22 0.04 0.34 0.28 0.06 
 0.21   0.27   
 0.26   0.23   
LcS-rTGEV-S 8.56 8.38 0.18 8.29 8.05 0.25 
 8.37   8.06   
 8.21   7.80   
LcS-pLP500 0.25 0.33 0.08 0.14 0.22 0.08 
 0.41   0.29   
 0.34   0.24   
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(c) Concentrations of rTGEV-S specific IgG isotypes in the sera of mice orally 
immunized with LcS-rTGEV-S 
 
 Serum IgG Isotype 
  IgG1 (ng/ml) IgG2a (ng/ml) 
 Day 32 Average SD Day 32 Average SD 
PBS 0.14 0.14 0.04 0.13 0.15 0.03 
 0.18   0.18   
 0.11   0.14   
LcS-rTGEV-S 2.24 1.98 0.22 4.77 4.49 0.28 
 1.83   4.48   
 1.88   4.22   
LcS-pLP500 0.15 0.17 0.02 0.16 0.16 0.03 
 0.17   0.19   
 0.19   0.14   
 
(d) Concentrations of PrTGEV-S specific IgA in the intestinal lavages of mice 
orally immunized with PP/PrTGEV-S 
 
 Intestinal IgA (ng/ml) 
 Pre-immune 
serum 
Average SD Day 18 Average SD 
PBS 0.49 0.50 0.09 0.54 0.47 0.08 
 0.42   0.39   
 0.59   0.47   
PP/PrTGEV-S 0.43 0.52 0.08 4.67 4.51 0.17 
 0.58   4.33   
 0.55   4.54   
PP/pGAPZ α C 0.61 0.55 0.06 0.51 0.52 0.08 
 0.49   0.45   
 0.56   0.60   
       
 Day 32 Average SD Day 48 Average SD 
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PBS 0.61 0.56 0.04 0.52 0.48 0.08 
 0.53   0.39   
 0.54   0.54   
PP/PrTGEV-S 4.47 4.55 0.12 4.31 4.48 0.15 
 4.69   4.54   
 4.49   4.58   
PP/pGAPZ α C 0.43 0.48 0.07 0.52 0.53 0.05 
 0.44   0.49   
 0.56   0.58   
 
(e) Concentrations of PrTGEV-S specific IgG in the sera of mice orally 
immunized with PP/PrTGEV-S 
 
 Intestinal IgG (ng/ml) 
 Pre-immune 
serum 
Average SD Day 18 Average SD 
PBS 0.53 0.58 0.06 0.62 0.61 0.06 
 0.65   0.55   
 0.56   0.67   
PP/PrTGEV-S 0.46 0.57 0.10 8.95 9.41 0.44 
 0.59   9.46   
 0.66   9.82   
PP/pGAPZ α C 0.52 0.50 0.08 0.57 0.51 0.06 
 0.57   0.46   
 0.41   0.51   
       
 Day 32 Average SD Day 48 Average SD 
PBS 0.59 0.58 0.09 0.64 0.54 0.09 
 0.48   0.51   
 0.66   0.48   
PP/PrTGEV-S 10.07 9.99 0.49 9.53 9.51 0.32 
 10.43   9.18   
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 9.46   9.82   
PP/pGAPZ α C 0.49 0.56 0.07 0.55 0.53 0.08 
 0.63   0.45   
 0.55   0.60   
 
(f) Concentrations of PrTGEV-S specific IgG isotypes in the sera of mice orally 
immunized with PP/PrTGEV-S 
 
 Serum IgG Isotype 
  IgG1 (ng/ml) IgG2a (ng/ml) 
 Day 32 Average SD Day 32 Average SD 
PBS 0.34 0.29 0.05 0.22 0.27 0.04 
 0.28   0.28   
 0.24   0.30   
PP/PrTGEV-S 2.95 2.81 0.18 5.81 5.46 0.31 
 2.61   5.32   
 2.88   5.24   
PP/pGAPZ α C  0.29 0.26 0.04 0.31 0.27 0.05 
 0.28   0.22   
 0.21   0.29   
 
(g) Inhibition of TGEV plaque formation by intestinal lavages from mice orally 
immunized with LcS/rTGEV-S 
  
 





LCS PBS Avg PBS PBS-LCS-
rTGEV-S 






2 2.83E+04 3.21E+04 3.24E+04 3.27E+04 13.46% 13.35% 0.77% 1.83% 1.12% 0.77%
 2.81E+04 3.23E+04 3.29E+04 3.27E+04 14.07%   1.22%   
 2.86E+04 3.26E+04 3.28E+04 3.27E+04 12.54%   0.31%   
4 2.84E+04 3.24E+04 3.21E+04 3.25E+04 12.62% 12.41% 0.64% 0.31% 0.31% 0.92%
 2.87E+04 3.21E+04 3.28E+04 3.25E+04 11.69%   1.23%   
 2.83E+04 3.27E+04 3.26E+04 3.25E+04 12.92%   -0.62%   
8 2.88E+04 3.25E+04 3.32E+04 3.27E+04 11.93% 12.33% 0.47% 0.58% 0.19% 0.45%
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 2.85E+04 3.28E+04 3.27E+04 3.27E+04 12.84%   -0.31%   
 2.87E+04 3.26E+04 3.22E+04 3.27E+04 12.23%   0.31%   
16 2.88E+04 3.23E+04 3.21E+04 3.24E+04 11.11% 10.49% 0.82% 0.28% 0.40% 0.48%
 2.93E+04 3.24E+04 3.25E+04 3.24E+04 9.57%   0.00%   
 2.89E+04 3.21E+04 3.26E+04 3.24E+04 10.80%   0.93%   
32 3.07E+04 3.26E+04 3.24E+04 3.22E+04 4.56% 5.60% 1.09% -1.35% -0.83% 0.47%
 3.00E+04 3.24E+04 3.21E+04 3.22E+04 6.74%   -0.73%   
 3.04E+04 3.23E+04 3.20E+04 3.22E+04 5.49%   -0.41%   
64 3.17E+04 3.26E+04 3.27E+04 3.25E+04 2.56% 2.46% 0.77% -0.20% 0.10% 0.81%
 3.15E+04 3.22E+04 3.26E+04 3.25E+04 3.18%   1.02%   
 3.20E+04 3.27E+04 3.23E+04 3.25E+04 1.64%   -0.51%   
128 3.25E+04 3.28E+04 3.21E+04 3.24E+04 -0.41% 0.00% 0.47% -1.34% -0.51% 0.78%
 3.22E+04 3.25E+04 3.26E+04 3.24E+04 0.51%   -0.41%   
 3.24E+04 3.23E+04 3.24E+04 3.24E+04 -0.10%   0.21%   
256 3.29E+04 3.25E+04 3.24E+04 3.27E+04 -0.61% -0.31% 0.53% 0.61% 0.71% 0.47%
 3.26E+04 3.23E+04 3.30E+04 3.27E+04 0.31%   1.22%   
 3.29E+04 3.26E+04 3.27E+04 3.27E+04 -0.61%   0.31%   
 









LCS PBS Avg PBS PBS-
LCS/rTGEV-S




Avg Std  
dev 
2 2.73E+04 3.23E+04 3.24E+04 3.27E+04 16.51% 15.70% 0.77% 1.22% 0.51% 0.98%
 2.78E+04 3.24E+04 3.29E+04 3.27E+04 14.98%   0.92%   
 2.76E+04 3.29E+04 3.28E+04 3.27E+04 15.60%   -0.61%   
4 2.79E+04 3.26E+04 3.21E+04 3.25E+04 14.15% 13.74% 0.47% -0.31% 0.31% 0.62%
 2.82E+04 3.22E+04 3.28E+04 3.25E+04 13.23%   0.92%   
 2.80E+04 3.24E+04 3.26E+04 3.25E+04 13.85%   0.31%   
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8 2.89E+04 3.23E+04 3.32E+04 3.27E+04 11.62% 11.42% 0.64% 1.19% 0.40% 0.75%
 2.92E+04 3.28E+04 3.27E+04 3.27E+04 10.70%   -0.31%   
 2.88E+04 3.26E+04 3.22E+04 3.27E+04 11.93%   0.31%   
16 2.98E+04 3.22E+04 3.21E+04 3.24E+04 8.02% 7.20% 0.78% 0.59% -0.42% 0.93%
 3.01E+04 3.26E+04 3.25E+04 3.24E+04 7.10%   -0.62%   
 3.03E+04 3.28E+04 3.26E+04 3.24E+04 6.48%   -1.23%   
32 3.17E+04 3.23E+04 3.24E+04 3.22E+04 1.45% 1.66% 0.65% -0.41% -0.21% 0.65%
 3.14E+04 3.24E+04 3.21E+04 3.22E+04 2.38%   -0.73%   
 3.18E+04 3.20E+04 3.20E+04 3.22E+04 1.14%   0.52%   
64 3.27E+04 3.23E+04 3.27E+04 3.25E+04 -0.51% 0.31% 0.77% 0.72% 0.82% 1.08%
 3.24E+04 3.19E+04 3.26E+04 3.25E+04 0.41%   1.95%   
 3.22E+04 3.26E+04 3.23E+04 3.25E+04 1.02%   -0.20%   
128 3.27E+04 3.22E+04 3.21E+04 3.24E+04 -1.03% -0.41% 0.62% 0.51% 0.10% 0.71%
 3.23E+04 3.26E+04 3.26E+04 3.24E+04 0.21%   -0.72%   
 3.25E+04 3.22E+04 3.24E+04 3.24E+04 -0.41%   0.51%   
256 3.31E+04 3.27E+04 3.24E+04 3.27E+04 -1.22% -0.61% 0.61% 0.00% 0.41% 0.47%
 3.27E+04 3.24E+04 3.30E+04 3.27E+04 0.00%   0.92%   
 3.29E+04 3.26E+04 3.27E+04 3.27E+04 -0.61%   0.31%   
 
 
(i) Inhibition of TGEV plaque formation by intestinal lavages from mice orally 
immunized with PP/PrTGEV-S 
 
 





PP PBS Avg PBS PBS-
PP/rTGEV-S




Avg Std  
dev 
2 2.02E+03 3.17E+04 3.30E+04 3.30E+04 93.88% 96.08% 2.13% 3.94% 3.23% 0.63%
 1.24E+03 3.21E+04 3.32E+04  96.24%   2.73%   
 6.20E+02 3.20E+04 3.28E+04  98.12%   3.03%   
4 1.58E+03 3.23E+04 3.31E+04 3.31E+04 95.22% 95.18% 1.51% 2.32% 2.42% 0.46%
 1.10E+03 3.21E+04 3.32E+04  96.67%   2.92%   
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 2.10E+03 3.24E+04 3.29E+04  93.65%   2.02%   
8 4.12E+03 3.23E+04 3.30E+04 3.27E+04 87.42% 83.66% 3.25% 1.19% 0.70% 0.62%
 5.90E+03 3.27E+04 3.25E+04  81.96%   0.00%   
 6.01E+03 3.24E+04 3.26E+04  81.62%   0.92%   
16 7.81E+03 3.26E+04 3.38E+04 3.29E+04 76.29% 72.23% 3.98% 0.98% 1.61% 1.61%
 9.20E+03 3.18E+04 3.21E+04  72.06%   3.44%   
 1.04E+04 3.28E+04 3.29E+04  68.33%   0.40%   
32 1.32E+04 3.19E+04 3.30E+04 3.29E+04 59.92% 60.00% 2.49% 3.14% 2.23% 0.91%
 1.23E+04 3.22E+04 3.32E+04  62.53%   2.23%   
 1.40E+04 3.25E+04 3.26E+04  57.55%   1.32%   
64 1.89E+04 3.27E+04 3.29E+04 3.31E+04 42.96% 39.03% 3.48% 1.31% 1.51% 0.92%
 2.06E+04 3.29E+04 3.34E+04  37.83%   0.70%   
 2.11E+04 3.23E+04 3.31E+04  36.32%   2.52%   
128 2.55E+04 3.26E+04 3.25E+04 3.27E+04 22.16% 20.79% 4.00% 0.41% 1.32% 0.81%
 2.74E+04 3.21E+04 3.29E+04  16.29%   1.93%   
 2.49E+04 3.22E+04 3.28E+04  23.93%   1.63%   
256 2.97E+04 3.29E+04 3.34E+04 3.28E+04 9.54% 9.14% 1.86% -0.20% 0.81% 0.93%
 3.05E+04 3.23E+04 3.27E+04  7.11%   1.62%   
 2.93E+04 3.25E+04 3.24E+04  10.76%   1.02%   
512 3.16E+04 3.32E+04 3.31E+04 3.31E+04 4.38% 2.26% 1.92% -0.24% 0.93% 1.10%
 3.25E+04 3.27E+04 3.28E+04  1.72%   1.09%   
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PP PBS Avg PBS PBS-
PP/rTGEV-S
Avg  Std 
Dev 
PBS-PP Avg Std  
dev 
2 2.86E+02 3.10E+04 3.10E+04 3.16E+04 99.09% 98.56% 0.79% 1.90% 2.43% 1.80%
 7.40E+02 3.02E+04 3.22E+04  97.66%   4.43%   
 3.35E+02 3.13E+04 3.16E+04  98.94%   0.95%   
4 1.09E+03 3.13E+04 3.21E+04 3.19E+04 96.59% 98.34% 1.59% 1.78% 1.26% 0.65%
 4.04E+02 3.17E+04 3.16E+04  98.73%   0.52%   
 9.70E+01 3.14E+04 3.19E+04  99.70%   1.46%   
8 3.67E+02 3.17E+04 3.20E+04 3.17E+04 98.84% 98.39% 1.29% -0.03% 0.83% 0.81%
 1.89E+02 3.12E+04 3.15E+04  99.40%   1.58%   
 9.71E+02 3.14E+04 3.16E+04  96.94%   0.95%   
16 5.69E+03 3.11E+04 3.11E+04 3.12E+04 81.74% 85.01% 3.06% 0.18% 0.95% 0.69%
 3.80E+03 3.08E+04 3.08E+04  87.81%   1.18%   
 4.53E+03 3.07E+04 3.16E+04  85.47%   1.50%   
32 1.22E+04 3.12E+04 3.20E+04 3.19E+04 61.67% 65.70% 4.75% 2.30% 1.15% 1.27%
 1.13E+04 3.20E+04 3.22E+04  64.49%   -0.21%   
 9.28E+03 3.15E+04 3.16E+04  70.94%   1.36%   
64 1.63E+04 3.19E+04 3.13E+04 3.13E+04 47.90% 42.23% 5.47% -2.03% -0.32% 1.61%
 1.97E+04 3.09E+04 3.17E+04  36.99%   1.17%   
 1.82E+04 3.13E+04 3.08E+04  41.79%   -0.11%   
128 2.47E+04 3.12E+04 3.15E+04 3.14E+04 21.32% 26.91% 4.86% 0.53% 1.17% 0.84%
 2.22E+04 3.11E+04 3.18E+04  29.22%   0.85%   
 2.19E+04 3.07E+04 3.08E+04  30.18%   2.13%   
256 2.67E+04 3.14E+04 3.14E+04 3.15E+04 15.15% 11.86% 4.38% 0.21% 2.01% 1.57%
 2.93E+04 3.06E+04 3.18E+04  6.89%   2.75%   
 2.72E+04 3.05E+04 3.12E+04  13.56%   3.07%   
512 3.09E+04 3.17E+04 3.21E+04 3.20E+04 3.22% 1.69% 1.42% 0.95% 1.19% 2.12%
 3.18E+04 3.22E+04 3.16E+04  0.42%   -0.80%   
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(k) Cytokine production by cells of the Peyer’s patches isolate from mice orally 





 rTGEV-S-GST Avg Std Dev RPMI Avg  Std Dev 
Day 2 351.23 375.55 22.85 16.86 16.16 3.04 
 396.57   18.79   
 378.84   12.83   
Day 3 381.94 347.56 31.62 17.27 14.31 3.08 
 319.73   14.54   
 341.02   11.13   
Day 4 376.12 335.51 37.86 18.46 16.34 2.95 
 301.19   12.97   
 329.22   17.59   
Day 5 365.18 366.15 27.92 16.17 15.12 3.21 
 394.54   11.52   
 338.72   17.68   
       
LcS 
 rTGEV-S-GST Avg Std Dev RPMI Avg  Std Dev 
Day 2 16.02 13.45 2.24 18.67 16.06 3.69 
 12.37   11.84   
 11.95   17.68   
Day 3 13.59 13.00 1.89 15.34 15.16 1.12 
 10.89   13.96   
 14.52   16.17   
Day 4 16.38 13.62 2.60 12.78 15.38 3.49 
 11.23   14.01   
 13.24   19.34   
Day 5 15.76 13.94 1.79 16.84 14.48 2.43 
 12.19   11.98   
 13.86   14.63   
       
IFN-g (pg/ml) 
LcS/TGEV 
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 rTGEV-S-GST Avg Std Dev RPMI Avg  Std Dev 
Day 2 762.37 773.90 32.29 12.68 13.09 2.68 
 810.37   15.96   
 748.96   10.64   
Day 3 982.65 1063.97 73.23 11.37 13.40 1.85 
 1124.69   13.85   
 1084.56   14.99   
Day 4 1361.33 1320.61 55.19 16.89 12.94 3.49 
 1342.71   10.27   
 1257.79   11.67   
Day 5 1314.21 1305.28 46.77 14.00 13.98 1.96 
 1254.69   15.93   
 1346.95   12.01   
       
LcS 
 rTGEV-S-GST Avg Std Dev RPMI Avg  Std Dev 
Day 2 16.38 13.67 3.11 11.15 12.89 3.17 
 14.36   10.96   
 10.27   16.55   
Day 3 12.31 14.17 1.63 10.87 12.69 1.85 
 15.33   14.56   
 14.86   12.63   
Day 4 17.01 14.81 2.09 12.54 13.21 2.84 
 14.57   16.33   
 12.85   10.77   
Day 5 12.37 13.26 2.17 11.23 13.31 1.89 
 15.73   13.78   
 11.68   14.91   
       
IL-4 (pg/ml) 
LcS/TGEV 
 rTGEV-S-GST Avg Std Dev RPMI Avg  Std Dev 
Day 2 406.34 443.61 41.63 10.84 12.77 1.91 
 488.54   14.66   
 435.94   12.81   
Day 3 498.74 525.52 27.76 17.98 15.23 2.79 
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 523.64   15.30   
 554.17   12.41   
Day 4 507.97 539.55 37.54 10.37 13.12 2.64 
 529.62   15.64   
 581.05   13.34   
Day 5 497.21 527.89 41.62 14.77 13.97 2.70 
 575.27   16.18   
 511.20   10.96   
       
LcS 
 rTGEV-S-GST Avg Std Dev RPMI Avg  Std Dev 
Day 2 13.41 16.41 2.81 11.51 13.11 1.89 
 18.99   12.63   
 16.83   15.20   
Day 3 19.94 17.71 1.93 16.47 14.81 1.44 
 16.53   14.08   
 16.67   13.89   
Day 4 16.42 17.35 1.75 14.54 13.17 1.92 
 19.37   10.98   
 16.26   13.99   
Day 5 15.53 15.74 2.58 12.78 14.35 1.72 
 18.42   16.19   
 13.27   14.07   
       
IL-5 (pg/ml) 
LcS/TGEV 
 rTGEV-S-GST Avg Std Dev RPMI Avg  Std Dev 
Day 2 246.65 217.35 26.31 17.51 14.90 2.46 
 209.67   12.63   
 195.74   14.55   
Day 3 296.48 328.43 33.54 11.38 13.78 2.42 
 325.44   13.75   
 363.36   16.21   
Day 4 358.76 400.93 38.34 14.67 13.76 1.34 
 410.34   12.22   
 433.68   14.38   
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Day 5 376.12 405.35 27.62 13.11 13.34 2.50 
 431.02   10.96   
 408.91   15.94   
       
LcS 
 rTGEV-S-GST Avg Std Dev RPMI Avg  Std Dev 
Day 2 15.88 14.63 2.60 13.64 12.24 1.75 
 16.37   12.79   
 11.64   10.28   
Day 3 14.08 13.51 0.74 16.37 14.24 1.94 
 12.67   12.58   
 13.79   13.76   
Day 4 12.51 14.01 2.28 12.69 15.00 2.14 
 16.63   16.93   
 12.89   15.37   
Day 5 14.21 14.07 2.06 11.74 13.68 1.86 
 16.05   13.84   
 11.94   15.45   
 
 
(l) Cytokine production by cells of the Peyer’s patches isolate from mice orally 






Avg Std Dev RPMI Avg  Std Dev Con A Avg  Std Dev
Day 2 409.13 403.11 38.89 15.59 15.23 2.41 10673.62 10220.58 392.42 
 361.57   17.43   9986.27   
 438.64   12.66   10001.85   
Day 3 456.73 455.01 34.65 16.74 14.44 2.02 - - - 
 419.53   12.96   -   
 488.76   13.63   -   
Day 4 471.17 454.26 20.20 15.46 15.48 2.34 - - - 
 431.89   17.83   -   
 459.71   13.15   -   
Day 5 375.54 400.40 27.28 15.62 15.07 2.47 - - - 
 396.07   12.38   -   
 429.58   17.22   -   
          





Avg Std Dev RPMI Avg  Std Dev Con A Avg  Std Dev
Day 2 11.37 14.04 2.76 17.54 15.25 2.15 10854.27 10536.69 275.16 
 13.85   13.28   10386.32   
 16.89   14.92   10369.47   
Day 3 11.79 13.89 1.84 13.76 13.76 1.90 - - - 
 14.67   15.66   -   
 15.22   11.87   -   
Day 4 10.87 13.29 2.93 14.52 14.70 1.74 - - - 
 16.55   13.06   -   
 12.44   16.53   -   
Day 5 15.76 13.94 1.79 11.98 13.19 1.43 - - - 
 12.19   14.77   -   
 13.86   12.82   -   





Avg Std Dev RPMI Avg  Std Dev Con A Avg  Std Dev
Day 2 774.71 799.70 22.82 11.74 13.63 2.03 6894.26 7049.30 160.13 
 819.44   15.77   7039.58   
 804.96   13.37   7214.07   
Day 3 1061.27 1100.69 35.79 12.86 12.74 2.42 - - - 
 1131.14   10.26   -   
 1109.67   15.09   -   
Day 4 1401.43 1402.67 24.68 13.22 13.32 2.21 - - - 
 1378.63   15.57   -   
 1427.95   11.16   -   
Day 5 1333.78 1299.77 37.95 13.37 14.92 1.76 - - - 
 1258.84   14.55   -   
 1306.70   16.84   -   




Avg Std Dev RPMI Avg  Std Dev Con A Avg  Std Dev
Day 2 10.84 12.20 1.41 11.54 10.70 0.94 7341.27 7173.65 160.64 
 13.66   10.88   7158.62   
 12.11   9.68   7021.05   
Day 3 13.83 13.96 1.28 15.47 13.81 1.53 - - - 
 15.30   13.53   -   
 12.75   12.44   -   
Day 4 11.56 12.88 1.75 11.70 10.88 0.83 - - - 
 14.86   10.91   -   
 12.21   10.04   -   
Day 5 13.66 15.36 1.98 12.88 14.15 1.72 - - - 
 17.54   13.46   -   
 14.88   16.11   -   
          






Avg Std Dev RPMI Avg  Std Dev Con A Avg  Std Dev
Day 2 29.68 30.92 5.14 11.81 11.83 1.80 9756.27 9937.24 167.63 
 26.51   13.64   10087.21   
 36.56   10.05   9968.24   
Day 3 117.32 101.79 13.73 15.74 14.16 1.43 - - - 
 96.78   13.81   -   
 91.26   12.94   -   
Day 4 310.14 296.86 17.85 14.22 12.11 2.00 - - - 
 276.57   10.24   -   
 303.88   11.86   -   
Day 5 354.81 375.21 19.62 16.79 14.87 1.89 - - - 
 393.94   14.81   -   
 376.89   13.01   -   




Avg Std Dev RPMI Avg  Std Dev Con A Avg  Std Dev
Day 2 13.22 15.74 2.25 10.74 12.04 1.62 10244.31 9986.81 245.72 
 16.47   13.86   9961.25   
 17.54   11.52   9754.87   
Day 3 17.66 16.30 1.19 15.41 13.68 1.67 - - - 
 15.81   13.56   -   
 15.44   12.07   -   
Day 4 19.79 17.84 1.71 15.06 13.96 1.11 - - - 
 17.18   12.84   -   
 16.56   13.97   -   
Day 5 15.38 15.59 1.71 15.81 13.50 2.42 - - - 
 17.40   13.71   -   
 13.99   10.99   -   





Avg Std Dev RPMI Avg  Std Dev Con A Avg  Std Dev
Day 2 28.87 25.67 3.18 15.87 14.46 1.45 11365.82 11116.10 466.18 
 22.51   14.55   10578.26   
 25.63   12.97   11404.21   
Day 3 92.62 80.45 11.28 13.76 13.78 1.93 - - - 
 70.33   15.71   -   
 78.41   11.86   -   
Day 4 133.14 150.11 19.45 12.94 14.88 1.89 - - - 
 145.87   15.00   -   
 171.33   16.71   -   
Day 5 293.91 273.35 22.41 11.76 11.36 0.99 - - - 
 249.46   12.09   -   
 276.67   10.24   -   
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Avg Std Dev RPMI Avg  Std Dev Con A Avg  Std Dev
Day 2 18.94 16.04 2.75 12.84 12.16 1.66 10748.96 10815.92 239.30 
 15.71   10.26   10617.24   
 13.47   13.37   11081.57   
Day 3 16.86 14.91 1.91 15.44 13.29 1.95 - - - 
 14.83   11.63   -   
 13.04   12.80   -   
Day 4 11.23 13.41 2.22 17.02 14.53 2.24 - - - 
 13.34   12.69   -   
 15.67   13.87   -   
Day 5 12.87 14.13 1.63 14.54 13.82 1.50 - - - 
 15.97   12.10   -   
 13.55   14.83   -   
 
 




DATA FOR CHAPTER 5 
 
(a) Concentrations of SARS-S-RBD specific IgA in the intestinal lavages of mice 
orally immunized with PP/SARS-S-RBD 
 
 Intestinal IgA (ng/ml) 
 Pre-immune 
serum 
Average SD Day 18 Average SD 
PBS 0.52 0.55 0.11 0.53 0.51 0.08 
 0.46   0.58   
 0.68   0.43   
PP/SARS-S-RBD 0.59 0.51 0.09 4.89 4.48 0.36 
 0.42   4.24   
 0.52   4.31   
PP/pGAPZ α C 0.43 0.52 0.10 0.61 0.55 0.07 
 0.62   0.56   
 0.52   0.48   
       
 Day 32 Average SD Day 48 Average SD 
PBS 0.61 0.56 0.04 0.52 0.48 0.08 
 0.53   0.39   
 0.54   0.54   
PP/SARS-S-RBD 4.56 4.52 0.37 4.46 4.51 0.26 
 4.87   4.28   
 4.14   4.79   
PP/pGAPZ α C 0.57 0.50 0.08 0.43 0.53 0.08 
 0.53   0.57   
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(b) Concentrations of SARS-S-RBD specific IgG in the sera of mice orally 
immunized with PP/SARS-S-RBD 
 
 Intestinal IgG (ng/ml) 
 Pre-immune 
serum 
Average SD Day 18 Average SD 
PBS 0.64 0.56 0.09 0.45 0.57 0.12 
 0.47   0.69   
 0.58   0.58   
PP/SARS-S-RBD 0.49 0.55 0.05 9.67 9.42 0.77 
 0.56   8.55   
 0.59   10.03   
PP/pGAPZ α C 0.68 0.61 0.09 0.43 0.53 0.11 
 0.63   0.51   
 0.51   0.65   
       
 Day 32 Average SD Day 48 Average SD 
PBS 0.67 0.56 0.09 0.58 0.53 0.10 
 0.53   0.41   
 0.49   0.60   
PP/SARS-S-RBD 9.61 9.49 1.01 8.71 9.45 0.86 
 10.43   9.26   
 8.42   10.39   
PP/pGAPZ α C 0.58 0.56 0.08 0.64 0.59 0.06 
 0.48   0.61   
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(c) Concentrations of SARS-S-RBD specific IgG isotypes in the sera of mice 
orally immunized with PP/SARS-S-RBD 
 
 Serum IgG Isotype 
  IgG1 (ng/ml) IgG2a (ng/ml) 
 Day 32 Average SD Day 32 Average SD 
PBS 0.28 0.26 0.04 0.24 0.24 0.05 
 0.21   0.19   
 0.29   0.29   
PP/SARS-S-RBD 4.87 5.26 0.48 2.35 2.59 0.32 
 5.12   2.96   
 5.79   2.47   
PP/pGAPZ α C  0.23 0.26 0.04 0.27 0.27 0.05 
 0.26   0.22   
 0.30   0.31   
 
(d) Inhibition of MLV(SARS) infection by intestinal lavages from mice orally 
immunized with PP/SARS-S-RBD 
 
 





PP PBS Avg PBS PBS-
PP/SARS-S-
RBD 




Avg Std  
dev 
2 4.70E+02 3.76E+04 3.84E+04 3.93E+04 98.80% 98.45% 0.80% 4.24% 5.00% 0.92%
 9.67E+02 3.69E+04 3.95E+04  97.54%   6.02%   
 3.89E+02 3.74E+04 3.99E+04  99.01%   4.75%   
4 7.54E+02 3.79E+04 4.12E+04 4.04E+04 98.13% 98.28% 0.74% 6.19% 5.28% 0.87%
 3.69E+02 3.86E+04 3.97E+04  99.09%   4.46%   
 9.57E+02 3.83E+04 4.03E+04  97.63%   5.20%   
8 1.45E+03 3.74E+04 3.89E+04 3.99E+04 96.36% 94.90% 1.29% 6.20% 5.12% 1.01%
 2.43E+03 3.79E+04 4.01E+04  93.91%   4.95%   
 2.23E+03 3.82E+04 4.06E+04  94.41%   4.20%   
16 6.68E+03 3.85E+04 4.11E+04 4.03E+04 83.42% 83.90% 1.46% 4.47% 4.96% 0.66%
 6.95E+03 3.84E+04 4.06E+04  82.75%   4.71%   
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 5.83E+03 3.80E+04 3.92E+04  85.54%   5.71%   
32 8.96E+03 3.84E+04 4.06E+04 4.04E+04 77.83% 72.25% 4.83% 5.03% 4.78% 0.89%
 1.23E+04 3.89E+04 3.96E+04  69.68%   3.79%   
 1.24E+04 3.82E+04 4.11E+04  69.26%   5.52%   
64 2.00E+04 3.78E+04 3.94E+04 3.98E+04 49.83% 48.96% 4.20% 5.10% 4.77% 0.81%
 1.89E+04 3.83E+04 3.89E+04  52.67%   3.85%   
 2.21E+04 3.77E+04 4.12E+04  44.40%   5.36%   
128 2.27E+04 3.78E+04 3.83E+04 3.95E+04 42.36% 38.23% 3.91% 4.22% 5.32% 1.14%
 2.46E+04 3.74E+04 3.98E+04  37.75%   5.24%   
 2.58E+04 3.69E+04 4.03E+04  34.59%   6.50%   
256 3.07E+04 3.82E+04 4.09E+04 4.02E+04 23.74% 20.37% 3.76% 5.05% 5.30% 0.90%
 3.18E+04 3.84E+04 4.13E+04  21.07%   4.56%   
 3.37E+04 3.77E+04 3.85E+04  16.31%   6.30%   
512 3.52E+04 3.75E+04 4.11E+04 4.00E+04 12.47% 11.59% 2.49% 6.79% 5.80% 1.14%
 3.48E+04 3.84E+04 4.02E+04  13.51%   4.56%   
 3.67E+04 3.78E+04 3.87E+04  8.78%   6.05%   
 









PP PBS Avg PBS PBS -
PP/SAR-S-
RBD 




Avg Std  
dev 
2 4.36E+02 3.73E+04 4.14E+04 3.98E+04 98.91% 99.40% 0.47% 6.36% 5.86% 0.87%
 6.00E+01 3.73E+04 3.93E+04  99.85%   6.36%   
 2.20E+02 3.79E+04 3.88E+04  99.45%   4.85%   
4 8.50E+02 3.72E+04 3.84E+04 3.99E+04 97.87% 99.08% 1.05% 6.78% 5.36% 1.29%
 1.21E+02 3.79E+04 4.03E+04  99.70%   5.03%   
 1.30E+02 3.82E+04 4.10E+04  99.67%   4.28%   
8 7.36E+02 3.78E+04 4.02E+04 4.01E+04 98.16% 96.80% 1.42% 5.74% 4.57% 1.42%
 1.87E+03 3.89E+04 3.89E+04  95.34%   2.99%   
 1.25E+03 3.81E+04 4.12E+04  96.89%   4.99%   
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16 5.90E+03 3.84E+04 4.16E+04 4.06E+04 85.46% 81.88% 3.48% 5.36% 4.37% 0.99%
 7.44E+03 3.92E+04 4.08E+04  81.66%   3.38%   
 8.72E+03 3.88E+04 3.93E+04  78.51%   4.37%   
32 1.28E+04 3.79E+04 3.98E+04 3.99E+04 67.87% 66.71% 4.87% 4.93% 4.52% 0.38%
 1.54E+04 3.82E+04 3.86E+04  61.37%   4.18%   
 1.16E+04 3.81E+04 4.12E+04  70.90%   4.43%   
64 2.19E+04 3.86E+04 4.11E+04 4.05E+04 45.93% 42.75% 5.08% 4.70% 5.03% 1.51%
 2.56E+04 3.78E+04 4.00E+04  36.89%   6.67%   
 2.21E+04 3.90E+04 4.04E+04  45.44%   3.71%   
128 2.76E+04 3.83E+04 3.94E+04 4.03E+04 31.46% 27.81% 4.88% 4.88% 3.97% 1.00%
 2.83E+04 3.91E+04 4.13E+04  29.72%   2.90%   
 3.13E+04 3.86E+04 4.01E+04  22.27%   4.14%   
256 3.31E+04 3.76E+04 3.98E+04 3.98E+04 16.76% 14.94% 3.43% 5.45% 4.27% 1.13%
 3.54E+04 3.85E+04 3.88E+04  10.98%   3.19%   
 3.30E+04 3.81E+04 4.07E+04  17.07%   4.19%   
512 3.48E+04 3.79E+04 4.11E+04 4.03E+04 12.49% 8.55% 3.52% 4.69% 6.29% 1.43%
 3.75E+04 3.68E+04 3.93E+04  5.70%   7.46%   




(f) Cytokine production by cells of the Peyer’s patches isolate from mice orally 






Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev
Day 2 221.74 231.58 29.11 11.26 12.21 1.10 11445.34 11238.75 193.78 
 208.66   13.41   11209.87   
 264.33   11.96   11061.03   
Day 3 217.96 227.39 23.71 9.87 11.10 1.29 - - - 
 254.36   10.98   -   
 209.84   12.44   -   
Day 4 246.80 250.12 23.45 9.18 11.62 2.35 - - - 
 275.06   13.86   -   
 228.51   11.82   -   
Day 5 214.93 234.23 17.28 10.63 11.97 1.23 - - - 
 239.47   13.04   -   
 248.28   12.24   -   
          





Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev
Day 2 12.23 13.45 1.08 10.97 11.14 1.19 11495.62 11269.10 230.66 
 13.84   12.41   11277.18   
 14.27   10.05   11034.51   
Day 3 12.74 11.76 0.93 13.58 11.81 1.67 - - - 
 11.67   11.61   -   
 10.88   10.25   -   
Day 4 11.97 11.79 1.86 13.41 11.31 2.13 - - - 
 13.56   11.37   -   
 9.85   9.16   -   
Day 5 12.23 12.30 1.60 12.60 12.18 1.32 - - - 
 10.74   10.71   -   
 13.93   13.24   -   





Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev
Day 2 121.54 126.61 20.85 12.84 11.19 1.62 6991.20 7179.07 167.35 
 149.53   9.61   7233.85   
 108.77   11.11   7312.17   
Day 3 135.67 134.33 17.82 8.79 11.59 2.49 - - - 
 151.44   12.44   -   
 115.87   13.54   -   
Day 4 127.69 135.62 24.06 10.96 12.50 1.47 - - - 
 162.65   12.67   -   
 116.53   13.88   -   
Day 5 154.64 126.09 24.80 12.61 10.73 1.77 - - - 
 109.88   10.48   -   
 113.74   9.10   -   




Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev
Day 2 12.24 12.20 1.21 8.89 11.08 1.97 7438.91 7214.67 211.55 
 10.97   11.63   7186.44   
 13.38   12.71   7018.65   
Day 3 12.40 11.72 1.61 13.57 12.12 1.75 - - - 
 9.89   12.62   -   
 12.88   10.17   -   
Day 4 10.64 12.18 1.52 10.84 11.78 1.46 - - - 
 12.24   13.46   -   
 13.67   11.05   -   
Day 5 10.37 11.88 1.68 13.23 12.01 1.13 - - - 
 13.69   11.81   -   
 11.57   10.99   -   
          






Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev
Day 2 27.64 36.00 7.73 12.12 12.03 1.88 9807.92 10128.73 330.01 
 37.49   13.86   10467.22   
 42.88   10.11   10111.05   
Day 3 287.65 282.44 26.32 13.21 11.66 1.81 - - - 
 253.91   9.67   -   
 305.77   12.10   -   
Day 4 668.34 625.69 39.25 10.86 11.51 0.93 - - - 
 591.08   12.57   -   
 617.64   11.10   -   
Day 5 1214.67 1188.67 60.25 10.14 11.45 1.26 - - - 
 1119.78   12.66   -   
 1231.55   11.54   -   




Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev
Day 2 12.41 12.30 1.41 9.75 11.35 1.42 10396.78 10772.10 565.78 
 10.84   12.46   11422.86   
 13.66   11.83   10496.67   
Day 3 14.20 12.48 1.54 11.51 11.73 1.65 - - - 
 11.22   13.48   -   
 12.01   10.21   -   
Day 4 13.84 12.03 1.59 13.52 12.07 1.83 - - - 
 11.36   10.01   -   
 10.88   12.69   -   
Day 5 12.98 12.09 1.68 10.15 11.94 1.60 - - - 
 10.15   12.44   -   
 13.13   13.23   -   





Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev
Day 2 329.27 376.57 41.22 10.86 11.37 0.63 11784.39 11406.45 368.26 
 395.66   12.08   11386.27   
 404.78   11.17   11048.69   
Day 3 587.66 616.12 29.29 13.64 11.76 1.63 - - - 
 614.51   10.75   -   
 646.18   10.88   -   
Day 4 1441.87 1449.88 64.70 12.52 11.11 1.36 - - - 
 1389.55   10.99   -   
 1518.21   9.81   -   
Day 5 786.51 732.16 47.99 13.37 11.70 1.51 - - - 
 714.33   11.28   -   
 695.64   10.44   -   
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Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev
Day 2 14.21 12.81 1.89 11.67 11.18 1.88 11812.14 11355.82 436.96 
 10.66   12.77   10941.20   
 13.57   9.11   11314.13   
Day 3 11.17 11.91 1.59 13.28 12.15 1.09 - - - 
 13.74   12.07   -   
 10.82   11.11   -   
Day 4 10.99 12.35 1.23 10.88 11.54 0.95 - - - 
 12.66   12.63   -   
 13.40   11.10   -   
Day 5 13.64 11.90 1.52 10.23 10.78 1.85 - - - 
 10.86   9.27   -   
 11.20   12.84   -   
 





 SARS S(M) Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev 
Day 2 62.38 56.09 7.19 21.36 19.26 1.90 15367.18 15114.36 251.97 
 57.65   18.75   14863.25   
 48.25   17.66   15112.66   
Day 3 101.36 112.13 9.39 19.64 20.05 2.07 - - - 
 116.47   22.30   -   
 118.56   18.22   -   
Day 4 138.96 134.99 11.68 17.28 19.36 1.85 - - - 
 144.17   19.97   -   
 121.84   20.83   -   
Day 5 135.55 125.65 9.33 16.75 19.08 2.22 - - - 
 117.02   19.33   -   
 124.39   21.17   -   
          
PP 
 SARS S(M) Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev 
Day 2 17.65 19.25 1.56 19.88 19.60 1.93 14386.61 14301.84 277.51 
 19.32   21.37   13991.84   
 20.77   17.54   14527.08   
Day 3 18.63 19.71 2.26 22.40 20.00 2.16 - - - 
 22.31   19.39   -   
 18.20   18.21   -   
Day 4 21.45 19.34 1.87 19.61 18.98 1.46 - - - 
 18.69   20.02   -   
 17.88   17.32   -   
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Day 5 20.68 19.34 1.62 22.65 20.54 1.86 - - - 
 19.81   19.87   -   
 17.54   19.11   -   
          
IFN-γ (pg/ml) 
PP/SARS-S-RBD 
 SARS S(M) Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev 
Day 2 37.65 33.27 3.85 24.08 22.52 2.11 9865.37 10015.75 198.96 
 30.44   23.35   10241.36   
 31.72   20.12   9940.52   
Day 3 64.51 70.96 5.86 23.84 21.84 2.11 - - - 
 72.43   19.63   -   
 75.94   22.04   -   
Day 4 84.29 82.02 5.57 21.10 23.08 2.32 - - - 
 75.67   22.51   -   
 86.10   25.63   -   
Day 5 85.64 79.85 6.96 25.84 23.88 1.76 - - - 
 81.78   23.38   -   
 72.12   22.43   -   
          
PP 
 SARS S(M) Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev 
Day 2 19.19 19.14 1.47 17.74 19.54 1.91 9697.52 9940.44 231.85 
 17.65   19.33   10159.36   
 20.58   21.54   9964.43   
Day 3 18.61 20.00 1.52 22.15 20.29 1.74 - - - 
 21.63   20.03   -   
 19.77   18.69   -   
Day 4 20.45 18.86 1.39 17.66 19.40 2.00 - - - 
 17.88   18.97   -   
 18.24   21.58   -   
Day 5 16.79 18.31 1.39 19.50 19.33 1.60 - - - 
 19.52   17.65   -   
 18.61   20.84   -   
          
IL-4 (pg/ml) 
PP/SARS-S-RBD 
 SARS S(M) Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev 
Day 2 29.98 29.79 3.96 18.08 18.28 1.40 13620.37 13842.30 207.18 
 33.66   16.99   14030.61   
 25.74   19.76   13875.91   
Day 3 76.67 70.06 5.80 21.34 19.57 1.59 - - - 
 67.68   18.26   -   
 65.84   19.11   -   
Day 4 297.61 318.15 18.10 16.87 18.28 1.39 - - - 
 325.08   19.65   -   
 331.77   18.33   -   
Day 5 437.87 462.20 30.65 21.04 19.59 2.06 - - - 
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 496.62   17.23   -   
 452.12   20.51   -   
          
PP 
 SARS S(M) Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev 
Day 2 20.64 20.10 1.42 19.75 19.62 1.32 14008.67 13829.97 156.73 
 21.17   18.24   13765.43   
 18.48   20.87   13715.82   
Day 3 17.58 18.84 1.10 17.68 19.42 1.93 - - - 
 19.62   19.08   -   
 19.31   21.49   -   
Day 4 20.52 19.66 1.81 16.69 18.65 1.72 - - - 
 20.88   19.37   -   
 17.58   19.89   -   
Day 5 18.69 20.11 1.29 21.56 19.95 1.67 - - - 
 20.41   20.06   -   
 21.22   18.22   -   
          
IL-5 (pg/ml) 
PP/SARS-S-RBD 
 SARS S(M) Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev 
Day 2 124.35 126.66 9.37 18.63 19.69 1.12 16127.87 15866.10 277.96 
 136.97   19.57   15896.05   
 118.66   20.86   15574.38   
Day 3 357.91 366.87 13.72 19.59 19.66 1.72 - - - 
 382.67   21.41   -   
 360.03   17.98   -   
Day 4 536.99 535.94 16.69 22.12 20.06 1.89 - - - 
 518.74   18.41   -   
 552.08   19.65   -   
Day 5 495.61 523.05 24.75 17.57 19.36 1.90 - - - 
 529.88   19.16   -   
 543.67   21.35   -   
          
PP 
 SARS S(M) Avg Std Dev RPMI Avg  Std Dev Con A Avg Std Dev 
Day 2 17.58 19.38 1.67 21.55 19.14 2.11 16007.02 15724.84 325.14 
 20.89   17.64   15798.21   
 19.66   18.24   15369.28   
Day 3 18.94 19.07 1.31 18.29 19.51 1.30 - - - 
 17.83   19.37   -   
 20.44   20.87   -   
Day 4 21.45 19.65 1.66 22.17 20.12 1.85 - - - 
 19.33   19.63   -   
 18.17   18.57   -   
Day 5 20.85 19.49 1.46 18.19 18.47 1.62 - - - 
 17.95   20.21   -   
 19.66   17.00   -   
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